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1 Abstract 
Introduction 
National data on the prevalence of chronic diseases on general practice registers is now 
available.  The aim of this PhD was to develop and validate epidemiological models for the 
expected prevalence of chronic obstructive pulmonary disease (COPD), coronary heart 
disease (CHD), stroke, hypertension, overall cardiovascular disease (CVD) and high CVD risk 
at general practice and small area level, and to explore the extent of undiagnosed disease, 
factors associated with it, and its impact on population health. 
 
Methods 
Multinomial logistic regression models were fitted to pooled Health Survey for England data 
to derive odds ratios for disease risk factors.  These were applied to general practice and 
small area level population data, split by age, sex, ethnicity, deprivation, rurality and 
smoking status, to estimate expected disease prevalence at these levels.  Validation was 
carried out using external data, including population-based epidemiological research and 
case-finding initiatives.  Practice-level undiagnosed disease prevalence i.e. expected minus 
registered disease prevalence, and hospital admission rates for these conditions, were 
evaluated as outcome indicators of the quality and supply of primary health care services, 
using ordinary least squares (OLS) regression, geographically-weighted regression (GWR), 
and other spatial analytic methods. 
 
Results 
Risk factors, odds of disease and expected prevalence were consistent with external data 
sources.  Spatial analysis showed strong evidence of spatial non-stationarity of undiagnosed 
disease prevalence, with high levels of undiagnosed disease in London and other 
conurbations, and associations with low supply of primary health care services.  Higher 
hospital admission rates were associated with population deprivation, poorer quality and 
supply of primary health care services and poorer access to them, and for COPD, with higher 
levels of undiagnosed disease.  
  
Conclusion 
The epidemiologic prevalence models have been implemented in national data sources such 
as NHS Comparators, the Association of Public Health Observatories website, and a number 
of national reports.  Early experience suggests that they are useful for guiding case-finding 
at practice level and improving and regulating the quality of primary health care.  
Comparisons with external data, in particular prevalence of disease detected by general 
practices, suggest that model predictions are valid. 
 
Practice-level spatial analyses of undiagnosed disease prevalence and hospital admission 
rates failed to demonstrate superiority of GWR over OLS methods.  Disease modellers 
should be encouraged to collaborate more effectively, and to validate and compare 
modelling methods using an agreed framework.  National leadership is needed to further 
develop and implement disease models.  It is likely that prevalence models will prove to be 
most useful for identifying undiagnosed diseases with a slow and insidious onset, such as 
COPD, diabetes and hypertension.    
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5 Background/policy context 
“A public health department really ought to be looking at doing our QOF analysis 
and saying actually ‘Do you know, you are two per cent lower than the practice 
next door on thyroid problems. Let’s see why that is.’ They don’t do that. They 
don’t look at my practice… I want to see a public health department that is 
actively engaged with the practices, that is linked to the practices to say ‘OK, we 
have got a named link for you. You have got a public health-type issue, you come 
to this guy and he will be the conduit through which the rest of the department 
will work with you.’ 
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A major problem with present public health information is the lack of population-based data 
on key metrics such as risk factor and disease prevalence at local i.e. primary care trust 
(PCT) and local authority (LA) level-  the Health Survey for England (HSfE) produces reliable 
data only to Regional level.1  This issue is highlighted in Securing Good Health for the Whole 
Population (the Wanless Report)2, which states: 
 
“Health data are essential for monitoring the health of the population and for 
evaluating the effects of health interventions. Yet the information collected 
nationally is often poor and there is no regular mechanism by which a PCT or LA  
can gather reliable information on its own population… To improve 
understanding of prevalence of disease and to enable proactive management of 
personal risk factors, much greater use needs to be made of primary care data 
systems”. 
 
This challenge was taken up by Informing Healthier Choices, the Department of Health (DH) 
public health information and intelligence strategy,3 which states that: 
 
 “reliable data on key contemporary health challenges will be collected and 
made available centrally as a by-product of care provision (for example 
information from general practice systems on hypertension or smoking 
prevalence) 
 
 prevalence models will be generated for the common health problems which 
commissioners need to address. These will allow the current situation in an 
area or group within the population to be evaluated against an expected level 
of need”. 
 
My thesis covers the research needed to support these objectives, i.e. to improve the 
estimation of risk factor and disease prevalence in small areas, and to determine the extent 
to which primary care data can be used to support estimation. 
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6 Aim, Objectives and Management 
6.1 Aims 
My PhD proposal initially contained the two broad aims of developing methods for 
prevalence estimation, of both disease risk factors and common chronic diseases.  The first 
research aim therefore proposed to assess the fitness of general practice (GP) data for the 
purpose of risk factor prevalence estimation, and to develop new methodologies to adjust 
primary care data for sources of bias.  In Phase 1 validation was to be undertaken against 
other estimates, and appropriate adjustment designed.  In Phase 2, new uses of this small 
area/population data was to have been explored, e.g. linkage with datasets including 
broader health determinants, and modelling future disease prevalence. 
 
However this aim relied heavily upon the availability of data from the GP Extraction Service 
(GPES), which was to have begun to provide data by late 2008, and then by Spring 2009.4  
This later deadline was missed- and in fact, there was still no data available at the time of 
writing this thesis.  When it became apparent that no data would be available during the 
course of the degree, I agreed with my Supervisors that the thesis would focus on the 
second aim, disease prevalence estimation.  The remainder of the thesis therefore excludes 
this aim.  However, I retain a close interest in GPES development and presented on this 
topic at a joint workshop organised by the Faculty of Public Health, NHS Connecting for 
Health (NHS CfH) and the Information Centre for health and social care (IC) entitled “The 
Future of Public Health Information and Intelligence: needs and applications.”5 
 
This second aim has proven to be ambitious in scope in itself.  For chronic disease 
prevalence estimation, Phase 1 of the research aimed to further develop the methodology 
for new and existing prevalence models, and Phase 2 to validate one or more models and 
develop case-finding strategies, and to explore the impact of undiagnosed disease as 
estimated by the models.   
6.2 Research Questions 
 How should the prevalence of chronic diseases be estimated? 
 
 How valid are chronic disease prevalence estimates? 
 
 How do different chronic disease prevalence estimation methods compare in terms of 
their validity? 
 
 What is the best available methodology given the requirements for prevalence models? 
 
 How useful are chronic disease prevalence estimates for case-finding at GP practice 
level? 
 
 Can chronic disease prevalence estimates be used with practice disease register 
prevalence to estimate the prevalence of undiagnosed disease? 
6.3 Objectives 
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For chronic disease prevalence estimation: 
 to develop a methodology for chronic disease prevalence modelling, initially by 
extending logistic regression modelling to examine predictors of chronic obstructive 
pulmonary disease (COPD), coronary heart disease (CHD), stroke, hypertension, overall 
cardiovascular disease (CVD) and high CVD risk using the HSfE datasets 
 to work with the Association of Public Health Observatories to publish new prevalence 
estimates and future projections at PCT and GP level and support their use by PCTs, 
practices and other agencies 
 to explore the use of risk factor prevalence to model future disease prevalence  
 to investigate the potential for applying Bayesian procedures as developed for HIV/AIDS 
to other chronic diseases. 
 to undertake a validation of one or more disease prevalence models, possibly through 
testing case-finding strategies at practice level.  This could involve data from Brent, 
Wandsworth, or Hammersmith & Fulham PCTs 
 to explore the links between registered and estimated disease prevalence and primary 
and secondary healthcare utilisation, with the aim of developing age-sex specific 
utilisation ratios which can be used to project future healthcare capacity requirements.   
6.4 Ethics 
As the PhD involved secondary analysis of existing data sources (apart from the pilot of 
COPD screening), ethical issues were dealt with in gaining access to the data for analytic 
purposes.  For example for Hospital Episode Statistics (HES) data, we complied with small 
cell number requirements for sensitive data items.6 
6.5 Outputs 
For Phase 1, a methodology paper was to be published for each disease prevalence model, 
and a paper providing results for English PCTs (including maps).  Later publications would 
include validation studies and case-finding strategy results. 
 
For Phase 2, publications were to explore the links between disease prevalence, health 
determinants and healthcare factors, ideally through fuzzy matching of anonymised person-
based data, but if not possible through practice-level analyses.  Current person-based ONS 
survey data is available via the UK Data Archive.  It was not clear at the outset whether the 
same level of access by researchers to person-based data will be permitted for other 
sources e.g. HES, but this would be an ideal eventual data linkage. 
6.6 Benefits expected 
The potential benefits of valid disease prevalence models have been outlined above. 
6.7 Risks 
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Risks and management strategies identified at the outset are listed below. 
 
Risk Risk management 
Inability to access person-based data (if needed) 
from QRESEARCH risk factor extract because of 
cost 
Consider application to DH or to a research 
funder e.g. Research for Patient Benefit 
Lack of suitable local survey data for validation Use other data sources e.g. Census 
Delays in establishment of GPES This is a major risk, and some implementation 
delays are possible.  In that case it may be 
possible to obtain some data from current PCT 
IT service providers e.g. Brent, Wandsworth 
Delays in researcher access to GPES data for 
ethical or administrative reasons 
Aim to obtain aggregate data in the interim, 
possibly from routine early reporting 
Low uptake/coverage of GPES This will affect the level of geography for which 
the estimates can be produced, but not the 
integrity of the project so long as robust 
PCT/LA level estimates can be produced. 
Inability to access person-based data from various 
data sources 
Use aggregate data provided it has reasonable 
age-sex breakdowns 
Currently unbudgetable costs for access to GPES, 
which could be significant 
Work with Information Centre to minimise 
delays; ensure that researcher access to GPES 
is considered early 
Complexity of statistical issues involved e.g. in 
imputation, and lack of resource 
Work with BIAS Project in EPHPC; contract in 
some expertise; collaborate with national 
expert e.g. Patrick Royston at Cambridge 
Interest/competition from other academic 
institutions or agencies which do not wish to 
collaborate 
Ensure that there is sufficient expertise within 
ICFM; ensure that other researchers’ needs are 
addressed 
Information Centre refuses to collaborate Unlikely given past experience.   
No 2008-9 DH funding for disease prevalence 
modelling 
Provide input to 2008-9 planning process in 
DH.  Ensure that current models are used 
frequently 
No funding for prevalence model validation or 
case-finding strategies 
Apply to multiple funding sources e.g. NHS 
Research for Patient Benefit stream, relevant 
voluntary organisations. 
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7 Disease prevalence models: background 
Parts of this section have been published as a paper in the Journal of Ambulatory Care 
Management.7 
 
Like healthcare systems in other countries, the United Kingdom’s NHS is moving from 
reactive to proactive care, leading to the establishment of programs for the management of 
chronic diseases. Better management of chronic diseases has consequently been an NHS 
priority, and there were three chronic disease-related national 2007–2008 Local Delivery 
Plan targets for English PCTs, the bodies responsible for administering the contracts of GPs 
in England and for commissioning other healthcare services. These were to reduce 
emergency bed days, to increase the number of staff in the community providing case 
management, and to increase the number of patients with chronic diseases and those who 
are very high intensity users, whose case is being managed by a specialist community-based 
nurse. 
 
Until now, most attention has been focused on the relatively small number of patients with 
a high disease burden who use about 30% of healthcare resources. Various tools have been 
provided to identify these patients, such as the Patients At Risk of Readmission (PARR) case-
finding algorithm that uses Admitted Patient Care data to identify patients at high risk of 
hospitalization,8 and the High-impact User Model (HUM) developed by Dr Foster Intelligence 
with support from Imperial College London.9 These tools use data collected by the NHS to 
monitor hospital activity, principally HES data. 
 
Other policies that cover the larger group of patients with a single high-impact chronic 
disease and management of this disease once it has been identified include the National 
Service Frameworks and the Quality and Outcomes Framework (QOF) of the new General 
GP Contract, which rewards GPs for improving chronic disease management using data 
coded into electronic patient records. A great deal remains to be done by PCTs to ensure 
that chronic disease management programs are functioning optimally, and to prevent 
patients with chronic diseases moving inexorably into the high disease burden group. 
 
Less attention has been directed toward detecting patients with undiagnosed chronic 
diseases. Since diagnosis and treatment usually slows disease progression, such patients 
may be more likely than those already known to general practices to increase the burden of 
disease and healthcare costs. Moreover, although some admissions for chronic diseases are 
of high disease burden individuals or those with comorbidities, the majority are of patients 
in the middle of the “chronic disease pyramid.”  Recent BMJ and Lancet news items10 have 
featured a study comparing disease prevalence and mortality in the US and UK.11 This found 
higher disease prevalence among older Americans than their British counterparts. In 
contrast, age-specific mortality rates are similar in the two countries, with an even higher 
risk among the English after age 65.   The study offers two possible explanations for the 
higher death rate among the English after the age of 65: that the illnesses looked at in the 
study resulted in higher mortality in England; or that in England the diseases are diagnosed 
at a later stage. Both of these explanations, says the report, “imply higher-quality medical 
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treatment (broadly defined) in the United States than in England, at least in the sense that 
mortality implications of disease are less severe in the United States.” 
 
I first became interested in modelling disease prevalence around 2001 while I was a Director 
of Public Health for Ealing Hammersmith & Hounslow Health Authority in West London.  
With its large South Asian population, the prevalence of diabetes and CVD was relatively 
high.  For example, according to the HSfE, the prevalence of diabetes in the English 
population is 4.9 per cent, but local data I obtained from practice registers showed a 
prevalence of three per cent.  It would clearly be useful to have better local estimates of 
disease prevalence. 
 
I discussed development of a diabetes prevalence model with Dr Nita Forouhi, a Specialist 
Registrar in Public Health, and she developed a simple model which included age, sex, 
ethnicity and obesity prevalence.  We discussed the model with Yorkshire and Humber 
Public Health Observatory (Y&HPHO) and with Sue Roberts, then National Clinical Director 
for diabetes at the Department of Health (DH).  At that stage, data from a diabetes register 
was being considered as a source of prevalence data.  However the advantages of an 
epidemiologic approach to prevalence estimation were accepted, and Y&HPHO were asked 
to host the model on their website.  This model, with some modifications, has been 
maintained there since 2002.12 
 
Disease prevalence information is also important for both public health monitoring and 
clinical management.  Since diagnosis and treatment usually slows disease progression, 
patients with undiagnosed long term conditions (chronic diseases) may be more likely than 
those already known to general practices to increase the burden of disease and healthcare 
costs.   
 
The QOF has provided for the first time UK population-based data on the detected (defined 
as having an appropriate diagnosis entered on GP electronic medical record systems 
according to QOF coding rules) prevalence of disease.  It also rewards practices for finding 
new cases through payments for quality of care that are weighted for the prevalence of 
disease in a practice i.e. practices with higher prevalence of a chronic disease are paid more 
than practices with a low prevalence.  Recent QOF results show generally small increases in 
detected prevalence since 2005-6.13 
7.1 Potential uses of disease prevalence estimation 
But how complete are QOF disease registers? Prevalence models, which provide survey-
based estimates for small populations, based on local data on known risk factors, may be 
useful in this regard. They can be used to: 
 assess the completeness of disease registers in primary care or assessing the 
completeness of case finding- the data could be used to guide case-finding at 
practice level; 
 compare complication rates or admission rates after adjustment for variation in 
expected prevalence; 
 compare service provision with population need- for example, if age-sex specific 
primary and secondary care utilisation ratios are known for specific chronic diseases, 
these can be applied to population projections to estimate future healthcare 
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capacity requirements.  We used this modelling methodology in Healthcare for 
London14; 
 undertake health equity audits; 
 allocate health service resources; 
 link to risk factor prevalence estimates.7 
7.2 Previous UK prevalence models 
The first national UK disease prevalence model for which local data was made available was 
the “PBS” (Public Health Observatory/Brent/Sheffield) Diabetes Prevalence Model, now 
hosted by Yorkshire and the Humber Public Health Observatory. The PBS model applies age, 
sex, and ethnic group-specific estimates of both type 1 and 2 diabetes prevalence rates, 
derived from epidemiological population studies, to 2001 Census resident populations.15 
Forecasts of 2010 diabetes prevalence are also presented for sub-national areas based on 
projected population change and trends in obesity. The PBS model estimates that diabetes 
prevalence in England was 4.37% overall in 2001, and that it will increase to 5.05% in 2010, 
assuming the prevalence of obesity continues to increase in line with historic trends. 
 
However, 2006–2007 QOF results show an England crude prevalence rate (using the entire 
population as a denominator as does PBS) of only 3.7%, when the estimated prevalence is 
about 4.8%.16 The National Clinical Audit Support Programme’s National Diabetes Audit 
Report for the period 2005–2006, which covered 43% of PCTs, shows that on average for 
the participating areas, 81.5% of the people predicted to have diabetes by the PBS model 
are actually recorded as having the disease, which has increased from the 2003–2004 figure 
of 77%.17 There is considerable local variation, with the percentage of predicted registered 
varying across the then 28 English Strategic Health Authorities from 72% to 95%. There is 
even more variation between general practices, with some recording only of the 15% 
expected prevalence of diabetes. 
 
Prevalence estimates can be produced for populations registered or enrolled for healthcare, 
or for resident, geographically based populations (for the former, geographically based risk 
factor data may need to be applied to the registered/enrolled population).  Models are 
being developed for other chronic diseases, and they can also be produced for other risk 
factors as well as for hypertension: modelled local estimates have also been developed 
recently for smoking, excessive alcohol intake, obesity, and fruit and vegetable consumption 
by the Information Centre for Health and Social Care and the Neighbourhood Statistics 
Service of the UK Office for National Statistics.18 These can be used to target area-based 
public health interventions. The Health Protection Agency for England has developed a 
sophisticated model for HIV/AIDS prevalence, which uses Bayesian methods to allow 
multiple evidence sources to be applied to any one parameter,19but this has not been 
applied to sub-national data. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
has also developed an HIV model for developing countries as part of its Estimation and 
Projection Package.20 Further methodological development is considered below.   
 
Case-finding to close disease prevalence gaps may be cost-effective—the 2003 National 
Institute for Clinical Excellence (NICE) COPD guidance states that the incremental cost-
effectiveness ratio of opportunistic case finding for this purpose is a cost per quality-
adjusted life year of £814.21 But although case finding may be justifiable, population 
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screening may not. Gillies and co-workers have recently modelled the cost-effectiveness of 
several diabetes sub-population screening strategies.22 The overall cost-effectiveness ratio 
was not sensitive to decisions about which groups to screen, nor the costs of screening or 
treatment, but was most strongly affected by assumptions about how treatments combine 
to reduce risk. 
 
This is also likely to be the case for other chronic diseases. Given the large populations 
involved, more systematic case finding or screening will also not be cheap. There is evidence 
that the rise in treated disease prevalence, rather than the rise in spending per treated case, 
was the most important determinant of the recent growth in US healthcare spending.23 
Similarly, reductions in diagnostic or treatment thresholds—the recent Joint British 
Societies’ recommendation to use lower cholesterol treatment targets is but one example—
need to be properly justified in terms of their cost effectiveness before they are adopted.24 
 
Further work is therefore needed to develop and test systematic case-finding strategies that 
produce a high yield but do not overburden general practice staff. Moreover, none of the 
models have yet been validated at general practice level against, for example, numbers of 
cases detected by case-finding initiatives. There must also be high-quality primary care 
services in place to manage new cases as they are identified. However, in many deprived 
areas in the United Kingdom, there are fewer than expected primary care services: a 2004 
review shows that the broadly upward trend in GP misdistribution in the United Kingdom 
from the mid- 1980s continued in the period 1995–2003.25 Valid prevalence models could 
be used to allocate primary care resources so that these better match actual need and 
further support case finding, and work continues to try to achieve this objective.  
7.3 Problems with current UK prevalence models 
The current models require validation, and cost-effective case-finding strategies are also 
needed.  The relative disease burdens and healthcare impacts of diagnosed and 
undiagnosed cases of chronic diseases are unknown.   Further methodological development 
is also required.  The diabetes, CHD and hypertension models use crude weighting of 
population data- for example, the HSfE shows that hypertension prevalence is correlated 
with age, sex and ethnic-group, so calculations were stratified to reflect variations in these 
factors at PCT level.  For the COPD model, the strength of association between each 
explanatory variable and COPD caseness was used to calculate the relative odds, which were 
applied to the baseline odds to derive the prevalence estimates.   HIV/AIDS models 
developed by the Health Protection Agency and the Joint UN Programme on HIV/AIDS use 
Bayesian procedures for prevalence estimation,19 which could be applied to other chronic 
diseases.  Finally, there is a need for additional prevalence models to cover other QOF (and 
non-QOF) diseases where there is evidence that early diagnosis improves outcomes. 
7.4 Small area prevalence estimation methodologies 
The main procedures include direct domain estimation, indirect domain estimation, and 
small area modelling. Direct domain estimation uses available sample units in the domain to 
estimate the quantity of interest, leading to unacceptably large standard are related in time 
and/or space to increase the effective sample size for small domains.  Given these problems 
I will not discuss it further. 
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Indirect domain estimation includes: synthetic estimation, i.e. using a reliable estimator for 
a large domain to derive an estimator for the small domain contained within the large 
domain under the assumption that the small domain has the same characteristics as the 
large domain; composite estimators, i.e. weighted averages of sample estimates for the 
same domain but from different surveys); and James-Stein estimators (also called shrinkage 
estimators because they shrink the mean squared error, sometimes also used in conjunction 
with the direct estimator in so-called “limited translation estimators”). 
 
In contrast to indirect domain estimation, small area modelling is explicit about the 
assumptions of relatedness in space and/or time and has variably used three strategies to 
deal with the limited availability of survey and administrative data: pooling data over several 
years; borrowing strength in space by exploiting spatial correlations; and using structured 
relationships with covariates to predict the quantity of interest.  I used the latter method in 
this research, but they can be combined. 
7.4.1 Simple multiple logistic regression modelling 
Multiple logistic regression modelling (MLM) using “classical” regression techniques is an 
obvious method for local prevalence estimation.  However, apart from the modelling 
described in this PhD, there have been surprisingly few published reports or applications 
based on MLM.  There are some reports from the USA using National Health and Nutrition 
Survey (NHANES) data.26;26;27  Other researchers have used more sophisticated methods 
which are described below. 
7.4.2 “Synthetic estimation” 
Synthetic estimates (SE) e.g. on the Neighbourhood Statistics website attempt to overcome 
some of the problems associated with local models by using auxiliary information i.e. more 
than one data source to produce small area estimates, without or usually with MLM.18;28;29  
As Chambers and Saie30 explain, auxiliary information may be attributes of surveyed 
individuals (e.g. age/sex/NS-SeC and ethnicity) and/or of the area in which they reside (e.g. 
claimant counts or area-based deprivation scores). Estimation and inference approaches 
based on using the relationship between the variable of interest and auxiliary information 
are called “model-based SE”.  
 
The form of the statistical model used for model-based SE depends on both the survey 
sampling and availability of auxiliary/covariate information e.g. Census data. As a first stage, 
regression analysis is performed by modelling the survey data against available predictors. 
This analysis is conducted for the subset of areas covered by the survey. The output from 
the first stage is a set of parameter estimates. 
 
At the second stage, the coefficients attached to the predictor variables obtained from the 
first stage model are attached to the identical set of variables available for all areas to 
produce an estimate for the area.  An alternative technique of multilevel modelling applies a 
statistical model to survey data that simultaneously accounts for both individual and area-
level influences. Prof Nicky Best’s team in the Imperial College School of Public Health have 
refined these methods,31;32 and they are now in widespread use33 (see also the BIAS Project 
website). Composite estimators consist of weighted combinations of direct and synthetic 
estimators.  However it is still necessary to have a sample or direct estimate in the area 
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concerned at the desired level of geographic concentration i.e. a geographically unclustered 
survey.  Table 1 summarises the data requirements/constraints which enable or prevent the 
use of alternative small area estimation techniques. 
Table 1: Summary of small area synthetic estimation methods 
Estimation approach 















Direct estimator Unclustered - - NUTS 4/5  








Individual  ditto 
Area-level synthetic estimator Clustered All areas Area  ditto 
Composite (EBLUP) estimator 
(1) 
Unclustered  All areas Area LA 
Regression synthetic 
estimation using area-level 
covariates (2) 
Clustered  All areas Individual  Ward/LSOA 
Regression using individual and 
area-level covariates (3) 
Clustered  Both sample 
members and 
all areas 
Individual  Ward/LSOA 
 
1 E.g. ONS estimates of ILO unemployment rates. 
2 E.g. ONS estimates of average income, NatCen SE I healthy lifestyles. 
3 E.g. University of Portsmouth for Health Development Agency. 
 
It is clear from the above that there are a number of methodological problems with SE 
relating to survey sampling techniques and covariate availability.  In addition, with NatCen’s 
current project to produce SEs of risk factors at LA and PCO levels, there are now problems 
with the detailed cross tabulations of 2001 Census data required becoming outdated.  In 
areas with rapidly growing or changing populations, this could lead to significant errors.  
Detailed cross-tabulations of Census population projections are thought to be unreliable. 
 
The very wide confidence intervals at small area level are alluded to above.  SEs are also 
inexact and cannot be used for performance monitoring, as they take no account of the 
impact of local inter-Censal interventions such as NHS stop smoking or primary care 
services, or regeneration or Neighbourhood Renewal schemes.  They are difficult to explain 
to non-statisticians and require statistical health warnings to prevent over-interpretation 
and misuse.  Finally, they will underestimate local socio-cultural factors such as different 
health behaviours amongst ethnic minority sub-groups, where data has had to be pooled. 
7.4.3 Markov models 
Markov modelling is a technique which has been used widely in pharmaco-economics, but 
also to develop incidence and prevalence models as estimate transitions between various 
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disease states.34  For example, Honeycutt et al developed a Markov model to forecast 
diabetes prevalence in the USA.35 This framework was used to generate forecasts by age, 
race and ethnicity, and sex. The model forecasts the number of individuals in each of three 
states (diagnosed with diabetes, not diagnosed with diabetes, and death) in each year using 
inputs of estimated diagnosed diabetes prevalence and incidence; the relative risk of 
mortality from diabetes compared with no diabetes; and estimates of current population, 
live births, net migration, and the mortality rate of the general population.  Other Markov 
models have been produced for CVD,36-38 depression,39 and hypertension.40  A very useful 
analysis has compared a Markov model with an agent-based discrete event simulation 
model.41 
 
However the complexity of combining multiple disease states with local population data has 
limited current models to whole country or large population applications. 
7.4.4 Bayesian approaches 
Professor Peter Congdon has developed a number of sophisticated prevalence models using 
Bayesian and multi-level modelling techniques.42,43  Some of these also use auxiliary 
information as for SE techniques to refine local estimates.  He has used a regression model 
of prevalence rates by age, sex, region and ethnicity from the 1999 and 2003 HSfE to 
estimate CHD prevalence for 354 English LA areas.44 To allow for the impact of social factors 
on prevalence, survey information on the deprivation quintile in the respondents’ micro-
area of residence was also used. Allowance was made for area CHD mortality rates 
(obtained from aggregated vital statistics data) which are positively correlated with, and 
hence a proxy for, CHD prevalence rates. An application involved assessment of surgical 
intervention rates in relation to prevalence at the level of 28 Strategic Health Authorities as 
they then were. 
 
He has used two national mental illness (MI) studies that provide estimates of relative 
morbidity risk by demographic, socio-economic and ethnic group for major psychiatric 
conditions to produce an MI model;45 household/marital and area status also figure in the 
regression. Relative risk estimates were used, along with suitably disaggregated census 
populations, to make mental illness prevalence estimates for LAs. Two applications were 
considered: the first involved analysis of variations in schizophrenia referrals and suicide 
mortality over English LAs that takes account of prevalence differences, and the second 
involved assessing hospital referral and bed use in relation to prevalence (for ages 16–74) 
for a case study area. 
 
He has also estimated diabetes prevalence46 using a regression analysis of prevalence rates 
according to age, sex and ethnicity from HSfE (together with Census) data for LAs and 8000 
smaller areas (electoral wards).45 An adjustment for social factors was based on a 
prevalence gradient over area-deprivation quintiles. A Bayesian estimation approach was 
used allowing simple inclusion of evidence on prevalence from other or historical sources.  
He used the prevalence estimates to assess variations between LAs in adverse 
hospitalization indicators for diabetics and to assess the relationship between diabetes-
related mortality and prevalence. Rates of diabetic ketoacidosis and coma were positively 
correlated with prevalence, while diabetic amputation rates are not.  
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There are two main problems with this otherwise excellent work.  Firstly, the estimates are 
all based on resident populations.  However prevalence estimates are most useful for GP 
registered populations where they can be compared with QOF registered prevalence.  
Secondly, to enhance prediction, these models use variables such as QOF prevalence, 
hospital admissions or mortality to combine with survey data.  This obviously compromises 
their use for primary care performance assessment.  As a result they have remained in the 
socio-geographical literature as interesting mathematical models with no practical 
implementation. 
7.4.5 Support vector machine modelling 
Support Vector Machine (SVM) is a supervised machine learning technique that is widely 
used in pattern recognition and classification problems. Since an SVM is a classifier, then 
given a set of training examples, each marked as belonging to one of two categories, an 
SVM training algorithm builds a model that predicts whether a new example falls into one 
category or the other. Intuitively, an SVM model is a representation of the examples as 
points in space, mapped so that the examples of the separate categories are divided by a 
clear gap that is as wide as possible. New examples are then mapped into that same space 
and predicted to belong to a category based on which side of the gap they fall on. The SVM 
algorithm performs a classification by constructing a multidimensional hyperplane that 
optimally discriminates between two classes by maximizing the margin between two data 
clusters. This algorithm achieves high discriminative power by using special nonlinear 
functions called kernels to transform the input space into a multidimensional space.47 
 
The basic idea behind the SVM technique is to construct an n-1 dimensional separating 
hyperplane to discriminate two classes in an n-dimensional space. A data point is viewed as 
an n-dimensional vector. For example, two variables in a dataset will create a two-
dimensional space; the separating hyperplane would be a straight line (one dimensional) 
dividing the space in half. When more dimensions are involved, SVM searches for an optimal 
separating hyperplane called the maximum-margin separating hyperplane. The distance 
between the hyperplane and the nearest data point on each side (called support vectors) is 
maximized. The best scenario is that two classes are separated by a linear hyperplane.  
 
SVM, which has been previously used in bioinformatics, has now been applied to disease 
prevalence estimation, to classify persons with and without common diseases.48 The 
method was used to detect persons with diabetes and pre-diabetes in the 1999-2004 
National Health and Nutrition Examination Survey (NHANES) to develop and validate two 
SVM models: for diagnosed or undiagnosed diabetes vs. pre-diabetes or no diabetes; and 
undiagnosed diabetes or pre-diabetes vs. no diabetes. The SVM models were used to select 
sets of variables that would yield the best classification of individuals into these diabetes 
categories. The discriminative abilities of the SVM models for Classification Schemes I and II, 
according to the area under the receiver operating characteristic (ROC) curve, were 83.5% 
and 73.2%, respectively. Validation indicated that the discriminative powers of the two SVM 
models were comparable to those of the multivariable logistic regression method.  
However, while SVM appears promising for prevalence estimation, it has not been widely 
validated, nor has it been shown to be superior to multiple logistic regression methods. 
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7.4.6 Simulation models 
Agent-based or “discrete-event” simulation modelling has developed rapidly in recent years, 
partly because of the availability of generic software which automates the process.49-52  A 
system dynamics model consists of an interlocking set of differential and algebraic equations 
developed from a broad spectrum of relevant measured and experiential data. A completed 
model may contain scores or hundreds of such equations along with the appropriate 
numerical inputs. Modelling is an iterative process of scope selection, hypothesis 
generation, causal diagramming, quantification, reliability testing, and policy analysis. 
 
For example, in the USA, the National Centers for Disease Control and Prevention used 
system dynamics simulation modelling to gain a better understanding of diabetes 
population dynamics and to explore implications for public health strategy.53 A model was 
developed to explain the growth of diabetes since 1980 and portray possible futures 
through to 2050.  The model simulations suggest characteristic dynamics of the diabetes 
population, including unintended increases in diabetes prevalence due to diabetes control, 
the inability of diabetes control efforts alone to reduce diabetes-related deaths in the long 
term, and significant delays between primary prevention efforts and downstream 
improvements in diabetes outcomes.  A recent paper has projected diabetes prevalence to 
2050.54 The authors project that annual diagnosed diabetes incidence will increase from 
about 8 cases per 1,000 in 2008 to about 15 in 2050. Assuming low incidence and relatively 
high diabetes mortality, total diabetes prevalence (diagnosed and undiagnosed cases) is 
projected to increase from 14% in 2010 to 21% of the US adult population by 2050. 
However, if recent increases in diabetes incidence continue and diabetes mortality is 
relatively low, prevalence will increase to 33% by 2050.  The agent-based approach is being 
taken to its logical conclusion in the USA by Archimedes, a vast simulation model of several 
diseases in several organ systems modulated by thousands of structural equations.26;55-57. 
 
However while these agent-based models are valuable tools for high-level policy analysis or 
population wide intervention, they do not provide support at the local level, where 
population factors may completely change incidence and prevalence.  Moreover in the UK, 
perhaps because of British caution and suspicion of “big ideas”, it appears that the 
development and application of public health modelling will occur in a classically 
incremental fashion.  For example, the UK Department of Health funded a discrete event 
simulation model of CHD prevention and treatment, but this was never validated or used for 
policymaking and soon became outdated.58  With the disease prevalence models described 
here I aimed to provide a useful local resource which would raise awareness of modelling 
methodologies and, through their transparency, avoid raising suspicions of academic black 
boxes. 
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8 Disease prevalence model development 
8.1 Chronic Obstructive Pulmonary Disease Model 
This model was developed with Dr Luis Nacul, while he was a Specialist Registrar in public 
health while I was at NW London Strategic Health Authority.  We later went on to document 
the methodology in a publication in Population Health Metrics about the time I started my 
PhD.59 
8.1.1 Introduction 
COPD is a chronic condition characterised by progressive airflow obstruction, which is not 
completely reversible. COPD contributes to nearly 30,000 deaths each year in the United 
Kingdom (UK), corresponding to 5.7 percent of adult male and 4 percent of adult female 
deaths, including a significant number of premature deaths. In addition, 1.4% of the 
population consult their GPs for COPD each year. It accounts for 2% of hospital admission 
spells and over 3 percent of bed-days in adults,60 costing the NHS £800 million, and leading 
to 24 million working days lost each year. 61 
 
Respiratory function indices have been shown to be predictive of mortality from respiratory 
disease, cardiovascular disease and all causes.62 Airflow limitation may precede the 
development of significant symptoms of COPD by many years and its progression is directly 
linked to the continuing exposure to risk factors, particularly tobacco smoking. As COPD is 
difficult to diagnose clinically (without spirometry) in its milder forms, it is often diagnosed 
late - the average age at diagnosis of COPD in the UK is 67 years.63 Widespread use of 
spirometry allowing early detection of airflow obstruction has been increasingly advocated 
as it enables early management of COPD.64 
 
As expected, the prevalence of COPD is higher in smokers and in men, and it increases with 
age. Other risk factors of public health importance include air pollution, socio-economic 
deprivation,65 occupational exposures66 and possibly ethnicity.67,68  Stopping smoking 
prevents the development of COPD, or slows its progress and reduces the risk of hospital 
admissions.69 Smoking cessation programmes are highly cost-effective, and crucially, have 
been specifically shown to be cost-effective when directed to individuals with asymptomatic 
airway obstruction.70 This is because smokers may be motivated to attempt to quit when 
given a diagnosis of airflow limitation.71 
 
The incremental cost effectiveness ratio (ICER) of opportunistic COPD case-finding for this 
purpose is a cost per life year gained of £713.16 and a cost per QALY of £814.56.60 The 
magnitude of undiagnosed cases can be ascertained by comparing the model estimates with 
the recorded prevalence of COPD, to indicate the extent of unmet needs in COPD. In the UK 
this is facilitated by GP performance payments for COPD management through the QOF of 
the GP Contract based on an electronic register of all patients with diagnosed COPD. If this is 
linked to case finding and intervention, there is a potential for reducing the population 
burden and progression of the disease. 
 
There is considerable variation in the reported prevalence of COPD. Models using smoking 
rates to estimate COPD prevalence have been previously proposed, but none has direct 
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relevance to the UK.72-75  With colleagues I developed a model  to estimate the prevalence 
of COPD based on existing data from the HSfE 2001,76 which had not been used for this 
purpose before. It uses the main risk factors for COPD reported in the literature, particularly 
those that are easily measured and for which information is readily available. This report 
explains how the model was developed, and uses the population of England to illustrate its 
application.  
8.1.2 Methods 
 Data sources 
The distribution of COPD in the population of England was based on the HSfE 2001 findings 
for lung function parameters and their association with relevant risk factors. The methods 
used in the HSfE 2001 are described in detail elsewhere.76 In brief, the survey included a 
representative sample of the population who had their lung function evaluated using a 
portable spirometer with a calibration device (Vitalograph 'Escort Spirometer'). 
Comprehensive data on risk factors were also collected as part of the survey. The data refer 
to 5,269 men and 6,133 women over 15 years old with valid lung function measures. This 
corresponds to 98% of men and 95% of women visited by a research nurse as part of the 
survey. For 99.3% of these, data were available for all of age-group, smoking status, 
ethnicity and degree of urbanisation. Data were available for deprivation score and all of the 
above risk factors in 94.3% of the final sample, which was used for the multivariate analysis. 
This included 4,970 men and 5779 women. COPD was defined according to British Thoracic 
Society (BTS) criteria,77 based on the values of forced expiratory volume in 1 second (FEV1 ) 
and the forced vital capacity (FVC) i.e. FEV1/ FVC < 0.70 and FEV1<80% predicted using 
British reference values derived from the HSfE.78  The second criterion is not part of the 
international GOLD definition.  The GOLD definition has also been used for prevalence 
estimates by NICE and the COPD National Strategy.  As a result, estimates from these 
sources are larger. 
 
 Model construction 
 The choice of variables for inclusion in the model was based on logistic regression analysis 
that examined predictors of COPD using the HSfE 2001 dataset. Explanatory variables 
obtained from the HSfE dataset and included in the final model were (categories of each 
variable shown in brackets): gender, age group (15-34 year olds, 10 year age groups from 35 
up to 74 years of age and 75 year olds and over), smoking status (smoker, former smoker, 
never smoker), ethnicity (White, Black or Black British, and Asian or Asian British), area of 
residence (rural, urban and suburban) and area based index of deprivation (quintile of 
deprivation score based on Index of Multiple Deprivation).79 The baseline odds of COPD (in 
non-smokers under 35 years old) were obtained directly from the data. Separate baseline 
odds were estimated for each gender, and also according to ethnicity, area of residence and 
area-based deprivation score. The logistic model was used to derive the odds ratios and 
prevalence ratios for COPD for subjects with various combinations of risk factors in relation 
to baseline. The prevalence in each age group, gender, ethnic group, area of residence and 
level of deprivation, and smoking status category were derived from the odds, using the 
formula: 
 
prevalence = odds/(1+odds). 
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 Model application 
 The input variables, which can be defined by the relevant user, e.g. at a PCT, include age-
group, gender, smoking prevalence by gender and age, area of residence, area based 
deprivation score and ethnic distribution of the population. The main model outputs are the 
prevalence of COPD by gender for the relevant geographic area, at national, regional or local 
level, as defined by the user. To illustrate the use of the model, we have used here 
population inputs for England, based on the mid-2005 estimated population distribution80 
and the national smoking prevalence by age-group and gender for 2004-2005.81 
 
Model assumptions 
 The model assumptions include: i) The real prevalence of COPD in non-smokers under 35 
years of age (baseline prevalence) is the same as the prevalence in non- smokers of the 
same age group and gender in the 2001 HSfE population; ii) The ratio of odds and 
prevalence of COPD in the various age groups compared to the baseline group is the same 
as in the HSfE for each gender, smoking status and other risk factors in the model; iii) the 
risks in those falling within each of the risk categories are uniform. We also obtained the 
prevalence of COPD considering alternative scenarios, which assume that: a) the prevalence 
of COPD in under 35s or under 40s is uniform across smoking status in each gender, and is 
equal to the average baseline prevalence found at the HSfE (therefore it does not consider 
any increase in risk due to smoking in this age group); or b) the prevalence of COPD is zero 
in under 35s or in under 40s; or c) ethnicity does not have an effect on the risk of COPD, and 
the risks in white populations apply to all ethnic groups.  
8.1.3 Results 
 Risk factors for COPD and selection of variables for COPD model 
 
Table 2 shows the results of the univariate and final regression logistic models assessing risk 
factors for COPD. Risk of COPD is significantly lower in women than in men (odds ratio (OR) 
=0.64; 95% CI= 0.54 - 0.76; p<0.001). As gender was shown to modify the effect of other 
variables on the outcome, the analyses were carried out separately for men and women. No 
other significant interactions were found in the data, including between age-group and 
smoking status. 
 
The final model shows age group and smoking history are the strongest predictors of COPD 
in both genders. Residence in urban areas and possibly black ethnicity are also associated 
with increased risk, particularly in women. Living in more deprived areas is associated with 
increased risk in men, but not in women. Being Asian appears to be protective in women, 




Table 3 shows the prevalence of COPD by age and gender in England. The overall prevalence 
in the population over 15 years of age was 3.1% (3.9% in men and 2.4% in women). For 
those over 45 years old, the estimated prevalence was 5.3% (6.8% and 3.9% in men and 
women respectively). This corresponds to over 1.3 million people in England with COPD, of 
whom nearly 800,000 or 60% are men. The assumption that ethnicity is not associated with 
being a case of COPD, i.e. that all population has the same risk of whites, did not change the 
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total national prevalence estimates considerably (1,297 thousand in 15 year-olds and over 
and 1,065 thousand over 45s under this assumption). When we considered the risk of COPD 
in under 35s as equal to the average baseline risk in this age group (in non- smokers), the 
total number of cases estimated was reduced by 60,800, resulting in an overall prevalence 
of 1.25 million or 3% (3.8% in men and 2.3% in women). Considering the risk in all over 40s 
as equal to the average baseline risk, the total number of cases is reduced further to 
1,223,200 (3.0% overall prevalence; 3.7% in men and 2.3% in women). If we consider the 
risk in under 35s as negligible, the total number of estimated cases decreases to 1,185,700 
(2.9% overall prevalence; 3.4% in men and 2.2% in women). Assuming the more extreme 
situation of zero risk in all under 40s, the prevalence comes down to 1,128,550 (2.7% 
overall; or 3.4% in men and 2.11% in women), representing a decrease of 174,500 compared 
to the original estimates. 
Table 2: Risk factors for COPD included in the final prevalence model 
Variable Odds Ratio (95% CI) 
(univariate model) 
Odds Ratio (95% CI) 
(final logistic model) 
MEN (n=4970) 
Smoking Status 
- Never smoker 
- Former smoker 
- Current Smoker 
(P<0.001) 
1 
3.63 (2.54 - 5.21) 
3.81 (2.64 - 5.52) 
(P<0.001) 
1 
2.18 (1.48 – 3.23) 
4.50 (3.01 – 6.74) 
Age-group (in years of age) 
- <35 







1.65 (0.86 - 3.17) 
 2.45 (1.33 - 4.50) 
 6.91 (4.02 - 11.89)    
10.40 (6.08 - 17.80)   
12.15  (6.78 - 21.76) 
(P< 0.001) 
1 
1.94 (0.99 – 3.78) 
2.66 (1.41 – 4.99) 
7.92 (4.46 – 14.07) 
12.69 (7.12 – 22.60) 
16.02 (8.57 – 29.94) 






0.70 (0.50 – 0.97) 
0.58 (0.39 – 0.86) 
(P=0.25) 
1 
0.74 (0.51 – 1.06) 
0.72 (0.46 – 1.15) 
Ethnicity 
- White 
- Black/ Black British 
- Asian/Asian British 
 (P=0.64) 
1 
1.20 (0.48 – 2.99) 
0.69 (0.28 – 1.70) 
(P=0.95) 
1 
1.17 (0.44 - 3.10) 
0.97 (0.37 – 2.51) 
Quintile of Multiple 
Deprivation Score 
1.22 (1.11 – 1.34) 
(P<0.001) 




- Never smoker 
- Former smoker 
- Current Smoker 
(P<0.001) 
1 
1.70 (1.07 – 2.64) 
3.53 (2.43 – 5.14) 
(P<0.001) 
1 
1.26 (0.79 – 2.01) 
4.11 (2.74 – 6.15) 
Age-group (in years of age) 
- <35 
- 35-44  
(P<0.001) 
1 
1.08  (0.53 - 2.19) 
(P<0.001) 
1 
1.35 (0.65 – 2.79) 
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Variable Odds Ratio (95% CI) 
(univariate model) 
Odds Ratio (95% CI) 





2.34  (1.28 - 4.30) 
4.18  (2.34 - 7.47) 
5.36 (2.99 - 9.61) 
5.34 (2.79 - 10.22) 
 
2.69 (1.42 – 5.09) 
6.03 (3.26 – 11.15) 
8.04 (4.33 – 14.91) 
10.40 (5.18 – 20.87) 






0.62 (0.42 – 0.92) 
0.47 (0.29 – 0.77) 
(P=0.04) 
1 
0.59 (0.39 – 0.90) 
0.55 (0.32 – 0.96) 
Ethnicity 
- White 
- Black/ Black British 
- Asian/Asian British 
(P=0.19) 
1 
1.14 (0.42 – 3.12) 
0.24 (0.03 – 1.76) 
(P=0.50) 
1 
1.81 (0.64 – 5.14) 
0.60 (0.08 – 4.47) 
Quintile of Multiple 
Deprivation Score 
1.18 (1.05 – 1.34) 
(P=0.005) 
1.11 (0.98 – 1.27) (P=0.11) 
 
Table 3: Number and proportion of people estimated to have COPD by age group and 









15-44 137,530 (1.30) 93,450 (  0.89) 230,980 (1.10) 
45-54  75,720 ( 2.38)  64,840 ( 2.00)  140,560(2.19) 
55-64 198,400( 6.90) 122,440 ( 4.11)   320,840 (5.48) 
65-74 199,840(10.03) 105,740 ( 4.81)  305,580 (7.29) 
75+ 172,700(11.65) 132,400 ( 5.55)  305,100 (7.89) 
Total 15+ 
Total 45+ 
784,190 ( 3.89) 
646,660 ( 6.76) 
518,870 ( 2.41) 
425,420 ( 3.92) 
1,303,060(3.15)  
1,072,080(5.27) 
* Values in brackets indicate age-gender specific prevalence rates (%) of COPD 
 
Table 4: Estimated prevalence P (percent) of COPD in England and according to area of 
residence 
Area P men age 15+ P men age 45+ P women 15+ P women 45+ 
Urban 4.86 (3.65-
6.47) 















6.76 (5.04-8.92) 2.41 (1.94-
2.92) 
3.92 (3.15-4.72) 
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* Values in brackets correspond to mean values in extreme quintiles of deprivation score, or 
approximately the 10th and 90th percentiles of the prevalence distribution. 
 
The latter estimates assume that all cases of airflow obstruction in the younger age groups 
are due to other diagnoses than COPD, such as asthma.   Table 4 shows the estimated 
prevalence of COPD in urban, suburban and rural England, based on the national population 
distribution and smoking prevalence. The values in brackets show the estimated average 
prevalence for areas in the lower and highest quintiles of deprivation. The average 
prevalence in over 45s varies 4-fold, with the highest values in men in deprived urban areas, 
and the lowest in women in wealthy rural areas. When the effect of ethnicity is also 
considered, the variation in prevalence reaches 7-fold, from 1.7% in Asian women from rural 
areas in the lower quintile of deprivation to 12.5% in black men from urban areas in the 
upper quintile of deprivation.  
8.1.4 Applications & discussion 
We developed a mathematical model that enables the prevalence of COPD to be estimated 
based on information that is easily available to PCTs. The model takes into account the 
increasing prevalence of COPD with age and smoking, and the modifying effect of gender. It 
also considers a higher risk of COPD among those living in urban environments and in areas 
of higher deprivation, and in black ethnicities. 
 
As expected, the risk associated with smoking and former-smoking is higher in men 
compared to women. This may be related to their longer history and intensity of smoking, as 
compared to women. The effects of ethnicity and area of residence are more evident in 
women, among whom deprivation score is not apparently relevant, after other variables are 
considered. Urban environment increases the risk of COPD, possibly through higher air 
pollution levels. Social deprivation may increase the risk of COPD through complex 
mechanisms in addition to the higher prevalence of smoking. This may include different 
smoking habits (the model does not take into account duration and intensity of smoking as 
such information is not readily available), and a higher likelihood of exposure to other risk 
factors, which are not easily measured, such as passive exposure to tobacco smoking, 
history of respiratory infections, and less access to health services and information. Ethnic 
differences in susceptibility are less clear and less well understood, but might involve a 
combination of behavioural, environmental and possibly genetic factors. 
 
We estimated the overall prevalence of COPD in England as 3.1% in people over 15 years old 
and 5.3% in those over 45 years old. The model illustrates the huge inequalities in the 
prevalence of COPD across England, with extreme risks in black men in urban deprived areas 
in one end of the risk spectrum, and Asian women in the lowest deprived rural areas, in the 
opposite end, between whom the risk of COPD varies 7-fold on average. Thus simpler 
models that do not take into account such variations in prevalence across population 
groups, or the extrapolation of national COPD prevalence figures for smaller areas, would be 
inappropriate for local use. 
 
A systematic review of good quality (the criteria included nationally-representative samples) 
COPD prevalence studies using spirometry yielded estimates for developed countries of 
between 4% and 10%.82  All were produced in Europe or North America, and all except one 
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were estimates for the adult population (aged ≥ 16 years),  The 2001 HSfE data was not 
included.  The Health Needs Assessment report suggests a prevalence of 5% for men and 3% 
for women of middle age and upwards.83  Our results are similar to the latter, but not as 
high as suggested by some of the studies used for the former review. The decreasing trend 
in smoking prevalence in England is likely to lead to slow reductions in the real prevalence of 
COPD. However, major causes of variations in estimates include differences in the 
populations and in the diagnostic criteria used. This is illustrated by the finding of a 
prevalence of 13.3% in over 35s in the HSfE survey, when a different definition of COPD was 
used.84 That study also calculated the prevalence directly from the survey data, differently 
from our study, where estimates were extrapolated for the population of England. 
 
The figures estimated by the model for England are in general slightly lower than, but 
comparable with other studies on COPD using the same BTS definition, i.e. 4.5% in 
Norway,85 6.8% in the US86 and 6.8% in white males 40-60 years old in Spain.87 They are also 
similar to the overall prevalence of 6.1% found in the NICECOPD study for Belfast white 
population aged 40 to 69 years.88 The slightly lower estimated prevalence in our study may 
be largely explained by the lower smoking prevalence in England, but also by differences in 
the study populations, and the larger study size of the HSfE. 
 
Comparisons of our results with studies that used other definitions of COPD are difficult to 
interpret. Estimates based on self-reported symptoms tend to overestimate the prevalence. 
This is because diagnostic specificity is reduced as other respiratory diseases may be 
misdiagnosed as COPD, although asymptomatic cases of airflow obstruction will be missed. 
On the other hand, medically diagnosed COPD tends to under-estimate the true prevalence 
of the disease, as diagnostic sensitivity is reduced. Compared to other commonly used COPD 
spirometric-based case definitions of, the BTS is based on quite conservative cut-off points, 
yielding relatively low estimate values.75;82 
 
Prevalence estimates from other sources are often poorly-defined and vary widely 
depending on the age ranges and exact definitions used.  The updated NICE guidance89 
quotes firstly a Healthcare Commission report (“the rate of COPD in the population is 
estimated at between 2% and 4%, representing between 982,000 and 1.96 million people in 
England”) and then Shahab et al (“...it is currently estimated that over 3 million people have 
the disease and that an estimated 2 million have undiagnosed COPD”), although the latter 
report does not estimate overall numbers of cases in England- it estimates national 
prevalence as 13% of over 35 year olds.84  The Consultation on a Strategy for Services for 
COPD states: “Quality and Outcomes Framework (QOF) records (suggest) that 
approximately 5.9% of the English population, around 3 million people, were affected in 
2008”.90  However this is incorrect.  The Information Centre QOF prevalence tables for 2008-
9 show there were 834,312 people on English COPD registers, and quote this as a raw 
prevalence of 1.5% of a GP-registered population of around 54 million.  Appendix 1 of the 
Strategy Impact Assessment gives an estimate of 8.2% to 8.3% of the over 16 population. 
However both the Strategy and Shahab et al use the GOLD definition of FEV1/FVC ratio of 
<0.7 alone.91  This has been criticised as failing to take into account normal decreases in the 
ratio with age.  The new NICE guidance states: “consider alternative diagnoses or 
investigations in: older people without typical symptoms of COPD where the FEV1/FVC ratio 
is < 0.7; younger people with symptoms of COPD where the FEV1/FVC ratio is ≥ 0.7”.89  
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The COPD prevalence model we used is more conservative in that it uses the BTS definition 
i.e. an additional criterion of FEV1<80% predicted for age using British reference values.  It 
estimates prevalence as 3.1% in the population over 15 years of age (similar age range to 
Shahab et al).  Without this second criterion the prevalence is 11.1%.   
 
A key advantage of the COPD model is that it is based on high quality data from a large 
representative sample of the population, and uses standard and specific diagnostic criteria 
for COPD, which is based on lung function rather than symptoms. Response rates were high 
in the survey with the achieved samples matching the target populations closely.92 
Prevalence estimates are based on the strength of association between key risk factors for 
COPD, including the effects of ethnicity, area of residence and deprivation, which were 
shown to be independent risk factors for COPD in the HSfE survey. This represents a 
significant advantage in relation to previous COPD prevalence models,73;74 which were based 
only on smoking status, age and gender (also used in the COPD model) of mostly white 
populations outside the United Kingdom. 
 
The input data are usually readily available at local level. The model uses current smoking 
status (never, former, current) as surrogates for total exposure to cigarette smoke, and is 
therefore not ideal to predict short term effects of changes in smoking prevalence (e.g. 
following intervention), due to long latent periods, large time lag between intervention and 
effects, and irreversibility of disease. However, the model is not static and will be updated 
over time, as parameters' values change, e.g. smoking prevalence (in England there are 
regular estimates of smoking prevalence at sub-regional level). Noteworthy, since intensity 
and duration of smoking (and thus smoking associated risk of COPD) tend to be lower in 
younger populations, the model may slightly overestimate the prevalence in young people. 
 
Another reason for prevalence overestimation in young ages is a possible misclassification 
of cases of asthma into COPD (note reversibility test was not used in the HSfE). We dealt 
with these by providing alternative estimates for the prevalence of COPD, applying baseline 
or nil prevalence rates in all those under 35 and under 40 years old. These brought the 
overall prevalence estimates down by 0.1% to 0.4%. The model also relies on the quality of 
smoking and other data, and does not take into account competing causes of morbidity and 
mortality in the population, e.g. cardiovascular disease and lung cancer, which may affect 
prevalence of COPD. Moreover, it still needs correction for populations with significant 
occupational exposures. 
 
There is some degree of imprecision in the estimates, which are larger when the rates are 
estimated for smaller populations or sub-groups, such as ethnic minorities and specific age-
groups. Therefore we recommend that it is used primarily to derive overall population 
prevalence estimates, rather than estimates within population sub-groups. Further 
validation with a representative sample of the UK population including large proportions of 
people from ethnic minorities is still needed, before it may be reliably used in small 
population groups, such as GP practices and in ethnic minorities. We are currently planning 
to validate the model at practice level in North West London and investigating the feasibility 
of two COPD case-finding strategies. 
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The average QOF-diagnosed prevalence of COPD in England reported in 2004-5 through the 
Quality and Outcomes Framework of the GP Contract was only 1.4%.16 This indicates that 
around 600,000 or nearly half of the 1.3 million COPD cases remain undiagnosed. A 
relatively large number of these individuals live in London or North of England (data not 
shown). Many of such cases will continue their risk behaviours and eventually present to the 
health services at later stages as more severe cases, possibly through emergency hospital 
admissions. Many of them will become high intensity users of health services, with 
considerable costs to individuals, the NHS and society. An audit of 80,000 COPD admissions 
showed that 70% of them are of patients not previously admitted with the condition (Bird 
M, personal communication). 
 
 The COPD model may be freely obtained directly from the authors and is publicly available 
on the Eastern Region Health Observatory website. It may be used, with the qualifications 
stated above, by general practices and PCTs, in England, and indeed in other user defined 
populations in the country and probably in other countries of the UK i.e. Wales, Scotland 
and Northern Ireland. General practices can use their own data on the population 
distribution by age-group and gender, smoking prevalence, ethnicity, degree of urbanisation 
and deprivation score for the area where the practice is located, to obtain indicative figures 
on the prevalence of COPD in their population. Data from the Primary Care Trust where the 
practice is located may be used as a proxy (with any relevant adjustments) in cases where 
practice specific data are not available. In addition it may be valid in Western populations 
that are not too dissimilar from England.  
 
Conclusions 
We believe that compared to previous models and prevalence estimates, the COPD model 
offers the most reliable estimates for England and the United Kingdom. It recognises 
deprivation, urban living and ethnicity as independent risk factors for COPD, which are taken 
into account in the estimates derived, in addition to smoking, age and gender. The model 
gives prevalence estimates for areas of varying sizes, including large populations at local 
level, however, the precision of the estimates will be higher for larger areas. The overall 
prevalence of COPD in England is estimated as 1.3 million, of whom as many as 600,000 
people may be unaware of their diagnosis, therefore missing the opportunity of benefiting 
from early interventions. This emphasises the importance of active case finding and the 
model can be used to identify areas with a high level of unmet needs, i.e. with a high 
proportion of undiagnosed disease, where the benefits of case finding would be optimised. 
This strategy may also have an impact on reducing health inequalities, due to the socio-
economic class gradient in COPD prevalence. The model should be validated, and case-
finding strategies using the model should be evaluated for their cost-effectiveness. 
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8.2 Coronary Heart Disease Model 
8.2.1 Introduction 
CHD is a relatively common condition, for which there are several evidence-based 
treatments that reduce mortality.  The HSfE for 2006 estimates that, based on respondents’ 
self-reports of doctor-diagnosed CHD, the prevalence is about 6.5 per cent in men and 4.0 
per cent in women 93, and this increases markedly with age.  This prevalence has remained 
static over the last ten years.  However the QOF, covering over 8,000 practices and 53 
million patients, shows a GP-registered unadjusted prevalence of only 3.5 per cent 94 (but 
note that unadjusted prevalence rates show these registers as a percentage of the total 
practice list size i.e. for all ages). 
 
The disparity between CHD prevalence estimates from large surveys, in particular the HSfE, 
and the number of patients diagnosed with CHD and registered in QOF led to demand for a 
CHD prevalence model at PCT and Local Authority level that gives an accurate estimate of 
true prevalence. The Association of Public Health Observatories (APHO) published a simple 
prevalence model to support development of 2007-08 Local Delivery Plans (1). However, it 
was acknowledged that this was a crude model and APHO subsequently asked me to 
develop a more robust model. 
 
Defining prevalence 
There are differences between various methods of estimating CHD prevalence.  
Questionnaire responses such as those used in HSfE to define CHD, may be less accurate 
than clinical diagnosis. Conversely, reliance on a medical diagnosis may underestimate 
prevalence, as patients with unrecognised angina or very mild symptoms may not attend (or 
be correctly identified by) their GP. 
 
A Belgian analysis of the records of four large Belgian epidemiological studies during the 
past 30 years compared clinical and electrocardiographic (ECG) findings (see Table 5)95. Q 
wave patterns, ST segment depression or elevation, T wave inversion or flattening, and left 
bundle branch block are often seen as indications of silent myocardial ischaemia.  The 
occurrence of ischaemia-like findings on the ECG  was comparable between men and 
women (9.0% v 9.8%).  The results from this and other studies consistently show that 
ischaemia-like ECG changes are associated with an approximately twofold increased risk of 
dying of CHD. 
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0.51 (0.46 to 0.56) 
for age < 55 years,  











1.00 (0.85 to 1.18) 
for age>55 years 
History of M 0.00 0.60 2.40 6.30% 12.80 3.60% 2.66 (2.20 to 3.22)  
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Source: De Bacquer D, De Backer G, Kornitzer M. Prevalence of ECG findings in large 
population based samples of men and women. Heart 2000 December 1;84(6):625-33. 
 
 In the British Regional Heart Study (BRHS), there was considerable overlap of questionnaire 
and ECG evidence of CHD, and high agreement between self-report and medical record for 
diagnosed CHD: for example, 80 per cent of men with a GP record of angina reported their 
diagnosis, and 70 per cent of men who reported an angina diagnosis had confirmation of 
this from the record review 96;97.  The prevalence of diagnosed angina in 1992 in these older 
men was 10.1 per cent according to self-reported history and 8.9 per cent according to GP 
record review.   
 
Nevertheless, more than half of those in the BRHS with possible myocardial infarction (MI) 
combined with angina had no resting electrocardiographic evidence of CHD, and half of 
those with definite myocardial infarction on electrocardiogram had no history of chest pain 
at any time 98. Only half of those with a definite MI on an electrocardiogram could recall a 
medical diagnosis of CHD 99. Even in patients with severe (grade 2) angina, 40 per cent could 
not recall being told that they had heart disease. Overall, only one in five of those regarded 
as having CHD was able to recall such a diagnosis having been made by a doctor, and these 
were likely to be those most severely affected.  
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However there was substantial agreement between self-report and GP record of angina. 
The BRHS subsequently combined two questionnaire-based definitions to define 
prevalence: either current angina symptoms, which were defined as a positive response to 
standard World Health Organization (Rose) questionnaires (overall prevalence 11.1 per 
cent); or history of diagnosed CHD was defined as subject recall of ever having had a 
doctor's diagnosis of either angina or heart attack (overall prevalence also 11.1 per cent) 100. 
 
The HSfE, however, uses only the latter questionnaire definition in its prevalence estimates.  
Trends in prevalence are shown in Table 6.  These are not dissimilar to the BRHS given the 















M F M F M F M F M F M F 
16-24 - 0.2 0.1 - - 0.2 0.2 0.1 - 0.3 0.1 0.1 
25-34 0.3 0.1 0.4 0.3 - - 0.2 0.2 - - 0.2 0.1 
35-44 0.5 0.3 0.9 0.6 0.9 0.4 0.7 0.3 1.0 0.5 0.6 0.3 
45-54 3.0 2.3 4.3 1.8 3.5 2.0 3.7 1.3 3.4 1.9 3.6 1.3 
55-64 10.3 5.9 13.6 6.3 11.1 5.9 10.7 3.4 11.1 5.8 10.6 3.5 
65-74 21.0 10.5 20.2 12.5 21.5 9.7 20.6 10.2 21.6 9.7 20.8 10.0 
75+ 22.7 15.9 23.4 18.4 26.4 18.4 28.5 19.3 26.5 18.1 28.4 19.3 
All  6.0 4.1 7.1 4.6 7.4 4.5 6.2 3.0 6.4 4.1 6.5 4.0 
 
Source: HSfE, Information Centre 
Other prevalence surveys 
While CHD mortality has greatly declined in the last four decades, the use of age-adjusted 
rates to describe CHD mortality obscures the fact that the decline largely represents the 
postponement of CHD deaths until older age. In fact, the overall burden of CHD is increasing 
in parallel with the increase in life expectancy.  As the burden of prevalent CHD is increasing, 
identifying persons with CHD, measuring its incidence and outcome and how these vary over 
time and across populations is essential to understand the determinants of the trends in 
CHD. This in turn is crucial to define the relative contributions of risk factor reduction and 
therapeutic improvements, which is necessary to design effective interventions to reduce 
CHD. 
 
I undertook a literature search for recent (post-1996) CHD prevalence surveys.  I included 
only articles in English, which covered groups represented in the UK population in significant 
numbers.  We also excluded surveys which covered CHD risk factor prevalence, or which 
sampled only sub-populations e.g. those with diabetes. 
 
Community surveillance is a comprehensive approach designed to track disease at the 
community level, and is less costly and more efficient than cohort studies. In the USA, 
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several community surveillance studies have reported on temporal trends in CHD 
prevalence e.g. the Atherosclerosis Risk in Communities study, the Minnesota Heart Survey 
the Olmsted County Study, and the Worcester Heart Attack Study 101. An analysis of US 
NHANES data on participants aged ≥ 40 years who attended the medical examination, the 
age-adjusted prevalence of angina pectoris, self-reported myocardial infarction, and ECG-
defined myocardial infarction were 5.8% of 9255, 6.7% of 9250, and 3.0% of 8206 
participants, respectively 102.  The age-adjusted prevalence of coronary heart disease 
defined by the presence of any of these conditions was 13.9% among men and 10.1% 
among women.  These studies suggested that in the US medical care of clinical CHD was the 
main contributor  to the mortality decline 103.   
 
Outside the USA, the World Health Organization (WHO) MONICA (Multinational MONItoring 
of trends and determinants in CArdiovascular disease) Project was established in the early 
1980s to monitor trends in cardiovascular diseases and to relate these to risk factor changes. 
Its central goal was to explain the trends in cardiovascular disease mortality observed from 
the 1970s. There were 32 MONICA centres in 21 countries.  In these populations, the decline 
in coronary disease mortality is mostly related to the decline in CHD events, thereby 
pointing to primary prevention as the main source 104.  However the study populations 
excluded over 65s in whom most CHD occurs. 
 
In a survey of a rural Indian population, CHD was diagnosed based on past documentation, 
response to WHO-Rose questionnaire, or changes in ECG. The prevalence of CHD (clinical + 
ECG criteria) was 3.4% in males and 3.7% in females. According to ECG criteria only, it was 
2.8% in males and 3.3% in females and according to Q-waves only, it was 1.6% in males and 
0.9% in females 105.  In a Finnish population survey Ahto et al found the prevalence of angina 
symptoms was 9.1% among men and 4.9% among women aged 64-97 106.  Ischaemic ECG 
findings were common: 32.9% of men and 39.3% of women had such changes.  An 
international systematic review and meta-analysis found that angina prevalence varied 
widely across populations, from 0.73% to 14.4% (population weighted mean 6.7%) in women 
and from 0.76% to 15.1% (population weighted mean 5.7%) in men 107. 
 
In the UK, Carroll et al used GP records in London and found a prevalence of 8 per cent of 
men and 5 per cent of women over 44 years of age- although this may be lower than the 
true national average 108. There was a history of myocardial infarction in 30 per cent of men 
and 22 per cent of women with CHD.  Lampe and colleagues examined trends in the 
prevalence of CHD in men participating in the BRHS 100.  The authors demonstrated a 
decrease in the prevalence of current angina symptoms: the age adjusted annual 
percentage change in odds was -1.8%. However, there was no evidence of a trend in the 
prevalence of history of diagnosed CHD. 
 
A study by Davies et al examined trends in CHD incidence, prevalence, and mortality in the 
UK between 1996 and 2005, using the THIN GP database (a total of 5 million patients).  The 
results indicate that, while CHD mortality declined, CHD incidence decreased less than 
mortality, resulting in an increase in CHD prevalence 109. From 1996 to 2005, age-
standardized incidence of CHD decreased by 2.2% in men and 2.3% in women per year 
(average percentage change).  Age-standardized all-cause mortality among those with CHD 
decreased by 4.5% in men and 3.4% in women per year (average percentage change). Age-
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standardized prevalence increased by 1.3% in men and 1.7% in women per year (average 
percentage change). The decline in incidence had some impact on limiting the increase in 
prevalence, but its effect was offset by the increase in prevalence occurring as a result of 
improved survival among people with CHD.  Although patients with nitrate prescriptions 
were also included, this study relied mainly on CHD diagnostic codes which may 
underestimate actual prevalence. 
 
Previous CHD prevalence modelling 
An epidemiologic CHD prevalence model was first developed in the UK to assist case-finding 
in Sheffield PCTs.  Subsequently, English PCTs were required to set targets for CHD case-
finding in their 2007-8 Local Delivery Plans negotiated with strategic health authorities.  To 
assist them, a simple PCT-based prevalence model was developed rapidly by the APHO.  
Stage 1 of the modelling predicts the number of people with identified CHD within each 
population, taking account only of the demographic distribution of the population.  The 
prevalence of patient-reported doctor-diagnosed CHD in each age/sex stratum is based on 
national data from the HSfE.  Stage 2 takes account of deprivation levels in different PCTs in 
England. In the absence of sufficiently precise published data on the relationship between 
deprivation and CHD prevalence, the model makes the assumption that areas with higher 
CHD mortality rates have comparably higher prevalence of CHD. Using data for all local 
authorities in England, a linear relationship  was calculated between 2002-04 SMRs for CHD 
and a deprivation score (UV67) derived from the 2001 Census Classification of Deprivation: 
 
CHD SMR = (2.604 × UV67) + 25.97 
 
Using UV67 scores calculated for each PCT, the above formula gives a multiplying factor for 
each PCT. For example, a PCT with a UV67 score of 40% (very deprived) has a multiplying 
factor of 1.3. 
 
APHO accepts that this current model is rather crude, and that a prevalence model based on 
a comprehensive regression model using HSfE data would be more robust.  This model was 
commissioned by APHO from the Department of Primary Care & Public Health (PCPH) 
Imperial College London. 
 
Congdon has also produced a CHD prevalence model using earlier HSfE data 44.  Data from 
the 1999 and 2003 HSfEs were used to provide model based rates of CHD prevalence by age, 
sex, ethnic group, region, and area deprivation category.  To take into account the effect of 
socio-economic factors, the HSfE model gradient over deprivation quintiles was applied to 
scale area prevalence estimates specific for age, sex and ethnicity.  The final stage of the 
prevalence estimation procedure incorporated proxy information from mortality. To adjust 
the HSfE-based prevalence rates to take account of interdependence of area mortality and 
prevalence, prevalence and mortality were taken as joint (i.e. correlated) outcomes in a 
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The HSfE was used as the data source, and the outcome of interest was patient-reported 
doctor-diagnosed CHD (called IHD in HSfE), which is the variable used for CHD prevalence in 
HSfE.  It was also chosen because, based on previous research, it appears to be the best 
single proxy for true prevalence.  (An alternative would be to combine patient-reported 
doctor-diagnosed CHD with a positive Rose angina questionnaire as in BRHS.) 
 
Because ethnicity is a known CHD risk factor, it was necessary to use a sample containing 
data from a large number of ethnic minority respondents.  The HSfE 2004 was the last 
survey to include an ethnic minority boost, and the boost sample was used for the 
modelling.  However, there were relatively small numbers of whites in the HSfE 2004 
sample, and they were not asked to respond to many questions, including those on CHD, 
presumably to save resources for the boost itself.  The HSfE 2004 boost sample was 
therefore merged with the HSfE 2003, which was the year with the largest number of 
identical variables.   
 
Table 7 shows the numbers of respondents in the original HSfE 2004 ethnic boost, and the 
number in the merged 2003-2004 dataset used for the model where a response for the CHD 
outcome variable was obtained.  Note that it was necessary to collapse two of the HSfE 
2003 ethnic group variables  to use the same classification as HSfE 2004. 
Table 7: Ethnic Group Breakdown of HSfE 2004 Dataset & Merged 2003-2004 Dataset 
Ethnic Group 
HSfE 2004 Merged 2003-4 Dataset 
Freq. Percent Cum. Freq. Percent Cum. 
No answer/refused  21 0.21 0.21 16 0.08 0.08 
Don't know  3 0.03 0.24 2 0.01 0.08 
White  1,597 15.79 16.03 14,575 68.58 68.67 
Mixed ethnic group  623 6.16 22.19 308 1.45 70.12 
Black or Black British  2,468 24.40 46.59 1,991 9.37 79.48 
Asian or Asian British  4,764 47.10 93.69 3,725 17.53 97.01 
Any other group  638 6.31 100.00 635 2.99 100.00 
Total  10,114 100.00  21,252 100.00  
(Note that there were 34 missing values.) 
 
Model construction: data issues 
The choice of variables for original inclusion in the merged dataset included all those known 
to be CHD risk factors.  The variable names and labels are shown in Table 3 below.  The HSfE 
dataset has a nested or hierarchical structure so three variables related to the sampling 
strata were included: area (sample point), cluster (stratification level), and hserial (serial 
number of household).  These were used in the model to adjust for clustering of 
respondents. In the analysis variables cholest and hdlchol were combined to give a lipid 
ratio. 
 
The bandings of Index of Multiple Deprivation 2004 scores were slightly different between 
the two years, but raw scores were not provided in the dataset so it was necessary to 
assume that the banding were the same (see Table 8 : Index of Multiple Deprivation 
Banding below). 
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The Stata10 software package was used for analysis.  All variables were re-coded to drop 
negative values for estimation purposes (in HSfE various non-response categories are 
assigned negative values).  The methodology applied was multinomial logistic regression 
with the “cluster” adjustment option for households (see above). For analysis of two 
categories as here, multinomial logistic regression is reduced to binomial logistic regression. 
However the reason for not using other logistic regression routines that take into account 
nested structures is that the other options available in Stata produced an estimation error, 
probably because of the small percentage of disease-positive respondents in the sample. 











HSfE 2003 HSfE 2004 
least 1 0.59-8.35  0.55-9.02 3,803 17.87 17.87 
 2 8.35-13.72 9.03-14.14 3,573 16.79 34.65 
 3 13.72-21.16 14.15-21.17 3,788 17.8 52.45 
 4 21.16-34.21 21.18-33.52 4,551 21.38 73.83 
most 5 34.21-86.36 33.53-85.69 5,571 26.17 100 
   Total 21,286 100   
 
The Stata software package was used for analysis.  As for the CHD model the methodology 
applied was  multinomial logistic regression with the “cluster” option (see above).  As 
previously the prevalence in each age group, gender, ethnic group, area of residence and 
level of deprivation, and smoking status category were derived from the odds, using the 
formula: prevalence = odds/(1 + odds). 
 
Model construction: interactions between variables 
Effect modification or interaction occurs if the effect of one exposure or risk factor on the 
outcome varies according to the level of another risk factor.  This can be tested using a χ2 
test of heterogeneity e.g. Mantel-Haenszel odds ratios, Wald or likelihood tests, or by 
introducing interaction terms or parameters into the regression model.  These allow the 
effect of one variable to be different in different categories of other variables.  In Stata, the 
xi command expands terms containing categorical variables into indicator (also called 
dummy) variable sets by creating new variables and estimates interactions and main effects. 
 
An initial examination for interactions was carried out using Mantel-Haenszel odds ratios, 
Wald and likelihood ratio tests.  Where these reached significance interaction terms were 
created as indicator variables in a regression model.  None of the interaction terms tested in 
this way showed consistent statistical significance.  The inclusion of interaction terms in the 
model was therefore rejected. 
 
Model construction: internal validation 
Ideally the best prediction should result from utilising the most risk factor information in the 
regression model.  However, only a limited range of HSfE variable data is either available or 
can be estimated at the PCT or LA level, so there is no purpose in including other variables 
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(see Table 9).  We decided to validate the local model by comparing it, in terms of 
prediction, to a model including all available and significant HSfE variables.  In addition, 
however, the amount of missing data affects the prediction of a model.  In the complete 
HSfE variables the largest proportion of missing data occurred in those variables related to 
drug treatment for high blood pressure.  We therefore excluded these variables in a second 
version of the model.  Hence the model COMP 1 included the “complete” list of variables, 
including BP drugs; model COMP 2 included the “complete” list of variables, but excluded BP 
drugs. 
8.2.3 Results 
LOCAL only used locally available data.  I included smoking and BMI variables on the basis 
that local synthetic estimates are now available.  Local GHQ-12 or Limiting Longstanding 
Illness score data will be available locally from 2009 and could be included later. 
Table 9: Variables Included in Merged Dataset 
COMP 1 = “Complete” variables with BP drugs 
COMP 2 = “Complete” variables without BP drugs 
LOCAL= only using locally available data 
Name Label COMP 1 COMP 2 LOCAL 
ihdis had IHD (angina or heart attack) X X X 
aceinh ace inhibitors (blood pressure) X   
addnum address number N/A N/A N/A 
adtot30 adults: total days/4 weeks active 30 mins + moderate + X X  
age age last birthday X X X 
area sample point N/A N/A N/A 
beta beta blockers (blood pressure) X   
bmival valid body mass index X X X 
calciumb calcium blockers (blood pressure) X   
cholest total cholesterol result (blood data) X X  
cigst1 cigarette smoking status - never/ex-reg/ex-occ/current X X X 
cluster stratification level N/A N/A N/A 
diabete2 doctor diagnosed diabetes (excluding pregnant) X X  
diur diuretics (blood pressure) X   
ethnici ethnic group X X  
famcvd family history of cvd X X  
fatvala fat score X X  
fldlchol LDL cholesterol result (fasting blood data) X X  
ftrigl triglycerides result (fasting) X X  
ghq12scr General Health Questionnaire score- 12 point scale X X  
glucval glucose result (fasting) X X  
hdlchol HDL cholesterol result (blood data) X X  
hserial serial number of household N/A N/A N/A 
imd2004 index of multiple deprivation (SOA level) X X X 
limitill limiting longstanding illness X X  
nssec8 National Statistics Socioeconomic Class (8 variable) X X  
obpdrug other drugs affecting BP X   
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Name Label COMP 1 COMP 2 LOCAL 
omdiaval omron valid mean diastolic BP X X  
omsysval omron valid mean systolic BP X X  
porftvg 
grouped portions of fruit (inc.orange juice) & veg 
yesterday 
X X  
roseanmi angina or MI (Rose angina questionnaire) N/A N/A N/A 
sex sex X X X 
topqual3 highest educational level X X  
 
The prediction of the three models was assessed in two ways: 
 by generating a receiver operating characteristics (ROC) curve using the predicted 
probabilities of the CHD outcome compared to the observed cases 
 by deriving predicted probabilities of the CHD outcome in Stata from the three 
models, and comparing these to the observed cases 
 
Model construction: external validation 
An early external validation will be carried out by examining the association between 
PCT/LA level CHD prevalence estimates and QOF registered prevalence.  The regression-
based model will also be validated against a prevalence model obtained by Bayesian 
strategies using WinBUGS.  Finally, funding will be sought to undertake a validation of 
practice-based prevalence estimates against registered prevalence supplemented by active 
case finding.  Table 10 shows the frequency of the CHD outcome by age group in the 
merged dataset. 
Table 10: Respondents Reporting Doctor Diagnosed CHD by Age Band 
 
 
Age Band  
16-24 25-34 35-44 45-54 55-64 65-74 75+ Total 
Don't know 0 0 0 0 0 1 2 3 
Yes 2 6 43 97 262 350 344 1,104 
No 2,500 3,855 4,409 3,379 2,792 1,928 1,316 20,179 
Total 2,502 3,861 4,452 3,476 3,054 2,279 1,662 21,286 
 
Local model 
The regression model for risk factors for CHD in the “local” prevalence model is shown in 
Table 11.  As expected ORs increase strikingly with increasing age in all models.  In the 
prevalence predictions using coefficients (not shown in these tables) this results in age-
related increases in prevalence which closely match the crude overall prevalence in Table 6.  
Surprisingly the only significant comparison for smoking is for category 3 “used to smoke 
regularly” i.e. this group is more likely to report CHD compared to the group “never smoked 
cigarettes at all”. There is a significant comparison for male sex.  ORs, p values and 
confidence intervals are generally similar to the “Complete” models.  Unfortunately, 
however, local synthetic estimates of smoking prevalence do not include categories for 
occasional/regular smokers. 
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Table 11: Odds Ratios for LOCAL, Model With Only Locally Available Variables 







Age 25-34 1.000      
Age 35-44 6.867 2.998 4.41 0 2.919 16.157 
Age 45-54 19.514 8.217 7.06 0 8.549 44.541 
Age 55-64 65.698 27.217 10.1 0 29.169 147.972 
Age 65-74 122.864 50.719 11.65 0 54.707 275.936 
Age 75+ 191.252 79.128 12.7 0 85.003 430.307 
Female sex 1.000      
Male sex 1.849 0.139 8.16 0 1.595 2.143 
Never smoker 1.000      
Used to smoke occasionally 0.757 0.131 -1.61 0.107 0.539 1.062 
Used to smoke regularly 1.484 0.119 4.91 0 1.267 1.737 
Current smoker 1.072 0.109 0.68 0.495 0.878 1.308 
Index of multiple deprivation    0.59-
8.35 1.000      
Index of multiple deprivation 8.35-
13.72 1.226 0.143 1.75 0.08 0.976 1.541 
Index of multiple deprivation 13.73-
21.16 1.350 0.154 2.63 0.009 1.079 1.689 
Index of multiple deprivation 21.17-
34.21 1.645 0.183 4.49 0 1.323 2.044 
Index of multiple deprivation 34.22-
86.36 2.420 0.256 8.36 0 1.967 2.978 
White 1.000      
Mixed 1.264 0.851 0.35 0.727 0.338 4.726 
Black/BB 0.763 0.168 -1.23 0.218 0.496 1.173 
Asian/AO 1.511 0.243 2.56 0.01 1.102 2.071 
Other 0.168 0.170 -1.76 0.079 0.023 1.227 
 
I examined the data for interactions between variables e.g. if there is an interaction 
between sex and ethnicity, there will be two separate effects of ethnicity on CHD: one for 
males and another for females.  We tested for interactions between local variables initially 
using Mantel-Haenszel odds ratios, and likelihood ratio and Wald tests.  These indicated a 
possible interaction between sex and ethnicity.  However a regression analysis showed 
significance for only one sex-ethnicity indicator level.  We therefore decided not to include 
an interaction variable in the model. 
  
Complete model excluding treatment for hypertension 
The regression model for risk factors for CHD in the “Complete” model excluding 
hypertension  either systolic or diastolic BPs or treatment for hypertension) is shown in 
Table 12.  This shows well the impact of additional variables on ORs for “local” variables.  
BMI is now recognised as an independent risk factor for CVD (although its effect is mediated 
largely through changes in “physiological” risk factors such as cholesterol: high density 
lipoprotein (HDL) ratio 110-112).  Although an expected higher OR is found in underweight 
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patients, this is not the case for overweight/obese categories.  This may be because this is 
cross-sectional rather than longitudinal data and that the prevalence of obesity in older age 
groups, where CHD is more common, is very low.  The regression model for risk factors for 
CHD in the “complete” model without BP drugs is shown in Table 13.  















CHD 12 187 386 268 251 1,104 
No CHD 306 6,693 6,502 3,483 3,194 20,178 
Total 318 6,880 6,888 3,751 3,445 21,282 




Error z P>z 
[95% 
Conf. Interval] 
Age 25-34 1.000      
Age 35-44 7.131 6.891 2.03 0.042 1.073 47.396 
Age 45-54 18.447 17.436 3.08 0.002 2.893 117.624 
Age 55-64 50.099 46.710 4.2 0 8.058 311.490 
Age 65-74 121.219 112.515 5.17 0 19.655 747.578 
Age 75+ 216.341 200.711 5.8 0 35.111 1333.034 
Female sex 1.000      
Male sex 2.258 0.320 5.74 0 1.710 2.981 
Never smoker 1.000      
Used to smoke occasionally 1.039 0.320 0.13 0.9 0.569 1.900 
Used to smoke regularly 1.512 0.238 2.63 0.009 1.111 2.057 
Current smoker 1.114 0.232 0.52 0.604 0.740 1.676 
Index of multiple deprivation    
0.59->8.35 1.000      
Index of multiple deprivation 8.35-
13.72 1.215 0.241 0.98 0.325 0.824 1.791 
Index of multiple deprivation 
13.73-21.16 1.025 0.217 0.12 0.907 0.677 1.551 
Index of multiple deprivation 
21.17-34.21 1.101 0.230 0.46 0.646 0.730 1.659 
Index of multiple deprivation 
34.22-86.36 1.424 0.323 1.56 0.119 0.913 2.219 
White ethnic group 1.000      
Mixed ethnic group 0.208 0.144 -2.26 0.024 0.054 0.810 
Black or Black British ethnic group 0.831 0.355 -0.43 0.666 0.360 1.922 
Asian or Asian British ethnic group 1.553 0.436 1.57 0.117 0.896 2.693 
Any other ethnic group 1.049 0.665 0.08 0.939 0.303 3.631 
BMI <18.51 1.000      
BMI >18.50 & <25 0.538 0.568 -0.59 0.557 0.068 4.268 
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Error z P>z 
[95% 
Conf. Interval] 
BMI >25 & BMI <30 0.890 0.936 -0.11 0.912 0.113 6.984 
BMI >30 & BMI <40 1.026 1.085 0.02 0.98 0.129 8.143 
BMI >40 0.693 0.734 -0.35 0.729 0.087 5.515 
Total cholesterol:HDL ratio 0.748 0.049 -4.44 0 0.658 0.850 
Diabetes; no 1.000      
Diabetes; yes 0.686 0.144 -1.8 0.072 0.455 1.035 
Family History of CVD; yes 1.000      
Family History of CVD; no 0.622 0.103 -2.87 0.004 0.450 0.860 
Limiting longstanding illness 1.000      
Non limiting longstanding illness 0.625 0.102 -2.89 0.004 0.454 0.859 
No limiting longstanding illness 0.318 0.058 -6.24 0 0.222 0.456 
Rose questionnaire: angina and MI 1.000      
Rose questionnaire: neither 
angina MI 0.007 0.004 -9.06 0 0.002 0.021 
Rose questionnaire: angina, but 
not MI 0.074 0.044 -4.36 0 0.023 0.239 
Rose questionnaire: MI, but not 
angina 0.174 0.096 -3.16 0.002 0.059 0.514 
Top qualification 
nvq4/nvq5/degree 1.000      
Top qualification higher ed below 
degree 1.479 0.428 1.35 0.176 0.839 2.607 
Top qualification nvq3/gce a level 
equiv 1.122 0.407 0.32 0.751 0.551 2.283 
Top qualification nvq2/gce o level 
equiv 1.227 0.334 0.75 0.453 0.719 2.092 
Top qualification nvq1/cse other 
grade equiv 1.443 0.504 1.05 0.294 0.728 2.861 
Top qualification foreign/other 0.875 0.305 -0.38 0.701 0.442 1.732 
Top qualification no qualification 1.458 0.355 1.55 0.121 0.905 2.349 
 
Complete model including treatment for hypertension 
The regression model for risk factors for CHD in the “complete” model with BP drugs is 
shown in Table 14.  Hypertension is a well-established risk factor, so it is desirable to include 
variables related to it in a “complete” model.  Treatment with ACE inhibitors, beta blockers 
and calcium blockers are highly significant.  However these may also be used to treat 
established CHD, so the association may be unrelated to hypertension.  In addition, the HSfE 
relies upon patient recall for drug treatment.  Not unexpectedly, much of the data for these 
variables is missing.  I added systolic and diastolic BP as ordinal variables to the model, but 
this resulted in major changes to ORs for other variables.  This may simply be related to 
model instability because of the large numbers of variables included.  The addition of a 
single variable for hypertension, either treated or untreated, will be explored as a further 
later step in model development. 
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Age 25-34 1.000      
Age 35-44 3.975 3.522 1.56 0.119 0.700 22.566 
Age 45-54 8.606 7.259 2.55 0.011 1.647 44.959 
Age 55-64 18.559 15.529 3.49 0 3.600 95.676 
Age 65-74 




61.082 50.587 4.97 0 12.050 
309.64
3 
Female sex 1.000      
Male sex 2.273 0.360 5.18 0 1.666 3.101 
Never smoker 1.000      
Used to smoke occasionally 0.989 0.342 -0.03 0.975 0.502 1.948 
Used to smoke regularly 1.450 0.246 2.18 0.029 1.039 2.023 
Current smoker 1.201 0.278 0.79 0.43 0.762 1.892 
Index of multiple deprivation    0.59-
>8.35 1.000      
Index of multiple deprivation 8.35-13.72 1.214 0.273 0.86 0.39 0.781 1.887 
Index of multiple deprivation 13.73-
21.16 1.033 0.248 0.13 0.893 0.645 1.653 
Index of multiple deprivation 21.17-
34.21 1.174 0.270 0.7 0.485 0.748 1.843 
Index of multiple deprivation 34.22-
86.36 1.394 0.366 1.26 0.206 0.833 2.331 
White ethnic group       
Mixed ethnic group 0.353 0.240 -1.53 0.125 0.093 1.336 
Black or Black British ethnic group 0.304 0.169 -2.14 0.032 0.102 0.902 
Asian or Asian British ethnic group 1.316 0.391 0.92 0.356 0.734 2.357 
Any other ethnic group 0.894 0.816 -0.12 0.902 0.149 5.345 
BMI <18.51 1.000      
BMI >18.50 & <25 0.435 0.441 -0.82 0.411 0.060 3.171 
BMI >25 & BMI <30 0.588 0.591 -0.53 0.597 0.082 4.218 
BMI >30 & BMI <40 0.680 0.689 -0.38 0.704 0.093 4.954 
BMI >40 0.519 0.525 -0.65 0.517 0.072 3.763 
Total cholesterol:HDL ratio 0.742 0.053 -4.14 0 0.644 0.854 
Diabetes; no 1.000      
Diabetes; yes 1.034 0.250 0.14 0.888 0.645 1.660 
Family History of CVD; yes 1.000      
Family History of CVD; no 0.630 0.115 -2.54 0.011 0.441 0.900 
Limiting longstanding illness 1.000      
Non limiting longstanding illness 0.592 0.102 -3.05 0.002 0.422 0.829 
No limiting longstanding illness 0.578 0.128 -2.48 0.013 0.375 0.892 
Rose questionnaire: angina and MI 1.000      
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Rose questionnaire: neither angina MI 0.007 0.004 -8.49 0 0.002 0.022 
Rose questionnaire: angina, but not MI 0.063 0.039 -4.4 0 0.018 0.215 
Rose questionnaire: MI, but not angina 0.182 0.107 -2.91 0.004 0.058 0.574 
Top qualification nvq4/nvq5/degree 1.000      
Top qualification higher ed below 
degree 1.655 0.549 1.52 0.129 0.864 3.173 
Top qualification nvq3/gce a level equiv 1.396 0.593 0.79 0.432 0.607 3.211 
Top qualification nvq2/gce o level equiv 1.510 0.457 1.36 0.173 0.834 2.733 
Top qualification nvq1/cse other grade 
equiv 1.768 0.665 1.52 0.129 0.847 3.694 
Top qualification foreign/other 0.922 0.371 -0.2 0.84 0.419 2.031 
Top qualification no qualification 1.496 0.408 1.48 0.14 0.876 2.553 
ACE inhibitor: no 1.000      
ACE inhibitor: yes 1.875 0.335 3.52 0 1.321 2.661 
Beta blocker: no 1.000      
Beta blocker: yes 3.467 0.570 7.57 0 2.512 4.785 
Calcium blocker: no 1.000      
Calcium blocker: yes 2.735 0.468 5.88 0 1.956 3.825 
Diuretic: no 1.000      
Diuretic: yes 0.832 0.140 -1.09 0.276 0.598 1.158 
Other BP drug: no 1.000      
Other BP drug: yes 0.869 0.279 -0.44 0.662 0.463 1.631 
  
Internal validation: area under Receiver Operating Characteristics curve (AUROC) 
ROC analysis was originally developed during World War II to analyse classification accuracy 
in differentiating signal from noise in radar detection. Recently, the methodology has been 
adapted to several clinical areas heavily dependent on screening and diagnostic tests, in 
particular, laboratory testing, epidemiology, radiology, and bioinformatics 113;114.  ROC 
analysis is a useful tool for evaluating the performance of diagnostic tests and more 
generally for evaluating the accuracy of a statistical model (e.g. logistic regression, linear 
discriminant analysis) that classifies subjects into one of two categories, diseased or non-
diseased, as in this model 115. Its function as a simple graphical tool for displaying the 
accuracy of a medical diagnostic test is one of the most well-known applications of ROC 
curve analysis. 
 
An ROC curve is a plot of sensitivity on the y axis against (1-specificity) on the x axis for 
varying values of the threshold, t. The 45° diagonal line connecting (0,0) to (1,1) is the ROC 
curve corresponding to random chance. The ROC curve for the gold standard is the line 
connecting (0,0) to (0,1) and (0,1) to (1,1). Generally, ROC curves lie between these two 
extremes. The area under the ROC curve is a summary measure that essentially averages 
diagnostic accuracy across the spectrum of test values.  The area under the curve is an 
overall summary of diagnostic accuracy. AUC equals 0.5 when the ROC curve corresponds to 
random chance and 1.0 for perfect accuracy. On rare occasions, the estimated AUC is <0.5, 
indicating that the test does worse than chance. 
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AUROCs for the three models tested above were estimated using Stata10.  These are shown 
in Figure 1.  If both sensitivity and specificity are of importance in a CHD model, the optimal 
threshold of t would be 0.75, where sensitivity and specificity equal 0.77.  The local model 
exceeds this level, although the two more complete models have even better performance.   
Figure 1: Comparison of AUROC for different CHD prevalence models 
 
Validation: model prediction 
Another method of assessing performance is to use the regression model to predict the 
response for each subject.  These predictions are called fitted values.  The difference 
between the fitted and the observed values are called residuals.  These can then be 
tabulated against the observed presence of CHD to assess “misclassification” by each model.  
The results for the three models are shown in Table 15: Comparison of predictions by 
model. 




Model No CHD CHD Total 
Local No CHD 17,614 3 17,617 
 CHD 1,098 1 1,099 
 Total 18,712 4 18,716 
 Complete, no BP drugs No CHD 3,879 64 3,943 
 CHD 1 230 219 
 Total 4,109 283 4,392 
Complete No CHD 3,883 60 3,943 
 CHD 203 246 449 
 Total 4,086 306 4,392 
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8.2.4 Application: PCT, LA and practice level models 
The local model (which includes only those variables that are available at population level 
i.e. age, sex, ethnicity, smoking status and deprivation score) has been applied to Local 
Authorities to create prevalence estimates of hypertension in those aged 16+ for 2005–
2020. Models for PCTs have been created for 2006-2020, along with practice level estimates 
for 2007.116 
 
Assumptions of the modelled estimates 
It is assumed that:  
 the proportion of smokers, ex-smokers and never-smokers is the same across ethnic 
groups. 
 the proportion of ex-smokers in each age-sex group is the same in all areas.  
 the smoking prevalence rates from the model-based estimates of lifestyle behaviours 
are reliable. 
 the prevalence of CHD in those aged 16-24 is negligible. 
Due to lack of data, it was not possible to treat ex-regular-smokers and ex-occasional-
smokers separately. Ex-occasional-smokers are treated as non-smokers. 
 
Populations 
The CHD prevalence model uses ONS 2005 mid-year LA population estimates by ethnic 
group, age and sex. The Office for National Statistics (ONS) publishes the data by broad age 
band, but supplied full quinary age-band data to APHO for the prevalence modelling project. 
Five ethnic groups were used: white, black, Asian, mixed and other.  The model uses ONS 
2006 mid-year PCT population estimates by ethnic group, age and sex. ONS publishes the 
data by broad age band, but supplied full quinary age-band data to APHO for the prevalence 
modelling project. Five ethnic groups were used: white, black, Asian, mixed and other. 
 
In order to calculate estimate prevalence of CHD in the future, population projections were 
incorporated into the model. ONS has not published population projections by ethnic group, 
so the 2005 (LA) or 2006 (PCT) distribution of ethnic groups was used to generate 
population estimates to 2020.  For 2006 and 2007, LA population projections the 
distribution of ethnic groups in 2005 was applied to ONS mid-year population estimates by 
quinary age band. For 2007 PCT population projections, the distribution of ethnic groups in 
2006 was applied to ONS mid-year population estimates by quinary age band.  For 2008 and 
2009, the distribution of ethnic groups in 2005 (LA) or 2006 (PCT) was applied to ONS 2006-
based population projections by quinary age band for LAs and PCTs.  For 2010, 2015 and 
2020 the distribution of ethnic groups in 2005 (LA) or 2006 (PCT) was lagged by 5, 10 and 15 
years respectively and combined with ONS 2006-based population projections by quinary 
age band for LAs and PCTs. For example, the ethnic proportions for the age band 40-45 in 
2005 were applied to the population aged 50-55 in 2015. With the exception of this ‘ageing’ 
of the ethnic population, no other changes to the distribution of ethnic groups were 
considered. 
 
Practice populations by age and sex were derived from a National Strategic Tracing Service 
(NSTS) extract taken on 31/03/2007. Patients with date of death before 31/03/07 were 
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excluded.  to improve the data quality GP codes were re-mapped to practices using NSTS 
files of February 2007 (available from the NHS Organisation Data Service). Some practices 
have missing PCT and SHA codes in the Feb 07 NSTS files, so these were populated using the 
May 07 NSTS files.  Practices with a population of <1000 patients are excluded from 
modelling due to the uncertainty associated with such small numbers. 
Ethnicity 
The proportion of practice population in ethnic groups was supplied by the Care Quality 
Commission (CQC).  The proportions were derived from HES admissions in 2005/06-
2006/07, excluding mental health and maternity admissions and records with unknown 
ethnicity. HES is the only routine dataset which includes GP practice and patient ethnicity, 
and has high levels of completion and data quality. It is assumed that the hospital 
admissions (excluding maternity and mental health) reflect the true ethnic population of the 
practice and there is no systematic bias. The proportions by ethnic group for each practice 
were calculated by dividing admissions within each ethnic category by the total admissions 
for the practice. The same ethnic distribution is applied across all age bands as there are 
insufficient hospital admissions to robustly calculate the distribution of ethnic groups by age 
and sex for practices. 
Smoking status 
National (England) proportions of smokers, ex-smokers and current smokers by age and sex 
are taken from HSfE (2003-2005 pooled, see Figure 2). These proportions were then 
adjusted for each LA/PCT using the synthetic estimates of smoking prevalence for 2003-
2005, using the following algorithm. 
 
Local proportion of smokers in age-sex category = national prevalence of smoking in 
age-sex category * local overall smoking prevalence / national overall smoking 
prevalence 




Local proportion of ex-smokers in age-sex category is not adjusted 
          
Local proportion of never-smokers in age-sex category = 1 – proportion of ex-
smokers in age-sex category – local proportion of smokers in age-sex category 
                 
Where: 
S = proportion of population who are smokers 
E = proportion of population who are ex-regular-smokers 
N = proportion of population who have never smoked 
l = local 
n = national 
as = by age and sex 
 
This approach assumes that the proportion of ex-smokers in each age-sex category is fixed 
and the number of never-smokers increases as the number of smokers decreases. Regional 
analysis of the relationship between prevalence of smokers and ex-smokers in the HSfE 
shows no systematic relationship and therefore it was decided that the ex-smoking rate 
should not be locally adjusted (see Figure 3). 
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Figure 2: Prevalence of smoking behaviours in England by age and sex, 2003-5 
 
Figure 3: Prevalence of smoking behaviours by Government Office Region, 2006 
 
 
The same smoking prevalence rates are applied across all ethnic categories.  Future changes 
in smoking prevalence are not taken into account in the CHD prevalence projections. This is 
because of the uncertainty associated with predictions of smoking prevalence, and the lag 
time between smoking cessation and improved health. Even if there was a rapid drop in the 
number of smokers over the next few years, any associated decrease in CHD would not be 
seen for many years. 
 
Deprivation 
Deprivation scores are taken from IMD 2004. Deprivation scores for PCTs were calculated by 

































Prevalence of smoking behaviours by Government Office 
regions, Health Survey for England 2006
Current cigarette smoker Ex-regular cigarette smoker Never regular cigarette smoker
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(MSOA) (which in turn were calculated by taking a weighted average of the IMD2004 scores 
of each Lower Super Output Area (LSOA) within the PCT.  Five deprivation categories are 
used in the model. Note that these categories are based on quintiles of IMD score at LSOA 
level. When the cut-offs are applied to larger geographies (LA or PCT) there is not an even 
distribution across the categories. 
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8.3 Stroke Model 
8.3.1 Introduction 
Prevalence of stroke 
A report from WHO estimated stroke incidence and prevalence for each European country 
from routine mortality statistics117.  Rates from studies that met the 'ideal' criteria were 
compared with WHO's estimates. Forty-four incidence studies and 12 prevalence studies 
were identified. WHO stroke estimates were in good agreement with results from 'ideal' 
stroke population studies. According to the WHO estimates, the number of stroke events in 
these selected countries is likely to increase from 1.1 million per year in 2000 to more than 
1.5 million per year in 2025 solely because of the demographic changes. 
 
In men, the lowest stroke prevalence rates are estimated for Cyprus, Lithuania, Poland, and 
Slovakia, whilst the highest rates are estimated for Czech Republic, Greece, Portugal, and 
Slovenia. In women, low prevalence rates are estimated for Cyprus, France, Lithuania, 
Poland, and Slovakia, whilst high prevalence rates are estimated for Czech Republic, Greece, 
Hungary, and Portugal.  Table 16: UK stroke prevalence rates, estimates from the World 
Health Organization, men and women per 1000 population  below shows the WHO 
prevalence estimates for the UK. 
Table 16: UK stroke prevalence rates, estimates from the World Health Organization, men 
and women per 1000 population 
 Men Women 
25–34 0.33 0.93 
35–44 0.63 1.77 
45–54 4.55 9.52 
55–64 8.47 20.21 
65–74 20.62 50.16 
75–84 39.11 79.18 
85+ 56.39 93.15 
 
Source: Truelsen T, Piechowski J, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke 
incidence and prevalence in Europe: a review of available data. European Journal of 
Neurology 2006; 13(6):581-598 
 
Another international review of stroke epidemiology found nine high quality prevalence 
studies118.  Overall, 8,788 strokes were reported, with age-specific prevalence increasing 
with age. The age-standardised prevalence for people aged 65 years or more ranged from 
46·1 to 73·3 per 1000 population, but ranged from 58·8 to 92·6 per 1000 population for 
men, and from 32·2 to 61·2 per 1000 population for women. The small variation in age-
specific and age-standardised prevalence of stroke across the populations (five to ten per 
1000) was consistent with the geographical similarity in stroke incidence and case-fatality. 
 
A systematic review of stroke epidemiology in South America found stroke prevalence rates 
ranging from 1.74 to 6.51 per 1000, and annual incidence rates from 0.35 to 1.83 per 
1000119. Community-based studies showed crude stroke prevalence rates ranging from 1.74 
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to 6.51 per 1000 and annual incidence rates from 0.35 to 1.83 per 1000.   In a population 
survey in Berlin of a total of 75,720 households (28,090 persons responded), a total of 4.5% 
reported a physician-diagnosed stroke (women 4.3%; men 4.9%)120. Combining reported 
stroke history with reported impaired vision and/or articulation problems, the prevalence of 
stroke increased to 7.6% (men 8.4%; women 7.2%). 
 
There have been three recent published UK prevalence studies.  A point prevalence study 
using postal questionnaires (n=18,000) in northern England found that prevalence  increased 
with age and, apart from the very elderly, males had a higher prevalence than females121. 
Overall prevalence was found to be 46.8/1,000 (95% CI 42.5, 51.6).  Full recovery from 
stroke was reported by 23% of respondents.  Cognitive impairments (33%), problems with 
lower limbs (33% for right leg; 27% for left leg) and speech difficulties (27%) were the most 
common residual impairments. 
 
In another UK prospective study, all incident cases of neurological disorders were 
ascertained in an unselected urban population based in 13 general practices in the London 
area122.   A population of 100,230 patients registered with the practices was followed 
prospectively for the onset of neurological disorders, using multiple methods of case finding.  
Lifetime prevalence rates, expressed as rate per 1,000 persons with 95% CI), were: 
completed stroke, 9/1,000 (CI: 8, 11); and for transient ischaemic attacks, 5/1000 (CI: 4, 6). 
 
A two-stage point prevalence study in Newcastle used a valid screening questionnaire to 
identify stroke survivors from a stratified sample123.  This was followed by assessment of 
stroke patients with scales of disability and handicap. The overall prevalence of stroke was 
found to be 17.5/1,000 (95% CI 17.0-18.0). The prevalence of stroke-associated dependence 
was 11.7/1,000 (95% CI 11.3-12.1).  
Table 17 and Table 18 show percentage prevalence of stroke in ethnic minority groups and 
the general population, and in various age groups, for the HSfE 2004124.  Informants are 
classified as having IHD or stroke if they reported having angina, or a heart attack or a 
stroke, confirmed by a doctor.  In summary, prevalence is estimated in these studies to be 
between one and five per cent, with the HSfE estimate falling midway in this range. 





Indian Pakistani Bangladeshi Chinese Irish General 
population 
Men         
Observed % 3.4 - 1.1 1.8 1.8 0.7 4.5 2.4 
Standardised risk ratios 1.26 0.00 0.59 1.06 2.05 0.71 1.98 1 
Standard error of the 
ratio 
0.55 0.00 0.25 0.46 1.02 0.43 0.70  
Women         
Observed % 1.8 0.5 1.2 1.7 1.8 0.4 2.7 2.2 
Standardised risk ratios 1.31 0.69 0.72 2.25 2.73 0.22 1.20 1 
Standard error of the 
ratio 
0.42 0.43 0.27 0.86 1.02 0.17 0.44  
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Table 18: Prevalence of stroke, by age within minority ethnic group and sex, aged 16 and 
over 2004 
 Men Women 
 16-34 35-54 55+ All 16-34 35-54 55+ All 
 % % % % % % %  
Black Caribbean - - 11.5 3.4 - 1.1 5.6 1.8 
Black African - - [-] - 0.4 0.4 [1.5] 0.5 
Indian - - 5.2 1.1 - 1.0 4.2 1.2 
Pakistani - 1.1 9.6 1.8 0.2 0.9 10.1 1.7 
Bangladeshi - 1.9 [9.2] 1.8 0.3 1.6 11.9 1.8 
Chinese - 0.8 2.2 0.7 - 0.5 0.8 0.4 
Irish - 2.2 9.4 4.5 0.9 0.6 6.3 2.7 
General population (2003) 0.3 0.7 6.4 2.4 0.3 0.7 5.2 2.2 
Source: HSfE 2004 
 
The GP practice ascertainment study in South London may therefore have underestimated 
prevalence because practices were unaware of a proportion of stroke victims.  This is 
consistent with 2006-7 QOF data, which shows an observed/registered crude prevalence 
(whole population denominator) of only 1.61 per cent. 
 
Incidence and outcomes of stroke 
In the review quoted above, eight population-based studies assessing secular trends in 
stroke incidence in a given population were identified118.  Although the studies covered 
different periods, several common themes were evident. Most of the studies showed a 
decline in stroke incidence, through to the late 1970s or early 1980s.  In several studies, 
however, this decline seemed to have reached a plateau or even reversed in the late 1980s 
and early 1990s.  Of the few population-based studies that reported time-trend data for 
stroke mortality, the consistent finding was of a decrease in rates from the 1970s through to 
the 1990s.  About half to three-quarters of cases had stroke-related disability. 
 
In South London, stroke incidence decreased over a 10-year time period125. The greatest 
decline in incidence was observed in black women, but ethnic group disparities still exist, 
indicating a higher stroke risk in black people compared to white people.  Total stroke 
incidence was higher in blacks compared to whites (IRR 1.27, 95% CI 1.10-1.46 in men; IRR 
1.29, 95% CI 1.11 to 1.50 in women), but the black-white gap reduced during the 10-year 
time period (IRR 1.43, 95% CI 1.13-1.82 in 1995 to 1996 to 1.18, 95% CI 0.93-1.49 in 2003 to 
2004).  Age- and sex-adjusted IRRs for haemorrhagic stroke were higher in Black Africans 
(IRR, 2.80; 95% CI, 2.00 to 3.91) than in Black Caribbeans (IRR, 1.46; 95% CI, 1.07 to 1.99) 
which could be explained by prestroke hypertension being more common among young 
blacks126. 
 
The South London study also used capture-recapture models including covariates to 
estimate incidence of stroke127.  This suggested that the stroke register was 88% complete. 
Adjusting for under-ascertainment increased the estimated incidence from 1.31 (95% CI : 
1.21-1.42) to 1.49 (95% CI : 0.38-2.60) per 1000. 
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Previous stroke prevalence modelling 
There has apparently been very little previous published modelling of stroke prevalence.  A 
simple prevalence model was included in the ASSET stroke package released by the 
Department of Health, but it is no longer available.  It used only South London study data. 
8.3.2 Methods 
Data Sources 
The stroke model described here uses data from the 2003 and 2004 Surveys.   The 2003 
HSfE contains data on a total of 18,553 individuals.  The 2004 data consists of two individual 
level files of which one (10,114 records) contains data for all individuals in the Ethnic Boost 
Sample and informants in the General Population Sample who were of the specified ethnic 
groups in co-operating households who gave a full interview. It contains information from 
the household questionnaire, main individual schedule, self-completions and the nurse visit 
(where one occurred).  Data on under 16s was dropped from both these raw data files for 
the regression modelling. 
 
Because the HSfE showed that stroke prevalence varies with ethnicity1, it was necessary to 
use a sample containing data from a large number of ethnic minority respondents.  The HSfE 
2004 was the last Survey to include an ethnic minority boost, and the boost sample was 
used for the modelling.  However there were relatively small numbers of Whites in the HSfE 
2004 sample, and BP was not measured for most respondents in the 2004 general 
population sample, presumably to save resources for the boost itself.  The HSfE 2004 boost 
sample was therefore merged with the HSfE 2003 data, which measured BP and which was 
the year with the largest number of identical variables.  Table 19 shows the ethnic group 
breakdown of the two samples.  Note that it was necessary to collapse two of the HSfE 2003 
ethnic group variables  to use the same classification as HSfE 2004. 
Table 19: Ethnic Group Breakdown of HSfE 2003 & 2004 Datasets & Merged 2003-2004 
Dataset 
  HSfE 2003 HSfE 2004 HSfE 2003+2004 
  Freq. Percent Freq. Percent Freq. Percent 
white 13,445 92.11 1,130 16.98 14,575 68.64 
mixed ethnic group 86 0.59 222 3.34 308 1.45 
black or black british 308 2.11 1,683 25.29 1,991 9.38 
asian or asian british 594 4.07 3,131 47.04 3,725 17.54 
any other group 163 1.12 472 7.09 635 2.99 
Total 14,596 100 6,638 100 21,234 100 
NB excludes no answer/refused/don’t know 
 
Model construction: data issues 
The choice of variables for original inclusion in the merged dataset included all those known 
to be stroke risk factors.  The variable names and labels are shown in  below.  The HSfE 
dataset has a nested or hierarchical structure so three variables related to the sampling 
strata were included: area (sample point), cluster (stratification level), and hserial (serial 
number of household).  These were used in the model to adjust for clustering of 
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respondents. In the analysis variables cholest and hdlchol were combined to give a lipid 
ratio. 
 
There was a problem with merging the variable for deprivation (IMD 2004).  The bandings of 
IMD scores were slightly different between the two years, but raw scores were not provided 
in the dataset so that it was necessary to assume identity (see Table 20 below). 











HSfE 2003 HSfE 2004 
least 1 0.59-8.35  0.55-9.02 3,803 17.87 17.87 
 2 8.35-13.72 9.03-14.14 3,573 16.79 34.65 
 3 13.72-21.16 14.15-21.17 3,788 17.8 52.45 
 4 21.16-34.21 21.18-33.52 4,551 21.38 73.83 
most 5 34.21-86.36 33.53-85.69 5,571 26.17 100 
   Total 21,286 100   
 
The Stata software package was used for analysis.  The Stata software package was used for 
analysis.  As for the CHD model the methodology applied was multinomial logistic regression 
with the “cluster” option (see above).  As previously, the prevalence in each age group, 
gender, ethnic group, area of residence and level of deprivation, and smoking status 
category were derived from the odds, using the formula: prevalence = odds/(1 + odds). 
 
Model construction: interactions between variables 
Effect modification or interaction occurs if the effect of one exposure or risk factor on the 
outcome varies according to the level of another risk factor.  This can be tested using a χ2 
test of heterogeneity, or by introducing interaction terms or parameters into the regression  
model.  These allow the effect of one variable to be different in different categories of other 
variables.  In Stata the xi command expands terms containing categorical variables into 
indicator (also called dummy) variable sets by creating new variables and estimates 
interactions and main effects. 
 
Model construction: validation 
Ideally, the best prediction should result from utilising the most information in the 
regression model.  However only a limited range of HSfE variable data is either available or 
can be estimated at the PCT level.  We decided to validate the local model by comparing it, 
in terms of prediction, to a model including all available HSfE variables.  In addition, 
however, the amount of missing data affects the prediction of a model.  For example, in the 
complete HSfE variables the largest proportion of missing data occurred in those variables 
related to particular drug treatment for high blood pressure.  Some clinical tests also have a 
high proportion of missing values.  Hence the “complete” model included the complete list 
of variables, including differing definitions of high blood pressure (history of high blood 
pressure, on drugs for high blood pressure, or clinically measured hypertension >140/90 at 
the time of the Survey. 
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The local model only used locally available data.  I included smoking because local synthetic 
estimates are now available.  Local General Health Questionnaire 12 (GHQ-12) or Limiting 
Longstanding Illness score data will be available locally from 2009 and could be included 
later. 
8.3.3 Results 
Table 21 shows crude stroke prevalence in the HSfE 2003-4 merged dataset. 
Table 21: crude stroke prevalence in 2003-4 dataset 
 Age 16-24 Age 25-34 Age 35-44 Age 45-54 Age 55-64 Age 65-74 Age 75+ Total 
No stroke  2,498 3,850 4,429 3,435 2,972 2,131 1,476 20,791 
% 99.84 99.72 99.48 98.82 97.31 93.51 88.86 97.68 
Stroke 4 11 23 41 82 148 185 494 
% 0.16 0.28 0.52 1.18 2.69 6.49 11.14 2.32 
Total 2,502 3,861 4,452 3,476 3,054 2,279 1,661 21,285 
 
Sensitivity/Specificity: ROC Curve 
Sensitivity and specificity were calculated using the area under the ROC curve.  Area under 
ROC curves for the local and complete models tested were estimated using Stata10.  These 
are shown in Table 22 and Figure 4 below.  The local model, with an AUROC of 0.834 
exceeds this level, although the complete model using a history of high blood pressure has 
even better performance, with an AUROC of 0.874.  This data would also be easiest to 
estimate at a local level (possibly using the hypertension model). The table illustrates well 
the impact of missing data on area under ROC curve.  Exact binomial and Hanley confidence 
intervals were calculated.  Hanley specifies that the standard error for the area under the 
ROC curve be calculated using the method suggested by Hanley and McNeil.  Otherwise, 
standard errors are obtained as suggested by DeLong and Clarke-Pearson. 
Table 22: Comparison of area under ROC curves for differing stroke models 






95% C. I. 
Upper 
95% C. I. 
Local Binomial Exact 21,136 0.834 0.009 0.829 0.839 
  Hanley-Asymp Normal 21,136 0.834 0.009 0.818 0.851 
Complete, 3 BP variables Binomial Exact 4,915 0.828 0.015 0.817 0.839 
  Hanley-Asymp Normal 4,915 0.828 0.015 0.799 0.858 
Complete, on BP meds Binomial Exact 6,003 0.819 0.014 0.809 0.829 
  Hanley-Asymp Normal 6,003 0.819 0.014 0.793 0.846 
Complete, ever had high BP Binomial Exact 16,669 0.874 0.010 0.869 0.879 
  Hanley-Asymp Normal 16,669 0.874 0.010 0.854 0.894 
Complete, hypertensive 
>140/90 Omron 
Binomial Exact 10,227 0.868 0.013 0.861 0.875 
  Hanley-Asymp Normal 10,227 0.868 0.013 0.843 0.894 
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Figure 4: Comparison of area under ROC curves for differing models 
 
 
Local  Model 
ORs, p values and confidence intervals are generally similar to the more complete models 
(see Table 23: Odds Ratios, Local Model).  Variables which should be included as inputs to 
the local model are highlighted.  Unfortunately, however, local synthetic estimates do not 
have separate categories for occasional/regular smokers. 
Table 23: Odds Ratios, Local Model 
 RRR Std. 
Err. 




Female 1.000      
Male 1.144 0.111 1.39 0.166 0.946 1.383 
Age 16-24 1.000      
Age 25-34 1.712 0.999 0.92 0.357 0.545 5.375 
Age 35-44 3.254 1.764 2.18 0.03 1.124 9.418 
Age 45-54 7.329 3.852 3.79 0 2.616 20.532 
Age 55-64 17.652 9.092 5.57 0 6.432 48.443 
Age 65-74 43.780 22.307 7.42 0 16.128 118.846 
Age 75+ 82.058 41.833 8.65 0 30.212 222.878 
Never smoker 1.000      
Used to smoke occasionally 0.947 0.212 -0.24 0.809 0.611 1.469 
Used to smoke regularly 1.353 0.150 2.72 0.006 1.088 1.682 
Current smoker 1.389 0.189 2.41 0.016 1.063 1.814 










Local Complete, on BP meds Complete, hypertensive 
>140/90
Complete, ever had high 
BP
Complete, all 3 BP 
variables
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 RRR Std. 
Err. 




IMD 2004 8.35->13.72 1.233 0.199 1.3 0.193 0.899 1.692 
IMD 2004 13.72->21.16 1.236 0.199 1.32 0.188 0.902 1.694 
IMD 2004 21.16->34.21 1.397 0.217 2.15 0.032 1.030 1.895 
IMD 2004 34.21->86.36 [most 
deprived] 
2.009 0.291 4.83 0 1.513 2.668 
 
Table 24 shows odds ratios and other statistics for the complete model, using history of high 
blood pressure as the variable with the highest area under ROC curve.  Included variables 
were selected by reverse stepwise selection using repeated likelihood ratios and Wald tests 
as recommended by Kirkwood and Sterne.  A threshold probability value of 0.2 was used 
(see Table 25). 
Table 24: Odds Ratios, Complete Model 







Age 16-24 1.000      
Age 25-34 1.434 0.853 0.61 0.544 0.447 4.599 
Age 35-44 1.785 1.003 1.03 0.303 0.593 5.369 
Age 45-54 2.907 1.591 1.95 0.051 0.995 8.499 
Age 55-64 5.724 3.040 3.29 0.001 2.022 16.207 
Age 65-74 15.196 8.026 5.15 0 5.397 42.787 
Age 75+ 21.734 11.547 5.8 0 7.672 61.571 
Limiting long-term illness 1.000      
Non limiting long-term illness 0.387 0.065 -5.6 0 0.278 0.539 
No long-term illness 0.291 0.051 -7.1 0 0.207 0.410 
IMD 2004 0.59->8.35 [least deprived]       
IMD 2004 8.35->13.72 1.305 0.250 1.39 0.165 0.896 1.900 
IMD 2004 13.72->21.16 1.008 0.202 0.04 0.968 0.680 1.494 
IMD 2004 21.16->34.21 1.012 0.202 0.06 0.951 0.685 1.497 
IMD 2004 34.21->86.36 [most deprived] 1.322 0.259 1.42 0.154 0.900 1.942 
Never had high BP       
Ever had high BP 2.767 0.385 7.31 0 2.106 3.635 
Never smoker       
Used to smoke occasionally 1.012 0.305 0.04 0.967 0.561 1.828 
Used to smoke regularly 1.392 0.209 2.2 0.028 1.037 1.868 
Current smoker 1.638 0.296 2.74 0.006 1.150 2.333 
BMI under 20       
BMI 20-25 0.822 0.278 -0.6 0.561 0.424 1.594 
BMI 25-30 0.494 0.169 -2.1 0.039 0.252 0.966 
BMI Over 30 0.661 0.225 -1.2 0.224 0.339 1.289 
Female sex       
Male sex 1.187 0.150 1.36 0.175 0.926 1.522 
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GHQ12 Score=0 [best psychosocial health]       
GHQ12 Score=1 1.369 0.238 1.8 0.071 0.973 1.926 
GHQ12 Score=2 1.149 0.294 0.54 0.587 0.696 1.898 
GHQ12 Score=3 1.332 0.361 1.06 0.291 0.783 2.267 
GHQ12 Score=4 2.192 0.613 2.81 0.005 1.267 3.791 
GHQ12 Score=5 2.710 0.746 3.62 0 1.580 4.647 
GHQ12 Score=6 1.614 0.623 1.24 0.215 0.758 3.439 
GHQ12 Score=7 1.686 0.658 1.34 0.181 0.785 3.621 
GHQ12 Score=8 1.307 0.642 0.54 0.586 0.499 3.424 
GHQ12 Score=9 3.814 1.267 4.03 0 1.989 7.312 
GHQ12 Score=10 2.586 1.164 2.11 0.035 1.070 6.250 
GHQ12 Score=11 1.700 0.843 1.07 0.285 0.643 4.495 
GHQ12 Score=12 [worst psychosocial health] 0.969 0.547 -0.1 0.956 0.321 2.930 
Table 25: complete model variable selection 
Variable Name LR Test Wald Test 
 χ2 Pr χ2 Pr 
Age Group 741.25 0 522.16 0 
IMD 2004 27.3 0 27.99 0 
Limiting illness 64.46 0 58.13 0 
Hypertensive 14.55 0.0001 13.92 0.0002 
Ever had high blood pressure 10.99 0.0009 10.92 0.001 
On drugs for BP 10.41 0.0013 9.85 0.0017 
Smoking 12.33 0.0063 12.24 0.0066 
BMI 9.78 0.0205 10.01 0.0185 
Sex 2.69 0.1012 2.69 0.1008 
GHQ 12 Screen 18.3 0.1068 20.75 0.0542 
 
Internal validation: prediction 
Prediction by the models is shown in Table 26 below. 
Table 26: Comparison of predictions by model 





Local No stroke 20,740 0 20,740 
 Stroke 493 0 493 
Complete, 3 BP 
variables 
No stroke 4,728 1 4,729 
  Stroke 183 3 186 
Complete, 
hypertensive 
No stroke 10,029 0 10,029 
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  Stroke 198 0 198 
 Complete, ever had 
high BP 
No stroke 
16,366 1 16,367  
 Stroke 302 0 302  
Taking drugs 
prescribed for BP 
No stroke 
5,772 0 5,772  
 Stroke 230 1 231  
8.3.4 Application: PCT, LA and practice level models 
The same practice, LA and PCT population data used for other models was used here.  In 
order to calculated estimate prevalence of hypertension in the future, population 
projections were incorporated into the model. Modelled estimates of disease prevalence at 
practice level were provided for the adult population (aged 16+ years) using a similar 
methodology to previous models. By assuming that the prevalence of disease is 0% in the 
under 16s, prevalence estimates for all ages were calculated. These all-age prevalence are 
more closely equivalent to QOF prevalence.  For each practice the model required the 
following input data: 
 Population by age and sex 
 Distribution of ethnic groups by age and sex (not required for stroke model) 
 Prevalence of smoking and ex-smoking by age and sex (not required for hypertension 
model) 
 IMD deprivation score 
 Urban-suburban-rural category (only required for COPD model) 
The following assumptions are made in the modelling process. For some practices, 
particularly those with a large BME population, these assumptions may not hold and the 
model may not be an accurate reflection of true prevalence. 
 The distribution of ethnic groups within each age-sex group is the same as the 
overall distribution of ethnicity for the practice. 
 Smoking prevalence is the same across ethnic groups 
 Ex-smoking prevalence by age group and sex is the same in all practices.  
 Disease prevalence in population aged <16 is 0%. 
The urban-suburban-rural categorisation of the MSOA where the practice is located is 
representative of the catchment population of the practice.  Only practices with a complete 
input dataset could be included in modelling. Table 27 summarises the number of practices 
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Table 27: Number of practices included in modelling 
 Number of practices 










As before practice populations by age and sex were derived from a National Strategic 
Tracing Service (NSTS) extract taken on 31/03/2007. Patients with date of death before 
31/03/07 were excluded. In order to improve the data quality, GP codes were re-mapped to 
practices using NSTS  files of February 2007 (available from the NHS Organisation Data 
Service). Some practices have missing PCT and SHA codes in the Feb 07 NACS files, so these 
were populated using the May 07 NSTS  files.  Practices with a population of <1000 patients 
are excluded from modelling due to the uncertainty associated with such small numbers. 
 
Ethnicity 
The proportion of practice population in ethnic groups was supplied by the CQC, as for the 
other models.  The proportions were derived from HES admissions in 2005/06-2006/07, 
excluding mental health and maternity admissions and records with unknown ethnicity. The 
proportions by ethnic group for each practice were calculated by dividing admissions within 
each ethnic category by the total admissions for the practice.  
 
Deprivation 
This model used IMD 2007 scores for practices, derived by South East PHO in August 2008. 
These scores are weighted MSOA IMD scores based on the March 2008 Attribution Data Set. 
There are 40339 registrations (0.07 per cent of the total of 57,374,247 for England and 
Wales) for which the postcode was either missing, obviously invalid, or failed to generate all 
the required area codes when matched to recent postcode directories. These registrations 
were re-assigned to the postcode geography of the lists of their practice, retaining the total 
number of registrations in the file. The resulting file of raw registrations was aggregated to 
give the numbers of registrations per practice per LSOA. This was matched to a file of IMD 
domain scores for LSOAs  to compute weighted average scores for each practice. 
 
Smoking status 
Practice smoking prevalence is based on National Centre for Social Research (NatCen) 
synthetic estimates of smoking at MSOA level 2003-2005 (available from Neighbourhood 
Statistics). Practice smoking prevalence was calculated as the weighted average of 
prevalence in MSOAs in the practice catchment area, determined from postcodes in cleaned 
2007 NSTS data (as above) for patients aged 16+. MSOA catchment weighting was limited to 
patients in England only (e.g. practices with some catchment in Wales have smoking 
prevalence derived from English part of catchment only).  The prevalence models require 
smoking status including prevalence of ex-smoking and non-smoking. However, this 
information is not available at practice level so national (England) proportions of smokers, 
ex-smokers and current smokers by age and sex are taken from HSfE 2003-2005 pooled as 
for previous models and adjusted for each practice.   
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Rurality  
The Urban-suburban-rural categorisation is based on the Rural and Urban area classification 
of Super Output Areas, 2004 (Table 28, available from Neighbourhood Statistics). 
 
Table 28: Definition of urban-suburban-rural categories 
 
Urban DEFRA MSOA category "Urban >10k" AND DEFRA LA category LU or MU 
Suburban (DEFRA MSOA category "Urban >10k" AND DEFRA LA category not LU or MU) OR 
DEFRA MSOA category "Town and Fringe" 
Rural DEFRA MSOA category "Village Hamlet and isolated dwelling" 
 
This definition gives a distribution of categories that differs from the 2001 HSfE distribution 
of LAs used in the model development (Table 29), but there is no other logical definition 
available. 
 




LA distribution used 
in COPD model 
Rural 10.09% 23% 
Suburban 42.04% 49% 
Urban 47.87% 27% 
 
The urban-suburban-rural category of the MSOA in which the practice is physically located is 
used in the COPD model. 
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8.4 Hypertension Model 
8.4.1 Introduction 
Hypertension is defined as a persistently raised blood pressure (BP) above a designated 
threshold (which has reduced over time). The current NICE guidance128 defines this further 
as follows: 
 measured at the past two GP visits i.e. an average and 
 systolic or diastolic pressure (SBP/DBP) or both are above 140/90 mmHg. 
 
Prevalence Studies 
Hypertension is an important public health challenge in both economically developing, and 
developed, countries. An international review estimated that 26·4% of the adult population 
in 2000 had hypertension129.  The estimated total number of adults with hypertension in 
2000 was 972 million, of which 333 million are in economically developed countries. The 
number of adults with hypertension in 2025 was predicted to increase by about 60% to a 
total of 1·56 billion.  Worldwide, hypertension caused 7.6 million premature deaths in 
2001130.  Hypertension is one of the main risk factors for heart attack and stroke131.   
Throughout middle and old age, usual blood pressure is strongly and directly related to 
vascular (and overall) mortality, without any evidence of a threshold down to at least 
115/75 mm Hg132. 
 
Numerous national and regional studies have been conducted worldwide to estimate the 
prevalence of hypertension: hypertension rates have varied from 3.4% in rural Indian men 
to as high as 72.5% in Polish women133;134.  Within developed countries, average BP is higher 
in Europe than North America, even after adjusting for treatment differences135.  A meta-
analysis of national studies showed a mean BP of 136/83 mm Hg in six European countries 
and 127/77 mm Hg in Canada and the United States among men and women combined who 
were 35 to 74 years of age. This difference already existed among younger persons (35-39 
years) in whom treatment was uncommon (i.e., 124/78 mm Hg and 115/75 mm Hg, 
respectively), and the slope with age was steeper in the European countries. For all age 
groups, BP measurements were lowest in the United States and highest in Germany. The 
age- and sex-adjusted prevalence of hypertension was 28% in the North American countries 
and 44% in the European countries at the 140/90 mm Hg threshold. 
 
Hypertension is more common among African Caribbeans and South Asians in Britain.  The 
table below from HSfE 2004 report shows that Black Africans and Caribbeans have the 
highest standardised risk ratios for hypertension (see Table 30).  Many studies in the UK and 
elsewhere have also shown that mortality rates for stroke, CHD, and end-stage renal failure 
are higher in South Asians than white Europeans133;136.  The NICE guidelines recommend a 
reduction of BP to <140/85, but give lower target BP levels (<130/80) for patients with 
diabetes or chronic renal failure128.  The majority of UK-based surveys have shown that 
people of Black African or Black Caribbean origin have higher average BP levels and rates of 
hypertension than their white counterparts.  Socioeconomic disadvantage was associated 
with the greatest risk of developing hypertension in whites and in blacks137-139. Aging-related 
increases in systolic blood pressure were inversely associated with socioeconomic position 
in whites. 
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There is strong evidence, including a systematic review and a meta-analysis, from diverse 
populations showing that BP “tracks” from childhood into adulthood. Childhood BP is 
associated with BP in later life, and early intervention is important137;140. 
Table 30: blood pressure levels, by minority ethnic group and sex, Aged 16 and over with 
valid blood pressure readings, 2004  
Minority ethnic group 
Gen 
population 
     Black              Black Pakistani   
Caribbean  African Bangladeshi Chinese Irish 
Me
n  
    
Observed 
%  
    
Normotensive untreatedb  62  75 









Hypertensive controlledb  10 4




4 7 5 





5 7 6 
Hypertensive untreatedb  19  16 









All with hypertension  38 25 














2 5 5 
Standardised risk 
ratios  
    
All with hypertension  1.37  1.21 









Standard error of the ratio  0. 9  0.22 












    
Observed 
%  
    
Normotensive untreatedb  68  81 














6 4 6 





3 9 8 








All with hypertension  32  19 














2 3 5 
Standardised risk 
ratios  
    
All with hypertension  1.58  1.71 









Standard error of the ratio  .19  0.37 










(weighted)      
Men  169  136 









Women  249 183 











    
Men  155  123 









Women  43 154 










Source: HSfE 2004 
Effects of reducing BP 
Epidemiological, clinical and animal experimental evidence show a direct relationship 
between dietary electrolyte consumption and blood pressure. Clinical trials have shown that 
reduction of salt (sodium chloride, NaCl) intake reduces BP levels in normotensive and 
hypertensive populations and prevents the development of hypertension.  Data from 
randomized controlled trials, in which mean age at event was approximately 70 years, 
indicate that a 10 mm Hg reduction in systolic BP is associated with a reduction in risk of 
stroke of approximately one third131.  The results of an international study provide evidence 
that antihypertensive treatment in persons 80 years of age or older is beneficial141. 
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Drug treatment is recommended in all people with sustained levels of blood pressure 
≥160/100, and at lower levels in those with additional risk factors, such as diabetes, or with 
end-organ damage132.   The threshold for offering drug treatment is defined by NICE128 as: 
 blood pressure of more than 160/100 mmHg or 
 isolated systolic hypertension (systolic blood pressure of more than 160 mmHg) or 
 blood pressure of more than 140/90 mmHg and: 
o 10-year CVD risk of at least 20%, or 
o existing CVD or target organ damage. 
 
Prevalence of treated and controlled hypertension 
The experience of high-income countries indicates that sustained interventions can achieve 
at least the required 4% annual average decline in stroke mortality for people age 60-69 
years142.  In Canada, 16% of participants were treated and controlled; 23% were treated and 
not controlled; 19% were not treated and not controlled; and 42% were unaware of their 
hypertension143.  In a French population, more than two-thirds of those with hypertension 
were aware of their diagnosis and 81% were treated with antihypertensive drugs144.  In the 
US, among adults with hypertension, 83.0% were diagnosed, 72.7% were treated, and 47.1% 
had hypertension controlled. Of those treated, 64.8% had hypertension controlled145.   
These results seem superior to UK figures in the table above.  Lower treatment thresholds 
and more intensive treatment contribute to better hypertension control in the United States 
compared with the western European countries (including the UK) studied146. 
 
Defining modelled prevalence 
The concept of “pre-hypertension” is gaining credence in the USA.  The Seventh Report of 
the US Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure provides a new classification of blood pressure levels147.  According to 
the new report, normal BP is defined as systolic BP (SBP) less than 120 mm Hg and diastolic 
BP (DBP) less than 80 mm Hg; a SBP of 120 to 139 mm Hg or a DBP of 80 to 89 mm Hg is 
defined as pre-hypertension. The low-end threshold for pre-hypertension is lower than the 
previous designation of high-normal BP (i.e., SBP/DBP: 130/85.  Approximately 60% of 
American adults (67% of men and 50% of women) have pre-hypertension or hypertension 
and 27% had hypertension. 
 
However, there is little separation between the distributions of the risk factors in people 
who over a specified period do or do not have a disease event. With such closely 
overlapping distributions there are no cut-off levels that include most people who will have 
disease events but few of those who will not have them, but rather there is a spectrum of 
risk as BP increases148.  In addition, management of overall CVD risk rather than managing 
individual risk factors is now recommended.  The definitions used by NICE and the HSfE have 
therefore been used for this model.  The prevalence of various categories of hypertension is 
shown in Table 31 below, taken from the HSfE 2003. 
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Table 31: Prevalence of Hypertensive Categories in HSfE 2003 (Adults aged 16 and over 
with a valid blood pressure reading and data on medication) 
2003 (unweighted)c 16-24 25-34 35-44 45-54 55-64 65-74 75+ Total 
Normotensive untreated 94.3 91.4 84.9 69.8 50.2 33.2 26.8 65.6 
Normotensive treated 0.1 0.2 1.5 5.3 10.2 14.3 10.7 5.9 
Hypertensive treated - 0.3 1.0 3.5 11.5 19.4 26.1 8.0 
Hypertensive untreated 5.5 8.0 12.6 21.4 28.1 33.0 36.4 20.5 
All with high blood pressure 5.7 8.6 15.1 30.2 49.8 66.8 73.2 34.4 
2003 (weighted)b         
Normotensive untreated 93.9 90.7 84.1 69.6 49.3 33.1 27.1 67.9 
Normotensive treated 0.1 0.2 1.6 5.3 10.5 14.9 10.4 5.4 
Hypertensive treated - 0.4 1.0 3.4 11.9 19.5 26.9 7.3 
Hypertensive untreated 6.0 8.8 13.3 21.7 28.3 32.6 35.5 19.4 
All with high blood pressure 6.1 9.3 15.9 30.4 50.7 66.9 72.9 32.1 
Bases                 
2003 (unweighted) 849 1272 1800 1536 1625 1194 907 9183 
2003 (weighted) 1201 1460 1765 1457 1346 1032 861 9122 
 
Previous hypertension prevalence modelling 
In the US, self-reported data on hypertension diagnosis from the Behavioral Risk Factor 
Surveillance System was used to obtain unbiased state-level estimates of blood pressure 
and uncontrolled hypertension as benchmarks for priority setting and for designing and 
evaluating intervention programmes149.  A crude epidemiologic hypertension model based 
on age and sex-specific prevalence was first developed in the UK by the Faculty of Public 
Health. Subsequently, English PCTs were required to set targets for hypertension case-
finding in their 2007-8 Local Delivery Plans negotiated with strategic health authorities.  To 
assist them a simple PCT-based prevalence model was developed rapidly by APHO. 
 
In the APHO model, numbers of persons predicted to be hypertensive were derived by 
multiplying April 2006 PCT registered populations by hypertension prevalence rates 
identified in the 2003 and 2004 HSfE, modified by ethnic-group age-standardised risk ratios 
from the 2004 HSfE.   Calculations were stratified to reflect variations in these factors at PCT 
level.  The PCT-registered populations were derived by aggregating April 2006 GP practice 
populations from the Exeter System using a practice to new PCT lookup table.  In the 
absence of age by sex by ethnic-group PCT populations, the age by sex registered 
populations of the current PCTs were attributed the ethnic-group distributions of their 
constituent former PCT/s resident populations from the 2001 Census. 
 
APHO accepts that this current model is rather crude, and that a prevalence model based on 
a comprehensive regression model using HSfE data would be more robust.  This model was 
commissioned from the Department of PCPH Imperial College London. 
8.4.2 Methods 
Data Sources 
The hypertension model described here uses data from the 2003 and 2004 HSfEs.   The 2003 
data in file hse03ah.dta contains data on 18,553 individuals.  The 2004 data consists of two 
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individual level files and one household level file: HSfE04gpa.sav (8,354 records) contains 
data for all individuals in the General Population Sample in co-operating households who 
gave a full interview.  This was not used for the reasons outlined above.  HSfE04etha.sav 
(10,114 records) contains data for all individuals in the Ethnic Boost Sample and informants 
in the General Population Sample who were of the specified ethnic groups in co-operating 
households who gave a full interview. It contains information from the household 
questionnaire, main individual schedule, self-completions and the nurse visit (where one 
occurred).  Data on under 16s was dropped from both these raw data files for the regression 
modelling. 
 
In HSfE 2003, a new oscillometric automated device, the Omron HEM 907, was introduced 
to measure blood pressure, as a replacement for the Dinamap 8100, which had become 
obsolete.  HSfE 2004 measures blood pressure as a one-off measurement in a cross 
sectional survey and does not provide information on whether high BP is sustained over 
time (the clinical definition in the NICE guidance), so this survey may slightly overestimate 
the prevalence of hypertension.  BP measurement by GPs or practice nurses may, however, 
increase BP slightly (so-called “white coat hypertension”).  The HSfE 2004 report introduced 
a change to a clearer terminology from previous years’ reports.  The specific definitions of 
the four levels used in the HSfE 2004 report are: 
 
Normotensive untreated SBP <140mmHg and DBP <90mmHg and not taking 
medicine prescribed for high blood pressure 
 
Hypertensive controlled SBP <140mmHg and DBP <90mmHg and taking 
medicine prescribed for high blood pressure (in 2003 this was called 
“normotensive-treated”) 
 
Hypertensive uncontrolled SBP ≥140mmHg and/or DBP ≥90mmHg and taking 
medicine prescribed for high blood pressure (in 2003 this was called 
“hypertensive-treated”) 
 
Hypertensive untreated SBP ≥140mmHg and/or DBP ≥90mmHg and not taking 
medicine prescribed for high blood pressure (in 2003 this was called 
“hypertensive-untreated”) 
 
However the actual definition did not change. 
 
Because hypertension prevalence is known to vary with ethnicity, it was necessary to use a 
sample containing data from a large number of ethnic minority respondents.  The HSfE 2004 
was the last Survey to include an ethnic minority boost, and the boost sample was used for 
the modelling.  However there were relatively small numbers of Whites in the HSfE 2004 
sample, and BP was not measured for most respondents in the 2004 general population 
sample, presumably to save resources for the boost itself.  The HSfE 2004 boost sample was 
therefore merged with the HSfE 2003 data, which measured BP and which was the year with 
the largest number of identical variables.  Table 32 shows the ethnic group breakdown of 
the two samples.  Note that it was necessary to collapse two of the HSfE 2003 ethnic group 
variables  to use the same classification as HSfE 2004. 
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Table 32: Ethnic Group Breakdown of HSfE 2003 & 2004 Datasets & Merged 2003-2004 
Dataset 
  HSfE 2003 HSfE 2004 HSfE 2003+2004 
  Freq. Percent Freq. Percent Freq. Percent 
white 13,445 92.11 1,130 16.98 14,575 68.64 
mixed ethnic group 86 0.59 222 3.34 308 1.45 
black or black british 308 2.11 1,683 25.29 1,991 9.38 
asian or asian british 594 4.07 3,131 47.04 3,725 17.54 
any other group 163 1.12 472 7.09 635 2.99 
Total 14,596 100 6,638 100 21,234 100 
NB excludes no answer/refused/don’t know 
 
In HSfE 2003, valid blood pressure readings were obtained from 80.8% of men and 80.3% of 
women aged 16 and over who were visited by a nurse. Response rates increased with age 
for both sexes. The main reason for exclusion was that the informant ate, drank or smoked 
in the half hour before the measurement (17.0% among men and 15.2% among women). 
The remainder were excluded because they were pregnant, (4.9% of women aged 16-44 
were excluded due to pregnancy) or because three valid readings had not been obtained or 
the measurement had been refused or not attempted.  
 
In 2004, nurse visits were offered to all individuals in minority ethnic groups in the boost 
sample (NB the general population data presented in the HSfE 2004 report are actually from 
HSfE 2003, as the general population did not receive a nurse visit in 2004). Response rates 
for BP measurements and urine samples are based on those receiving a nurse visit, though 
women who were pregnant were not asked for a urine sample. Section 6.3 in Volume 2 of 
the 2004 report gives more details response rates to the different stages of the survey. 
Among those who participated in a nurse visit, the proportion with three valid blood 
pressure readings ranged from 69% of Bangladeshi men, to 84% of Chinese and Indian men. 
Among women, the proportion with three valid blood pressure readings ranged from 71% of 
Black African women to 84% of Indian women.  As in 2003, informants were excluded if they 
were pregnant or had eaten, drunk, exercised vigorously or smoked in the half hour before 
the measurement; a proportion of the remainder refused to have their blood pressure taken 
or failed to complete the measurements or measurements were not possible for technical 
reasons.  Table 33shows the numbers in each survey with valid BPs and their hypertensive 
categories. 
Table 33: Hypertensive Categories of HSfE 2003 & 2004 Datasets & Merged 2003-2004 
Dataset 
 HSfE 2003 HSfE 2004 HSfE 2003+2004 
 Freq. Percent Freq. Percent Freq. Percent 
Refused/not applicable 5,569 38.1 3966 59.6 9,535 44.8 
normotensive untreated 6,037 41.3 1,983 29.8 8,020 37.7 
normotensive treated 579 4.0 180 2.7 759 3.57 
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 HSfE 2003 HSfE 2004 HSfE 2003+2004 
 Freq. Percent Freq. Percent Freq. Percent 
hypertensive treated 699 4.8 171 2.6 870 4.09 
hypertensive untreated 1,746 11.9 356 5.4 2,102 9.88 
Total with valid BP 9,061 61.9 2,690 40 11,751 55.2 
Total 14,630 100 6,656 100 21,286 100 
 
Model construction: data issues 
The choice of variables for original inclusion in the merged dataset included all those known 
to be high blood pressure risk factors.  The variable names and labels are shown in Table 34  
below.  The HSfE dataset has a nested or hierarchical structure so three variables related to 
the sampling strata were included: area (sample point), cluster (stratification level), and 
hserial (serial number of household).  These were used in the model to adjust for clustering 
of respondents. In the analysis variables cholest and hdlchol were combined to give a lipid 
ratio. 
Table 34: Variables Included in Merged Dataset 
Variable Description Source 
ADDRESS5 Address number Sample 
ADTOT30 Adults: Total days/ 4week active 30min + moderate Derived 
ADTOT30C Adults: Total days per week active 30min + moderate Derived 
AG16G10 (D) Age 16+ in ten year bands Derived 
AGE Age last birthday Individual 
BIRTWT Birth weight (kg) Individual 
BMI BMI - inc unreliable measurements Derived 
BMIVAL Valid BMI Derived 
BMIVG4 Valid BMI (grouped:<20,20-25,25-30,30+) Derived 
BP1 Doctor diagnosed high blood pressure (excluding pregnant) Derived 
BPMEDC Whether taking drugs affecting blood pressure Derived 
BPMEDD Whether taking drugs prescribed for blood pressure Derived 
CIGST1 Cigarette Smoking Status - Never/Ex-reg/Ex-occ/Current Derived 
COOKSALT Salt added at when cooking? SC 16+  Individual 
CVDDEF Had cardiovascular condition Derived 
CVDDEF1 Had cardiovascular condition (excluding diabetes/high BP) Derived 
EQMEAN EQ-5D social preference weight (mean) Derived 
ETHCIND Ethnic group Individual 
EVERBP Ever had high BP Individual 
GHQ12SCR GHQ Score - 12 point scale Derived 
HBP140OM Whether hypertensive: 140/90: all prescribed drugs for BP 
(Omron reading) 
Derived 
HHOLD Household Sample 
HIBP1OM Whether hypertensive: all prescribed drugs for BP (Omron 
reading) 
Derived 
HY140OM Hypertensive categories: 140/90: all prescribed drugs for BP 
(Omron reading) 
Derived 
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Variable Description Source 
HYPER1OM Hypertensive categories: all prescribed drugs for BP (Omron 
reading) 
Derived 
IMD2004 Index of multiple deprivation (SOA level) Derived 
LIMITILL Limiting longstanding illness Derived 
MEDCINBP Take medicines for high BP Individual 
NOBPCVD Had CVD excludes those with high BP Derived 
NSSEC5 NS-SEC 5 variable classification (individual) Derived 
NSSEC8 NS-SEC 8 variable classification (individual) Derived 
OMDIAST Omron Diastolic BP (mean 2nd/3rd) inc. invalid Derived 
OMDIAVAL Omron Valid mean diastolic BP Derived 
OMMAP Omron Mean arterial pressure (mean 2nd/3rd) inc. invalid Derived 
OMMAPVAL Omron Valid mean arterial pressure Derived 
OMPULS Omron Pulse pressure, systolic-diastolic inc. invalid Derived 
OMPULVAL Omron Valid pulse pressure Derived 
OMSYST Omron Systolic BP (mean 2nd/3rd) inc. invalid Derived 
OMSYSVAL Omron Valid mean systolic BP Derived 
POINT Sample point Sample 
SERIALH Serial number of household Hhold 
SERIALI Serial number of individual Individual 
SEX Sex Individual 
STRATA Stratification level Individual 
TABSALT Salt added at table? SC 16+  Individual 
TOPQUAL2 (D) Highest Educational Qualification - Students separate Derived 
TOPQUAL3 (D) Highest Educational Qualification Derived 
 
There was a problem with merging the variable for deprivation (Index of Multiple 
Deprivation 2004).  The bandings of IMD scores were slightly different between the two 
years, but raw scores were not provided in the dataset so that it was necessary to assume 
identity (see Table 35: Index of Multiple Deprivation Banding below). 











HSfE 2003 HSfE 2004 
least 1 0.59-8.35  0.55-9.02 3,803 17.87 17.87 
 2 8.35-13.72 9.03-14.14 3,573 16.79 34.65 
 3 13.72-21.16 14.15-21.17 3,788 17.8 52.45 
 4 21.16-34.21 21.18-33.52 4,551 21.38 73.83 
most 5 34.21-86.36 33.53-85.69 5,571 26.17 100 
   Total 21,286 100   
 
The Stata software package was used for analysis.  As for the CHD model the methodology 
applied was multinomial logistic regression with the “cluster” option (see above).  As 
previously the prevalence in each age group, gender, ethnic group, area of residence and 
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level of deprivation, and smoking status category were derived from the odds, using the 
formula: prevalence = odds/(1 + odds). 
 
Model construction: interactions between variables 
Effect modification or interaction occurs if the effect of one exposure or risk factor on the 
outcome varies according to the level of another risk factor.  We tested for interactions 
using a χ2 test of heterogeneity (Mantel-Haenszel Odds Ratio) and Wald test.  Where 
significant interaction was found, we performed a regression analysis of a generated 
interaction term.  Where evidence of interaction was found across a range of strata, we 
introduced interaction terms or parameters into the final regression model.  These allow the 
effect of one variable to be different in different categories of other variables.  In Stata the 
xi command expands terms containing categorical variables into indicator (also called 
dummy) variable sets by creating new variables and estimates interactions and main effects. 
 
Model construction: internal validation 
Ideally the best prediction should result from utilising the most information in the 
regression model.  However only a limited range of HSfE variable data is either available or 
can be estimated at the PCT level.  We decided to validate the local model by comparing it, 
in terms of prediction, to a model including all available and significant HSfE variables.  In 
addition, however, the amount of missing data affects the prediction of a model.   
 
The local model used only used locally available data.  In future body mass index (BMI) could 
be included on the basis that local synthetic estimates are now available and good local data 
from primary care may soon be.  Local Limiting Longstanding Illness score data will be 
available locally from 2009 and could also be included later. 
 
Model construction: external validation 
An early external validation will be carried out by examining the association between 
PCT/LA level high blood pressure prevalence estimates and QOF registered prevalence.  The 
regression-based model will also be validated against a prevalence model obtained by 
Bayesian strategies using WinBUGS.  Finally, funding will be sought to undertake a validation 
of practice-based prevalence estimates against registered prevalence supplemented by 
active case finding. 
 
Model application 
The model input variables, which could be defined by the relevant user, e.g. at PCT or 
practice level, or pre-populated, include age-group, gender, smoking prevalence by gender 
and age, area of residence, area based deprivation score and ethnic distribution of the 
population.   
8.4.3 Results 
In developed countries, increasing age is by far the most important risk factor for high blood 
pressure, although this is not the case in non-developed agrarian societies.  The age-related 
increase in hypertension prevalence appears after migration to urban environments.  Table 
36 shows the increasing numbers of treated and hypertensive untreated respondents in the 
dataset. 
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Table 36: Hypertension Category By Age Band 
 Age Band  




2,132 1,408 979 498 
293 
8,020 
normotensive treated 1 7 45 123 239 224 120 759 
hypertensive treated 0 6 31 93 225 265 250 870 
hypertensive untreated 49 125 283 400 487 417 341 2,102 
Total 1,097 1,801 2,491 2,024 1,930 1,404 1,004 11,751 
 
“Local” model 
The regression model for hypertension risk factors for in the “local” prevalence model is 
shown in Table 37.  As expected ORs increase strikingly with increasing age in all models.  In 
the Excel-based prevalence predictions using coefficients (not shown in these tables), this 
results in age-related increases in prevalence which closely match those crude overall 
prevalence in Table 37.  An age-sex interaction was found (see Figure 5: modelled 
proportion hypertensive by age group and sex) and so interaction terms for age and male 
sex were created.  As expected a significant association was found between Black or Black 
British ethnicity and the outcome, and also with increasing deprivation. 










Female Sex 1.000      
Male sex 3.197 1.010 3.680 0.000 1.721 5.937 
Females Age 16-24 1.000      
Females Age 25-34 2.271 0.675 2.760 0.006 1.267 4.068 
Females Age 35-44 5.201 1.431 5.990 0.000 3.034 8.917 
Females Age 45-54 14.069 3.814 9.750 0.000 8.270 23.933 
Females Age 55-64 39.730 
10.72
0 13.650 0.000 
23.41
3 67.420 
Females Age 65-74 87.067 
23.89
9 16.270 0.000 
50.84
0 149.107 




2 17.510 0.000 
77.63
6 232.580 
Interaction Male Sex & Age 16-24 1.000      
Interaction Male Sex & Age 25-34 0.684 0.251 -1.030 0.301 0.333 1.404 
Interaction Male Sex & Age 35-44 0.572 0.191 -1.670 0.095 0.297 1.102 
Interaction Male Sex & Age 45-54 0.574 0.190 -1.680 0.093 0.300 1.098 
Interaction Male Sex & Age 55-64 0.370 0.121 -3.030 0.002 0.195 0.703 
Interaction Male Sex & Age 65-74 0.265 0.089 -3.970 0.000 0.137 0.510 
Interaction Male Sex & Age 75+ 0.191 0.066 -4.800 0.000 0.097 0.376 
White ethnic group 1.000      
Mixed ethnic group 0.920 0.256 -0.300 0.764 0.534 1.586 
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Black or Black British ethnic group 1.706 0.174 5.240 0.000 1.397 2.083 
Asian or Asian British ethnic group 1.054 0.083 0.660 0.509 0.902 1.230 
Any other ethnic group 0.972 0.155 -0.180 0.858 0.711 1.328 
Index of multiple deprivation    
0.59-8.35 1.000      
Index of multiple deprivation 8.35-
13.72 0.996 0.073 -0.060 0.953 0.862 1.150 
Index of multiple deprivation 13.73-
21.16 1.159 0.085 2.010 0.044 1.004 1.339 
Index of multiple deprivation 21.17-
34.21 1.210 0.092 2.520 0.012 1.043 1.404 
Index of multiple deprivation 34.22-
86.36 1.346 0.105 3.810 0.000 1.156 1.568 
 
Interactions between variables 
We tested for interactions between variables.  Significant interactions were found on 
Mantel-Haenszel Odds Ratio and Wald tests for sex and ethnicity, and sex and age.  We 
therefore generated interaction terms for these variables in a regression model.  Only age 
and sex showed a number of significant associations across strata, for the three oldest age-
sex categories (p<0.001-0.003).  We therefore included an interaction term in the final local 
model.  This means that there are two separate effects of age on the outcome: one for 
males and another for females.  The interaction terms shown represent the interaction 
between sex and age, and show the combined effect of being male and of a particular age 
group.  The interaction is clearly demonstrated in the chart below of the prevalence of 
hypertension by age and sex.  The prevalence of hypertension in females crosses over that 
in males in the older age groups. 
Figure 5: modelled proportion hypertensive by age group and sex 
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“Complete” model 
The regression model for risk factors for high blood pressure in the “complete” model with 
BP drugs is shown in Table 38: Odds ratios for Ntiles of IMD score (stepwise regression).  
Stepwise addition of variables in addition to age and sex was undertaken and only 
independent variables which were significant in this case were included in the final 
complete model.  Variables which were eliminated through this process were: 
 Cigarette Smoking Status - Never/Ex-reg/Ex-occ/Current 
 Salt added at when cooking? SC 16+ 
 EQ-5D social preference weight (mean) 
 GHQ Score - 12 point scale 
 NS-SEC 5 variable classification (individual) 
 
Although EQ-5D social preference weight (mean) and GHQ Score - 12 point scale were 
marginally significant when tested stepwise, they ceased to be so in the complete model 
and were excluded.  On the other hand, although ORs increase with increasing deprivation.  
Index of multiple deprivation (SOA level) also ceased to be significant in the complete 
model, but has been retained as it is included in the local model.  ORs for IMD score from 
stepwise regression are shown in Table 38 below for comparison, and are similar to the local 
model.  This could be explained by collinearity with highest educational qualification in the 
complete model. 
Table 38: Odds ratios for Ntiles of IMD score (stepwise regression) 
 RRR 
Std. 
Err. z P>z 
[95% 
Conf. Interval] 
0.59->8.35 [least deprived] 1.000      
8.35->13.72 0.999 0.073 -0.02 0.987 0.865 1.153 
13.72->21.16 1.178 0.086 2.24 0.025 1.021 1.360 
21.16->34.21 1.267 0.095 3.15 0.002 1.093 1.467 
34.21->86.36 [most 
deprived] 1.458 0.109 5.05 0 1.260 1.688 
 
As expected, ORs increase markedly with increasing age in all models, with confidence 
intervals above 1 from age 35.  Note that age group 16-24 has been defined as the baseline 
odds.  There is a significantly lower overall OR for female sex and for most categories of 
increasing physical activity.  This latter relationship has been described in numerous other 
studies and is one of the most important pathways through which physical activity reduces 
CVD risk.  There is also a strong significant increase in ORs with increasing BMI.  The result 
for Salt added at table is unexpected and counter-intuitive, with a significant increase in ORs 
for “rarely, or never, add salt at the table”.  There was a good response rate for this 
question (14,478/21,286). 
 
Table 39 shows odds ratios for the “complete” model.  ORs are significantly higher in the 
Black or Black British ethnic groups.  There are some associations between measures of 
deprivation and educational level and the high blood pressure outcome. 
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Females 1.000      
Males 3.173 1.057 3.47 0.001 1.651 6.096 
Females Age 16-24 1.000      
Females Age 25-34 1.834 0.584 1.9 0.057 0.982 3.423 
Females Age 35-44 4.101 1.202 4.82 0 2.309 7.284 
Females Age 45-54 9.937 2.881 7.92 0 5.630 17.540 
Females Age 55-64 26.757 7.746 11.35 0 15.171 47.191 
Females Age 65-74 54.697 16.224 13.49 0 30.583 97.824 
Females Age 75+ 99.816 30.945 14.85 0 54.363 183.270 
Interaction Male Sex & Age 16-24 1.000      
Interaction Male Sex & Age 25-34 0.787 0.306 -0.62 0.537 0.367 1.686 
Interaction Male Sex & Age 35-44 0.589 0.208 -1.5 0.134 0.295 1.177 
Interaction Male Sex & Age 45-54 0.600 0.210 -1.46 0.144 0.302 1.190 
Interaction Male Sex & Age 55-64 0.375 0.130 -2.82 0.005 0.190 0.741 
Interaction Male Sex & Age 65-74 0.286 0.102 -3.52 0 0.143 0.574 
Interaction Male Sex & Age 75+ 0.187 0.070 -4.49 0 0.090 0.389 
Ethnic Group       
white 1.000      
mixed ethnic group 0.943 0.297 -0.19 0.853 0.510 1.747 
black or black british 1.668 0.190 4.49 0 1.334 2.086 
asian or asian british 1.092 0.095 1 0.315 0.920 1.296 
any other group 1.095 0.197 0.51 0.612 0.770 1.558 
Total days/4 weeks active 30 mins + moderate 
+ 
      
none 1.000      
less than 1 0.762 0.066 -3.16 0.002 0.644 0.902 
1 or 2 a week 0.832 0.063 -2.44 0.015 0.717 0.965 
3 or 4 a week 0.750 0.069 -3.13 0.002 0.626 0.898 
5 or more a week 0.694 0.052 -4.86 0 0.599 0.804 
Body mass index (BMI)       
under 20 1.000      
20-25 1.860 0.318 3.64 0 1.331 2.600 
25-30 2.996 0.506 6.5 0 2.153 4.171 
Over 30 5.413 0.931 9.82 0 3.864 7.582 
Salt added at table       
generally add salt to food without tasting it 
first 
1.000      
taste the food, but then generally add salt 1.121 0.103 1.24 0.217 0.935 1.343 
taste the food, but only occasionally add salt 1.078 0.089 0.91 0.365 0.917 1.268 
rarely, or never, add salt at the table 1.225 0.093 2.66 0.008 1.055 1.423 
Ntiles of IMD score       
0.59->8.35 [least deprived] 1.000      
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8.35->13.72 0.959 0.075 -0.54 0.591 0.822 1.118 
13.72->21.16 1.105 0.087 1.26 0.206 0.946 1.291 
21.16->34.21 1.118 0.094 1.32 0.186 0.948 1.318 
34.21->86.36 [most deprived] 1.163 0.102 1.72 0.086 0.979 1.381 
Highest educational qualification separate       
NVQ4/NVQ5/degree or equiv 1.000      
higher ed below degree 1.014 0.100 0.14 0.891 0.835 1.231 
NVQ3/GCSE A level equiv 1.159 0.123 1.39 0.164 0.942 1.426 
NVQ2/GCSE O level equiv 1.157 0.100 1.69 0.09 0.977 1.370 
NVQ1/CSE other grade equiv 1.212 0.163 1.43 0.152 0.932 1.577 
foreign/other 1.440 0.195 2.7 0.007 1.105 1.878 
no qualification 1.262 0.108 2.71 0.007 1.066 1.494 
Full time student 1.363 0.184 2.29 0.022 1.046 1.776 
Limiting long-term illness       
limiting long-term illness 1.000      
non limiting long-term illness 1.560 0.109 6.35 0 1.360 1.789 
no long-term illness 0.882 0.055 -2.01 0.045 0.781 0.997 
 
Internal validation: area under Receiver Operating Characteristics curve (AUROC) 
AUROCs for the local and complete models tested above were estimated using Stata10.  
These are shown in Figure 6and Figure 7 below.  If both sensitivity and specificity are of 
importance in a high blood pressure model, the optimal threshold of t would be 0.75, where 
these 2 accuracy measures equal sensitivity and specificity equal 0.77.  The local model, 
with an AUROC of 0.8071 exceeds this level, although the complete model has even better 
performance, with an AUROC of 0.8304. 
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Figure 6: ROC Curve for local hypertension model 
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Validation: model prediction 
Residuals were tabulated against the observed presence of high blood pressure to assess 
“misclassification” by each model (in shaded cells).  The results for the local and complete 
models are shown in Table 40 and Table 41 below.  The complete model shows slightly 
lower misclassification but this is minimal in view of the lower overall numbers in this 
model. 
Table 40: comparison of observed: predicted hypertension- local model 
  Predicted  
  Not_hypertensive Hypertensive Total 
 
Observed 
Not_hypertensive 6,886 1,129 8,015 
Hypertensive 1,717 2,012 3,729 
Total 8,603 3,141 11,744 
Table 41: comparison of observed: predicted hypertension- complete model 
  Predicted  
  Not_hypertensive Hypertensive Total 
 
Observed 
Not_hypertensive 6,446 938 7,384 
Hypertensive 1,424 1,878 3,302 
Total 7,870 2,816 10,686 
8.4.4 Application: PCT, LA and practice level models 
The same practice, LA and PCT population data used for the other models was used here.  In 
order to estimate prevalence of hypertension in the future, population projections were 
incorporated into the model. Modelled estimates of disease prevalence at practice level 
were provided for 2007 for the adult population (aged 16+ years) using a similar 
methodology to previous models. By assuming that the prevalence of disease is 0% in the 
under 16s, prevalence estimates for all ages were calculated. These all-age prevalence are 
more closely equivalent to QOF prevalence.  For each practice the model required the 
following input data: 
 Population by age and sex 
 Distribution of ethnic groups by age and sex (not required for stroke model) 
 Prevalence of smoking and ex-smoking by age and sex (not required for hypertension 
model) 
 IMD deprivation score 
 Urban-suburban-rural category (only required for COPD model) 
The same assumptions have been made as previously in the modelling process. For some 
practices, particularly those with a large minority ethnic population, these assumptions may 
not hold and the model may not be an accurate reflection of true prevalence. 
 The distribution of ethnic groups within each age-sex group is the same as the 
overall distribution of ethnicity for the practice. 
 Smoking prevalence is the same across ethnic groups 
 Ex-smoking prevalence by age group and sex is the same in all practices.  
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 Disease prevalence in population aged <16 is 0%. 
The urban-suburban-rural categorisation of the MSOA where the practice is located is 
representative of the catchment population of the practice.  Only practices with a complete 
input dataset could be included in modelling. 
 
 Data sources 
As before practice populations by age and sex were derived from a NSTS extract taken on 
31/03/2007. The proportion of practice population in ethnic groups was supplied by the 
CQC, as for the other models.  The proportions were derived from HES admissions in 
2005/06-2006/07, excluding mental health and maternity admissions and records with 
unknown ethnicity. The proportions by ethnic group for each practice were calculated by 
dividing admissions within each ethnic category by the total admissions for the practice.  
 
This model also used IMD2007 scores for practices, derived by SEPHO in August 2008. These 
scores are weighted MSOA IMD scores based on the March 2008 Attribution Data Set. 
Practice smoking prevalence is based on NatCen synthetic estimates of smoking at MSOA 
level 2003-2005 (available from Neighbourhood Statistics). Practice smoking prevalence was 
calculated as the weighted average of prevalence in MSOAs in the practice catchment area, 
determined from postcodes in cleaned 2007 NSTS data (as above) for patients aged 16+.  
The Urban-suburban-rural categorisation is based on the Rural and Urban area classification 
of Super Output Areas, 2004 (available from Neighbourhood Statistics) shown previously. 
The urban-suburban-rural category of the MSOA in which the practice is physically located is 
used in the COPD model. 
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8.5 Cardiovascular Disease Model 
8.5.1 Introduction 
The CQC commissioned Eastern Region PHO to develop prevalence models for 
cardiovascular disease and cardiovascular disease including diabetes, to complement 
models already developed for stroke, CHD and hypertension.  They in turn commissioned 
the CVD model development from ICL.  These models were also developed from person-
specific data from HSfE.  For the CVD and CVD+diabetes models, data for the 2003, 2004 
and 2005 Surveys were merged, as all three cover (to a variable extent) established CVD and 
known CVD risk factors.  The 2003 HSfE covered CVD in detail, the 2004 Survey included a 
boost for ethnic minorities (some of which are known to have higher prevalence of CVD), 
and the 2005 HSfE covered older people- age is the most important risk factor for CVD. The 
outcome variables CVDDIS, a derived variable, defined as “has had CVD (Angina, Heart 
Attack or Stroke only)”, and excluding heart murmur, irregular heartbeat and other heart 
disease was selected from the HSfE datasets for modelling. Review of CVD, stroke & CHD 
Prevalence 
 
Overall CVD Prevalence 
Unadjusted trends in CVD prevalence from the HSfE are shown in Table 42.  This table uses 
the same definition of CVD used for modelling. 
Table 42: trends in HSfE prevalence of overall CVD (ever), by survey year, age and sex (all 
adults) 




16-24 0.1 0.3 0.3 0.2 0.3 0.2 
25-34 0.3 0.5 0.3 0.3 0.3 0.2 
35-44 0.6 1.3 1.0 0.8 1.1 0.8 
45-54 3.0 3.8 3.5 3.3 3.4 3.3 
55-64 9.8 11.5 10.0 8.6 10.1 8.7 
65-74 18.5 19.6 19.3 18.7 19.5 18.6 
75+ 22.8 26.7 28.4 31.6 28.4 31.3 
All adults 6.1 7.2 7.5 5.8 6.8 6.8 
Source: The Information Centre for Health & Social Care 150 
 
I performed a literature search of the MEDLINE database using "cardiovascular disease" and 
prevalence as keyword and title search terms. The HSfE is unusual in that most cross-
sectional prevalence studies have focused on IHD/CHD or stroke separately.  In the US 
equivalent of HSfE, the 1999-2002 NHANES,151 a history of myocardial infarction and stroke 
was reported by 3.29% and 2.41%, respectively, of adults, which is very similar.  Other 
published reports of overall CVD prevalence are rare.  The Framingham Study is the best 
known long-term cohort study of CVD incidence and associated risk factors 152.  Although 
                                                     
1   Data up to 2002 are unweighted; from 2003 onwards data have been weighted for non-response. From 
2003 onwards data are shown both unweighted (for consistency with previous years) and weighted 
(shaded columns). 
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most initial work was on CHD events,153 and stroke was classified as cerebrovascular disease 
rather than CVD, data collection also included stroke152.  However, only stroke/CVA 
incidence data, gathered from hospitals and death certificates, was published. 
 
The SCORE project assembled a pool of datasets from 12 European cohort studies, mainly 
carried out in general population settings 154. There were 205,178 persons representing 2.7 
million person years of follow-up. There were 7934 CVD deaths of which 5652 were deaths 
from CHD.  However the published SCORE report also does not report the prevalence of 
CVD, and it may be that respondents with pre-existing CVD were excluded from the analysis.  
The WHO MONICA Project was established in the early 1980s to monitor trends in CHD and 
to relate these to risk factor changes, but it did not cover stroke 155.  Studies of overall CVD 
prevalence have been carried out in New Zealand.156  Other papers which studied CHD or 
stroke separately are reviewed in the sections describing these models. 
 
Previous CVD prevalence modelling 
There has apparently been very little previously published modelling of CVD prevalence.  A 
report from New Zealand estimated the prevalence of CVD and distribution of CVD risk in 
New Zealanders for healthcare planners, funders, and providers 157.  Survey data provided 
estimates of CVD prevalence and absolute CVD risk distributions, and these were applied to 
population data using the Framingham CVD risk prediction equation.  About 7% of the 
population were estimated to have suffered a non-fatal heart attack or stroke or have 
angina. A further 13% were estimated to have a 5-year CVD risk greater than 15% based on 
New Zealand CVD risk charts. 
8.5.2 Methods 
Data Sources 
The CVD model described here uses data from the 2003, 2004 and 2005 HSfE.   Because the 
HSfE has shown that CVD prevalence varies with ethnicity 1, I used a sample containing data 
from a large number of ethnic minority respondents.  The HSfE 2004 was the last Survey to 
include an ethnic minority boost, and the boost sample was used for the modelling.  
However, there were relatively small numbers of Whites in the HSfE 2004 sample, and BP 
was not measured for most respondents in the 2004 general population sample, 
presumably to save resources for the boost itself.  The HSfE 2004 boost sample was 
therefore merged with the HSfE 2003 and 2005 data, both of which measured BP.  Table 43 
shows the ethnic group breakdown of the merged dataset.  Note that it was necessary to 
collapse two of the HSfE 2003 ethnic group variables  to use the same classification as HSfE 
2004 and 2005. 
Table 43: Ethnic Group Breakdown of merged dataset 
Ethnic Group N Percent 
White 24,025 76.62 
Mixed 384 1.22 
Black or Black_British 2,146 6.84 
Asian or Asian British 4,107 13.1 
Chinese or Other 696 2.22 
Total 31,358 100 
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NB excludes no answer/refused/don’t know 
Definitions 
There were 31,458 respondents in the merged dataset, of whom around 31,430 answered 
questions on CVD.  The definitions used in the relevant HSfE variable and for the models are 
as follows (variable name in capitals): 
 CVDIS: a derived variable, defined as “has had CVD” including angina, heart attack or 
stroke.  This variable was used for the overall CVD prevalence model 
 CVDDEF: a derived variable, defined as “has had a cardiovascular condition”,  
including heart murmur, diabetes, high blood pressure, angina, heart disease,  
irregular heartbeat, other heart disease, or stroke 
 CVDDEF1: a derived variable, defined as “has had a cardiovascular condition 
excluding diabetes/high BP”, but including heart murmur, angina, heart disease, 
irregular heartbeat, other heart disease, or stroke.   
 NOBPCVD: a derived variable, defined as “has had a cardiovascular condition 
excluding those with high blood pressure”, but including heart murmur, diabetes, 
angina, heart disease, irregular heartbeat, other heart disease, or stroke.  This 
variable was used for the overall CVD+diabetes prevalence model 
 IHDIS: a derived variable, defined as “has had IHD/CHD” including only angina or 
heart attack.  This variable was used for the CHD prevalence model 
 STRODEF: a derived variable, defined as “doctor-diagnosed stroke”.  This variable 
was used for the stroke prevalence model 
 
All these variables are based on a patient-reported but doctor-diagnosed history of the 
disease.  There are differences between various methods of estimating CVD prevalence.  
The positive predictive value of questionnaire responses such as those used in HSfE may be 
sub-optimal in comparison with clinical diagnosis. Conversely, reliance on a medical 
diagnosis may underestimate prevalence, as patients with unrecognised disease or very mild 
symptoms may not attend (or be correctly identified by) their GP. 
 
Table 44: Comparison of HSfE CVDEF1 & CVDIS variables in model dataset below compares 
the HSfE definitions of CVDIS and CVDDEF1 in the merged dataset.  The definition of 
CVDDEF1 is broader than CVDIS, incorporating heart murmur, irregular heartbeat and other 
heart disease (this presumably including heart failure).  The greater proportion of the latter 
two categories will have been originally caused by IHD/CHD.  However CVDIS has therefore 
been used in the model fitting because this corresponds most closely to the definitions used 
in the development of the Framingham/Joint British Societies and QRISK2 risk scoring 
algorithms.   
Table 44: Comparison of HSfE CVDEF1 & CVDIS variables in model dataset 
  CVDIS: has had CVD (angina, 
heart attack or stroke) 
Total 
  yes no  
CVDDEF1: Has had CVD condition 
(excluding diabetes/high BP) 
no 0 27,325 27,325 
yes 2,452 1,654 4,106 
 Total 2,452 28,979 31,431 
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In the HSfE, ‘diabetes’ means self-reported doctor-diagnosed diabetes, excluding pregnancy 
(DIABETE2). The HSfE interview makes no distinction between type 1 and 2 diabetes. For 
HSfE classification purposes, type 1 diabetes is defined as being diagnosed before the age of 
35 and being on insulin therapy at the time of the survey.  For those respondents who had a 
fasting blood sample taken, a fasting blood plasma glucose level ≥ 7mMol/l in the absence 
of a reported diagnosis of diabetes is considered indicative of ‘undiagnosed diabetes’. The 
prevalence of undiagnosed diabetes is reported separately in the HSfE for the subgroup with 
a valid fasting blood sample and aged over 35.  The prevalence of ‘controlled diabetes’ is 
assessed by measuring glycated haemoglobin, but the HSfE bases were too small to examine 
levels in subgroups. 
 
In the merged 2003-5 dataset, the crude prevalence of self-reported doctor-diagnosed 
diabetes is 4.83% (1,518 of 31,457 respondents).  Blood samples were tested for glucose 
only in the 2003 and 2004 Surveys.  In the merged dataset, only 2,148 respondents had a 
fasting plasma glucose (FPG), of whom 90 had a result ≥ 7mMol/l (Table 45).  Of these, only 
35 had undiagnosed diabetes.  I considered imputing FPG values for other patients in the 
dataset.  This could be done if requested but will require more methodological 
development.  We would expect about 1.74% of patients without patient-reported doctor-
diagnosed diabetes to have undiagnosed diabetes. 
Table 45: frequency of patient-reported doctor-diagnosed diabetes and undiagnosed 
diabetes in respondents with an FPG 







2,007 35 2,042 
% 97.52% 38.89% 95.07% 
Patient-reported diabetes 51 55 106 
% 2.48% 61.11% 4.93% 
Total 2,058 90 2,148 
 
Model construction: data issues 
The choice of variables for original inclusion in the merged dataset included all those known 
to be CVD risk factors.  The HSfE dataset has a nested or hierarchical structure so three 
variables related to the sampling strata were included: area (sample point), cluster 
(stratification level), and hserial (serial number of household).  These were used in the 
model to adjust for clustering of respondents. In the analysis variables CHOLEST and 
HDLCHOL were combined to give a lipid ratio.  IMD 2004 score bands were slightly different 
between the two years, but raw scores were not provided in the dataset so it was necessary 
to assume identity. 
 
The Stata software package was used for analysis.  The methodology applied for model 
fitting was multinomial logistic regression with the “cluster” option as for previous models.  
The prevalence in each age group, gender, ethnic group, area of residence and level of 
deprivation, and smoking status category were derived from the odds, using the formula: 
Estimating disease prevalence in small populations 
 
89 
M Soljak PhD Thesis 
prevalence = odds/(1 + odds).  Variables for both “local” and “complete” models were 
selected by reverse stepwise selection using likelihood ratio (LR) and Wald tests i.e. the 
model was fitted using all available exposure variables, omitting each in turn and recording 
p values 158.  The variable with the highest p value was omitted and the tests were repeated.  
Since the models were to be used for prediction rather than hypothesis testing, a p value of 
0.2 was used.  No significant interactions were found using χ2 tests. 
8.5.3 Results 
The local model only used locally available data.  I included smoking as practice synthetic 
estimates are now available.  Local GHQ-12 or Limiting Longstanding Illness score data will 
be available locally from 2009 and could be included later.  Ideally, the best prediction 
should result from utilising the most information in the regression model.  However only a 
limited range of HSfE variable data is either available or can be estimated at the PCT level.  
We decided to validate the local model by comparing it, in terms of prediction, to a model 
including all available HSfE variables.  In addition, however, the amount of missing data 
affects the prediction of a model.  For example, in the complete HSfE variables the largest 
proportion of missing data occurred in those variables related to particular drug treatment 
for high blood pressure.  Some clinical tests also have a high proportion of missing values.  
Hence the “complete” model included the complete list of variables, including differing 
definitions of high blood pressure (history of high blood pressure, or clinically measured 
hypertension >140/90 at the time of the Survey).   Table 46 shows crude CVD, diabetes and 
CVD+diabetes prevalence in the merged dataset, using the stated variables. 
Table 46: Crude CVD, diabetes and CVD+diabetes prevalence rates in 2003-5 dataset 
 Age in 10 year bands 
 16-24 25-34 35-44 45-54 55-64  65-74 75+  Total 
No CVD 99.82 99.66 98.95 97.34 92.64 80.57 71.14 86.94 
CVD 0.18 0.34 1.05 2.66 7.36 19.43 28.86 13.06 
No diabetes 99.6 99.32 98.16 96.53 93.91 87.69 89.84 95.17 
Diabetes 0.4 0.68 1.84 3.47 6.09 12.31 10.16 4.83 
No CVD or 
diabetes 97.04 95.9 93.21 90.29 83.58 64.96 55.73 83.86 
CVD+diabetes 2.96 4.1 6.79 9.71 16.42 35.04 44.27 16.14 
Raw numbers 3,273 5,023 5,817 4,808 4,313 4,629 3,567 31,430 
 
Local  CVD Model 
Table 47 shows ORs, p values and confidence intervals for the local CVD model.  Values are 
generally similar to the more complete model.  Unfortunately, however, local synthetic 
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Table 47: odds ratios, local CVD model 
 RRR Std. 
Err. 




Female 1.000      
Male 1.550 0.073 9.32 0 1.414 1.700 
Age 16-24 1.000      
Age 25-34 1.790 0.852 1.22 0.221 0.704 4.549 
Age 35-44 6.119 2.628 4.22 0 2.637 14.198 
Age 45-54 15.591 6.539 6.55 0 6.853 35.470 
Age 55-64 47.533 19.727 9.3 0 21.073 107.214 
Age 65-74 144.217 59.426 12.06 0 64.309 323.416 
Age 75+ 255.112 105.356 13.42 0 113.554 573.138 
Never smoker 1.000      
Used to smoke occasionally 0.858 0.094 -1.4 0.161 0.692 1.063 
Used to smoke regularly 1.384 0.077 5.87 0 1.241 1.542 
Current smoker 1.140 0.083 1.81 0.07 0.989 1.314 
IMD 2004 0.59->8.35 [least 
deprived] 
1.000      
IMD 2004 8.35->13.72 1.184 0.089 2.24 0.025 1.021 1.373 
IMD 2004 13.72->21.16 1.295 0.100 3.35 0.001 1.113 1.506 
IMD 2004 21.16->34.21 1.497 0.114 5.31 0 1.290 1.737 
IMD 2004 34.21->86.36 [most 
deprived] 
2.176 0.163 10.36 0 1.879 2.522 
White 1.000      
Mixed 0.809 0.320 -0.54 0.591 0.372 1.756 
Black/BB 0.781 0.104 -1.85 0.064 0.602 1.014 
Asian/AO 1.613 0.150 5.15 0 1.345 1.935 
Other 0.692 0.190 -1.34 0.181 0.404 1.186 
 
Sensitivity/Specificity: ROC Curve 
Sensitivity and specificity were calculated using the area under the receiver operating 
characteristics (ROC) curve.  The AUC for the local CVD model is 0.8601 
 
Internal validation: prediction 
Another method of assessing performance is to use the regression model to predict the 
response for each subject.  These predictions are called fitted values.  The difference 
between the fitted and the observed values are called residuals.  These can then be 
tabulated against the observed presence of CHD to assess “misclassification” by each model. 
Prediction by the models is shown in Table 48: actual vs predicted CVD below. 
Table 48: actual vs predicted CVD 
  Predicted 
Model  No CVD CVD Total 
Actual 
No CVD 27,095 11 27,106 
CVD 4,073 7 4,080 
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  Predicted 
Model  No CVD CVD Total 
Total 31,168 18 31,186 
8.5.4 Application: PCT, LA and practice level models 
The local model (which includes only those variables that are available at population level 
i.e. age, sex, ethnicity, smoking status and deprivation score) has been applied to Local 
Authorities to create prevalence estimates of coronary heart disease in those aged 16+ for 
2005–2020. Models for PCTs have been created for 2006-2020. 
 
Assumptions of the modelled estimates 
It is assumed that:  
 the proportion of smokers, ex-smokers and never-smokers is the same across ethnic 
groups. 
 the proportion of ex-smokers in each age-sex group is the same in all areas.  
 the smoking prevalence rates from the model-based estimates of lifestyle 
behaviours (43) are reliable. 
 the prevalence of CVD in those aged under 16 is negligible. 
Due to lack of data, it was not possible to treat ex-regular-smokers and ex-occasional-
smokers separately. Ex-occasional-smokers are treated as non-smokers. 
 
Populations 
The CVD prevalence model uses ONS 2005 mid-year population estimates by ethnic group, 
age and sex as for other models. Population projections were incorporated into the model. 
For 2008 and 2009, the distribution of ethnic groups in 2005 (LA) or 2006 (PCT) was applied 
to ONS 2006-based population projections by quinary age band for LAs and PCTs. National 
(England) proportions of smokers, ex-smokers and current smokers by age and sex were 
taken from HSfE (2003-2005 pooled). Practice smoking prevalence is based on NatCen 
synthetic estimates of smoking at MSOA level 2003-2005 (available from Neighbourhood 
Statistics). These proportions were then adjusted for each practice/LA/PCT as above.  The 
same smoking prevalence rates are applied across all ethnic categories. This model also 
used IMD2007 scores for practices, derived by SEPHO in August 2008. These scores are 
weighted MSOA IMD scores based on the March 2008 Attribution Data Set.  
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8.6 Cardiovascular Disease Risk Model 
The development of this model was commissioned by NE London Cardiac & Stroke Network 
on behalf of NE London PCTs, through the Public Health Action & Support Team, a 
community interest company.  I worked on model development with Andrew Dalton, and 
we have also submitted it for publication. 
8.6.1 Introduction 
The NHS Health Checks Programme159 is a high profile national policy in England designed to 
CVD mortality and health inequalities. It aims to lower CVD risk factors in those without pre-
existing CVD or diabetes160 through risk assessment and treatment of the entire 40-74 year 
old English population- about 22.4 million people- over a five year period. The local Health 
Check process is loosely specified by national guidance159;161, although PCTs have scope for 
innovation and originality to suit their population’s need. A minimum battery of procedures 
has been prescribed159, with further details following the release of a ratified minimum 
dataset in early 2011. 
 
The Health Checks, along with guidance on the use of statins for the primary prevention of 
CVD162, rely heavily on the notion of stratifying patients by absolute risk of developing CVD. 
Those designated at high risk will be offered a number of risk lowering interventions; 
including statins and weight management; and will be recalled for annual follow up. High 
risk is defined as an absolute or “global” risk of a CVD event within ten years of over 20%, 
designated by an appropriate risk calculator. The concept of global risk has changed CVD 
prevention in recent years and been shown to be a more cost effective strategy than 
managing individual risk factors163;164. There are many CVD risk scores available, although in 
the UK NICE has specified the use of either the Joint British Societies 224 (JBS2) or QRISK2111 
algorithms.  The JBS2 algorithm is a modification of the original Framingham risk score, 
which was developed from a North American cohort study,153 whereas QRISK2 was derived 
from a large sample of the English population using the QRESEARCH database (derived from 
the electronic medical records of general practices that use the EMIS system).   The 
unmodified Framingham risk score is known to over-estimate CVD risk in European 
populations.154 
 
High CVD risk status is central to the Health Checks programme, yet there are few estimates 
of the numbers at high risk in England, merely estimates from small populations111;165. 
Although the programme commenced in April 2009 and general practices will be capturing 
data electronically, there are as yet no national data.  Before the programme roll out, DH 
issued economic modelling 166 presenting the cost and cost effectiveness of different 
methods of CVD screening. They demonstrated the preference for a total population-based 
approach to screening, with risk reduction interventions for everyone found to have a risk 
factor whether high risk or not. Recent work, however, has suggested a more targeted 
approach may be of value167;168. DH modelling did not quote an estimate of the numbers 
expected to be at high risk, or estimates of the prevalence of CVD risk factors within the 
high risk population. Further, when estimating CVD risk factors in the high risk population, 
prevalence estimates from the general population were used. The population with high CVD 
risk will have a higher prevalence of risk factors than the general population; therefore 
prevalence in this group will be underestimated. 
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We were commissioned to develop this model by North East London Cardiac & Stroke 
Network, whose funding is gratefully acknowledged.  Previous work has demonstrated the 
ability to use HSfE data in the modelling of CVD risk169.  We used HSfE data to model the 
number of patients with a QRISK2 score of ≥20% in each general practice in England, and the 
number of patients within this group with CVD risk factors. We estimated the resultant costs 
of the programme, the reductions made in both hospital admissions and mortality 




We merged person-specific data from the HSfE from 2003 to 2006 inclusive.  Of 71,717 
informants, 28,209 were aged 40-74. We removed patients with diagnosed CVD, diabetes 
and hypertension i.e. those not eligible for the Health Checks. All further work was carried 
out using this population. In addition to the standard HSfE data we obtained the 2001 
Townsend deprivation score from the postcode of residence of each participant. 
 
Imputation of Missing Data 
One method of dealing with missing data in surveys or GP systems is imputation.  Multiple 
imputation aims to allow for the uncertainty about missing data by creating multiple copies 
of the dataset under analysis, in which the missing values are replaced by imputed values 
drawn using a statistical prediction based on the observed data. Standard statistical analyses 
are performed on each of the imputed datasets and the results are combined in an 
appropriate way to obtain final conclusions.170;171 
 
For example, this method was used in the development of QRISK2.110  Their model was 
initially fitted using patients without any missing data (complete case analysis), and the 
fractional polynomial terms were obtained from the complete case analysis using a 
multivariable approach. However, because patients with complete data might have a 
different health status and CVD risk compared with those with missing data, they fitted the 
principal models on the basis of multiple imputed datasets using Rubin's rules to combine 
effect estimates and estimate standard errors.158;172;173  They subsequently improved their 
implementation of multiple imputation for missing data by including more variables. 
 
The validity of imputation depends on the modelling being done carefully and appropriately, 
and it is not possible to automate the procedure. A number of pitfalls can arise. In 
particular, when an analysis explores the association between one or more predictors and 
an outcome, but some of the predictors have missing values, the outcome carries 
information about the missing values of the predictors, and this information must be used in 
the imputation procedure.  Given the relatively large sample size, it is uncertain to what 
extent imputation will improve the estimation of population prevalence from GP data.  We 
used multiple imputation in the development of our CVD risk model. 
 
We applied the QRISK2111 and JBS224 CVD risk algorithms to each informant’s data. The 
variables in each algorithm are shown in Table 49 below. Age, sex, ethnicity, smoking status 
and deprivation values were complete; 18,426 (65.3%) had blood pressure recorded, 17,373 
(61.6%) BMI and 12,621 (44.7%) had lipid ratios (total cholesterol and high density 
Estimating disease prevalence in small populations 
 
94 
M Soljak PhD Thesis 
lipoprotein). For the remainder we used multiple imputation based on complete data to 
estimate missing values173. QRISK2 contains additional data concerning chronic conditions 
which increase CVD risk. In the algorithm these can be assumed to be absent if data are 
missing174.  Family history of CVD was near complete, with the 973 missing assumed null; 
there are no data in the HSfE for chronic kidney disease (CKD) or rheumatoid arthritis 
therefore these were excluded. Finally there were no data on atrial fibrillation (AF), however 
using estimates from a population-based survey of ECG abnormalities95 we estimated the 
number of cardiac arrhythmias (found in HSfE) caused by AF, and applied this prevalence at 
random to the population with arrhythmias. 
Table 49: variables included in QRISK2 and JBS2 algorithms 
Variable QRISK2 JBS2 
age X X 
sex X X 
body mass index X  
deprivation score (Townsend) X  
systolic blood pressure X X 
cholesterol ratio X X 
family history of coronary heart 
disease 
X X 
smoking status X X 
treated hypertension X  
type 2 diabetes X X 
atrial _fibrillation X  
rheumatoid arthritis X  
chronic renal disease X  
history of cardiovascular disease X  
ethnicity X X* 
 
* NICE guidance recommends that, if JBS2 is used, the risk score should be increased by a 
factor of 1.4 for men with a South Asian background, by a factor of 1.5 if one first-degree 
relative has a history of premature CHD, and by a factor of up to 2.0 if more than one first-
degree relative has a history of premature CHD 
 
High risk models 
We partitioned the population based on age (40-49, 50-54, 55-64, 65-74); gender; ethnicity 
(white, south Asian, black, other) and deprivation (national thirds of Townsend score), giving 
96 data cells. We applied the risk algorithms to the data then calculated proportions at high 
risk (≥20%) in each cell. Any cell with fewer than 10 entrants was combined with the 
adjacent cell (the next age group). 
 
We obtained age and sex breakdowns of every general practice in England175 and subtracted 
the number of patients on the CHD, Stroke/TIA, diabetes and hypertension registers13. 
Based on the HSfE data, we assumed 40% of diabetes patients appear on a CVD register and 
37% of the hypertension register have CVD or diabetes. Using HSfE data we estimated the 
age distribution of each condition, and hence the proportion in the 40-74 age group. We 
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obtained estimates of the ethnic breakdown of each practice from the CQC, which were 
derived by assuming the proportions of ethnic minority populations admitted to hospital 
reflected the ethnic composition of LSOA resident populations, and applying these to 
practice populations. We applied the ethnicity proportions to our population data assuming 
the ethnic breakdown was equal over age/ sex groups. We used CQC Townsend Deprivation 
scores for each practice, based on the residency of their registered population, and assigned 
each practice to a national third. We assumed that the whole practice population lay in the 
same third. Each practice was broken down into the same 96 cells as the risk proportions 
and we applied the risk proportions to each, giving the number of patients with a ≥20% 
score for each risk score; these were summed to give PCT level estimates. We then mapped 
the estimated PCT prevalence of high risk status in England. 
 
CVD risk factors in high risk group 
From within the HSfE population found to be high risk we modelled the number of patients 
with individual CVD risk factors. These were BMI greater than 25; undiagnosed hypertension 
(assuming 50% of patients with a raised blood pressure proceed to be diagnosed with 
hypertension166); physical inactivity; undiagnosed impaired glucose tolerance (IGT) (fasting 
plasma glucose between 6 and 7) and smoking. Additionally, we assumed all patients ≥20% 
risk were prescribed statins 162 and estimated the prevalence of undiagnosed diabetes 
(fasting plasma glucose  greater than 7). Taking the high risk population, we found the 
proportion in the HSfE data of patients in each age/ sex category with risk factors, and 
transposed the proportions onto the PCT high risk estimates. 









Smoking 19% 15% 51% 0.36  £ 176.80  
Anti-Hypertensive 40% 87% 24% 0.24  £ 29.64 (£70†) 
Exercise 77% 23% 63% 0.14  £ 33.50  
IGT lifestyle 85% 90% 90% 0.09  £ 462.00  
Statin prescription 85% 70% 50% 0.31  £ 60.52  
Weight management 85% 68% 47% 0.36  £ 51.00  
 
Costs and benefits  
We used the DH costs of the basic NHS Health Check and initial interventions and referrals 
(related to the major risk factors in Table 50 above). Model assumptions were derived from 
the DH impact assessment166. We assumed 70% attendance at the initial health check based 
on DH assumptions; additional model assumptions are shown in the appendix (box A1). We 
estimated the costs of the basic health check; including time, diagnostic tests and resultant 
referrals but not additional time for the diagnoses. 
 
By applying formula 1, where RRRi = relative risk reduction for intervention i; Ni = the 
number of patients completing intervention i; Rx = the mortality or admission rate, we 
estimated the reduction in mortality or admissions as a result of each intervention. 
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( )                 
 
Using the numbers taking up and adhering to the interventions we estimated savings in 
hospital admissions and mortality. We obtained PCT level hospital mortality and admission 
data, using International Classification of Disease (ICD) codes I20-I25, I63 and I64 for 
mortality and the associated Healthcare Resource Group (HRG) codes for admissions, the 
case mix groupings used to fund NHS acute hospitals according to a standard national tariff.  
We assumed an immediate impact of the interventions on CVD risk and estimated the 
reductions in mortality and hospitals costs after the whole population has been screened. 
All data analyses were carried out using Stata 11.1SE. 
8.6.3 Results 
Prevalence of high CVD risk 
We estimate a total of 3,020,786 people in England, aged 40-74, have a QRISK2 score ≥20% 
out of a population of 22,397,278 (13.5% [95% CI= 13.47-13.50]) (Table 51). The mean 
number per PCT was 19,874 [95% CI= 18,019- 21,729], and the median 16,392 (range = 
6,007- 71,239; IQR= 12,350). As a percentage of the 40-74 population the PCT mean was 
13.6% [95% CI = 13.39-13.81]; median =13.7% (range= 10.3%- 17.3%; IQR= 1.95%).  Table 51 
further presents the practice level numbers and percentages of the 40-74 population at high 
risk.  Figure 8 shows the geographical distribution of high risk status in England, with the 
highest prevalence is centred on the major urban areas in northern England. 
























13.5% 13.6% 13.4% -13.8% 10.3%-17.3% 13.7% 1.95% 
  
Practice-level 






 367 362-372 0-2,272 316 332 
Prevalence High 
Risk 
 13.6% 13.5%-13.7% 0%-30.8% 13.6% 3.0% 
 
Prevalence of risk factors in the high risk population 
Within the high risk population the number with individual CVD risk factors can be seen in 
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Table 52. A large proportion of the population were both physically inactive (79.1%) and 
overweight or obese (81.6%). We estimate Health Checks will find 768,405 undiagnosed 
hypertensive patients and 438,015 with IGT, and will detect 126,876 patients with 
undiagnosed diabetes, a mean of 835 [757-913] per PCT. 
Figure 8: the prevalence of high risk status, using the QRISK2 score, in the 40-74 year old 
population in England 
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Table 52: the prevalence of CVD risk factors in the high risk population, † due to small 
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Comparison to JBS2 
 Using the JBS2 algorithm, there were a larger number of people classified as high risk; 
4,634,965 aged 40-74 (20.69% [20.67-20.71]), with a mean of 30,493 [27,698-33,289] per 
PCT, and a median 24,707 [range =9,197-106,010; IQR= 18,147]. There were more patients 
with CVD risk factors (table 3); these did not increase uniformly with the increase in 
numbers at high risk. Figure 9 shows the proportions of the high risk population with each of 
the five risk factors using the two risk scores. The JBS2 population had an especially large 
proportion of smokers (35.9%) and undiagnosed hypertension (29.7%), whilst QRISK2 had a 
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Figure 9: percentage of the high risk population with CVD risk factors using the QRISK2 
and JBS2 risk scores 
 
 
Costs and risk reductions 
 In the 3,020,786 high risk patients, with a total of 2,114,539 screened (70% uptake), we 
estimate the total cost of the basic health check for the high risk population in England to be 
£ 34,063,143. The average cost per PCT was £224,100 and median £184,847, ranging from 
£67,757 to £803,236. The total cost, including the six risk factor interventions, was 
£358,900,728. The mean per PCT was £2,361,189, median= £1,947,958, ranging from 
£731,440-£8,652,724. 
 
Screening the high risk patients in England, taking 2008-9 admission rates as the baseline, 
will save  6,824 admissions per year, out of a total of 661,199 (1.0%). Per PCT there will be 
44.9 [40.3-49.4, median =36 (range 10-142)] admissions saved per annum. Health Checks in 
the high risk population will reduce CVD mortality by 1,252 deaths per annum in England 
(1.1% reduction), with a median of 7 per PCT (range = 2-28).  In comparison, the total costs 
using JBS2 would be £ 469,359,340, ranging from £845,812- £9,701,207, with the cost of 




Our model using the QRISK2 risk score, estimates 3 million patients aged 40-74 at high 
(≥20%) risk of CVD in England, 13.5% of the population. There was wide geographic variation 
in the prevalence. Using the JBS2 risk score to risk stratify patients, results in considerably 
larger numbers at high risk. Within the high risk population we estimate a high prevalence 
of cardiovascular risk factors; for example 82% of the high risk will be overweight or obese 
(BMI >25), 79% physically inactive and over 400,000 with undiagnosed impaired glucose 
tolerance. The levels of cardiovascular risk factors captured by the high risk population were 
dependent on the risk score used; with high levels of obesity and physical inactivity with 
QRISK2 and smoking with JBS2. Including the five risk interventions the total cost of 
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screening the high risk population using the QRISK2 score was £359 million; with the cost 
per PCT ranging from £67,757 to £803,236, whilst using JBS2 would be £469 million. 
 
Our estimates of the total cost of Health Checks in the high risk population, 16% of the 
eligible age group, are greater than the DH estimates of £180-243 million per year. The NHS 
Health Checks once fully implemented will be a five year rolling programme, with 20% of the 
eligible population screened per year. The high risk cohort identified here is fewer in 
number than the annual target for screening, although they posses increased levels of risk 
factors which the costs of management. Previous estimates suggest the majority of the 
programme cost will come from follow-up intervention and not the basic health check166. 
Both the cost of screening and of the entire programme is larger using the JBS2 score, 
although the total programme is relatively less costly than using QRISK2. The QRISK2 score 
identifies a large number of patients requiring IGT, weight management and physical activity 
interventions within the high risk group. These are expensive interventions (compared to 
statin and anti-hypertensive prescription) and we assume a higher uptake, inflating the 
programme costs despite fewer at high risk overall. 
 
Although risk scores were derived as clinical tools for the treatment of single patients, they 
are also of use when comparing levels of risk between populations176. There is a large 
amount of geographic variation in the distribution of high cardiovascular risk across England, 
with prevalence higher in the urban centres of the north. There have been lasting health 
inequalities in England, with high prevalence of both poor health outcomes and the causes 
of ill health in the northern regions92. Our data provide further evidence of this divide. The 
NHS Health Check will create a large workload for general practice from cardiovascular risk 
assessment177. Further to this, we estimate 316 patients designated as high risk per general 
practice, with a high prevalence of risk factors; management of these further adds to the 
workload created. 
 
NHS Health Checks focus on cardiovascular and chronic kidney disease, although the 
programme may have wider impacts, especially for diabetes166. Our data estimate that 
within the high risk population there will be a large amount of undiagnosed diabetes; early 
diagnosis can lead to appropriate treatment and a reduction in complications178. In the 
population with undiagnosed impaired glucose tolerance, interventions to reduce the 
progression from IGT to diabetes are effective179 and can have prolonged effects.180 Slowing 
progression to diabetes is both beneficial to patients in terms of increases in life expectancy, 
and to the health system in terms of cost savings181. 
 
The profiles of CVD risk factors differ between the high risk population defined by the two 
risk scores, an artefact of the populations in which the scores were derived. The most 
prevalent risk factors in the derivation dataset are the most common in a high risk 
population defined by that risk score182. The JBS224, based on a Framingham risk score153, 
was produced using data from the USA in the 1970s where smoking prevalence was higher 
than today183. Likewise the QRISK2 dataset was from the UK between 1993 and 2003, a time 
with higher levels of inactivity and obesity, with for example a threefold increase in the 
prevalence of obesity from 1980 to 1998184. 
 
What is already known? 
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Modelled data presented here are to our knowledge the first estimates of the prevalence of 
high risk status in England, using a now common definition from national guidance161;162. 
Our estimates of 13.5% of the 40-74 population using QRISK2 and 20.7% using JBS2 are in 
line with previous estimates from smaller populations. Using Framingham risk scores there 
have been estimates of 15.8%185 and 19.1%111 in the 35-74185, 15.5% in the 30-74 and 17.8% 
in the 40-70186; with 13.3% of the 35-74 population for QRISK2111. Estimates from DH put 
the cost of the NHS Health Checks at £180-243 million per year.  The higher costs presented 
here are the result of increased interventions required  in the high risk population- the DH 
modelling assumed that prevalence of risk factors was the same as in the general 
population. The evaluation of a pilot CVD risk assessment service in pharmacies found 70% 
of the population screened required a referral to general practice because of a raised risk 
factor186. This population was not at high risk, but still had a large need for referral. 
 
Strengths and limitations 
NHS Health Checks, although a national programme in England, are being carried out by 
local service providers. With no national call-recall system or national minimum data set, 
the programme is likely to remain fragmented into the near future.  There has been no 
collation of data from across the whole of England, especially at a patient level. This makes 
modelling, such as the data presented here, a vital element in the evaluation of the 
effectiveness of the programme. Our modelling estimates CVD risk factors using prevalence 
estimates bespoke to the high risk population, instead of using general population 
estimates. We also use population data which captured local level differences in the 
population make-up, with modelling taking place at a general practice level. 
 
 Although our data from the HSfE contained a large amount of missing data for risk factors, 
this is not uncommon when using large population based datasets. In the modelling carried 
out by DH, 166 there were also considerable missing data. The recording of blood pressure in 
the HSfE data was poor; we used multiple imputation to replace missing data, though with 
hypertension, one of the Health Check exclusion criteria more complete data would be 
preferred. We only estimate the cost of the Health Checks in the high risk population, not 
the entire eligible cohort, although they will be the priority in the screening programme, and 
arguably any risk factor interventions should be based on global risk not the presence of a 
single risk factor. Our modelling was dependent on a number of assumptions. We based 
these on evidence from either the HSfE dataset or other literature, although a number 
including an equal ethnic breakdown across all age groups were unavoidable due to the 
availability of data, and no formal sensitivity analysis was carried out due to the complexity 
of the model assumptions. Finally we feel a need for more complete analysis to be carried 
out on the cost effectiveness of the programme. 
 
Implications for practice 
DH and NICE have specified the use of either QRISK2 or JBS2 in NHS Health Checks or when 
using statins for primary prevention of CVD162. Our modelling suggests the choice of risk 
score is important, with the two scores capturing different profiles of high risk patient. 
Although risk scores have been adapted and used in a wide range of settings, they perform 
better in a population similar to their derivation cohort187. Recent work has suggested the 
QRISK2 score may outperform Framingham scores in England188, and a screening 
programme using it may cost less. 
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The high risk population in England suffers from a far greater burden of obesity and physical 
inactivity- two risk factors seeing a sharp rise in the developed world- than smoking and 
hypertension. Both are risk factors for a variety of other health conditions189 and constitute 
health concerns in their own right. Their management must focus on more than a solely 
clinical approach128, with wider lifestyle and community based interventions crucial. Local 
service providers involved in the NHS Health Checks must ensure there is sufficient provision 
to manage the community referrals generated by the programme. With the extent of both 
obesity and physical inactivity, it may be necessary to use a wider population approach to 
manage the societal causes, not simply manage individual cases as they arise. 
 
The screening of high risk patients is estimated to make national reductions in 
cardiovascular mortality and admissions, greater than DH estimates of 650 deaths saved per 
year. Targeted screening has recently been suggested as a more cost effective approach 
than the universal method of the NHS Health Checks167;168. Risk prediction using data from 
patients’ electronic records can be efficient in prioritising treatment190;has been shown to 
be more accurate with improved data records185, with some relevant areas of medical 
records largely complete177. The targeted approach may also be effective in reducing 
geographic health inequalities in England if there is successful risk reduction in the high risk 
population. Modelling presented includes the offer of a statin to all patients at a greater 
than 20% risk of CVD; this will generate large prescribing costs, with over 3 million patients 
eligible for therapy. Recent evidence has questioned the effectiveness of statins in their role 
in primary prevention191, and further work is required to ensure the cost effectiveness of 
this national expenditure. 
 
Conclusions 
There is a high prevalence of patients at high risk of CVD in England, and therefore eligible 
for a series of interventions through the NHS Health Check. Within the high risk population 
there is a high prevalence of CVD risk factors, especially obesity in physical inactivity. The 
choice of CVD risk score will affect the nature of the high risk population identified by the 
programme and the costs of managing the high risk population. 
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9 Model Validation 
Prevalence model validation is problematic for a number of reasons.  There is no other 
major or definitive source of the national HSfE prevalence data we used for the models, 
apart from population-based prevalence research for specific diseases.  The literature 
search before developing each model revealed what studies there were, and was useful in 
initially validating the models.  Similarities and differences are discussed in the sections 
dealing with model development.  Nor is there any similar local data for validation purposes.  
QOF data is useful to an extent, but as a major objective of developing the models was to 
support case-finding in practice populations, it ought not to be used to validate them.  In 
general, we would expect modelled prevalence estimates to exceed QOF registered 
prevalence for 90 per cent of practices, with previously-described model limitations leading 
to under-prediction in perhaps ten percent of practices. 
 
So how should the “fitness for purpose” of prevalence models, including validity, be 
defined?  In the case of disease risk scores, the technical criteria are widely agreed.188;192  
The accuracy of a risk prediction score can be judged on two main components—calibration 
and discrimination. A well-calibrated score is one in which the predicted risk is similar to the 
observed risk.  The more important component of accuracy is discrimination or the ability of 
a score to differentiate between people who will have an event from those who will not, 
over a defined period of time. There are two types of discrimination measures—summary 
measures and threshold measures. ROC curves are summary measures of discrimination, 
which can also be used for prevalence models as illustrated here.  Threshold measures 
compare discrimination at a previously- agreed risk threshold.  Net reclassification 
improvement at this threshold is commonly used in comparisons. 
 
In the case of prevalence models, there is no such agreement as yet on technical criteria for 
internal validity- a gold standard.  This issue is considered in more depth in the Discussion.  
However this Section considers a number of other analyses of external validity using 
prevalence model data. 
 
One method of assessing external validity is to map observed and expected prevalence and 
investigate associations with a low ratio of observed to expected cases, at both local 
authority, PCT, and/or practice levels.  We did this for both COPD (Section 9.1) and 
cardiovascular diseases (Section 9.2, funded by the CQC).  The gold standard validation 
would be comparison of model predictions with a comprehensive population survey or 
extensive case-finding efforts in a number of differing populations: deprived and 
advantaged, rural and urban etc.  In the absence of local or national disease screening 
programmes (although this is planned for CVD risk), we obtained funding from the Lung 
Foundation to carry out a pilot COPD screening programme in Westminster PCT (section 
9.3).  The initial results are also presented in this Chapter. 
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9.1 COPD in England: a comparison of expected, model-based prevalence and observed 
prevalence from general practice data 
9.1.1 Introduction 
This section reports a national comparison of modeled COPD prevalence, using the model 
described previously,59 with QOF-registered COPD prevalence. It was published recently in 
the Journal of Public Health.  We present the estimated population prevalence of COPD for 
LAs in England, and compare them with the prevalence of GP-diagnosed COPD, as reported 
in national GP Contract QOF data.16  We investigated geographical patterns in this ratio 
using classical and GWR to compare the methods. 
9.1.2 Methods 
Model development has been reported in Population Health Metrics59  The HSfE is a 
representative population-based annual survey which in 2001 included the assessment of 
respiratory function using spirometry, as well as comprehensive data on risk factors. COPD 
was defined using the British Thoracic Society (BTS) criteria:193  FEV1) divided by FVC under 
0.70, and FEV1<80%of predicted using reference values from the HSfE
78.  However in the 
HSfE, spirometry was not carried out after bronchodilator challenge.   The variables included 
in the model, based on their association with COPD in logistic regression analysis, were age-
group, gender, ethnicity, smoking prevalence, area of residence (rural, suburban or urban) 
and area-based deprivation score.79 
 
We previously externally validated the model by comparing COPD expected prevalence 
results to an alternative model, based on a survey of prevalence studies.  The comparative 
prevalence was similar.  We also applied the model to the Belfast, Northern Ireland 
population, and compared the results with those from a population survey of the same 
population.88  Our results were slightly lower, but within the 95% confidence interval of 
those estimated from the survey (4.9% total prevalence in 40—69 year olds compared with 
6.1% (95% CIs= 4.5 – 7.7) in the survey).  Our prevalence estimates for the total England 
population were also similar to those in the Health Needs Assessment Report194 and to 
other studies that used the BTS definition of COPD, albeit ours were in general slightly 
lower.  The significant correlations between expected prevalence, and both diagnosed COPD 
and COPD mortality, gives us further reassurance of validity. 
 
We also present data on the GP-diagnosed and registered prevalence of COPD, obtained 
from the QOF,16 and COPD-specific directly standardised mortality rates for comparison.195  
QOF COPD prevalence estimates are based on populations registered with GPs.  We derived 
residence-based registered prevalence estimates for LAs using a lookup table- a pooled 
extract of England GP registers- from the National Strategic Tracing Service (NSTS),196 which 
matched GP practice populations to LA areas as at January 2006.  We apportioned counts of 
COPD patients by practice to LAs, in accordance with the proportion of each practice 
population in that area, assuming that COPD prevalence was geographically uniform across 
a practice population. We divided this count of COPD patients by the mid-year LA 
population to give estimated crude prevalence.  Where less than 50 patients fell into an LA, 
the numbers were excluded from the look-up process.  Three LAs could not be mapped due 
to discrepancies between QOF and NSTS datasets. 
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Comparison of diagnosed with expected prevalence 
The ratio of the QOF COPD observed or diagnosed prevalence to the expected prevalence 
was used to estimate unmet needs for COPD diagnosis. We compared the ratios across LAs, 
English Regions and within population sub-types (rurality and IMD quintiles), to identify 
possible risk factors for under-diagnosis.  Simple and multiple linear regression analysis were 
used to investigate correlations between diagnosed and expected prevalence; and between 
these and directly standardised mortality rates for COPD.158  Geographical clustering in the 
ratio was identified using the Local Moran’s I cluster test, which measures associations with 
neighbouring areas.197  The data were analysed using Microsoft Excel 2007©, Stata 9© and 
ArcGIS 9© software. 
 
In classical regression we assume that a modelled relationship holds consistently across the 
study area. In many situations this is not the case, a phenomenon known as spatial non-
stationarity.198  We used GWR3© software to perform GWR modelling to investigate spatial 
variation in the association between the diagnosed: expected ratio.  GWR is a local version 
of spatial regression that generates parameters disaggregated by the spatial units of 
analysis.199-201 This allows assessment of spatial heterogeneity in estimated relationships 
between independent and dependent variables. Mapping GWR local correlation coefficients 
(strength of association), residuals (the difference between observed and predicted data) 
and Cook’s D values (the effect of removing a single data observation from the dataset, a 
test of model robustness) provides an elegant method for modelling geographical variation 
in regression relationships.  The disaggregation of the full dataset into spatial units for 
analysis is performed using a probability kernel which moves across the study area. 
 
In order to estimate the optimal kernel bandwidth we used the Akaike Information 
Criterion.202  We compared classical regression with GWR for the diagnosed: expected ratio 
by testing for spatial non-stationarity using a Monte Carlo simulation.199  The results of the 
GWR analysis were mapped to visualize any geographic variation in the diagnosed: expected 
relationship.  Two GWR models were run, the first a basic diagnosed: expected regression, 
and the second a bivariate regression involving diagnosed prevalence as the dependent 
variable with expected prevalence and primary care supply as the independent variables.  
The number of full-time GP equivalents per practice, sourced from the Information 
Centre,203 was mapped to geographic areas in the same way as QOF prevalence above, using 
the NSTS lookup table. This was used as a proxy for primary care supply, to explore any 
potential association between COPD prevalence and physician availability.  Unfortunately 
national data on practice nurse and other staff supply is only available at PCT level, and so 
could not be mapped as accurately to geographic areas. 
9.1.3 Results 
Expected prevalence of COPD 
The overall estimated/expected prevalence of COPD in people over 15 years old in England 
was 3.58% i.e. just over 1.4 million people. LA prevalence ranged from 1.88% to 6.02%, with 
a median of 3·14% and inter-quartile range (IQR) 2·69 – 3.78 (see Figure 10: expected 
prevalence of COPD ). The North West and North East regions had some of the highest 
prevalence observed. The overall expected prevalence in all age groups was 2.58% (95% 
CIs= 2.49 - 2.66). The rate for 15- 45 year olds was 1.32%, for 45-64s 4.22%, and for those 
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65-74 and over 75 7.93% and 8.72%, respectively. The mean expected prevalence by region 
varied from 2·90% in the South East of England to 4·02% in the North East. 
 
Diagnosed prevalence of COPD 
The mean prevalence of QOF-diagnosed COPD in LAs was 1·37% (95% CIs 1·33 – 1·42), and 
varied between 0.65% and 3.13% (median 1.29%, IQR 1·05 – 1·61). Figure 11: 
diagnosed/QOF registered prevalence of COPD shows the geographical distribution of 
diagnosed COPD.  There is a north-south gradient; the prevalence of diagnosed COPD was 
generally low in southern England.   
 
Ratio of diagnosed to expected prevalence 
The ratio of diagnosed to expected prevalence in each LA varied from 0·20 to 0·95, with a 
mean of 0·52 (95% CIs= 0·50 – 0·53). There was pronounced variation (p<0.001) between 
urban (mean ratio 0.38, 95% CIs 0.36-0.40) and rural areas (mean ratio 0.56, 95% CIs 0.54-
0.58). The mean ratio of diagnosed to expected cases in London was lowest at 0·31 (95% 
CIs= 0·29 – 0·33), illustrated in Figure 12.   
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Figure 10: expected prevalence of COPD 
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Figure 11: diagnosed/QOF registered prevalence of COPD 
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Figure 12: diagnosed over expected prevalence of COPD 
 
 
Comparisons between diagnosed and expected prevalence, and mortality 
Figure 10, Figure 11, and Figure 12  illustrate the geography of diagnosed and expected 
prevalence.  We found a moderate correlation between diagnosed and expected prevalence 
of COPD in people over 15 years old (r=0·48, p<0·001). The expected prevalence also 
showed a significant association with mortality risk (r=0·24, p<0·001) and diagnosed 
prevalence similarly (r=0·21, p<0·001).  Figure 13: local Moran’s I cluster significance scores 
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for the diagnosed: expected ratio.  The z scores from the Local Moran’s I analysis (Figure 13) 
indicated that there are statistically significant clusters in the diagnosed: expected ratio for 
London and its hinterland.  Positive spatial autocorrelation is observed for London (coloured 
red) and negative spatial correlation for much of its hinterland (coloured blue) suggesting 
that the low diagnosed: expected ratios for London is a genuine cluster with sharp contrast 
to its hinterland.  Some other parts of England, particularly in parts of Yorkshire and the 
North East, also showed significant positive autocorrelation, though unlike London these 
clusters were associated with relatively high diagnosed: expected ratios. 
 
Figure 13: local Moran’s I cluster significance scores for the diagnosed: expected ratio 
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Comparison of correlation coefficients between classical regression results and those of 
GWR, as well as the use of analysis of variance and Akaike Information Criterion methods, 
confirmed that GWR modelled the dataset more accurately than classical regression (Table 
53: comparison of classical regression and GWR results).  The Cook’s D and standardised 
residuals were small, the former indicating robust local regression results and the latter 
indicating no obvious outliers.  Neither test showed evidence of geographic clustering.  The 
Monte Carlo tests confirmed strong spatial non-stationarity in the diagnosed: expected 
association (p<0.000001).  GWR analyses revealed clear geographic variation in the 
association at the LA level (Figure 14: local regression coefficients for the association 
between diagnosed and expected prevalence) with the weakest associations in the West 
Midlands, Cornwall and part of Yorkshire, and strongest in the South East and East Anglia.  
The inclusion of GP supply as an additional independent variable increased the local 
correlation coefficient for most LAs in both classical regression and GWR, particularly the 
latter (see Table 53: comparison of classical regression and GWR results) and especially for 
the East Midlands. 
Table 53: comparison of classical regression and GWR results 
Diagnostics Classical regression Geographically-weighted 
regression 
O:E ratio O:E+GP O:E ratio O:E+GP 
Residual sum of squares 0.007210 0.006633 0.004940 0.003428 
Standard deviation 0.004545 0.004366 0.003878 0.003329 
Akaike Information Criterion -2786.19513 -2813.43807 -2874.37046 -2955.98465 
Correlation coefficient 0.17881 0.24456 0.43733 0.60958 
Adjusted correlation 
coefficient 
0.174100 0.23803 0.39862 0.55693 
Sum of squares 0.0 0.0 0.0 0.0 
Degrees of freedom 2.0 3.0 328.47 309.41 
 
O:E: ratio of observed to expected prevalence of COPD 
O:E+GP: inclusion of GP supply as an additional independent variable 
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Main findings of this study 
We compared diagnosed COPD prevalence in English LAs with those predicted by a model 
derived from HSfE data. The main findings were that both diagnosed and expected 
prevalence varied widely, and that the discrepancy between diagnosed and expected 
prevalence, as a measure of unmet need, also varied considerably, being significantly 
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greater in urban than rural areas.  However, the highly mobile populations of all these urban 
areas also may be contributing to the low level of diagnosed prevalence.  Local Moran’s 
analysis revealed a statistically significant clustering of similar ratios comprising much of 
London, surrounded by a hinterland of dissimilar ratio values, indicating COPD under-
diagnosis in this metropolitan area.  Similar but less extensive clusters are evident in 
metropolitan areas of Yorkshire and the North East. 
 
Differing patterns are evident from the Local Moran’s I and GWR analyses, with the Moran’s 
test highlighting clusters and outliers within Regions, whilst the GWR analyses summarise 
variation between Regions. They suggest that Regional boundaries may not be optimal for 
epidemiological purposes and that further analyses at finer geographic scales e.g. practice 
level may be warranted.  The inclusion of GP supply as an additional independent variable in 
the GWR analyses yielded a stronger regression relationship for most parts of the country, 
supporting the notion of GP numbers as a factor affecting diagnosis levels, with implications 
for resource allocation.   
 
What is already known on this topic 
Our findings are consistent with a number of recent small primary care screening studies 
showing COPD under-diagnosis.  In a survey in the Netherlands, the prevalence of self-
reported asthma or COPD (9.7%) was almost twice as high as the prevalence based on GP 
information (5.2%).204  Vandevoorde et al screened patients in six Belgian semi-rural 
practices if they were current smokers between ages 40-70, and had a smoking history of at 
least 15 pack-years.205 Excluding those with known COPD, spirometry revealed a 29.5% 
prevalence, with greater under-diagnosis in younger age categories.  Tinkelman et al 
recruited patients via random mailing from a primary care practice in Aberdeen, Scotland, 
and Denver, Colorado, who were current and former smokers aged over 40 with no prior 
diagnosis.206 Of 818 patients, 18.9% had a post-bronchodilator diagnosis of COPD, which 
was mild in 57.4%, moderate in 36.8%, and severe in 5.8%. 
 
What are the benefits of early diagnosis?  There is some evidence that effective 
management of COPD may reduce the risk of hospital admission.  Gotfredsen et al found a 
gradient of relative risk of hospital admission with increasing tobacco exposure.69  Telling 
smokers their lung age significantly improves the likelihood of them quitting smoking,  
Practices could be incentivised to deliver smoking cessation advice and prescriptions, or to 
refer to stop smoking services.  The updated NICE COPD guidelines that are currently out for 
consultation recommend that pulmonary rehabilitation should be made available to all 
appropriate patients with COPD, including those who have had a recent hospitalisation for 
an acute exacerbation, and that newer long-acting drugs be prescribed to appropriate 
patients.207  In addition, combination treatment with long-acting beta-agonists and inhaled 
corticosteroids reduces the annual rate of COPD exacerbations and improves health status 
and spirometric values.208;209  A nurse-led self-management programme for COPD patients 
reduced unscheduled practice attendances.210   
 
What this study adds 
Diagnosed COPD prevalence apparently grossly underestimates true population prevalence, 
a finding that supports the use of case-finding strategies.  Under-diagnosis of COPD varies 
systematically and is more pronounced in urban areas, where the risks of COPD are also 
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higher. Under-diagnosis appears particularly severe in London, with up to five unknown 
cases for each case diagnosed in the worst-performing LA.  However, relatively wide 
confidence intervals are involved, and combined with the results of the GWR analyses this 
suggests the model’s results for London are less certain than those for the West Midlands, 
Yorkshire and North East conurbations. 
 
GP supply appears to be a key factor affecting diagnosis levels.  This suggests greater 
emphasis on GP-based COPD management would be beneficial, particularly in local 
authorities such as in the East Midlands, for which the inclusion of GP supply in our model 
markedly improved local correlation coefficients.  Nevertheless there is considerable 
unexplained variation in the observed to expected relationship even after GP supply and the 
model variables are taken into consideration, especially in Cornwall and the West Midlands.   
 
While opportunistic case-finding may be cost-effective, screening of even high risk groups 
may not. Practices may lack the resources to extend spirometry to invited patients. The 
variability in the ratio of diagnosed to expected prevalence may reflect patient and/or 
provider factors, and in highlights the need for additional case-finding support for practices 
in low diagnosis areas; many younger patients may attend infrequently and may need to be 
invited for screening.  A strategy we are exploring in London involves applying the model at 
practice level and providing additional lung function testing alongside active patient recall.  
There is a strong case for evaluating the feasibility and yield of several such case-finding 
strategies and using the data to further validate the predictions of the prevalence model, 
especially at practice level.  
 
Limitations of this study 
The estimates need to be interpreted with caution and are subject to a degree of 
imprecision, particularly when applied to small populations. We used robust Census-based 
demographic data for each LA, but QOF data refers to the PCTs of patients’ GPs, which does 
not always coincide with their LA area of residence, although they overlap considerably. We 
attempted to overcome this by apportioning practice populations to LAs, but this may have 
been erroneous in some areas.  Limitations of the study may result from inaccuracies in the 
model parameters or assumptions, and from the quality of the input data. For example, we 
used current smoking status as a proxy for lifetime tobacco exposure.  Post-bronchodilator 
spirometry is not part of the BTS case definition and was not carried out in the HSfE 
respondents, so the model results will slightly overestimate prevalence.  The screening 
studies above show that in older age groups the proportion with bronchodilator-responsive 
airflow obstruction is small.  We have confirmed this is a case-finding pilot study in London.  
However, a recent analysis of the BOLD study data found that that the spirometric 
prevalence of COPD was reduced by 25 per cent after bronchodilator challenge.211  We 
carried out a sensitivity analysis by adjusting the expected prevalence accordingly, which 
changed the minimum value of the observed:expected ratio from 0.015 to 0.020, the 
maximum from 0.872 to 1.163, and the median to 0.363 to 0.484.  This adjustment did not 
alter the findings of our study. 
 
Misclassification of diagnosis at primary care level may also have had additional minor 
influence on the estimates of under-diagnosis. Some people not meeting the BTS definition 
may be misdiagnosed as having COPD by their GPs.  This would increase the diagnosed but 
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not the expected prevalence, leading to an underestimation of the proportion with 
undiagnosed COPD.  On the other hand, the numerator (diagnosed prevalence) will not 
include patients with known COPD criteria who do not appear in the QOF statistics e.g. non-
NHS patients or those for whom diagnostic Read codes have not been entered.  Although 
there are financial rewards for GPs to record diagnosis of COPD, if a GP believes that 
fulfilling QOF required criteria for payment is not in the interests of an  individual patient 
they may avoid entering READ codes which include the patient  in the QOF denominator. 
For a QOF included diagnosis such as COPD, where  clinical judgement is explicitly 
sanctioned by NICE, deliberate systematic  under-recording is inevitable. 
 
Much of practices’ screening activity is carried out by practice nurses.  However, we were 
unable to examine any effects of the supply of practice nurses or other staff because 
national data is not collected in sufficiently disaggregated form.  Some PCTs commission 
services delivered by specialist COPD nurses, but these staff mainly provide care for patients 
with severe COPD, so they are unlikely to affect initial diagnosis levels 
 
Conclusions 
GPs should examine how clinical judgment might account for the substantial differences in 
observed and expected prevalence we have shown. The distinct geographical variation 
suggest that these are not simply the results of good clinical judgment.  Ultimately, the 
validity and utility of the model depends on its identification of practices where there is 
under-diagnosis.  The COPD prevalence model now available on the APHO website now 
contains estimates for GP practices’ registered populations, a number of PCTs are already 
using it as a tool for COPD case-finding, and it may also be useful for health planning, and to 
direct resources to areas of greater need.   In other countries, national health surveys can be 
used to develop prevalence models in a similar way. 
 
Two online resources based on the model are available at: 
http://tools.erpho.org.uk/copdprev.aspx and  
http://www.erpho.org.uk/viewResource.aspx?id=18024 
 
The former allows the user to enter relevant populations, smoking prevalence estimates and 
other variables to generate COPD prevalence estimates for that population. The latter 
contains pre-calculated COPD estimates for English local authorities and primary care trusts, 
based on post October 2006 boundaries, with projections to 2020. 
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9.2 Variations in cardiovascular disease under-diagnosis in England: national cross-
sectional spatial analysis 
This section results from work on mapping CVD prevalence commissioned by the CQC, with 
help from Edgar Samarasundera, who provided GIS expertise and invaluable training in GWR 
including the use of GWR3 software.  We were also joined by Tejal Indulkar, who carried out 
the actual mapping.  This section has been submitted as a paper to BioMed Central 
Cardiovascular Disorders, and is still out for peer review. 
9.2.1 Introduction 
Geographic variation in the incidence and prevalence of CVD is a well-known phenomenon 
in population surveys.  Such variations in both CHD and stroke incidence and prevalence are 
largely explained by area- and person-specific factors such as population socio-economic 
composition, demographic structure and ethnic diversity,107;133;212;213 mediated through 
established CVD risk factors.214  In the case of England, this is exemplified at a regional level 
by a North-South gradient in prevalence and outcomes, with higher prevalence in the 
North.215 
 
From a health services perspective, it is important to ensure that as high a proportion as 
possible of actual disease prevalence has been diagnosed and is well-managed when 
secondary prevention is known to be effective, as is the case for CVD.216;217  Under-diagnosis 
and/or under-treatment of CVD has been suspected in some previous UK studies,218;219 but 
it was not possible to differentiate these causes. The recent availability of QOF registered 
prevalence data, has provided accurate counts of diagnosed disease prevalence, and 
assurance that identified CVD is being increasingly well-managed.  For example, in 2008-9, 
achievement by English general practices of all the 89 QOF points available for CHD 
management was 99.1 per cent.220   The QOF also provides a financial reward for registering 
new cases of disease. 
 
A recent study which compared observed (QOF-registered) and expected prevalence of CHD 
and hypertension suggested that under-diagnosis may vary geographically.221  However, the 
CHD model used by the authors was derived from General Practice Research Database 
(GPRD) data, resulting in a lack of independence between the observed and predicted 
datasets.  A number of disease prevalence models are now available on the APHO 
website.222  These provide independently-derived prevalence estimates for resident 
populations of English LA, PCT, and practice populations, which can be compared with QOF 
disease registers.222  Using these models we investigated the observed and expected 
prevalence of three cardiovascular conditions (CHD, hypertension and stroke) at LA level to 
identify unmet population health care needs, their geographical variation, and population 
and healthcare predictors which might influence diagnosis. 
9.2.2 Methods 
Data sources: registered prevalence and primary care supply 
Counts of practice-registered prevalence of CHD, stroke and hypertension in April 2007 
were obtained from English practice disease registers, produced for the purposes of 
incentivizing practices for achievement of QOF treatment targets.  QOF prevalence rates are 
based on total populations registered with practices, but to compare observed prevalence 
with resident population-based contextual data from the Census and other sources e.g. 
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deprivation and proportion ethnic minority population, we derived residence-based QOF 
prevalence estimates for LAs using a lookup table- a pooled extract of England practice 
registers- from the NSTS which matched practice populations to LA areas as at January 
2006.223 
 
We apportioned counts of CVD patients by practice to LAs, in accordance with the 
proportion of each practice population in that area, assuming that CVD prevalence was 
geographically uniform across a practice population. We divided this count of CVD patients 
by total mid-2006 LA population estimates to give estimated crude prevalence.  Where less 
than 50 patients fell into an LA, the numbers were excluded from the look-up process.  
Three LAs could not be mapped due to discrepancies between QOF and NSTS datasets.  In 
order to investigate the effect of healthcare supply upon diagnosis levels we included a 
measure of general practitioner availability in the form of the number of GPs per thousand 
LA population, calculated in the same way.203 
 
Data sources: expected/estimated prevalence 
Expected prevalence for each LA was obtained from the APHO epidemiologic models, which 
are based on the socio-demographic and behavioural characteristics of respondents with 
the respective conditions in the HSfE.  To produce the models, HSfE data for the years 2003-
6 was pooled to obtain sufficient cases of diseases.  Surveys over this period included boosts 
for ethnic minority and older people, and focused on CVD and its risk factors.  The outcome 
variables were patient-reported doctor-diagnosed CHD and stroke, and for hypertension, 
normotensive-treated, hypertensive-treated but uncontrolled, and hypertensive-untreated 
groups i.e. a combination of patient-reported and objectively-measured variables.  Patient 
reports of doctor-diagnosed CHD and stroke have been extensively validated 
elsewhere.96;97;224-226 Ordinary least-squares (OLS) logistic regression models were fitted and 
explanatory variables for each disease outcome identified by reverse stepwise selection. 
 
The baseline odds of each disease were obtained directly from the HSfE dataset. The 
strength of association between each explanatory variable and disease caseness was then 
used to calculate the relative odds, which were applied to the baseline odds to derive the 
prevalence estimates for sub-groups of risk factors.  The variables which can be included in 
each local model are limited by the availability of local data for them.  The core model 
variables are (ten-year age band), gender (male and female), ethnicity (Asian/Asian British, 
Black/Black British and White) and deprivation (quintiles of Index of Multiple Deprivation 
2004 scores).79  The models use 2006 mid-year quinary and ethnic population estimates 
from the UK Office for National Statistics (ONS).80  The latter dataset provides estimates in 
wider age bands, so the models assume that the distribution of ethnic populations is 
uniform across quinary age bands. LAs are stratified into deprivation score quintiles and 
other categories based on the ONS system used in the HSfE.   
 
In the case of CHD smoking status is also included.  Local smoking prevalence estimates are 
not available from the HSfE because of small sample sizes, so the CHD model uses synthetic 
estimates from the Neighbourhood Statistics website.227  Model assumptions include that 
the proportion of smokers, ex-smokers and never-smokers is uniform across ethnic 
categories and that the proportion of ex-smokers in each age-sex group is constant across 
areas.   Further technical details of the models are available on the APHO website.222 
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Spatial analyses 
Observed: expected prevalence ratios for LAs were calculated in Excel 2007 and mapped 
using the geographic information systems package ArcGIS 9.  Two exploratory spatial data 
analysis methods commonly used in geographical studies were used to investigate patterns 
in O:E relationships, Local Moran’s I (LMI) analysis and geographically weighted regression 
(GWR).  The LMI technique is used to identify geographic clusters and outliers in data by 
testing for randomness in spatial distribution across a dataset, localities with significance 
scores (Z scores) greater than two standard deviations being considered to be either clusters 
or outliers.197  Strongly positive Z scores indicate statistically significant similar values in 
close geographic proximity hence the presence of a cluster; a strongly negative Z score 
demonstrates a locality with a significantly dissimilar value in relation to its neighbouring 
localities thus indicating an outlier.   
 
GWR is a form of spatial statistics which disaggregates geographic data into spatial blocks 
using a probability distribution kernel, which moves from location to location across the 
dataset to test for geographic variation in regression relationships.  In situations where 
there is geographic variation in the strength of a regression relationship, a phenomenon 
referred to as spatial non-stationarity, GWR will produce higher correlation coefficients, 
lower residuals and higher degrees of freedom than traditional ordinary least squares (OLS) 
regression.198;199 
 
In this section, we used GWR to assess whether a linear regression relationship between 
observed and expected prevalence existed and if so whether it varied in strength over 
space, the purpose of which should be viewed as distinct from that of mapping observed to 
expected ratios, as the latter aims to measure equality between two variables rather than to 
assess predictability of an association.  Both OLS and GWR models were run in the software 
package GWR3 to test for spatial non-stationarity.  The optimal bandwidth for the kernel 
was estimated using the Akaike Information Criterion.202  Two rounds of regression were 
performed, the first a univariate regression involving expected prevalence as the 
independent variable and observed prevalence as the dependent variable; the second 
bivariate including whole-time equivalent GP supply as an additional variable. 
9.2.3 Results 
Observed/diagnosed prevalence of CVD 
Observed (O) and expected (E) prevalence summary statistics are shown in Table 54.  Total 
English population was used as the denominator for consistency with standard reporting of 
QOF prevalence.  The mean prevalence of QOF-diagnosed CHD in LAs was 2.57% (95% CIs 
2.45-2.69), and the expected prevalence was 4.52% (95% CIs 4.42-4.61), giving an O:E ratio 
of 0.57 i.e. about 60 per cent of expected cases are diagnosed.  Although the prevalence of 
stroke is less than half that of CHD, the O:E ratio is very similar.  The expected prevalence of 
hypertension is much higher (about 24% of over 16s), and the O:E ratio is only 0.37 i.e. less 
than 40% of cases may be diagnosed.  There was wide variation in the O:E ratio between 
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Mapping of observed and expected prevalence demonstrated that observed and predicted 
prevalence for both diseases showed strong north-south and southwest-southeast 
gradients, with the southeast generally showing lowest disease levels, especially in the case 
of expected prevalence.  However, within these geographical trends in both QOF and 
modelled prevalence, mapping of O:E ratios demonstrated spatial variation between 
neighbouring LAs.  LMI Z scores indicated the presence of some statistically significant 
clusters and outliers in O:E ratios (red indicates clusters and blue indicates outliers), as 
shown in Figure 15, Figure 16 and Figure 17). 
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Median 2.40% 4.48% 0.55 8.77% 24.77% 0.36 1.11% 1.99% 0.57 
Maximum 5.47% 7.78% 1.10 16.62% 35.17% 0.63 2.48% 3.26% 1.08 
Minimum 0.14% 2.61% 0.04 0.57% 17.71% 0.02 0.06% 1.24% 0.03 
1st 
quartile 
1.56% 3.89% 0.38 5.92% 23.06% 0.25 0.74% 1.77% 0.40 
3rd 
quartile 
3.31% 5.10% 0.69 11.10% 26.75% 0.43 1.49% 2.23% 0.73 
IQR 1.75% 1.22% 0.32 5.18% 3.69% 0.18 0.75% 0.47% 0.33 
Standard 
deviation 
0.01147 0.00912 0.21 0.03486 0.02822 0.13 0.00513 0.00364 0.22 
                                                     
2 The England population denominator used for all three diseases was 50,598,200 
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Figure 15: clusters and outliers in observed to expected ratios for CHD (red indicates 
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Figure 16: Clusters and outliers in observed to expected ratios for hypertension (red 
indicates clusters and blue indicates outliers) 
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Figure 17: Clusters and outliers in observed to expected ratios for stroke (red indicates 
clusters and blue indicates outliers) 
 
 
For all three conditions, particularly CHD and stroke, London and much of its hinterland 
showed statistically significant discrepancies in O:E ratios, with observed prevalence much 
lower than the epidemiological models predicted.  For CHD there were also significant 
clusters and outliers in parts of northern England, especially in Cumbria and Yorkshire, 
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though unlike for the London area the clusters typically related to O:E ratios tending 
towards unity. 
 
Further geographic analysis with GWR revealed significant spatial variation in the O:E 
relationship for CHD, hypertension and stroke, with GWR describing the dataset more 
accurately than traditional OLS regression.  The linearity of the relationship between 
observed and expected prevalence was weakest for hypertension with the lowest overall 
regression coefficients and highest residual sum of squares for observed against expected 
prevalence; stronger associations were observed for CHD and stroke. 
 
Even maximum coefficient values for hypertension, found along the south and east coasts, 
were less than 0.26; coefficients were lowest in the north and a pronounced north-south 
gradient was observed.  The pattern for stroke was somewhat more complex with 
coefficients typically less than 0.21 for much of the northern parts of the country and the 
Midlands, yet with parts of Kent and the Sussex Counties having coefficients up to 0.69.  
CHD followed a similar geographic structure to stroke, with values of less than 0.08 for 
much of the Midlands and north, yet rising to 0.66 in eastern and southern coastal areas.  
There were no statistically significant patterns in Cook’s D and standardised residual results 
for any of the three conditions examined.  It should be noted that although O:E ratios 
tended towards 1 in the north and declined further south, the GWR results showed that the 
predictability of the relationship between observed and expected prevalence decreased 
with an increasing latitude. The addition of GP supply as a variable yielded stronger 
regression results for all three conditions (Table 55: comparison of classical regression and 
GWR results). 
Table 55: comparison of classical regression and GWR results 
CHD Classical regression GWR 
O against E O = E+GP O against E O = E+GP 
Residual sum of squares 0.032246 0.025831 0.026362 0.016685 
Standard deviation 0.009612 0.008615 0.008964 0.007374 
Akaike Information Criterion -2260.431534 -2336.249712 -2285.749801 -2393.809008 
Correlation coefficient 0.299110 0.438554 0.427014 0.637331 
Adjusted correlation 
coefficient 
0.295081 0.433700 0.386880 0.584988 
Sum of squares 0.0 0.0 0.0 0.0 
Degrees of freedom 2.00 3.00 328.09   306.86    
Hypertension Classical regression GWR 
O against E O = E+GP O against E O = E+GP 
Residual sum of squares 0.373755 0.249962 0.361588 0.241345 
Standard deviation 0.032725 0.026801 0.032380 0.026486 
Akaike Information Criterion -1400.410427 -1539.568186 -1403.498576 -1543.667517 
Correlation coefficient 0.121033 0.412159 0.149645 0.432425 
Adjusted correlation 
coefficient 
0.115981 0.407077 0.134488 0.420914 
Sum of squares 0.4 0.2 0.4 0.2 
Degrees of freedom 2.00    3.00 344.87    344.04 
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CHD Classical regression GWR 
O against E O = E+GP O against E O = E+GP 
Stroke Classical regression GWR 
O against E O = E+GP O against E O = E+GP 
Residual sum of squares 0.006790 0.005595 0.005318 0.003484 
Standard deviation 0.004411 0.004010 0.004049 0.003392 
Akaike Information Criterion -2807.247922 -2873.159418 -2838.923853 -2932.935545 
Correlation coefficient 0.261902 0.391824 0.421924 0.621315 
Adjusted correlation 
coefficient 
  0.257660 0.386566 0.374319 0.560939 
Sum of squares 0.0 0.0 0.0 0.0 
Degrees of freedom 2.00 3.00 324.37 302.87 
 
O against E: ratio of observed against expected prevalence 
O = E+GP: inclusion of GP supply as an additional independent variable 
9.2.4 Discussion 
Main findings 
The findings presented here indicate that despite almost universal access to free primary 
healthcare services, and a significant financial incentive for these services to find and 
register new cases on their computer systems, there may be significant under-diagnosis of 
all three CVD conditions in many areas in England.  Under-diagnosis is most marked for 
hypertension, with strikingly wide variation in diagnosis levels between areas.  Hypertension 
and stroke showed similar geographic variation to CHD, but without the clusters/outliers for 
northern England; additionally the contrast between the ratios for London and LAs 
immediately to the north was more pronounced for stroke. 
 
An obvious question is: why was there such a discrepancy between expected and practice-
registered disease prevalence, when the model-based CHD and stroke prevalence estimates 
were based on patient reports of doctor-diagnosed disease?  Reasons are likely to include 
inadequate searching of practice records (which are now in the UK mainly electronic in 
primary care) for previous diagnoses or CVD-related prescriptions,228;229 lack of linkage of 
practice and hospital records (practice still have to enter codes for hospital admissions 
manually), and high population mobility in urban areas with concomitant changes (or 
delays) in registration with general practices.230  In the case of hypertension, for which the 
modelled estimates used a combination of doctor-diagnosed disease and blood pressure 
measurements, the gap is greatest in younger and middle age groups, when males in 
particular are less likely to be seen by their practices.184   In contrast, diagnosis appears to be 
more complete in the north of England. 
 
From a spatial analytic perspective, there are significant geographic discrepancies between 
QOF prevalence and modelled prevalence for all three conditions in much of London and its 
hinterland.  The inclusion of a measure of GP supply in the GWR analyses suggests that, 
despite needs-based healthcare resource allocation in the UK, persistent differences in 
availability of primary care services is an important limiting factor in diagnosis.  An analysis 
of Gini coefficients to measure geographical equity in GPs per 100,000 population in England 
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and Scotland showed that equity in England rose between 1974 and 1994, but then 
decreased, and in 2006 it was below the 1974 level.231 
 
The results also provide some contrast to a study investigating revascularisation rates in 
males,  which found that even after adjusting for the higher CHD burden in the north of the 
country related to socio-demographic composition, the likelihood of receiving surgery 
during the 1990s decreased outside of southern England, suggesting a geographic imbalance 
in the provision of tertiary cardiology care.232  Considerable efforts have been made 
subsequently to ensure that access to tertiary care is more equitable.  However our analysis 
suggests that from a primary care perspective, it is London and its hinterland which would 
benefit most from increased resource allocation, although GP supply itself seems to be only 
one influential factor affecting diagnosis levels.  Further work will need to investigate the 
effectiveness and yield of strategies for CVD case-finding by practices, and to validate the 
predictions of the prevalence models at practice level. 
 
Strengths and limitations of the study 
Strengths of the study include the use of new data from practice disease registers and 
recently-developed geographical analytical techniques and software.  Limitations include 
the fact that it was carried out at LA level, which may conceal much wider variation at lower 
levels.  The spatial scale of the analyses includes many LAs which are highly heterogeneous 
in socio-demographic composition, so the study may have missed significant small area 
variation; this is especially likely in northern areas where regression associations were 
weakest.  The prevalence models are constrained by the availability of local data on risk 
factors, some of which rely on 2001 Census data, although this will be improved by, for 
example, more accurate and timely data on smoking prevalence from the new ONS 
Integrated Household Survey. 
 
Conclusions 
Despite the absence of barriers to primary healthcare, it is likely that there is significant and 
highly variable under-diagnosis of CVD across England, which can be partially explained by 
persistent inequity in GP supply.  However, it is also plausible that the distinctive 
composition and dynamics of London’s population adds complexities to the identification of 
CVD in that region.  Studies of disease management should consider the impact of this 
“iceberg” of undiagnosed disease on hospital utilisation and population health outcomes.  
Spatial analytic techniques can provide additional information about geographical variation 
compared to classical regression modelling, and can suggest where additional healthcare 
resources may be most needed. 
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9.3 Case-finding strategies for COPD in primary care 
This section results from work carried out with respiratory physician colleagues at ICL and 
Imperial College Healthcare Trust- Drs Nick Hopkinson, Sarah Elkin and Irem Patel.  The pilot 
study itself was carried out by Julia Kelly, who is based at Royal Brompton & Harefield NHS 
Trust. 
9.3.1 Background 
This pilot study was funded by the British Lung Foundation and had an overall aim of testing 
the feasibility of targeted COPD case-finding or “targeted screening” in an urban, deprived 
general practice  to assess the challenges involved.   It also offered the potential of 
validating the COPD prevalence model.  As noted previously, risk factors for COPD include 
smoking, age, area of residence, occupation, ethnicity and deprivation.  The practice, 
situated in Westminster PCT, was in a deprived area with a multi-ethnic and highly mobile 
population, which was thought to have a high prevalence of smoking. 
 
There are numerous obstacles to COPD case-finding.  For example, 89 per cent of people in 
UK have never heard of COPD.233.  As noted previously (Section 9.1), there is geographical 
clustering of observed: expected prevalence ratios which is particularly prominent in 
London, possibly because of high population mobility.  There have been a number of 
primary care COPD screening studies in other European countries, but none in England (see 
Table 56 below).  Various age bands were screened.  An important issue is which definition 
of COPD to use: the BTS definition77 FEV1) divided by FVC under 0.70, and FEV1<80%of 
predicted using reference values from the HSfE) is much more conservative than the GOLD 
definition91, and so gives a lower prevalence. 
Table 56: summary of primary care COPD screening studies 







Mohangoo et al204 
National, 
Netherlands  
Random patient population 
survey (self reports)  






screen of current smokers  
146  40-70  29.5%  
Tinkelman et al206 
NS, Scotland & 
Colorado  
Random mailing of smokers & 
ex-smokers  
818  >40  18.9%  
Bednarek et al234 Semi-rural, Poland  
Mailing of whole practice 
population  
1,960  >40  11%  
Stratelis et al235 Small city, Sweden  
Practice posters & 
advertisements, current 
smokers  




The objectives and outcomes defined for the project are in Table 57 below. 
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Table 57: objectives and outcomes of pilot study 
Objective Outcome measure 
to validate smoking status recorded in 
electronic patient records  
smoking prevalence in GP system and at 
screening  
to estimate the prevalence of COPD in a 
diverse urban population  
frequency of abnormal spirometry  
to assess the feasibility of two directed 
COPD screening strategies compared to 
current practice  
response rate to letter/telephone invitation 
or invitation on attendance for other 
reasons  
to provide initial validation of COPD 
prevalence model predictions  
post-study observed: expected prevalence  
to provide initial data on the relationship 
between respiratory symptoms and muscle 
strength  
associations between spirometry, 
respiratory symptoms and quadriceps 
strength  
to act as a pilot for an RCT of the cost-
effectiveness of COPD screening  
response rates, costs  
 
Data collection 
The study aimed to perform spirometry screening of 320 over 35s with a smoking history in 
the practice.   Patients were informed that a “Lung Health Screen” was being offered.  This 
involved a short symptom questionnaire, smoking history and MRC dyspnoea score , a 
medication discussion, height, weight and BMI measurement,  spirometry  including ‘lung 
age’ calculation and COPD staging (Table 58), bioelectrical impedance analysis, quadriceps 
strength using a hand-held dynamometer, feedback to patient, including smoking cessation 
advice, referral if results abnormal including post-bronchodilator spirometry.   
Table 58: definitions of GOLD COPD stages 
GOLD Stage Spirometry Symptoms 
0: At Risk Normal spirometry Chronic symptoms (cough, sputum 
production) 
I: Mild COPD FEV1/FVC <70%, FEV1≥80% 
predicted 





30%<FEV1≤80% predicted  
With or without chronic symptoms (cough, 
sputum production, dyspnoea)  
III: Severe COPD FEV1/FVC<70%, FEV1≤30% 
predicted 
or the presence of respiratory failure, or 
clinical signs of right heart failure 
 
Results 
A total of 1896 patients over 35 were selected from the practice register.  Of these, 969 
(51%) were recorded as smokers, but because of concern over accuracy of this data, all 1896 
randomised to either a letter/phone call or invitation for opportunistic screening when they 
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attended (see Figure 18: study design & flow chart).  Non-smokers were asked to disregard 
the letter. 
Figure 18: study design & flow chart 
 
 
Smoking status of screened population is shown in Table 59 below.  Concordance between 
the smoking status at time of spirometry and practice computer system data (n=257) is 
shown in highlighted cells.  Only 13 smokers (four per cent of the over 35 sampled 
population) would be misclassified as non-smokers if the practice data were used. 




non-smoker ex-smoker smoker Total 
Non-smoker  21 1 0 22 
Ex-smoker  26 89 20 135 
Smoker  4 9 147 160 (50.4%) 
Total 51 99 167 (52.6%) 317 
 
Initial spirometry results and GOLD category are shown in Table 60 below.  As expected 
patients with more severe disease (GOLD Stage 3 and 4) were more likely to be on the 
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Table 60: spirometry results and GOLD category of screened patients 
 
Spirometry n (%) On COPD register n (%) 
Normal 177 (55.5) - 
Restrictive pattern 45 (14.1) - 
Obstructive pattern 97 (30.4) 24 (24.7) 
GOLD stage 1 33 (10.3) 2 (6.1) 
GOLD stage 2 46 (14.4) 10 (21.7) 
GOLD stage 3 14 (4.4) 9 (64.3) 
GOLD stage 4 4 (1.3) 3 (75.0) 
Total 319 (100) 24 (7.5) 
 
Based on this sample, what is the actual prevalence of smoking and COPD in this practice?  
Study and practice system results are both very similar, giving a smoking prevalence of over 
50 per cent.  This seems very high, but the CQC practice-level smoking prevalence estimates 
also predict some practices have prevalence of 50-60 per cent.  Before screening, there 
were 42 patients on the practice COPD register.  The COPD prevalence model predicted a 
prevalence of 5.2 per cent- but according to the more conservative BTS definition.  The 
detected prevalence in the sample was 15.3 per cent using the GOLD definition.  At this 
stage, we do not have data on the age-based predicted FEV1 from this sample, but these 
figures correspond with national estimates quoted in Section 10.4.3 Results using both 
definitions. 









England  24.1% 1.8% 3.1% 
Westminster PCT  23.1%2 0.8% 3.6% 
Harrow Road pre-study  23.1%2 1.2% 3.8% 
Harrow Road post-study  51%? 2.8% 5.18% 
Harrow Road possible  51%? 15.3%?3 N/A 
1 all denominators = 15+ or 16+ population 
2 NatCen modelled smoking prevalence 
3 assuming study sample is unbiased 
9.3.3 Discussion 
In summary, of 319 over 35 current/ex smokers 177 (55.5%) had normal spirometry, and 97 
(30.4%) had an obstructive pattern.  Only 24 of these were previously known to have COPD.  
Only 106/948 invited patients responded to a letter, and a further 50 to a follow-up phone 
call- 163 were screened using systematic, opportunistic screening at the time of an 
attendance for other reasons.  There was abnormal spirometry in 32 per cent of letter 
responders, 36 per cent of call responders and 55 per cent of patients screened 
opportunistically (χ2 test p=0.0004).  All methods effectively detected cases, but the yield 
was greatest from systematic, opportunistic screening at the time of an attendance.  
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Systematic, opportunistic screening may be the most efficient strategy, but this can only be 
confirmed by a cost-effectiveness analysis based on a much larger study. 
 
This pilot study has a number of limitations, not least its small size.  It is based on a single 
practice, which may be unrepresentative.  There may be sampling bias, in that responders 
to letter/phone invitations and practice attenders may be more likely to have disease. 
Diagnosis based on spirometry will over-estimate actual prevalence: complete post-
bronchodilator diagnosis data is awaited, but the great majority so far have an 
irreversible/obstructive pattern.  Practice data under-estimated the number of ex-smokers, 
and practice data missed a small proportion of smokers, which may have implications for 
screening.  On the other hand, it demonstrated the feasibility of screening in a deprived 
urban practice.  In rural or suburban areas response rates to invitations are likely to be 
much higher.  A logical third strategy may be to include screening with NHS (Vascular) 
Health Checks. 
 
In terms of prevalence model validation, it did not over-predict in this practice.  This will be 
confirmed by including the second BTS criterion in the data analysis.  A letter has recently 
been published in Thorax which 236 reports on financial incentives for COPD case-finding in 
Kensington & Chelsea PCT.  Between 2005 and 2008 there was a linear increase in COPD 
prevalence in K&C (r2=0.997). If the preceding trend had continued, the predicted COPD 
prevalence for 2009 would have been 0.87% (95% CI 0.84% to 0.90%), whereas following 
the introduction of the LES it was 0.98%.  The modelled COPD prevalence for the PCT in 
2008 is 3.9%. 
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10 Model Implementation 
The four disease prevalence models I developed have had significant impact on public 
health practice since they were disseminated.  Dissemination has occurred through the 
APHO website as previously noted, and through NHS Comparators, a website established by 
CfH.237  This Chapter explores how the models have been implemented and used to support 
primary care quality improvement nationally. 
 
10.1 Evaluation of the uptake of the models by York University Health Economics 
Consortium 
An evaluation of the uptake of the models was undertaken by York University Health 
Economics Consortium (Dr Peter West and Sophie Tatlock) in 2009.238  A national telephone 
survey of 104 PCTs (out of 145) was carried out to ascertain how many PCTs were using 
the models and how many were not. For those PCTs who had confirmed that they had 
used the models, public health analysts in 75 PCTs were interviewed regarding types of use, 
barriers to use and suggested improvements; 14 Directors of Public Health (DsPH) were 
interviewed regarding the outcomes of model use and the potential impacts upon the 
service planning and commissioning within PCTs. A thematic analysis was conducted on 
all qualitative data. Themes and codes from interviews in Phase 1 were quantified  for 
frequency analyses to be conducted. Frequency analyses were not conducted on Phase 2 
interview data due to the small sample size and therefore limited amount of data obtained.  
 
Findings from the interviews in Phase 1 indicated the models were being used by the 
majority of PCTs in a sample of 104 and that users appreciated the potential benefits 
that the models offered. The most frequent forms of use reported were:  
 comparisons of prevalence estimates with QOF registered prevalence figures 
 case finding 
 service planning 
 performance monitoring 
 health needs assessment 
 strategic commissioning plans 
 health equity audit; and 
 annual public health reports.  
 
However, the extent of model use to inform or change World Class Commissioning 
processes was dependent upon a number of limiting factors and reported barriers to use. 
These fell into four main categories, which also serve as indicators of requests for 
improvement:  
 
Flexibility: the PBS Diabetes model was reported to be used most frequently and was 
valued for its additional flexibility in comparison to the other models. The PBS Diabetes 
model goes down to ward level data and enables the user to input their own (most 
commonly practice level) data, whilst at the time of the survey the other models only went 
down to PCT or LA level. Although the extent of use varied and was often dependent 
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upon the users' knowledge of model usage outcomes, basic comparisons of prevalence 
figures with QOF registered prevalence was the most frequently reported form of use. 
Therefore, the ability to work with practice level data in the Diabetes model led to its further 
use, and requests for more flexibility in the other models were common in the responses. 
The inability to extract practice level prevalence estimates from the other 5 models was 
reported as a limitation upon the extent of use.  
 
The Doncaster PCT prevalence models were reported to be used the most frequently by 
users, when not using APHO models. The Doncaster PCT prevalence models produce 
estimates at practice level, which was reported as an attractive option for analysts, with QOF 
comparisons being the most frequently reported form of use. However, one of the authors of 
the Doncaster models has confirmed that they were developed rapidly for local use based 
on rapid scans of literature, and they should not be assumed to be the most accurate 
models. It would be appropriate for them to be replaced by a set of robustly-researched, 
nationally agreed models offering similar functionality.  
 
It was also noted that practice profile tools are increasingly being developed by PHOs. 
These tools offer prevalence estimates at practice level for the associated PCTs, and were 
not known to most respondents. This is perhaps indicative of the need for APHO to 
'advertise' their available tools and resources to PCTs in a more effective manner.  
 
Transparency: a lack of methodological detail and clarity of assumptions within the 
documents which accompany each model was reported as a limitation by users. This 
reportedly reduced the "statistical" confidence of users and therefore limited the extent of 
use. A frequent issue reported was that of approaching GPs for case finding visits to discuss 
differences between prevalence estimates and QOF figures. With GPs questioning the 
figures and analysts being unable to provide enough methodological detail to support 
the figures, confidence was reduced and therefore the productivity of GP meetings, in 
stimulating case finding initiatives, was also reduced. This issue in particular regards the 
Diabetes model only, as it is the only model to offer the function of inputting local practice 
level data.  
 
A lack of transparency of the assumptions within the models, as well  as the associated 
caveats and confidence intervals, were reported as a limitation of use by some analysts. A 
commonly reported challenge was other members of staff with non-statistical backgrounds 
misusing the estimates and treating them as "true" figures within documents, due to a 
conceptual lack of understanding of confidence intervals. A clearer presentation of the 
assumptions and caveats, as requested by users, would reduce the chances of this misuse, as 
well as the inclusion of confidence intervals within the actual models themselves.  
 
A lack of a clear help desk function was also reported as a limitation to use, with many users 
being unsure as to whom to contact for what were often simple queries. A more 
transparent help desk function would reduce the amount of time taken to answer simple 
queries. A 'Frequently Asked Questions' page on the APHO website might also have been 
helpful. 
 
Consistency: limitations to use regarding consistency were reported in three main areas:  
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Accessibility: The models were reportedly difficult to locate, both within the APHO 
website itself and through internet search engines. The links for all models can be found on 
the APHO website but the models themselves are hosted on different sites (mainly Eastern 
Region PHO and Yorkshire and Humber PHO). To compound these issues, the models 
have undergone various Phases of development, and various methods of approaching 
the models led to users reporting uncertainty regarding which model Phase they were 
using. There were frequent requests for the models to be centrally hosted on the 
APHO site,  to improve accessibility and certainty of using the most up to date tools and 
resources.  
 
Control and updates: further to the issues of accessibility, users reported the lack of control 
over the models and updates as a barrier to use, in particular being notified of new 
and upcoming work. Requests for user registration upon download of the models, as well 
as email notifications of any problems with the models or upcoming work were frequent. 
This would assure users they were using the most up-to-date models, and enable them 
to maintain contact with APHO through version control and a release policy.  
 
Model format: the various formats of the model (with the Diabetes model seen as the most 
user-friendly and intuitive) were reported as barriers to use, in particular when other 
members of staff from non-statistical backgrounds attempted to use the models or their 
outputs. A single interface was proposed to be used for all models. This would ensure all 
users were comfortable with the interface and would provide a familiar APHO format for 
public health analysts within PCTs.  
 
Training and Support: the qualifications, experience and skill base of public health analysts 
varied greatly across the sample. The various levels of skills were potentially linked to the 
fact that some users encountered practical issues with the models whilst others did 
not. A lack of full communication in PCTs was also noted, with analysts often not aware 
of the use of their outputs. This led to two recruitment Phases to find out more about the 
use of outputs from DsPH. Some DsPH interviewed also raised issues about the skills of staff 
and about being generally understaffed within their public health departments.  
 
In response, a proportion of analysts requested further training to be offered to them, to 
streamline their career pathway within the PCT (currently not viewed by most as 
apparent) and to also improve their skill base. In particular, there were requests for training 
to develop their own models, which can be tailored towards the requests of clinical leads and 
commissioning. Not only would this enable PCTs to produce more localised data but it 
would also potentially save costs of commissioning third parties (i.e. external consultants) to 
develop models on their behalf.  Basic statistical training was also suggested as an 
improvement for all staff members who encounter prevalence estimates and models 
within PCTs, including members of commissioning teams, where "misuse" was reported. 
This would improve the understanding of estimates and their role within the world class 
commissioning process.  
 
10.2 Vascular Programme briefing packs 
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In 2009, the DH Vascular Policy Programme incorporated prevalence estimates from the 
CHD and stroke models into its Vascular Programme Briefing Packs.239  PCT-level modelled 
estimates were used as denominators for QOF indicators (rather than disease register 
totals) so that the extent of undiagnosed disease was highlighted (see Figure 19). 
Figure 19: use of modelled CHD prevalence in Vascular Programme Briefing Packs 
 
Similarly, expected prevalence was used to show the extent of unrecorded disease by 
Spearhead and non-Spearhead PCT (see Figure 20). 
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Est Not Reg Not Cont
Reg but BP Not Measured
BP > 150/90 
BP 150/90 or less
Org Level PCT PCT Code (All) Practice Code (All) SHA London Year 2007/8
Spearhead PCT Short
Data
Coronary Heart Disease – QOF – CHD06. Blood Pressure of 150/90 or less –
As a percentage of Estimated CHD Prevalence (1) – 2007/8 By SHA & PCT
(1) Modelled estimates of prevalence of CHD for PCTs in England Version 1.0 (Eastern Region Public Health Observatory, September 2008)
These estimates of the prevalence of CHD in people aged 16+ have been calculated using a model developed at the Dept of Primary 
Care and Social Medicine, Imperial College, London. The model was developed using data from the 2003-2004 Health Surveys for England.  
The model takes into account age, sex, ethnicity, smoking status and deprivation score.
BP Measured 
150/90 or less




- as a % of estimated
CHD Prevalence
BP Not Measured 
but on CHD Register 
- as a % of estimated
CHD Prevalence
BP Not Measured 
& not on CHD Register 
- as a % of estimated
CHD Prevalence
NHS London
% of the estimated people with CHD 
who are at increased risk because 
BP is not 150/90 or less
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Stroke – % Change in QOF Prevalence Aged 16 plus between 2006/7 & 2007/8
&  QOF Prevalence 2007/8 as a % of Estimated Prevalence (1) – by PCT
% of Stroke Diagnosed-
Ranked QOF 2007/8 Prevalence
as a % of Estimated Prevalence
Stroke - Change in Prevalence (%)
Growth or reduction in 2007/8 Prevalence 
Compared with 2006/7 Prevalence
SpearheadNon-spearhead
(1) Modelled estimates of prevalence of stroke for PCTs in England version 1.0 (Eastern Region Public Health Observatory, October 2008)
These estimates and projections of the prevalence of stroke in people aged 16+ have been calculated using a model developed at the Dept of Primary Care and Social 
Medicine, Imperial College, London. The model was developed using data from the 2003-2004 Health Surveys for England. The model takes into account age, 
sex, smoking status and deprivation score.
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10.3 Case-finding pilots and case studies 
Five case studies explain how the disease prevalence models are being used by PCTs, for 
Joint Strategic Needs Assessment (JSNA), case-finding, preparing for NHS Health Checks, and 
targeting investment to improve the health of communities. 
10.3.1 Case Study 1: Northamptonshire PCT 
Northamptonshire PCT used the COPD model to inform a programme of work to identify 
and address significant health inequalities. They were able to identify possible under-
diagnosis of COPD in a number of GP practices.  As a result, the PCT has commissioned 
additional screening for certain groups and in certain geographical areas of the trust, and in 
particular in those areas where the model suggests COPD would be more prevalent, because 
of levels of deprivation, smoking and even some industrial pollution issues. 
 
This should lead to significant health benefits from earlier diagnosis.   The strength of the 
model was that it enabled the trust to target resources at a specific problem with 
confidence that they had correctly identified what was going on and where.  If the tool had 
not been available, the Trust’s analysts would have had to try to calculate expected 
prevalence from a range of disparate published sources.  
 
The work would have been more labour intensive, and the analysts would perhaps only 
have been able to look at COPD as part of the current JSNA. Instead they were able to look 
in detail at prevalence of not only COPD, but of all the diseases for which models have been 
made available. 
 
David Pearce, Senior Public Health Analyst at Northamptonshire, explains: “Having centrally 
produced numbers from a respected source, using robust methodology, makes a real 
difference and is less open to challenge and criticism.  It gives a better understanding of 
what is going on in the Trust area and provides a reality check. By comparing the figures 
from the model to the figures emerging in the QOF, it became clear that there were 
significant gaps in diagnosis in some areas.  The updated tools allowing comparisons at GP 
Practice level will enhance their use even further.” 
10.3.2 Case Study 2: South West Essex PCT 
 South West Essex PCT has been using the COPD model with data on QOF prevalence and 
emergency admissions, to identify GP practices who might have incomplete disease 
registers, or those who have complete disease registers but are not managing their COPD 
patients as well as others. Quadrant charts are produced that categorise GP practices into 4 
groups: 
  
Quadrant 1: Lower than expected recorded prevalence and high emergency admissions 
Quadrant 2: Higher than expected recorded prevalence and high emergency admissions 
Quadrant 3: Lower than expected recorded prevalence and low emergency admissions 
Quadrant 4: Higher than expected recorded prevalence and low emergency admissions 
  
This information is to be used to support GP practices depending on the needs of the 
patients.  The PCT also identified high intensity users of emergency admissions for COPD 
(and other disease areas) in the GP practices in Quadrants 1 and 2, so that the PCT could 
Estimating disease prevalence in small populations 
 
138 
M Soljak PhD Thesis 
report the information to the GP who can in turn review whether they have the person on 
their disease register and whether they have had a recent medication review or other 
clinical intervention. 
  
Emma Sanford, Senior Epidemiologist at South West Essex, added: “The next step is to pass 
the lists to specialist COPD nurses to make sure the patients are registered on their case 
load.  It was also possible, using the costing templates, to attach costs (tariffs) to these 
emergency admissions, which we can then ensure are offset against any costs of improving 
the COPD care pathway.” 
10.3.3 Case Study 3: Leicestershire County and Rutland PCT 
Leicestershire County and Rutland PCT has used all of the models and has them embedded 
in the JSNA process.  CVD mortality is a key World Class Commissioning issue for the PCT, 
and they are using the CHD, hypertension and PBS diabetes models to try to help plan for 
the possible outcomes of extended NHS health checks. 
 
They were able to identify a gap between those with CVD who have been picked up already 
by GPs, and the numbers that the new health checks are likely to. The costing templates 
then enabled them to estimate the costs of picking up these additional cases. They were 
able to calculate the likely impact on the medicines budget of ensuring that people are put 
on to the right medical regime. 
 
The model tools have created an evidence base unavailable before, and Janine Dellar, 
Associate Director of public health intelligence at Leicestershire and Rutland says that 
without them, the PCT would have had to implement NHS Health Checks with less 
understanding of the impacts. 
 
“Before the models were produced, we would have used a range of other, but less 
satisfactory models, none of them as well worked through as the models produced by APHO.  
Over time we will need to be clear about how good they are by reviewing the outcomes. It 
will also be important to be sure that there are user guides so that people are using them 
properly. The fact that some of the tools are now available to operate at GP practice level is 
a major step forward. It is important for APHO to be very proactive in letting users know 
about such useful developments.” 
10.3.4 Case Study 4: South Staffordshire PCT 
South Staffordshire PCT has used the models for CHD, stroke, hypertension, COPD and CKD 
to compare estimates of expected prevalence with QOF data on recorded prevalence on GP 
disease registers and also to predict the impact of an ageing population on the numbers 
with these long term conditions.  The data was used to produce a report which will help 
commissioners planning health services across different local authorities in Staffordshire.  
They are also included as part of the JSNA. 
 
Without the model, the analysts would have estimated prevalence from HSfE data and 
other epidemiological reports, but with serious health warnings about their not accounting 
for differences in smoking, deprivation and ethnicity levels.  The PCT particularly 
appreciated the fact that estimates of smoking, deprivation and other factors affecting 
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diseases are used within the models and also that the methods and assumptions are 
comprehensively documented. 
 
Divya Patel, Public Health Epidemiologist at South Staffordshire, added: “The recent 
enhancement of practice level estimates will enable us to drill down further and will be 
useful in terms of monitoring health inequalities and identifying unmet need. It is also useful 
to have comparative local authorities and PCTs against which to benchmark.” 
10.3.5 Case Study 5: Nottinghamshire County PCT 
Nottinghamshire County PCT took the 2006/07 QOF data and compared it with the model 
estimates across four conditions, by practice and by geography, to help map unmet need.  
They found the surprising result that the amount of undiagnosed COPD in 2007 was higher 
in parts of the southern, less deprived area of the County. This borders an area of high 
deprivation where there is less undiagnosed COPD, suggesting that the GPs there have done 
better in targeting and preventing the disease.  The next step was to reapply the model to 
the current QOF data, looking at unmet need by GP Practice, including looking at GP 
Practices in other bordering PCTs, who have patients who live in Nottinghamshire PCTs area 
– quite a significant number. 
 
This created an important  opportunity to work in partnership with bordering PCTs, 
contacting all GP Practices with patients in the Nottingham PCT wherever they are located. 
This was only made possible because the model is available for all GP practices in England.   
David Gilding, Health Improvement Practitioner at Nottinghamshire County PCT, explained: 
“We could only do this because we had the models for the whole of England and for small 
geographical areas, such as wards. The models are helping us to build a really detailed local 
picture.  We’ve used the tools to look at what is happening in QOF and because the data 
comes from a validated source, people are more likely to accept and have confidence in it.” 
 
10.4 Modelling risk factor scenarios and impact on disease prevalence 
This section comes from an unpublished report on stroke needs commissioned by London 
PCTs from PHAST.  The lead author of the report was Dr John Hayward. 
 
The concept of population attributable risk (PAR) is fundamentally important for evidence-
based public health decision-making, because it allows for the quantification of the impact 
of a risk factor on a population, as opposed to an individual level.240 PAR measures potential 
impact of control measures in a population.  Thus, the considerable increase of studies 
addressing the PAR in the course of time is encouraging.241  It is usually defined as: 
 
PAR= (prevalence exposure (RR-1))/(1+ prevalence exposure(RR-1)) 
 
where RR = relative risk.  Because stroke is a comparatively rare outcome, we 
can assume RR= odds ratio240 
 
Estimates of the attributable number of deaths (AD) from all causes can also be obtained by 
first estimating PAR adjusted for confounding covariates, and then multiplying the PAR by 
the number of deaths that occurred in the population for a specific time period. 
Proportional hazard regression estimates of adjusted relative hazards obtained from 
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mortality follow-up data from a cohort is combined with a joint distribution of risk factor 
and confounders to compute an adjusted PAR.242  Current and future disease prevalence can 
be attributed to individual risk factors by calculating PAR.  This has been done by WHO to 
attribute overall disease burden to individual risk factors.243 
10.4.1 Predicting the impact of risk factor reductions on stroke prevalence 
WHO has also looked specifically at the effect of changes in hypertension prevalence on 
stroke prevalence and disease burden.244  We were commissioned by London Cardiac and 
Stroke Networks to predict the likely impact of reducing two important stroke risk factors by 
differing extents – hypertension and smoking.   To do this, I used the stroke prevalence 
model and PAR estimates. The PAR of smoking for stroke in England is 13.3% and of 
hypertension 34.8%.  Thus about half the risk for stroke is preventable from controlling 
these two risk factors together, without considering the additional contribution of atrial 
fibrillation or obesity.  Using this information, I modelled the impact of four feasible primary 
prevention scenarios on stroke prevalence: 
 Scenario 1a assumed that smoking prevalence falls by 1% from the current level by 
2010, a further 1% by 2015 and a further 1% by 2020, but the prevalence of 
hypertension is unchanged. 
 Scenario 1b assumed that the prevalence of hypertension is reduced by 3% over each 
five-year period, but the prevalence of smoking is unchanged.   
 Scenario 2a assumed that smoking prevalence falls by 2% from the current level by 
2010, a further 2% by 2015 and a further 2% by 2020, but the prevalence of 
hypertension is unchanged. 
 Scenario 2b assumed that the prevalence of hypertension is reduced by 6% over each 
five-year period but the prevalence of smoking is unchanged.   
 Scenario 3 assumed that smoking prevalence falls by 1% from the current level by 2010, 
a further 1% by 2015 etc, and that the prevalence of hypertension is reduced by 3% over 
each five year period 
 Scenario 4 assumed that smoking prevalence falls by 2% from the current level by 2010, 
a further 2% by 2015 etc, and that the prevalence of hypertension is reduced by 2% over 
each five-year period. 
An example of the impacts is shown in Figure 21: Stroke Prevalence scenarios, Camden PCT; 
other PCT charts (and charts for the London sectors as a whole) were also produced.  
National trends in smoking and hypertension prevalence were included, along with an Excel-
based modelling package which allowed PCTs to enter their own scenarios.  
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Figure 21: Stroke Prevalence scenarios, Camden PCT 
 
 
The figures shown on the vertical axis are the predicted prevalence numbers for the PCT 
concerned – (i.e. number of individuals in that PCT who will be living having had a stroke by 
the year concerned). 
 
In the absence of a change in risk factors, a substantial increase in stroke numbers is 
expected as the population ages.  The reason for this is the dominant impact of 
demographic change between now and 2020 across the whole of London. The important 
element of that change is the increase in population age during the period. Age is a very 
powerful determinant of overall stroke risk, and the prevalence model shows that it will 
have a dominant impact on future stroke prevalence unless there is a significant reducing 
effect from smoking cessation or better blood pressure control.  Reductions in smoking 
prevalence would reduce the rate of stroke increase, but changes in hypertension 
prevalence would have greater impact.  Best impact can be achieved in Scenario 4 (serial 
reduction of 2% in smoking, plus 2% reduction of hypertension every five years). In this 
scenario, in most PCTs’ stroke prevalence would have fallen slightly between 2006 and 
2020.  
 
This methodology can also be used to apply multifactorial exposure situations and embraces 
various types of attributable fractions including adjusted, sequential and average 
attributable fractions. Scaled Venn diagrams can be used to illustrate total disease risk and 
excess disease risk attributable to the exposures as areas in a unit square. This allows 
display of simple pie charts of attributable fractions summing to 1 (or 100%).245;246 However 



























Stroke prevalence prevention scenarios: Camden PCT
No change
Scenario 1- hypertension 3% decrease/5 years
Scenario 1- smoking 1% decrease/5 years
Scenario 2- hypertension 6% decrease/5 years
Scenario 2- smoking 2% decrease/5 years
Scenario 3- small decrease both
Scenario 4- larger decrease both
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confounding or effect-modifying – factors to obtain valid estimates for the effect of the 
factor under consideration. 
10.4.2 Comment on time lags 
I did not incorporate any time lags for the effects of prevention greater than five years in 
the model, although this is possible with a Markov model,35;40 because there is evidence 
that reduction in CVD risk occurs rapidly after smoking cessation or control of hypertension.  
The US Nurses Study showed that the risk decline after smoking cessation occurred for CHD 
and total CVD within two years, and for stroke after 2-4 years.247  Similarly, the Japanese 
JACC study showed that for mortality alone, much of the reduction in the excess risk were 
realized within the first five years for CHD disease and stroke.248 Sixty-one percent of the full 
potential benefit of quitting in regard to CHD mortality and 42% of the full potential benefit 
of quitting in regard to stroke mortality was realised within the first 5 years of quitting 
smoking.  There is less evidence about risk reduction rates after control of hypertension, but 
it is biologically plausible that this happens quite quickly. 
 
The hypertension model uses as an outcome overall hypertension (treated controlled, 
treated uncontrolled and untreated).  A rapid reduction in overall prevalence would only 
result from improving management of treated hypertension and finding new cases of 
established hypertension, and not from “primordial” prevention e.g. by increased physical 
activity.  In other words, a rapid reduction in overall stroke prevalence requires clinical 
action in addition to broad population health improvement initiatives.  
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10.5 CVD prevalence modelling by the Care Quality Commission 
The CVD prevalence model was commissioned by the CQC to assist them in assessing the 
performance of PCTs in supporting practices in the task of identifying and managing CVD.  
The CQC published a report on their investigations, entitled Closing the gap: Tackling 
cardiovascular disease and health inequalities by prescribing statins and stop smoking 
services.249 The model was used to help answer the question: does estimated unrecorded 
CVD prevalence increase with deprivation? Figure 3.2 in the report (shown here as Figure 
22) shows that the level of estimated unrecorded prevalence in each practice increased with 
greater deprivation.  
Figure 22: estimated unrecorded CVD prevalence by deprivation at GP practice level 
 
Source: Care Quality Commission.  Closing the gap: Tackling cardiovascular disease and 
health inequalities by prescribing statins and stop smoking services 
 
The variation in unrecorded prevalence also increased markedly with deprivation.  Overall, 
the median level of estimated unrecorded prevalence was just over 1% and a large number 
of GP practices had median unrecorded prevalence rates of over 2%. The report concluded 
that QOF was not designed to be an epidemiological disease register, and is therefore likely 
to miss a proportion of those with established CVD.  Some reasons given why CVD 
prevalence may be unrecorded include patients who are registered with a GP but whose 
CVD has not yet been diagnosed, people in the community who are not registered with a GP 
but who have CVD, or because some GP practices in deprived inner city areas may not have 
systems in place to capture the data in electronic format for the QOF.  
 
The median level of unrecorded prevalence appeared to be low at just over 1%, but this is 
significant in public health terms, and it is worrying that the level of unrecorded prevalence 
increases with increasing deprivation. People who have CVD and who also live in relatively 
poor social and economic circumstances are more likely to be in greater need of 
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preventative treatment because of the added burden of deprivation. Variations in the 
performance of GP practices are inevitable. However, high levels of variation can indicate 
that they are either not consistently observing national guidelines, they do not have a 
focused approach or that there are challenges associated with deprivation in the local area.  
 
The report also addressed the question: does statin prescribing increase with recorded CVD 
prevalence and deprivation?  Volumes of statin prescribing as average daily quantity of 
statins per standardised population (ADQ/STAR PU) increased only marginally as the 
prevalence of CVD increases. However, the increase in prescribing was more noticeable with 
increasing deprivation (see Figure 23: average daily quantity of statins per standardised 
population).  There appeared to be a wider variation in statin prescribing in GP practices 
with a lower estimated CVD prevalence. Conversely, in the context of deprivation, variation 
in statin prescribing is greater in the more deprived GP practices.  
Figure 23: average daily quantity of statins per standardised population 
 
The report concluded that statin prescribing increases more noticeably with increasing 
deprivation than with increasing CVD prevalence. This may be because deprivation is a 
better predictor of the prevalence of CVD than QOF (as stated above, QOF was not designed 
to be an accurate epidemiological disease register). Prescribing statins to people who are 
not yet recorded as having established CVD might explain why it appears that there is more 
statin prescribing in deprived areas than in areas of higher CVD prevalence.  It suggested 
that GPs are undertaking some preventive statin prescribing to patients at high risk of 
developing CVD. If this is the case, it is good news for people's health and fits in with both 
the Department of Health's policy and guidance from NICE on reducing risks of CVD, 
although not consistently so. Further research may clarify how much of the above 
prescribing is to those whose CVD is unrecorded and to those who are at high risk. 
 
This application of the CVD prevalence model demonstrates its utility in combination with 
other indicators of population needs and healthcare use. 
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10.6  Does undiagnosed COPD increase hospital admission rates? 
 
This sub-section is part of a paper (Association of population and primary healthcare factors 
with hospital admission rates for chronic obstructive pulmonary disease in England: national 
cross-sectional study) published by Thorax.250  It explores the associations between 
registered, estimated and undiagnosed disease prevalence (using prevalence models), 
primary healthcare quality, and hospital utilisation.  There are a number of potential 
benefits in evaluating these associations, for example: 
 
 to establish a firmer evidence base for the identification of primary care sensitive 
conditions (PCSCs) 
 to model future healthcare capacity requirements, and the impact of quality 
improvements on them 
 to achieve better value in healthcare resourcing, and improve healthcare outcomes. 
10.6.1 Introduction 
The total annual cost of COPD to the English National Health Service (NHS) is over £800 
million ($1,215 million), and it has become the second largest cause of emergency hospital 
admissions in the UK.251 DH for England has released a COPD national strategy252 and it also 
has a range of policies to improve long term condition management in primary care, with 
the aim of improving quality and length of life and reducing hospital admissions. 
 
Reducing unnecessary hospital admissions will play a critical role in ensuring the NHS and 
other health systems meet the challenge of real terms reductions in resources - the 2010 UK 
Budget report factors in potential savings of £2.4bn from this source.253  COPD is one of a 
number of PCSCs, for which it is hypothesised that risk of hospital admission will be reduced 
by effective primary care management.254-256  However PCSCs have mainly been identified 
by expert opinion rather than empirically.257;258  Previous research has also been hampered 
by lack of detailed data about practice populations and the quality of primary care services, 
such as is now available through QOF, or has been carried out only at PCT level .259-261 
 
Some population factors- especially deprivation - are strongly associated with PCSC 
admission rates, and there are weaker associations with primary care access and supply 
factors.262  Effective management of COPD may reduce the risk of hospital admission.  
Gotfredsen et al found a gradient of relative risk of hospital admission with increasing 
smoking prevalence.69  In addition, combination treatment with long-acting beta-agonists 
and inhaled corticosteroids reduces the annual rate of COPD exacerbations and improves 
health status and spirometric values.208;209  A  systematic review demonstrated that patients 
with COPD who received interventions with two or more components of the Chronic Care 
Model had lower rates of hospitalizations.263 
 
The aim of this study was to examine the associations between population characteristics, 
including both diagnosed and undiagnosed prevalence, primary healthcare factors, and 
COPD admission rates at PCT and practice levels in England. Both levels of analysis are 
desirable, as aggregation to PCT level could mask important associations present at practice 
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level.  Specific objectives were firstly to investigate the associations between rates of 
hospital admission for COPD and population factors (deprivation, smoking prevalence, QOF 
registered/diagnosed prevalence rates, and undiagnosed i.e. expected minus QOF 
registered prevalence rates).  The second objective was to investigate associations between 
admission rates and a range of healthcare factors, after adjustment for population factors.  
These included access factors (general practitioner and practice nurse supply and QOF 
access indicators), COPD-specific QOF quality indicators, and smoking cessation advice or 
referral, to explore their relative impacts.  As all UK residents are entitled to primary care 
consultations which are free at the point of use, and as the vast majority of residents are 
registered with a practice, there are no apparent barriers to access.  However, despite NHS 
resources being allocated on a needs-weighted population basis, there are quite wide 
variations in access as measured by patients’ experience of the availability of unscheduled 
care and appointments - hence the inclusion of these indicators in QOF. 
10.6.2 Methods 
Hospital Episodes Statistics Data 
NHS-funded hospitals in England are responsible for providing data to the HES database. A 
hospital episode forms all or part of an overall hospital spell (one complete admission). We 
used hospital spells for this analysis to avoid multi-counting,  Admissions were selected 
where the primary diagnosis i.e. main reason for admission met ICD version 10 J44.0-44.9 
(Other chronic obstructive pulmonary disease, excluding asthma and other non-COPD) for 
all patients 15 years of age and over admitted during financial years 2006-7, 2007-8, 2008-9 
to maximise the number of admissions per practice. It was not possible to validate the HES 
diagnosis against data from practice COPD registers as only aggregate QOF data is available. 
 
Quality & Outcomes Framework Data 
We used QOF data from the IC website for April 2008 - March 2009.220 QOF indicators are 
split between four quality domains (clinical, organisational, patient experience and 
additional services). The QOF clinical domain included 129 evidence-based indicators of the 
clinical quality of care including five indicators for COPD (Table 62: Quality and Outcomes 
Framework indicators for COPD management and Patient Experience in 2008-2009 which 
were analysed). We used the number of COPD patients recorded by general practices 
(registered prevalence), the total list sizes of patients per practice as denominators (the 
definition used by the Information Centre),  the total QOF points achieved for the COPD 
domain and individual indicators for specific COPD care (i.e. spirometric confirmation of 
diagnosis, recent record of forced expiratory volume in one second (FEV1), inhaler 
technique and influenza immunisation offered).  Since stopping smoking affects the 
prognosis of COPD, we also included the percentage of patients with a chronic disease 
whose notes record that smoking cessation advice or referral to a specialist service has been 
offered within the previous 15 months (Smoking 4).  To measure broad access to care from 
the patient perspective we used two new patient experience (PE) indicators introduced in 
the 2008-9 QOF, which were derived from the results of the national GP Patient Survey, and 
which measure ability to access a GP consultation within two days (PE7), and ability to book 
an appointment with a GP more than two days ahead (PE8).  
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Table 62: Quality and Outcomes Framework indicators for COPD management and Patient 




COPD quality indicators   
Records   
COPD 1 
The practice can produce a register of patients with COPD 
3  
Initial diagnosis   
COPD 12 
The percentage of all patients with COPD diagnosed after 1st April 
2008 in whom the diagnosis has been confirmed by post 
bronchodilator spirometry 
5 40-80% 
Ongoing management   
COPD 10 
The percentage of patients with COPD with a record of FeV1 in the 
previous 15 months 
7 40-70% 
COPD 11 
The percentage of patients with COPD receiving inhaled treatment in 
whom there is a record that inhaler technique has been checked in 
the previous 15 months 
7 40-90% 
COPD 8 
The percentage of patients with COPD who have had influenza 
immunisation in the preceding 1 September to 31 March 
6 40-85% 
Smoking quality indicator   
Smoking 4 
The percentage of patients with coronary heart disease, stroke or 
TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, 
bipolar affective disorder or other psychoses who smoke whose 
notes contain a record that smoking cessation advice or referral to a 
specialist service, where available, has been offered within the 
previous 15 months 
35 40-90% 
Patient Experience indicators   
PE 7 Patient experience of access (1) 
The percentage of patients who, in the appropriate national survey, 
indicate that they were able to obtain a consultation with a GP (in 
England)  
23.5 70-90% 
PE 8 Patient experience of access (2) 
The percentage of patients who, in the appropriate national survey, 
indicate that they were able to book an appointment with a GP more 
than 2 days ahead 
35 60-90% 
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The IC provided data on GP and nurse supply (GPs and practice nurses per 100,000 
population), at practice and PCT level respectively, as of September 2007.203  Practice nurse 
numbers do not include other nurses working in the community, such as “community 
matrons” or district nurses, who may have contact with COPD patients. 
 
Undiagnosed prevalence data 
We used practice-level predictions of COPD prevalence from the APHO website, which uses 
a model developed by Nacul et al.59 This uses spirometry data from the 2001 HSfE to 
produce prevalence estimates for population subgroups.  It uses the British Thoracic Society 
definition of COPD i.e. FEV1 FVC under 0.70, and FEV1 less than 80% of predicted, a more 
stringent definition than the National Strategy.  The model includes practice-level values of 
age, sex (population data as of March 2007), ethnicity, deprivation, smoking and 
urbanisation to estimate overall COPD prevalence, and has been validated against estimates 
from population surveys.  Practice-registered COPD prevalence was then subtracted to 
estimate undiagnosed prevalence.  Further information about the COPD model 
development is provided on the APHO website.116 
 
Population Data 
The CQC (CQC) provided estimates by sex and five-year age band of registered patients by 
practice and PCT in England, as of April 2008. The Department of Communities & Local 
Government Index of Multiple Deprivation (IMD) 2004 data for England was used to 
measure deprivation79-  high scores indicate a high level of deprivation. IMD data were 
available for 152 PCTs. A deprivation weighting for each practice was obtained from the 




The basic unit of analysis was the general practice population. Indirect standardisation is 
generally accepted as more robust when counts are relatively small, so indirectly 
standardised admission rates were calculated at the practice level, to produce overall 
expected admission rates for each practice based on the England  age/sex specific rates. 
These were compared to the observed practice-level admission numbers.  Baseline PCT 
characteristics were then calculated including registered population (the sum of registers of 
general practices located within PCTs’ geographic boundaries), age distribution, IMD, 
practices per PCT and practice list size. Practice level characteristics (QOF points and 
indicator breakdown) were aggregated to PCT level, as required. As admission counts were 
larger at PCT level, directly standardised (age and sex) admission rates were calculated per 
100,000 GP registered population, using the total England population as the standard with 
which to weight the PCT rates.  Three year averages of registered and estimated COPD 
prevalence were summarised and undiagnosed prevalence calculated.  
 
At practice and PCT levels, bivariate associations between admission rates and the above 
continuous independent variables were first assessed using Spearman’s correlation 
coefficient.  For the PCT level analysis least squares linear multivariate regression models 
were then fitted to examine the effects of all independent variables. At the practice level, 
because of low admission numbers, we applied Poisson regression, where standard errors 
have been scaled using the square root of the deviance-based dispersion. The dependent 
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variable was observed count of hospital admissions and the offset was the expected number 
of admissions. Poisson regression returns incidence rate ratios (IRRs), which in this context 
can be considered as analogous to odds ratios.  Microsoft Excel and Access were used to 
manage the data and the software package Stata10 was used for all statistical analysis. 
10.6.3 Results 
The 152 English PCTs had a total GP-registered population of 53,547,488 patients (Table 63: 
characteristics of PCT and practice populations). The GP-registered population in each PCT 
varied from 94,635 to 1,294,596 (mean 352,286). We were able to match all the data 
required for 8,064 (90.3%) GP practices from a total of 8,932.  List size varied from 984 to 
38,343 (mean 6,603).  Estimated smoking prevalence at practice level varied from 13.2 to 
51.7%. QOF scores achieved were generally high, for influenza immunisation, inhaler 
technique and spirometry, although there was a wider variance in PCTs recording 
spirometry (76.0% - 96.4%) and recording FEV1 (75.5% - 89.3%). The range of QOF Patient 
Experience scores also tended to be lower. 
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- - - - 
Practice population 
6,603 - - - - 4,011 984 - 38,343 5,774 
3,394 - 
9,011 
Percent of people 15-34y 27.5 25.7 19.6 - 43.1 43.1 25.7 7.8 10.5 - 98.5 25.7 22.4 - 30.0 
Percent people 35-74y 48.1 3.8 34.2 - 53.7 49.3 45.5 - 50.9 6.6 1.3 - 64.4 49.5 45.3 - 52.5 
Percent people 75+y 7.2 1.8 2.9 - 12.3 7.2 6.3 - 8.2 2.9 0.0 - 26.4 7.2 5.3 - 8.9 
IMD (deprivation) score 23.7 9.1 8.1 - 48.3 23.6 16.1 - 29.8 12.6 2.2 - 71.9 21.3 13.4 - 32.0 
Smoking prevalence 24.7 4.3 14.5 - 40.9 24.3 21.7 - 27.1 6.4 13.2 - 51.7 23.7 19.7 - 28.9 
GPs/100,000 population 60 7 44 - 81 59 55 - 64 17 8 - 334 55 10 - 180 
Practice nurses/100,000 
population 
28 7 0 - 60 28 24 - 32 - - - - 
QOF Clinical Indicators* 
   Total COPD score 96.2% 2.6% 83.7% - 99.9% 96.8% 94.8% - 98.2% 9.9% 0.0%  - 100% 100% 99.4% - 
100% 
   Influenza immunisation 91.6% 1.2% 86.9% - 95.5% 91.8% 90.9% - 92.4% 6.3% 0.0%  - 100% 92.7% 89.5% - 
96.1% 
   Record of FEV1 82.4% 2.6% 75.5% - 89.3% 82.4% 81.0% - 84.2% 12.1% 0.0%  - 100% 83.8% 77.3% - 
89.7% 
   Record of inhaler technique 91.6% 1.6% 87.4% - 95.1% 91.8% 90.6% - 92.7% 8.9% 0.0%  - 100% 93.4% 90.9% - 
96.2% 
   Record of post- 
   bronchodilator spirometry 
90.1% 3.4% 76.0% - 96.4% 90.9% 88.8% - 92.2% 25.0% 0.0%  - 100% 100% 86.2% - 
100% 
   Smoking cessation advice or   
referral to a specialist service 
92.7% 1.1% 89.2% - 95.3% 92.9% 92.1% - 93.5% 5.3% 26.6% - 100% 93.1% 91.1% - 
95.8% 
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QOF Patient Care Experience Indicators* 
  Ability to obtain a 
  consultation within 2 
  working days 
84.8% 8.4% 0.0% - 92.8% 85.6% 82.9% - 88.3% 14.1% 0.0%  - 100% 87.3% 79.3% - 
93.0% 
  Ability to book an 
  appointment with a GP 
  more than 2 days ahead 
77.3% 8.4% 0.0% - 89.0% 77.8% 75.2% - 81.0% 17.6% 0.0%  - 100% 80.8% 67.3% - 
90.3% 
* Total Points / Available % 
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Table 64 summarizes the observed, estimated and calculated undiagnosed prevalence levels 
for COPD at the PCT and practice level. The England mean prevalence of registered COPD in 
the whole population is 1.5% (SD 0.0%), and undiagnosed COPD is 2.2% (SD 0.1%).  Mean 
(over three years) annual hospital admission rates for COPD per 100, 000 population varied 
from 124.7 to 646.5 (median 241.5, inter-quartile range 178.1 to 331.4) at PCT level and 0.0 
to 2175.2 (median 179.0, inter-quartile range 111.1 to 288.2) at general practice level, 
illustrating the greater variance observable in a practice level analysis.  Over 98% of 
admissions were in the 45 years and over age group. 
 
Regression modelling 
In the bivariate regression of exposure variables against hospital admission rates at PCT 
level, deprivation and smoking prevalence were the variables with highest explanatory 
power, accounting for 59.3% and 51.4% of the total variance respectively (p<0.001). 
Estimated prevalence accounted for 45.1% of the variance (p<0.001) compared to the 
observed (registered) COPD prevalence (21.9%, p<0.001). About 14.4% of the variance in 
hospital admissions was explained by GP supply (p<0.001). The QOF COPD overall clinical 
quality score was shown to account for only 2.1% of the variance (p=0.034).  Among all 
specific clinical QOF indicators, the score for influenza immunisation showed the highest 
explanatory capacity (6.9%, p<0.001). In the multivariate regression model using reverse 
stepwise variable selection (R2=75.0%), the undiagnosed disease prevalence as well as all 
QOF clinical indicators were not retained in the model using a probability criterion of 0.1 
(Table 64). 
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Table 64: Summary of estimated, observed and undiagnosed COPD prevalence and admission rates 
   PCT-level Practice-level 















5,774 3,394 - 
9,011 
Estimated prevalence 3.8% 0.9% 2.1% - 6.0% 3.6% 3.1% - 4.4% 1.1% 0.7% - 7.5% 3.6% 2.9% - 4.6% 




2.2% 0.9% 0.6% - 4.3% 2.0% 1.5% - 3.0% 1.0% -2.6% - 
6.0% 
2.1% 1.4% - 3.0% 
Estimated/observed 
prevalence ratio 
2.6 0.7 1.4 - 5.0 2.4 2.0 - 3.0 8.4 0.5 - 577.4 2.5 1.9 - 3.5 
Undiagnosed/observed 
prevalence ratio 
1.6 0.7 0.4 -  4.0 1.4 1.0 – 2.0 8.4 -0.5 - 576.4 1.5 0.9 - 2.5 
Admissions/100,000 
population* 




179.0 111.1 - 
288.2 
* Admission rates are directly standardized at PCT-level and adjusted for age and sex (indirectly standardized) at practice-level. 
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Table 65 also shows the practice-level analysis using Poisson regression with reverse 
stepwise variable selection . The highest incidence rate ratio (IRR) was estimated for 
observed prevalence (IRR=1.224, p<0.001), and undiagnosed prevalence, deprivation, 
smoking prevalence, GP supply and access to a GP consultation, and influenza immunisation 
status were also retained in the final model using reverse stepwise variable selection and a 
probability criterion of 0.1.  Overall COPD score, and clinical quality indicators COPD 10, 
COPD 11, COPD 12 and Smoking 4 all dropped out of this model.  




























a Stepwise linear regression. Adjusted R-squared= 0.75. Dependent variable: admission rates 
for COPD. 
b Stepwise Poisson regression,  Dependent variable: observed admission count. 
PE 7: Score for ability to obtain a consultation within 2 working days. 
PE 8: Score for ability to book an appointment with a GP more than 2 days ahead. 
COPD 8: The percentage of patients with COPD who have had influenza immunisation in the 




95% CIs p-value 
Observed prevalence 1.325 1.204-1.459 <0.001 
IMD (deprivation) score 1.023 1.018-1.028 <0.001 
GPs/100,000  population 0.995 0.991-1.000 0.052 
Practice nurses/100,000 
population 
0.992 0.987-0.996 0.001 
Smoking prevalence 1.023 1.012-1.033 <0.001 




95% CIs p-value 
Observed prevalence 1.224 1.206-1.243 <0.001 
Undiagnosed prevalence 1.045 1.032-1.059 <0.001 
IMD (deprivation) score 1.009 1.006-1.012 <0.001 
Smoking prevalence 1.036 1.031-1.042 <0.001 
GPs/100,000 population 0.998 0.998-0.999 <0.001 
QOF patient experience 7 0.790 0.730-0.855 <0.001 
QOF patient experience 8 0.902 0.850-0.957 0.001 
COPD clinical quality 8 (influenza 
immunisation)  
0.825 0.690-0.987 0.036 
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10.6.4 Discussion 
In this cross-sectional study of hospital admissions for COPD, registered COPD prevalence, 
undiagnosed prevalence, smoking prevalence and deprivation were all risk factors for 
hospital admission (p<0.001). Primary healthcare factors such as being offered influenza 
immunisation, patient-reported access to primary care consultations within two days, and 
primary care supply (GPs and practice nurses per 100,000 population) were protective 
factors (p<0.05).  There was an overall consistency in the findings at organisation and 
practice levels, but with additional independent variables being retained in the practice level 
model, and with stronger associations apparent.   At practice level, after adjustment for 
deprivation, undiagnosed COPD prevalence as well as diagnosed disease was strongly 
associated with the rate of hospital admission.  Primary healthcare factors such as being 
offered influenza immunisation, patient-reported good access to GP consultation, and GP 
and practice nurse supply were also significantly associated with reduced hospital admission 
rates.  
 
Hospital admissions for COPD were strongly associated with deprivation scores and smoking 
prevalence at both PCT and practice level.  This relationship has been documented 
previously,264;265 but associations with primary care supply less often.  Saxena et al studied 
the association at London PCT level between population and practice factors with hospital 
admission rates for PCS conditions (including COPD).262 They found some associations 
between primary healthcare factors and admission rates, but not with practice resourcing. In 
contrast, a practice level analysis of hospital admissions for asthma in East London, found 
that practice characteristics were the strongest predictor of the admission rate, but the most 
likely explanation for this result could be that the geographically small region under 
investigation was uniformly deprived.261  In our study, GP supply was inversely associated 
with hospital admission rates at the practice (but not PCT) level.  Conversely, practice nurse 
supply was associated with lower admission rates at PCT level, but unfortunately these data 
are not readily available at practice level.  These and similar findings, together with the 
impacts demonstrated in our QOF indicator analysis, highlight the need for adequate 
primary care provision in deprived areas.  Geographical inequalities in GP supply have been 
persistent despite needs-based funding of PCTs.231 
 
Our study was strengthened by using data from a national population, giving a high level of 
statistical power, and by combining practice-level data and estimates from a number of 
sources which were previously unavailable, or only available locally.  This revealed 
associations which may have been masked in previous studies which used the organisation 
as the level of analysis.  This study is also the first to examine estimates of undiagnosed 
disease and its association with hospital admissions.  
 
The BTS definition of COPD used for the prevalence estimates is stringent, which may lead to 
underestimation of the effect of undiagnosed disease prevalence.  Conversely, the COPD 
model does not include lack of bronchodilator responsiveness in the definition of COPD, so 
this will slightly overestimate prevalence.  Moreover, practice registers can include patients 
with no spirometry.  We were able to include several new QOF clinical quality and patient 
experience indicators.  Our analysis also illustrates the greater benefits of using practice 
level rather than organisation level data.  Our findings would be strengthened by similar 
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analyses of other long term conditions, which would also validate the selection of PCS 
conditions, and assist in regulation of primary care. 
 
There are several limitations.  Hospital or general practice diagnostic coding may be 
incorrect.  However, the advent of diagnosis-based payment of hospitals has accelerated 
improvement in data quality.  We only considered primary or principal diagnosis, and 87.2% 
of primary diagnoses for hospital admissions in England are coded correctly.266  Counts of 
annual hospital admissions per practice were relatively low, even using means of three 
years’ data (mean per year=12.9, median per year=10.0).  We used appropriate methods 
(indirect standardisation and Poisson regression) to deal with this, and were reassured by 
the overall consistency between the results at organisation and practice levels.  
Furthermore, a number of UK agencies use practice-level admission data to support 
commissioning and quality improvement, so its use should prompt similar scrutiny to that 
which followed use of similar data at hospital level.  In the case of COPD, general practices 
may add patients to COPD registers without necessary confirmatory spirometry- only 82.4 
per cent have a record of this test.  This will overestimate the diagnosed prevalence. 
 
Reported practice populations may overestimate actual numbers, especially in urban areas 
with high mobility.  Conversely, a small number of residents may not be registered with a 
practice.  There is also a high level of achievement of many QOF indicators which results in a 
“ceiling effect”, which may reduce the ability to detect real differences in clinical quality.  
Many QOF indicators measure care processes which may not be strongly related to disease 
outcomes (as our analysis suggests).  The impact of recent changes in quality of care on 
outcomes such as hospital admission may be delayed, but changes in QOF scores between 
2005 and 2007 were small.  Other data inevitably covered slightly different periods and 
dates.  HES data does not include privately-funded hospital admissions, but the vast majority 
of unplanned admissions for COPD are to NHS hospitals. We did not analyse readmissions 
separately as the focus was on factors affecting exacerbations in the community.  Practice-
level COPD and smoking prevalence estimates are based on the limited range of risk factor 
data available locally.   
 
There are now several disease prevalence models for England which enable comparisons of 
QOF-registered and expected prevalence counts.  We showed an association between 
admission rates and undiagnosed prevalence.  The National COPD Audit has shown that 90% 
of those hospitalised with COPD were known to have the diagnosis before admission and to 
suffer exacerbations frequently.267  However, a population survey from Spain showed a high 
rate of undiagnosed COPD, and significant impairment in health-related quality of life and 
activities of daily living in undiagnosed individuals.268   Patients who have frequent 
exacerbations irrespective of disease severity may represent a distinct COPD phenotype, 
implying that earlier diagnosis and intervention may improve outcomes.269  The validity of 
the model, and the cost-effectiveness of targeted COPD case-finding strategies in practices 
with high estimates of undiagnosed disease, should therefore be evaluated. 
 
The new QOF Patient Experience indicators were introduced, as their title suggests, to 
improve patient satisfaction with access to primary healthcare.  However the strong 
association between these indicators and admission rates suggests that they also reflect 
clinically important aspects of access.  The National COPD Audit showed that 74% of 
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admitted patients make contact with their general practice in the month before admission 
and 31% have three or more contacts in those four weeks.267  Given that the ability to access 
primary care rapidly during a COPD exacerbation may well reduce admission risks, the 
association with PE07, the ease of obtaining a consultation, is plausible.  That there is also an 
association with PE08, the ease of making non-urgent appointments, and with GPs per 
100,000 practice population, suggests that access barriers may also affect ongoing COPD 
management. 
 
At practice level, only QOF COPD indicator 8, uptake of influenza immunisation, was 
associated with hospital admission rates.  This is clinically plausible.  The other QOF COPD 
indicators are measures of clinical processes and standards which are less likely to affect 
outcomes.  Alternatives which are more likely to affect outcomes should be considered.  For 
example, practices could be incentivised to deliver more intensive smoking cessation 
services to COPD patients.  The updated NICE COPD guidelines currently out for consultation 
recommend that pulmonary rehabilitation should be made available to all appropriate 
patients with COPD, and that newer long-acting drugs be prescribed to appropriate 
patients.89  The interventions in the Chronic Care Model reduce admission rates, although 
they are difficult to measure.263 Finally, other factors which could affect admission rates 
include the quality of out of hours services,  the presence of specialist nurse services, and 
the supply and quality of hospital services. 
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10.7 Exploring the utility of mapping and spatial statistics in the context of 
health & social care regulation 
10.7.1 Introduction 
This section illustrates some of the analyses carried out for the CQC as part of a project we 
were commissioned to carry out to explore the utility of mapping and spatial statistics in the 
context of primary healthcare regulation. 
 
The role of the CQC includes the registration and regulatory assessment of primary health 
care.  Providers of NHS primary care medical services that provide regulated activities must 
be registered from 1 April 2012. This includes general practices and out-of-hours services.  
Research carried out by the CQC has demonstrated the importance of conducting analyses at 
sub-PCT/practice level  to disseminate salient messages to local commissioning and public 
health teams.  In addition, methodological advances in quantitative geography have led to 
the development of GWR and related spatial statistical techniques.  These examine spatial 
relationships and could add another dimension to CQC practice-level analyses.  The use of 
mapping facilities in modern GIS also provides helpful methods of displaying geo-referenced 
data.  The CQC has therefore commissioned a small project to investigate the application of 
GIS and GWR to CQC healthcare data, and to explore its utility for local monitoring purposes 
within the context of CQC’s functions to register and regulate primary healthcare services 
delivered by GP practices. 
 
The specific objectives were: 
 to use the LMI method for detecting outlying performance of individual PCTs and GP 
practices, including statistically significant geographical clustering 
 to investigate the relationship between cross-, intra- and inter-PCT performance 
variation with and without adjustment for confounding factors using classical regression 
and GWR, to compare the two methods 
 to demonstrate options for displaying and mapping this variation using GIS for purposes 
of local monitoring and regulation. 
  
To explore spatial relationships in this context, the two scenarios chosen as a “proof-of-
concept” were (Table 66): 
 
Scenario 1/disease detection: associations with practice-registered (“observed”) coronary 
heart disease (CHD) and stroke prevalence and undiagnosed CHD and stroke prevalence as 
outcome variables.  This can be viewed as a metric of the success of practices in identifying 
and registering cases of disease in their registered populations. 
 
Scenario 2/disease management: associations with PCT and practice level 
unscheduled/emergency admission rates for CHD and stroke as outcomes of disease 
management by general practices.  There are therefore analyses for two scenarios and two 
disease groups for each, as shown in Table 1. 
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Table 66: Analytic scenarios and data sources 




Outcome (y) variables Registered and 
undiagnosed CHD and 
stroke prevalence 
Admission rates for CHD 




Age, sex, deprivation 
score, ethnicity, 
smoking 
Age, sex, deprivation, 
ethnicity, smoking, 




GP supply, CQC PCT 
ranking  
GP supply, CQC PCT 
ranking, quality of care 
 
A characteristic of most of the ordinary least squares (OLS) or classical regression analyses is 
IRRs/ORs mainly very close to unity, suggesting that effect sizes are relatively small.  This is 
somewhat surprising as several other published PCT-level analyses show, for example, 
relatively strong positive associations of prevalence with deprivation,270  and it is included in 
the model used to estimate overall prevalence, which is based on HSfE patient-reported 
doctor-diagnosed CHD (OR for fifth IMD quintile 2.4).  It does not appear that this is mainly 
due to multicollinearity. 
 
Nevertheless, because of the 8,000 practices included in the analyses, a number of the IRRs 
are statistically significant.  For unregistered prevalence of CHD (Scenario 1), IMD score, GP 
supply/100,000 population, and the QOF Patient Experience Indicator PE08 (can book an 
appointment with a GP > 2 days ahead) are marginally positively associated in a multivariate 
OLS model.  Smoking prevalence and the QOF Clinical Indicator CHD08 
(Cholesterol<5Mmol/L) were negatively associated.  Other variables were not retained in the 
model.  The directions of some of these associations are unexpected: one might expect GP 
supply to be negatively associated and smoking prevalence to be positively associated.  One 
explanation for this could be multi-collinearity. However only IMD score and estimated 
smoking prevalence (which uses IMD score as an input) showed evidence of 
multicollinearity. 
 
Simple practice-level mapping of registered and expected prevalence rates shows the typical 
North-South divide, with higher prevalence in South coastal areas because of population age 
structure.  However unregistered (expected minus registered) CHD prevalence rate, shows 
evidence of possible spatial clustering, with the highest rates clustered in London and West 
Midlands conurbations. 
 
For stroke, OLS multivariate stepwise analysis results are similar to CHD.  As for CHD, 
practice-level mapping of the unregistered stroke prevalence rate, shows evidence of 
possible spatial clustering, with higher rates in the London and West Midlands conurbations, 
but there is a more dispersed pattern than for CHD.  We also performed Local Moran’s I 
(LMI) tests on unrecorded prevalence of stroke.  There is marked clustering of high levels of 
unrecorded prevalence evident in London and other conurbations, which is even more 
prominent in the 5 km map.  There is some, but much less, clustering of low levels of 
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unrecorded prevalence which tends to be in the hinterlands of urban areas.  The results of 
the spatial non-stationarity test for stroke prevalence revealed little difference between the 
AIC values for the non-spatial and GWR models. 
 
For CHD (MI+angina) admission rate as the outcome variable, observed prevalence, IMD 
score, smoking prevalence and Asian population are as expected all risk factors for hospital 
admission- the IRR for the latter is comparatively high.  The IRR for unregistered prevalence 
is less than unity, which is unexpected, as patients with undiagnosed disease might be 
expected to be more likely to be admitted.  The directions of other associations are generally 
as expected, with higher scores on QOF Clinical Indicators as protective, apart from CHD06 
(BP<150/90mm Hg).  We carried out LMI tests on stroke only. 
 
As for MI+angina, observed prevalence, IMD score and smoking prevalence are as expected 
all risk factors for hospital admission for stroke.  The IRR for unregistered prevalence is less 
than unity, which is unexpected, as patients with undiagnosed disease might be expected to 
be more likely to be admitted.  In comparison with a similar analysis on COPD admissions we 
have carried out recently, IRRs were generally smaller for CHD and stroke, and the results for 
COPD were more consistent with our prior hypotheses.250  We also have some concerns 
about the provenance of the CQC HES data, as we have been unable to ascertain how it was 
grouped into spells.  Only one QOF Clinical Indicator, Stroke08 (Last cholesterol <5mmol/l), 
remains in the model and is as expected, with higher scores protective.   
 
LMI tests at 2km and 5km for stroke admission rates showed marked clustering of high-high 
admission rate values evident in London and other conurbations, which is even more 
prominent in the 5 km map.  However there is also clustering of low-low levels, especially in 
West London and in the West Midlands.  The results of the spatial non-stationarity test 
reveal little difference between the AIC values for the non-spatial and GWR models, with 
marginal improvement with the spatial model.  Nevertheless, the AIC values confirmed that 
it was statistically valid to use spatial regression as a basis for exploratory mapping. 
 
Practice-level local R-squared maps were produced for stroke admission rates to 
demonstrate the utility of this analytic approach.  We used a split-variable analysis (grouping 
population factors and healthcare factors together) to illustrate the differing contributions of 
these variables on admission rates.  We have demonstrated, for example, that in one 
region’s more rural PCTs there are associations of practices for whom service delivery factors 
predict admissions more strongly than population factors: these associations do not appear 
to cross boundaries into the more urban PCTs in the centre of the region.  In NW England, 
the socio-demographic model shows a general south to north statistical incline and the 
healthcare model the reverse.  On the other hand, along the South Coast, the maps show 
remarkably strong agreement between the healthcare/institutional and population models 
in terms of directionality. 
 
In summary, although the analysis did not demonstrate that GWR is definitely superior to 
OLS analysis in this situation, it is at least as useful, and in addition provides the opportunity 
to visualise and investigate spatial  relationships more easily, as we have shown.  
Performance-related practice associations identified by the use of GWR provides a basis for 
further investigation of potential ‘overachievers’ and ‘underachievers’.  Mapping of results 
Estimating disease prevalence in small populations 
 
161 
M Soljak PhD Thesis 
enables visualisation readily interpretable by CQC statisticians, and with adaptation 
cartographic output can be understood by lay members of the public, a facet important in a 




We recommended that CQC: 
1. Make a senior manager within CQC responsible for the implementation of mapping 
and GIS techniques for the general public and healthcare professionals, and spatial 
analytic techniques (either in the form of GWR or Bayesian methods271 using 
WinBUGS) for internal and external analytic staff; 
2. Use one or more GIS packages to display national data on its website e.g. InstantAtlas 
or GapMinder 
3. Procure training and guidance in the use of relevant analytic methods and 
technologies from an external body; a two-day course should cover the requisite 
material.  Core topics covered must include an introduction to GIS, effective map 
communication, spatial cluster/outlier analysis, spatial regression and software 
implementation; 
4. After the training of key individuals, hold a brainstorming workshop to discuss how 
mapping and GIS can be used in practice within CQC; 
5. Develop data exchange agreements between the CQC and other institutions such as 
the Ordnance Survey, and ensure that a core database of key variables is developed 
and maintained.   
10.7.2 Background/Introduction 
The role of the Care Quality Commission 
The CQC regulates health and adult social care services in England, including monitoring and 
inspection of all health and adult social care, and improving health and social care services 
by undertaking regular reviews of how well those who arrange and provide services locally 
are performing and special reviews on particular care services, pathways of care, or themes 
where there are particular concerns about quality. 
 
 A significant division of its responsibilities includes the registration and regulatory 
assessment of primary health care.  Providers of NHS primary medical services that provide 
regulated activities must be registered from 1 April 2012. This includes general practices and 
out-of-hours services.  The new registration system will bring all providers of health and 
adult social care under a single set of essential standards of quality and safety for the first 
time.249  Different methods will be used for different providers depending on the regulated 
activities they provide, and information that is available to CQC about their activities and 
performance. CQC will constantly update information about providers from people who use 
services, organisations and other regulators.  
 
This will be managed through a Quality and Risk Profile for each registered provider that will 
gather all CQC knows about a provider in one place.  They will enable CQC to assess where 
risks lie and prompt front line regulatory activity, such as inspection, and will support teams 
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to make robust judgments about the quality of services. These Profiles will develop over 
time as the information about a provider increases. 
 
Currently, the CQC also has a responsibility to ensure that primary care trusts (PCTs) are 
monitoring and assisting practices and achieving the standards for commissioning laid out in 
World Class Commissioning.  If there are differences in PCT performance, this could be 
reflected in performance of practices within the PCT.  The NHS White Paper Equity and 
excellence: Liberating the NHS states that PCTs’ role will be taken over by consortia of GP 
practices, working with other health and care professionals, and in partnership with local 
communities and local authorities.272  To avoid double jeopardy and duplication, the NHS 
Commissioning Board will take over the current CQC responsibility of assessing NHS 
commissioners and will hold GP consortia to account for their performance and quality.  
However, there will still be a need to assess the impact consortia are making on health 
outcomes. 
 
Spatial Analytic Methods 
Research carried out by the CQC has demonstrated significant deprivation-related variations 
in the quality of primary care as measured by key outcome measures in the Quality and 
Outcomes Framework (QOF). Furthermore, a recent national report by the CQC also 
highlights primary medical care inequalities in the assessment and treatment of people with 
cardiovascular disease (CVD).249  These findings highlight the importance of conducting 
analyses at sub-PCT level  to disseminate salient messages to local commissioning and public 
health teams. 
 
Methodological advances in quantitative geography have led to the development of 
GWR)and related spatial statistical techniques.  These examine spatial relationships and can 
add another dimension to health-related analyses.  The use of mapping facilities in modern 
GIS also provides helpful methods of displaying geo-referenced data.   
 
A further consideration is that, while mapping of data is becoming very pervasive because of 
the internet and computer software development, understanding of GWR and spatial 
statistical methods is not widespread in commissioners or providers.  A recent report from 
Canada illustrated how these methods could be used by local public health departments to 
investigate cancer risks,273 using the LMI test and subsequently Bayesian hierarchical models 
to smooth small area incidence rates.  However because of lack of familiarity with these 
methods, local use is rare even for environmental health risk data.  There is an obvious need 
to accompany the use of any GIS techniques for regulatory purposes with appropriate raising 
of awareness and training, through multiple channels, and to use a stepwise approach in 
doing so.  The LMI test provides an excellent stepping stone to GWR initially, and then to the 
use of Bayesian techniques where they add understanding and value. 
 
For example, using local data on the observed and expected prevalence of COPD, we 
recently compared classical regression results and those of GWR, using analysis of variance 
and AIC methods, and confirmed that GWR modelled the dataset more accurately than 
classical regression.274  The supplementary employment of cluster detection methods, such 
as the LMI test, additionally enabled hotspots and outliers to be detected.    The CQC 
therefore commissioned a small project to investigate the application of GIS, GWR and LMI 
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to CQC healthcare data, and to explore its utility for local monitoring purposes within the 
context of CQC’s functions to register and regulate primary healthcare services delivered by 
GP practices. 
10.7.3 Project Description/Methods 
Aims and Objectives 
The overall aim of the project was to explore the utility of GIS and GWR in the context of 
healthcare regulation of PCTs as commissioners and developers of primary care services and 
general practices as providers.  The specific objectives were: 
 to use the LMI method for detecting outlying performance of individual PCTs and GP 
practices, including statistically significant geographical clustering 
 to investigate the relationship between cross-, intra- and inter-PCT performance 
variation with and without adjustment for confounding factors using classical regression 
and GWR 
 to demonstrate options for displaying and mapping this variation using GIS for purposes 
of local monitoring and regulation. 
 
To explore spatial relationships in this context, the two scenarios chosen as a “proof-of-
concept” were: 
 
Scenario 1/disease detection: associations with practice-registered (“observed”) coronary 
heart disease (CHD) and stroke prevalence and undiagnosed CHD and stroke prevalence as 
outcome variables.  This can be viewed as a metric of the success of practices in identifying 
and registering cases of disease in their registered populations.  The latter was calculated by 
subtracting observed prevalence from the expected prevalence of disease estimated by the 
APHO/ICL CHD and stroke prevalence models.116 
 
Scenario 2/disease management: associations with PCT and practice level hospital 
admission rates for CHD and stroke as outcomes of disease management by general 
practices.  While unscheduled/emergency admissions for CHD could be viewed as an adverse 
outcome of primary care management, elective CHD admissions, for example for 
revascularisation, should be viewed as appropriate care.  We therefore agreed with CQC that 
the appropriate admission diagnostic groups for CHD were MI and angina. 
There are therefore analyses for two scenarios and two disease groups for each. 
 
Business Case/Benefits Expected 
The main benefits for the CQC were expected to be: 
 a better understanding of the specific associations between local variables and the 
detected prevalence of CVD at PCT and practice levels 
 identification of geographical associations and clusters of care indicators within, between 
and across PCT boundaries 
 an example of an approach to mapping and geographic analysis of primary care and 
associated datasets which could be applied across a range of primary care indicators 
 options for further application of available data and methods developed. 
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Data sources 
The data used fell into three main categories: 
1. contextual/population data (independent/predictor variables in both scenarios, apart 
from registered and undiagnosed disease prevalence, which became independent 
variables in Scenario 2) 
2. primary healthcare service access data 
3. healthcare activity and quality data 
 
Contextual/population data 
Data on practice populations by sex and five-year age band of registered patients, as of April 
2008, was obtained from the Practice-Based Commissioning Toolkit produced by the DH. The 
Department of Communities & Local Government IMD 2004 data for England was used to 
measure deprivation. A deprivation weighting for each practice (aggregated from patient-
level post codes) was provided by the CQC- high scores indicate a high level of deprivation.   
Estimates of the proportions of practice populations in major Census ethnic groups and the 
proportion who were smokers were provided by CQC. 
 
Undiagnosed prevalence data 
We used practice-level predictions of CHD and stroke prevalence from the APHO website.  
Further information about model development is provided on the APHO website.116  
Practice-registered prevalence was then subtracted to estimate undiagnosed prevalence.   
 
Healthcare access/supply data 
The IC provided data on GP and nurse supply, at practice and PCT level respectively, as of 
September 2007.  To measure broad access to care from the patient perspective we used 
two new patient experience (PE) indicators introduced in the 2008-9 QOF, which were 
derived from the results of the national GP Patient Survey, and which measure ability to 
access a GP consultation or appointment (see Table 2).220 
 
Quality & Outcomes Framework (QOF) Data 
QOF includes standardised information on the quality of care provided by 8.229 general 
practices in 152 English PCTs. We used QOF data from the IC website for April 2008-March 
2009.220 QOF indicators are split between four quality domains (clinical, organisational, 
patient experience and additional services). The QOF clinical domain included 129 evidence-
based indicators of the clinical quality of care, of which 10 cover CHD and eight stroke (Table 
67).  We selected three CHD and three stroke indicators which we considered to be good 
intermediate outcomes of primary healthcare services (as opposed to indicators purely of 
the process of care).  We also included blood pressure control (from the hypertension 
domain) as it is a strong risk factor for stroke, and two indicators of the accessibility of 
primary care.  The CHD indicators were CHD6 (blood pressure <150/90), CHD8 (cholesterol 
<5mmol/l), CHD11 (treated with an ACE inhibitor or Angiotensin II antagonist).  The stroke 
indicators were STROKE6 (blood pressure <150/90), STROKE8 (cholesterol <5mmol/l), 
STROKE12 (on an anti-platelet agent or an anti-coagulant), and BP05 (blood pressure 
<150/90 in patients with hypertension only).  The access indicators were PE7 (able to obtain 
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a consultation with a GP within 2 working days) and PE8 (able to book an appointment with 
a GP more than 2 days ahead).   
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CHD quality indicators   
Records   
CHD 1: The practice can produce a register of patients with coronary heart disease. 4  
Initial diagnosis   
CHD 2: The percentage of patients with newly diagnosed angina (diagnosed after 1 April 2003) who are referred for exercise 
testing and/or specialist assessment. 
7 40-90% 
Ongoing management   
CHD 5: The percentage of patients with coronary heart disease whose notes have a record of blood pressure in the previous 
15 months.  7 40-90% 
CHD 6: The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the 
previous 15 months) is 150/90 or less.  17 40-70% 
CHD 7: The percentage of patients with coronary heart disease whose notes have a record of total cholesterol in the 
previous 15 months.  7 40-90% 
CHD 8: The percentage of patients with coronary heart disease whose last measured total cholesterol (measured in the 
previous 15 months) is 5mmol/l or less.   17 40-70% 
CHD 9: The percentage of patients with coronary heart disease with a record in the previous 15 months that aspirin, an 
alternative anti-platelet therapy, or an anti-coagulant is being taken (unless a contraindication or side-effects are recorded).   7 40-90% 
CHD 10: The percentage of patients with coronary heart disease who are currently treated with a beta blocker (unless a 
contraindication or side-effects are recorded).  7 40-60% 
CHD 11: The percentage of patients with a history of myocardial infarction (diagnosed after 1 April 2003) who are currently 
treated with an ACE inhibitor or Angiotensin II antagonist.  7 40-80% 
CHD 12: The percentage of patients with coronary heart disease who have a record of influenza immunisation in the 7 40-90% 
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preceding 1 September to 31 March. 
Records   
STROKE 1. The practice can produce a register of patients with stroke or TIA  2  
Initial diagnosis   
STROKE 13. The percentage of new patients with a stroke or TIA who have been referred for further investigation  2 40-80% 
Ongoing management   
STROKE 5. The percentage of patients with TIA or stroke who have a record of blood pressure in the notes in the preceding 
15 months 2  
2 40-90% 
STROKE 6. The percentage of patients with a history of TIA or stroke in whom the last blood pressure reading (measured in 
the previous 15 months) is 150/90 or less 
5 40-70% 
STROKE 7. The percentage of patients with TIA or stroke who have a record of total cholesterol in the last 15 months 2 40-90% 
STROKE 8. The percentage of patients with TIA or stroke whose last measured total cholesterol (measured in the previous 15 
months) is 5mmol/l or less  
5 40-60% 
STROKE 12. The percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record 
that an anti-platelet agent (aspirin, clopidogrel, dipyridamole or a combination), or an anti-coagulant is being taken (unless a 
contraindication or side-effects are recorded)  
4 40-90% 
STROKE 10. The percentage of patients with TIA or stroke who have had influenza immunisation in the preceding 1 
September to 31 March  
2 40-85% 
Smoking quality indicator   
Smoking 4 
The percentage of patients with coronary heart disease, stroke or TIA, hypertension, diabetes, CHD, CKD, asthma, 
schizophrenia, bipolar affective disorder or other psychoses who smoke whose notes contain a record that smoking 
cessation advice or referral to a specialist service, where available, has been offered within the previous xx months 
30 40-90% 
Patient Experience indicators   
PE 7 Patient experience of access (1) 
The percentage of patients who, in the appropriate national survey, indicate that they were able to obtain a consultation 
with a GP (in England)  
23.5 70-90% 
PE 8 Patient experience of access (2) 35 60-90% 
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The percentage of patients who, in the appropriate national survey, indicate that they were able to book an appointment 
with a GP more than x days ahead 
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Hospital Episodes Statistics Data 
We were given HES data by CQC for this analysis, apparently grouped into spells to avoid 
multi-counting of admissions/Finished Consultant Episodes (FCEs).  Admission events were 
selected where the primary diagnosis i.e. main reason for admission met ICD version 10 
J44.0-44.9, for all patients over the age of 15 admitted during financial years 2006-7, 2007-8, 
2008-9 to maximise the number of admissions per practice.   
 
Statistical analyses 
Analytic scenarios are shown in Table 68. 
Table 68: analytic scenarios and data sources 




Outcome (y) variables Registered and 
undiagnosed CHD and 
stroke prevalence 
Admission rates for CHD 






Age, sex, deprivation, 
ethnicity, smoking, 




GP supply, CQC PCT 
ranking,   
GP supply, CQC PCT 
ranking, quality of care 
 
Scenario 1/ disease detection: 
 The basic unit of analysis was the general practice population. Counts of QOF registered 
CHD and stroke prevalence for 2008-9 were subtracted from counts of estimated prevalence 
for each practice to calculate undiagnosed prevalence.  Independent variables were age, sex, 
IMD score, practice smoking prevalence (%), Asian population (%), Black population (%), GP 
supply/100.000 population, CQC PCT ranking, and QOF Clinical and Patient Experience 
Indicators as in the table above).  
 
Indirect standardisation is generally accepted as more robust when counts are relatively 
small, but prevalence counts were generally much higher than for admissions e.g. mean 233 
and median 190 per practice for registered CHD prevalence.  Baseline PCT characteristics 
were then calculated including registered population (the sum of registers of general 
practices located within PCTs’ geographic boundaries), age and sex distribution, IMD scores, 
practices per PCT and practice list size.  
 
After producing summary statistics (mean, standard deviations, minima/maxima, median 
and interquartile ranges) we used OLS linear regression to perform univariate analyses for 
registered and unregistered CHD and/or stroke prevalence separately.  We then performed 
multiple linear regression (using the GLM command in Stata) with reverse stepwise variable 
selection to fit the most parsimonious model for each population outcome variable, initially 
separating healthcare and institution-type variables. Practice characteristics were 
aggregated to obtain PCT-level results, and the same tests were performed. 
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For the spatial analyses, we applied two methods commonly used in geographical studies: 
LMI and GWR.  The LMI technique is used to identify geographic clusters and outliers in data 
by testing for randomness in spatial distribution across a dataset, localities with significance 
scores (Z scores) greater than two standard deviations being considered to be either clusters 
or outliers.197  Strongly positive Z scores indicate statistically significant similar values in close 
geographic proximity hence the presence of a cluster; a strongly negative Z score 
demonstrates a locality with a significantly dissimilar value in relation to its neighbouring 
localities thus indicating an outlier.  It is very useful as a means of identifying and 
introducing, for a non-specialist audience, the concept of geographical “hot” and “cold” 
spots where spatial autocorrelation may be occurring. Like temporal autocorrelation, spatial 
autocorrelation means that adjacent observations of the same phenomenon are correlated. 
However, temporal autocorrelation is about proximity in time. Spatial autocorrelation is 
about proximity in (two-dimensional) space.  Spatial autocorrelation is more complex than 
autocorrelation because the correlation is two-dimensional and hence bi-directional unlike 
in time-based studies. 
 
GWR is a form of spatial statistics which disaggregates geographic data into spatial blocks 
using a probability distribution kernel and Monte Carlo simulations, which moves from 
location to location across the dataset to test for geographic variation in regression 
relationships.  In situations where there is geographic variation in the strength of a 
regression relationship, a phenomenon referred to as spatial non-stationarity, GWR will 
produce higher correlation coefficients, lower residuals and higher degrees of freedom than 
traditional OLS regression.198;199;275 
 
For this project, we used GWR to assess whether linear regression relationships existed 
between observed and expected prevalence in Scenario 1 (and admission rates in Scenario 
2), and if so whether they varied in strength over space.  This purpose should be viewed as 
distinct from that of mapping, for example, observed to expected prevalence ratios, as the 
latter aims to measure equality between two variables rather than to assess predictability of 
an association.  Both OLS and GWR models were run in the software package GWR3 to test 
for spatial non-stationarity.  The optimal bandwidth for the kernel was estimated using the 
AIC.202  Two rounds of regression were performed, the first a univariate regression involving 
expected prevalence as the independent variable and observed prevalence as the 
dependent variable; the second bivariate including whole-time equivalent GP supply as an 
additional variable. 
 
For the GWR, we used the sub-regional groupings or analysis blocks shown in Table 69 
below. These were chosen because on the one hand, we wished to show spatial 
relationships which might overlap PCT boundaries, while on the other hand, Government 
Regions were too large to visualise practices and were beyond the software capacity in 
terms of practice numbers. 
 
Microsoft Excel and Access were used to manage the data and the software package Stata10 
was used for OLS statistical analysis.  The geographical activity was also divided into 2 
phases. Phase 1 involved basic mapping of observed, expected and unrecorded disease 
prevalence, as well as of admission rates. This was followed by the use of LMI for 
unrecorded prevalence and admission rates to facilitate the Phase 2 use of GWR. Disease 
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prevalence was mapped using ESRI shapefiles.  GeoDa was used for the LMI tests, which 
required a spatial weights matrix that defines a local neighbourhood around each geographic 
unit. The value at each unit is compared with the weighted average of the values of its 
neighbours. A weights file identifies the neighbours; 2km and 5km weight matrices were 
created for sensitivity analyses. The LMI results were mapped in QGIS. 
Table 69: Rationale behind analysis blocks used in the split-variable spatial regression 
models 
ANALYSIS BLOCK MEAN 
IMD 
SCORE 
DOMINANT OAC GROUPS ANALYSIS BLOCK 
DESCRIPTION 
Home Counties 12.72 New and Growing Towns, 
Prospering Southern England 
Affluent, mixed urban-rural 
North West 
London 
25.37 London Centre, London 
Suburbs 
Mixed SES, metropolitan 
North East 
London 
31.82 London Cosmopolitan Deprived, metropolitan 
South West 
London 





26.45 London Cosmopolitan, London 
Suburbs 
Deprived, metropolitan 
South Coast 18.91 Coastal and Countryside, 
Regional Centres 




16.91 Coastal and Countryside, 
Prospering Small Towns 
Mixed SES, mixed urban-
rural 
West Midlands 23.00 Cities and Services Mixed SES, metropolitan 
East Midlands 19.49 Prospering Smaller Towns, 
New and Growing Towns 
Mixed SES, urban 
East of England 17.45 Prospering Smaller Towns, 
Coastal and Countryside 
Mixed SES, mixed urban-
rural 
Yorkshire and the 
Humber 
23.39 Prospering Smaller Towns, 
Manufacturing Towns 
Mixed SES, urban 
Greater 
Manchester 
28.79 Centres with Industry Deprived, metropolitan 





26.05 Centres with Industry, 
Prospering Smaller Towns, 









Scenario 2/disease management 
Again the basic unit of analysis was the general practice population. Indirectly standardised 
admission rates were calculated at the practice level, to produce expected admission rates 
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based on the England level, for comparisons with observed counts. Indirect standardisation 
is generally accepted as more robust when counts are relatively small.   
 
The same baseline practice and PCT characteristics were used as for Scenario 1, including 
registered population (the sum of registers of general practices located within PCTs’ 
geographic boundaries), age and sex distribution, IMD scores, practices per PCT and practice 
list size. Practice level characteristics (QOF points and indicator breakdown) were aggregated 
to PCT level, as required.  As counts were much larger, PCT directly standardised (age and 
sex) admission rates were calculated per 100.000 GP registered population, using the total 
England population as the standard.  The same counts of registered, estimated and 
undiagnosed CHD and stroke prevalence used for Scenario 1 were used as independent 
variables in this analysis.  
 
Univariate associations between admission rates and possible explanatory factors at practice 
and PCT levels were first assessed using Spearman’s correlation coefficient. OLS linear 
multivariate regression models were then fitted to examine the effects of all independent 
variables. At the practice level, because of low admission numbers we applied Poisson 
regression, where standard errors have been scaled using the square root of the deviance-
based dispersion. The dependent variable was observed count of hospital admission and the 
offset was the expected number of admissions. 
 
Phase 2 GWR involved statistical mapping results for stroke and CHD. The outputs of GWR 
models were stored in .csv format to facilitate import in any GIS package. QGIS can only 
access .csv files via “add delimited text layer” plug-in to add a point layer (general practices) 
to the map. Local R-squared correlation coefficients were mapped using quantile 
classifications and drawn using diverging red to blue colour schemes analysis region. PCT 
(source: CQC) and England boundaries (source: http://www.edina.ac.uk/digimap) were 
overlain to the final maps to aid visualisation of results.  CQC data for stroke and CHD was 
manipulated using Microsoft Excel and GWR 3 so that it could be mapped in QGIS 1.3.0 
(source: http://www.qgis.org). The datasets were projected to the British National Grid, 
which is based on a Transverse Mercator projection. 
 
Two batches of GWR analysis were performed to reflect analysis 1 and analysis 2 in the 
foundation non-spatial regression modelling.  The GWR 3.0 software permits the choice of 
different probability distribution models, Gaussian, logistic and Poisson.  For analysis 1, a 
Gaussian model was chosen as unrecorded prevalence is a continuous variable.  The 
situation proved to be more complex for analysis 2, for which a Poisson model would strictly 
speaking be appropriate, as admission rates are treated as discrete variables in 
epidemiology.  However, we were obliged to use a Gaussian GWR model for analysis 2 as the 
Poisson functionality in the software was found not to operate correctly (this problem may 
have been remedied in more recent versions of the package).  The spatial kernel options 
offered are fixed distance and adaptive distance; adaptive was selected to reflect the 
heterogeneous density of GP locations across the country and even with analysis regions.  
Statistical significance testing and optimal bandwidth selection was performed using Monte 
Carlo simulations.  The GWR software generates a dichotomous output – spreadsheet and 
text file. The spreadsheet holds standardised residuals, Cook’s D and Local R square values 
for every regression point (in our case general practice). The text file contains diagnostics for 
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the global model fitted to the data and GWR estimates. AIC values are compared to test for 
spatial non-stationarity.  
10.7.4 Results 
This section contains a sample of results from each scenario, disease and type of analysis 
(OLS, GWR).   
 
Scenario 1/ disease detection: outcome=registered and undiagnosed prevalence 
Scenario 1 aims to describe the effectiveness of general practices in detecting disease and 
registering cases on QOF registers so that patients are offered regular evidence-based 
management.  We therefore used as the outcome variable the estimated prevalence of 
undiagnosed CHD and stroke in each practice.  We undertook an OLS analysis and then 
LMI/GWR. 
 
We have used selected QOF clinical indicators as independent variables in these analyses 
because, although they reflect the standard of care after diagnosis, it is possible that quality 
of care post-diagnosis is also a predictor of successful case-finding by practices (for example, 




Table 70 provides a descriptive analysis of the variables used.  Data from 7,969 practices was 
analysed. Nationally the overall prevalence of CHD is estimated to be about 4.5 per cent, 
with about 20 per cent of cases unregistered as such by practices.  Rather than using 
estimated proportion of ethnic minority population per practice, we have used estimated 
proportion South Asian because it is known to be a risk factor for CHD. 
Table 70: Descriptive analysis 
 Mean (SD) Min - Max Median IQR 
Observed prevalence (%) 3.50 1.19 0.00 - 9.81 3.47 2.70 - 4.25 
Unregistered prevalence (%) 0.95 0.87 0.00 - 5.78 0.87 0.40 - 1.44 
IMD score 23.63 12.61 2.24 - 71.85 21.31 13.32 - 31.89 
Smoking prevalence (%) 24.87 6.43 13.18 - 51.73 23.68 19.71 - 28.81 
Asian population (%) 0.06 0.15 0.00 - 0.97 0.01 0.00 - 0.05 
GP supply/100.000 population 56.17 17.98 0.00 - 337.08 55.10 45.80 - 65.28 
QOF Clinical Indicators 
CHD06 (BP<150/90mm Hg) 89.82 5.03 0.00 - 100 90.29 87.16 - 93.05 
CHD08 (Cholesterol<5Mmol/L) 81.71 6.78 0.00 - 100 82.07 77.83 - 86.15 
CHD11 (treated with an ACE 
inhibitor/ Angiotensin II antagonist) 
90.23 7.40 0.00 - 100 90.00 85.71 - 95.24 
QOF Patient Care Experience Indicators 
PE07 (can obtain a consultation 
with GP in 2 days) 
84.19 14.07 0.00 - 100 87.28 79.39 - 92.97 
PE08 (can book an appointment 
with a GP > 2 days ahead) 
76.97 17.57 0.00 - 100 80.67 67.23 - 90.28 
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For Scenario 1, we were interested to see whether there were associations between the 
quality of primary care for diagnosed and registered disease and its initial identification.  We 
therefore used the same individual QOF indicators which we used for Scenario 2, that is, 
those we considered to be more likely to affect patient outcomes or intermediate outcome 
indicators.  Total QOF achievement for a domain reflects a combination of intermediate 
outcome indicators and process of care indicators.  The former may be better indicators of 
quality of care.  In addition, achievement of process indicators is almost uniformly very high, 
creating a “ceiling effect” with little dispersion of practice values.  As shown in Table 70, the 
chosen QOF indicators have mean achievements of 80-90 per cent. 
 
We initially fitted models using observed/registered prevalence as the outcome variable to 
gain an understanding of associations with population and healthcare factors.  A 
characteristic of most of the OLS analyses is incidence rate/odds ratios (IRRs/ORs) mainly 
very close to unity, suggesting that effect sizes are relatively small.  This is somewhat 
surprising as several other published PCT-level analyses show, for example, relatively strong 
positive associations of prevalence with deprivation,270  and it is included in the model used 
to estimate overall prevalence, which is based on HSfE patient-reported doctor-diagnosed 
CHD (OR for fifth IMD quintile 2.4). 
 
Table 71 shows a univariate analysis with unregistered CHD as the outcome variable.  
Deprivation, smoking and South Asian ethnicity are risk factors i.e. predictors of unregistered 
disease, whereas higher scores for QOF indicators CHD06 and CHD08 are protective.   
Table 71: OLS univariate analysis. Dependent variable: unregistered CHD count 2008-9 
 IRR Std. Err. z P>|z| [95% Conf. Interval] 
IMD score 1.025 0.001 40.280 0.000 1.024 1.027 
Smoking prevalence (%) 1.045 0.001 34.840 0.000 1.042 1.047 
Asian population (%) 2.098 0.127 12.240 0.000 1.863 2.362 
GP supply/100,000 population 1.000 0.001 0.560 0.575 0.999 1.002 
QOF Clinical Indicators 
CHD06 (BP<150/90mm Hg) 0.993 0.002 -3.940 0.000 0.989 0.996 
CHD08 (Cholesterol<5Mmol/L) 0.993 0.001 -5.110 0.000 0.990 0.996 
CHD11 (treated with an ACE inhibitor/ 
Angiotensin II antagonist) 1.000 0.001 0.200 0.840 0.998 1.003 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with GP 
in 2 days) 0.998 0.001 -2.930 0.003 0.997 0.999 
PE08 (can book an appointment with a 
GP > 2 days ahead) 0.999 0.001 -1.790 0.073 0.998 1.000 
 
Table 72 shows a multivariate analysis with unregistered CHD count as the outcome variable, 
using the practice population as the offset variable in the Poisson regression.  The sign for 
smoking prevalence is now negative, which is unexpected, and suggests that 
multicollinearity may be present.  Other variables were not retained in the model.  The 
directions of some of these associations are unexpected: one might expect GP supply to be 
negatively associated and smoking prevalence to be positively associated.  In the presence of 
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multicollinearity, the estimate of one variable's impact on y while controlling for the others 
tends to be less precise than if predictors were uncorrelated with one another. If, for 
example, smoking is highly correlated with deprivation, we have many observations for 
which these two variables have a particular relationship, and fewer observations for which 
smoking changes independently of deprivation, or vice versa, so we have an imprecise 
estimate of the effect of independent changes in each variable.  However, in the presence of 
multicollinearity we expect larger standard errors, and this is not the case in our dataset. 
Table 72: OLS multivariate stepwise analysis. Dependent variable: unregistered CHD count 
2008-9 Independent variables: population + institutional factors 
 IRR Std. Err. z P>|z| [95% Conf. Interval] 
IMD score 1.048 0.002 20.680 0.000 1.043 1.053 
Smoking prevalence (%) 0.957 0.004 -9.900 0.000 0.948 0.965 
GP supply/100.000 population 1.001 0.001 2.590 0.010 1.000 1.002 
QOF Clinical Indicators 
CHD08 (Cholesterol<5Mmol/L) 0.998 0.001 -1.910 0.056 0.995 1.000 
QOF Patient Experience Indicators 
PE08 (can book an appointment with a GP 
> 2 days ahead) 1.002 0.000 3.470 0.001 1.001 1.003 
 
The variance inflation factor (VIF) can be estimated to quantify the severity of 
multicollinearity in OLS regression analysis. It provides an index that measures how much 
the variance of an estimated regression coefficient (the square of the estimate's standard 
deviation) is increased because of collinearity.  A VIF>10 and a tolerance<0.1 indicates 
multicollinearity (see Table 73).  Only IMD score and estimated smoking prevalence (which 
uses IMD score as an input) showed evidence of multicollinearity. 
Table 73: Collinearity Diagnostics 
                   Variable VIF SQRT VIF Tolerance Local R-
squared 
Observed CHD prevalence 1.44 1.20 0.6923 0.3077 
Unregistered CHD 
prevalence 
1.39 1.18 0.7198 0.2802 
IMD score 14.74 3.84 0.0678 0.9322 
Smoking prevalence 13.46 3.67 0.0743 0.9257 
Asian population (%) 1.23 1.11 0.8101 0.1899 
 
The next section illustrates practice-level mapping of prevalence data.  Figure 24 shows 
expected CHD prevalence rate by practice, for England in 2008 (so that it is comparable with 
the latest available QOF prevalence data), using estimates from the ICL/APHO prevalence 
models.  Higher rates are evident in the North and in coastal (retirement) areas.  Lower rates 
are seen in London (because of its relatively young population age structure) and the Home 
Counties (because they are less deprived).  Figure 25 shows QOF registered CHD prevalence 
rate by practice in England in 2008.  At first sight there are many similarities with expected 
prevalence.  However, Figure 26, unregistered (expected minus registered) CHD prevalence 
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rate, shows evidence of possible spatial clustering, with higher rates in urban areas and vice 
versa.  Figure 27, observed divided by expected CHD prevalence rate by practice, is an 
alternative means of displaying this.  The lowest proportions are clearly clustered in London 
and West Midlands conurbations. 
 
The next step would be to visualise this data using the LMI test.  To avoid making the report 
excessively detailed, yet to demonstrate utility, we have carried out LMI tests for stroke 
only. 
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Figure 24: expected CHD prevalence rate by practice, England 2008 
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Figure 25: QOF registered CHD prevalence rate by practice, England 2008 
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Figure 26: unregistered CHD prevalence rate by practice, England 2008 
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Figure 27: observed: expected CHD prevalence rate by practice, England 2008 
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Table 74 provides a descriptive analysis of the stroke variables used.  Data from 7,969 
practices was analysed. Nationally the overall prevalence of stroke is estimated to be about 
1.6 per cent, with about 25 per cent of cases apparently unregistered as such by practices.  
As a general rule, the proportion of expected cases undiagnosed is lower for conditions like 
stroke which have a sudden as opposed to gradual or insidious onset.  Rather than using 
estimated proportion of ethnic minority population per practice, we have used estimated 
proportion of Black/Black Caribbean because it is known to be a risk factor for stroke. 
Table 74: descriptive analysis 
 Mean (SD) Min - Max Median IQR 
Observed prevalence (%) 1.61 0.67 0.00 - 18.55 1.61 1.15 - 2.02 
Unregistered prevalence (%) 0.42 0.44 0.00 - 3.83 0.31 0.01 - 0.65 
IMD score 23.67 12.62 2.24 - 71.85 21.34 13.35 - 31.99 
Smoking prevalence (%) 24.90 6.44 13.18 - 51.73 23.71 19.73 - 28.89 
Black population (%) 3.43 7.35 0.00 - 72.39 0.52 0.15 - 2.58 
GP supply/100.000 population 56.10 18.06 0.00 - 337.08 55.05 45.72 - 65.26 
QOF Clinical Indicators 
Stroke06 (Last BP < 150/90) 88.09 6.73 0.00 - 100 88.64 84.67 - 92.12 
Stroke08 (Last cholesterol <5mmol/l) 76.82 9.31 0.00 - 100 77.55 71.72 - 82.86 
Stroke12 (on anti-platelet agent/anti-
coagulant) 
94.56 5.53 0.00 - 100 94.74 92.45 - 97.53 
BP05 (In all hypertensives,BP<150/90)  78.90 6.35 22.22 - 100 79.04 75.10 - 83.00 
QOF Patient Care Experience Indicators 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with 
GP in 2 days) 
84.21 14.05 0.00 - 100 87.30 79.39 - 92.98 
PE08 percentage of patients who 
were able to book an appointment 
with a GP > 2 days ahead 
77.07 17.54 0.00 - 100 80.79 67.32 - 90.36 
 
Table 75 shows the results of a univariate analysis.  Once again effect sizes and standard 
errors are small. 
Table 75: OLS univariate analysis. Dependent variable: unregistered stroke count 2008-9 
  IRR Std. Err. z P>|z| [95% Conf. Interval] 
IMD score 1.037 0.001 45.550 0.000 1.036 1.039 
Smoking prevalence (%) 1.066 0.002 39.220 0.000 1.062 1.069 
Black population (%) 1.000 0.000 24.640 0.000 1.000 1.000 
GP supply/100.000 population 0.990 0.001 -12.710 0.000 0.988 0.991 
QOF Clinical Indicators 
Stroke06 (Last BP < 150/90) 0.991 0.002 -4.430 0.000 0.987 0.995 
Stroke08 (Last cholesterol <5mmol/l) 0.990 0.001 -7.100 0.000 0.987 0.993 
Stroke12 (on anti-platelet 1.011 0.003 3.560 0.000 1.005 1.017 
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  IRR Std. Err. z P>|z| [95% Conf. Interval] 
agent/anti-coagulant) 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with 
GP in 2 days) 0.992 0.001 -10.790 0.000 0.991 0.994 
PE08 (can book an appointment with 
a GP > 2 days ahead) 0.995 0.001 -6.930 0.000 0.994 0.997 
Blood pressure 05 0.997 0.002 -1.490 0.136 0.992 1.001 
CQC PCT rating = fair vs. poor 0.594 0.044 -7.050 0.000 0.514 0.686 
CQC PCT rating = good vs. poor 0.534 0.040 -8.470 0.000 0.462 0.617 
CQC PCT rating = excellent vs. poor 0.527 0.071 -4.730 0.000 0.404 0.687 
 
Table 76 shows a multivariate model with reverse stepwise variable selection.  Results are 
generally similar to the CHD analysis. 
Table 76: OLS multivariate stepwise analysis. Dependent variable: unregistered stroke 
count 2008-9 Independent variables: population + institutional factors 
 IRR Std. Err. z P>|z| [95% Conf. Interval] 
IMD score 1.071 0.003 22.580 0.000 1.065 1.078 
Smoking prevalence (%) 
0.931 0.006 
-
12.010 0.000 0.921 0.942 
Black population (%) 1.000 0.000 5.310 0.000 1.000 1.000 
GP supply/100.000 population 0.994 0.001 -9.020 0.000 0.992 0.995 
QOF Clinical Indicators 
BP05 (In all hypertensives, 
BP<150/90) 1.007 0.002 3.560 0.000 1.003 1.011 
Stroke08 (Last cholesterol 
<5mmol/l) 0.989 0.001 -8.260 0.000 0.986 0.991 
Stroke12 (on anti-platelet 
agent/anti-coagulant) 1.012 0.003 4.770 0.000 1.007 1.017 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation 
with GP in 2 days) 0.998 0.001 -3.010 0.003 0.996 0.999 
CQC PCT rating = good vs. poor 0.931 0.021 -3.230 0.001 0.891 0.972 
 
The next section illustrates practice-level mapping of stroke prevalence data.  Figure 28 
shows expected stroke prevalence rate by practice, for England in 2008 (so that it is 
comparable with the latest available QOF prevalence data), using estimates from the 
ICL/APHO prevalence models.  As for CHD, higher rates are evident in the North and in 
coastal (retirement) areas, and lower rates are seen in London (because of its relatively 
young population age structure) and the Home Counties (because they are less deprived).  
Figure 29 shows QOF registered stroke prevalence rate by practice in England 2008.  Again, 
there are many similarities with expected prevalence.  Figure 30, unregistered (expected 
minus registered) stroke prevalence rate, shows evidence of possible spatial clustering, with 
higher rates in urban areas and vice versa.  Figure 31, observed divided by expected stroke 
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prevalence rate by practice, is an alternative means of displaying this.  The lowest 
proportions are clustered in London and West Midlands conurbations, but there is a more 
dispersed pattern than for CHD. 
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Figure 28: expected stroke prevalence rate by practice, England 2008 
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Figure 29: QOF registered stroke prevalence rate by practice, England 2008 
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Figure 30: unregistered CHD prevalence rate by practice, England 2008 
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Figure 31: observed: expected CHD prevalence rate by practice, England 2008 
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The next two practice level maps (Figure 32 and Figure 33) show Local Moran’s I tests at 2km 
and 5km for unrecorded prevalence of stroke.  There is marked clustering of high levels of 
unrecorded prevalence evident in London and other conurbations, which is even more 
prominent in the 5 km map.  There is some, but much less, clustering of low levels of 
unrecorded prevalence which tends to be in the hinterlands of urban areas. 
 Figure 32: Local Moran’s I (2km) of stroke unrecorded prevalence 
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Figure 33: Local Moran’s I (5 km) of stroke unrecorded prevalence 
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Table 77 compares OLS and geographical analyses for stroke prevalence.  Comparison with 
classical regression outcomes was made using the AIC202 to test for spatial non-
stationarity.276  Identification of the optimal bandwidth for each analysis block was made 
using Monte Carlo simulations.  The results of the spatial non-stationarity test revealed little 
difference between the AIC values for the non-spatial and GWR models, with marginal 
improvement with the spatial model.  For example AIC values ranged from -1567 to -7032   
between analysis blocks for the non-spatial model using primary care quality variables; the 
comparable range for the GWR model was -1565 to -7062.  Whilst non-stationarity was not 
significant nevertheless the AIC values confirmed that it was statistically valid to use spatial 
regression as a basis for exploratory mapping.   
Table 77: regression diagnostics for stroke prevalence 















  Classical Regression 
East Midlands 0.02 12.00 0.01 -6258.58 0.22 0.00 12.00 0.21 
East of England 0.01 12.00 0.00 -2588.62 0.19 0.00 12.00 0.16 
Greater Manchester 0.01 12.00 0.01 -2645.27 0.25 0.00 12.00 0.22 
Home Counties 0.05 12.00 0.01 -7032.45 0.06 0.10 12.00 0.04 
Merseyside 0.01 12.00 0.01 -2079.41 0.25 0.00 12.00 0.22 
North East England 0.01 12.00 0.01 -2855.90 0.29 0.00 12.00 0.26 
North East London 0.01 12.00 0.01 -2864.06 0.13 0.00 12.00 0.10 
North West England 0.02 12.00 0.01 -4126.28 0.19 0.00 12.00 0.17 
North West London 0.02 12.00 0.01 -4589.65 0.17 0.00 12.00 0.15 
South Coast 0.01 12.00 0.00 -4184.88 0.20 0.00 12.00 0.18 
South East London 0.01 12.00 0.01 -2147.34 0.20 0.00 12.00 0.16 
South West England 0.01 12.00 0.00 -4800.19 0.13 0.00 12.00 0.12 
South West London 0.00 12.00 0.00 -1567.75 0.17 0.00 12.00 0.12 
West Midlands 0.03 12.00 0.01 -6996.77 0.27 0.00 12.00 0.26 
Yorks & Humberside 0.03 12.00 0.01 -5342.75 0.24 0.00 12.00 0.23 
 GWR Estimation 
East Midlands 0.02 21.79 0.01 -6280.93 0.26 0.00 9.79 0.24 
East of England 0.01 26.60 0.00 -2585.45 0.26 0.00 14.60 0.20 
Greater Manchester 0.01 22.63 0.01 -2649.56 0.30 0.00 10.63 0.26 
Home Counties 0.05 49.27 0.01 -7062.32 0.15 0.00 37.27 0.11 
Merseyside 0.01 19.28 0.01 -2074.25 0.28 0.00 7.28 0.23 
North East England 0.01 25.18 0.01 -2864.45 0.36 0.00 13.18 0.31 
North East London 0.01 20.11 0.01 -2856.82 0.15 0.00 8.11 0.10 
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North West England 0.02 23.12 0.01 -4129.83 0.23 0.00 11.12 0.19 
North West London 0.02 24.98 0.01 -4595.40 0.21 0.00 12.98 0.18 
South Coast 0.01 18.84 0.00 -4185.28 0.23 0.00 6.84 0.20 
South East London 0.01 23.49 0.00 -2152.77 0.28 0.00 11.49 0.22 
South West England 0.01 21.05 0.00 -4823.66 0.19 0.00 9.05 0.16 
South West London 0.00 20.51 0.00 -1565.15 0.24 0.00 8.51 0.16 
West Midlands 0.03 42.72 0.01 -7009.74 0.33 0.00 30.72 0.29 
Yorks & Humberside 0.03 21.37 0.01 -5362.36 0.28 0.00 9.37 0.26 
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Scenario 2/disease management: outcome=admission rates 
CHD (MI+angina) 
Table 78 shows descriptive data for Scenario 2.  As noted in the Objectives (Section 4.1), 
while unscheduled/emergency admissions for CHD could be viewed as an adverse outcome 
of primary care management, elective CHD admissions, for example for revascularisation, 
could be viewed as appropriate care.  We therefore agreed with CQC that the appropriate 
admission diagnostic groups for CHD were MI and angina, which are mainly 
unscheduled/emergency admissions. 
Table 78: descriptive analysis 
 Mean (SD) Min - Max Media
n 
IQR 
Admissions/100.000 population 782.56 340.66 0.00 - 3966.02 720.02 559.92 - 933.88 
Observed prevalence (%) 3.50 1.19 0.00 - 9.81 3.47 2.70 - 4.25 
Unregistered prevalence (%) 0.95 0.87 0.00 - 5.78 0.87 0.40 - 1.44 
IMD score 23.63 12.61 2.24 - 71.85 21.31 13.32 - 31.89 
Smoking prevalence (%) 24.87 6.43 13.18 - 51.73 23.68 19.71 - 28.81 
Asian population (%) 0.06 0.15 0.00 - 0.97 0.01 0.00 - 0.05 
GP supply/100.000 population 56.17 17.98 0.00 - 337.08 55.10 45.80 - 65.28 
QOF Clinical Indicators 
CHD06 (BP<150/90mm Hg) 89.82 5.03 0.00 - 100 90.29 87.16 - 93.05 
CHD08 (Cholesterol<5mmol/l) 81.71 6.78 0.00 - 100 82.07 77.83 - 86.15 
CHD11 (treated with ACE 
inhibitor/angiotensin antagonist) 
90.23 7.40 0.00 - 100 90.00 85.71 - 95.24 
QOF Patient Care Experience Indicators 
PE07 (can obtain a consultation 
with GP in 2 days) 
84.19 14.07 0.00 - 100 87.28 79.39 - 92.97 
PE08 (can book an appointment  
with GP more than 2 days ahead) 
76.97 17.57 0.00 - 100 80.67 67.23 - 90.28 
 
Table 79 shows a univariate analysis with practice level CHD (MI+angina) admission rate as 
the outcome variable.  Observed prevalence, unregistered prevalence, IMD score, smoking 
prevalence and Asian population are all risk factors, whereas as expected higher scores for 
GP supply and QOF indicators are protective.   
Table 79: OLS univariate analysis. Dependent variable: observed admission count. 
 IRR Std. Err. z P>|z| [95% Conf. Interval] 
Observed prevalence (%) 1.089 0.004 24.750 0.000 1.081 1.096 
Unregistered prevalence (%) 1.008 0.005 1.670 0.094 0.999 1.019 
IMD score 1.015 0.000 54.090 0.000 1.015 1.016 
Smoking prevalence (%) 1.029 0.001 50.240 0.000 1.028 1.030 
Asian population (%) 2.221 0.072 24.530 0.000 2.083 2.367 
GP supply/100.000 population 0.999 0.000 -5.340 0.000 0.998 0.999 
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 IRR Std. Err. z P>|z| [95% Conf. Interval] 
QOF Clinical Indicators 
CHD06 (BP<150/90mm Hg) 0.998 0.001 -1.810 0.071 0.996 1.000 
CHD08 (Cholesterol<5Mmol/L) 0.996 0.001 -5.510 0.000 0.995 0.998 
CHD11 (treated with an ACE inhibitor/ 
Angiotensin II antagonist) 0.998 0.001 -3.360 0.001 0.996 0.999 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with GP in 
2 days) 0.996 0.000 13.770 0.000 0.996 0.997 
PE08 (can book an appointment  with GP 
more than 2 days ahead) 0.996 0.000 15.860 0.000 0.996 0.997 
 
Table 80 shows a multivariate analysis with MI+angina admission rate as the outcome 
variable, with the expected practice rate (as we used indirect standardisation here) as the 
offset variable in the Poisson regression.  Other variables not shown were eliminated from 
the model by reverse stepwise variable selection.  Observed prevalence, IMD score, smoking 
prevalence and Asian population are as expected all risk factors for hospital admission- the 
IRR for the latter is comparatively high.  The IRR for unregistered prevalence is less than 
unity, which is unexpected, as patients with undiagnosed disease might be expected to be 
more likely to be admitted.  The directions of other associations are generally as expected, 
with higher scores on QOF Clinical Indicators as protective, apart from CHD06 
(BP<150/90mm Hg).  GP supply/100.000 population is not retained in the model. 
Table 80: OLS multivariate stepwise analysis. Dependent variable: observed admission 
count. Independent variables: population + institutional factors 
 IRR Std. 
Err. 
z P>|z| [95% Conf. 
Interval] 
Observed prevalence (%) 1.086 0.004 23.56
0 
0.000 1.078 1.093 
Unregistered prevalence (%) 0.954 0.004 10.40
0 
0.000 0.945 0.962 
IMD score 1.007 0.001 6.660 0.000 1.005 1.009 
Smoking prevalence (%) 1.014 0.002 7.030 0.000 1.010 1.018 
Asian population (%) 1.835 0.054 20.60
0 
0.000 1.732 1.944 
QOF Clinical Indicators 
CHD06 (BP<150/90mm Hg) 1.002 0.001 2.520 0.012 1.000 1.004 
CHD08 (Cholesterol<5mmol/l) 0.998 0.001 -2.600 0.009 0.997 1.000 
CHD11 (treated with ACE 
inhibitor/angiotensin antagonist) 
0.998 0.001 -3.500 0.000 0.997 0.999 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with GP 
in 2 days) 
0.999 0.000 -4.320 0.000 0.998 0.999 
PE08 (can book an appointment  with GP 
more than 2 days ahead) 
0.999 0.000 -5.950 0.000 0.998 0.999 
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Other results are shown in Section 9 Appendix C: detailed results.  The next step would be to 
visualise this data using the LMI test.  To avoid making the report excessively detailed, yet to 
demonstrate utility, we have carried out LMI tests for stroke only. 
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Table 81 provides a descriptive analysis of the stroke variables used.  The mean admission 
rate is 104/100,000 practice population, with very wide variation.  Rather than using 
estimated proportion of ethnic minority population per practice, we have used estimated 
proportion Black/Black Caribbean because it is known to be a risk factor for stroke. 
Table 81: descriptive analysis 
 Mean (SD) Min - Max Median IQR 
Admissions/100.000 population 103.74 39.13 0.00 - 
476.51 
99.28 79.02 - 
123.77 
Observed prevalence (%) 1.61 0.67 0.00 - 18.55 1.61 1.15 - 2.02 
Unregistered prevalence (%) 0.42 0.44 0.00 - 3.83 0.31 0.01 - 0.65 
IMD score 23.67 12.62 2.24 - 71.85 21.34 13.35 - 31.99 
Smoking prevalence (%) 24.90 6.44 13.18 - 
51.73 
23.71 19.73 - 28.89 
Black population (%) 3.43 7.35 0.00 - 72.39 0.52 0.15 - 2.58 
GP supply/100.000 population 56.10 18.06 0.00 - 
337.08 
55.05 45.72 - 65.26 
QOF Clinical Indicators 
Stroke06 (Last BP < 150/90) 88.09 6.73 0.00 - 100 88.64 84.67 - 92.12 
Stroke08 (Last cholesterol <5mmol/l) 76.82 9.31 0.00 - 100 77.55 71.72 - 82.86 
Stroke12 (on anti-platelet agent/anti-
coagulant) 
94.56 5.53 0.00 - 100 94.74 92.45 - 97.53 
BP05 (In all hypertensives,BP<150/90) 78.90 6.35 22.22 - 100 79.04 75.10 - 83.00 
QOF Patient Care Experience Indicators 
PE07 (can obtain a consultation with GP in 2 
days) 
84.21 14.05 0.00 - 100 87.30 79.39 - 92.98 
PE08 (can book an appointment  with GP 
more than 2 days ahead) 
77.07 17.54 0.00 - 100 80.79 67.32 - 90.36 
 
Table 82 shows a univariate analysis with practice level stroke admission rate as the 
outcome variable.  Observed prevalence, unregistered prevalence, IMD score, smoking 
prevalence and Asian population are all risk factors, whereas as expected higher scores for 
GP supply and QOF indicators are protective. 
Table 82: univariate analysis. Dependent variable: observed admission count 
  IRR SE z P>|z| [95% Conf. Interval] 
Observed prevalence (%) 1.026 0.006 4.650 0.000 1.015 1.037 
Unregistered prevalence (%) 1.066 0.009 7.580 0.000 1.049 1.084 
IMD score 1.009 0.000 33.890 0.000 1.009 1.010 
Smoking prevalence (%) 1.017 0.001 32.340 0.000 1.016 1.018 
Black population (%) 1.004 0.001 6.500 0.000 1.003 1.005 
GP supply/100.000 population 1.000 0.000 -0.170 0.868 1.000 1.000 
QOF Clinical Indicators 
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  IRR SE z P>|z| [95% Conf. Interval] 
Stroke06 (Last BP < 150/90) 0.999 0.001 -1.900 0.057 0.998 1.000 
Stroke08 (Last cholesterol <5mmol/l) 0.999 0.000 -1.500 0.134 0.999 1.000 
Stroke12 (on anti-platelet agent/anti-coagulant) 1.000 0.001 -0.520 0.604 0.998 1.001 
BP05 (In all hypertensives,BP<150/90) 0.999 0.001 -1.390 0.163 0.998 1.000 
QOF Patient Experience Indicators 
PE07 (can obtain a consultation with GP in 2 
days) 0.999 0.000 -3.950 0.000 0.998 0.999 
PE08 (can book an appointment  with GP more 
than 2 days ahead) 0.999 0.000 -5.890 0.000 0.998 0.999 
CQC PCT rating = fair vs. poor 0.964 0.027 -1.270 0.202 0.912 1.020 
CQC PCT rating = good vs. poor 0.993 0.028 -0.250 0.800 0.939 1.050 
CQC PCT rating = excellent vs poor 0.939 0.037 -1.590 0.111 0.869 1.015 
 
Table 83 shows a multivariate analysis with stroke admission rate as the outcome variable, 
with the expected practice rate (as we used indirect standardisation here) as the offset 
variable in the Poisson regression.  Other variables not shown were eliminated from the 
model by reverse stepwise variable selection.  As for MI+angina, observed prevalence, IMD 
score and smoking prevalence are as expected all risk factors for hospital admission.  The IRR 
for unregistered prevalence is less than unity, which is unexpected, as patients with 
undiagnosed disease might be expected to be more likely to be admitted.  Only one QOF 
Clinical Indicator, Stroke08 (Last cholesterol <5mmol/l), remains in the model and is as 
expected, with higher scores protective.  GP supply/100.000 population is not retained in the 
model. 
Table 83: OLS multivariate stepwise analysis. Dependent variable: observed admission 
count. Independent variables: population + institutional factors 
 IRR SE 
z 
P>|z| [95% Conf. 
Interval] 
Observed prevalence (%) 1.033 0.006 5.120 0.000 1.020 1.045 
Unregistered prevalence (%) 0.957 0.010 -4.290 0.000 0.937 0.976 
IMD score 1.008 0.001 7.600 0.000 1.006 1.010 
Smoking prevalence (%) 1.005 0.002 2.370 0.018 1.001 1.008 
QOF Clinical Indicators 
Stroke08 (Last cholesterol <5mmol/l) 0.998 0.000 -3.750 0.000 0.998 0.999 
CQC PCT rating = fair vs. poor 0.983 0.006 -2.680 0.007 0.971 0.995 
CQC PCT rating = excellent vs. poor 0.954 0.025 -1.780 0.075 0.906 1.005 
 
The next two practice level maps (Figure 34 and Figure 35) show Local Moran’s I tests at 2km 
and 5km for stroke admission rates.  Once again there is marked clustering of high-high 
admission rate values evident in London and other conurbations, which is even more 
prominent in the 5 km map.  However there is also clustering of low-low levels, especially in 
West London and in the West Midlands. 
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Figure 34: Local Moran’s I (2km) of stroke admission rates 
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Figure 35: Local Moran’s I (5km) of stroke admission rates 
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Table 84 compares OLS and geographical analyses for stroke admissions, including all 
variables except PCT CQC scores.  Comparison with classical regression outcomes was made 
using the Akaike Information Criterion (AIC)202 to test for spatial non-stationarity.276  
Identification of the optimal bandwidth for each analysis block was made using Monte Carlo 
simulations.  The results of the spatial non-stationarity test reveal little difference between 
the AIC values for the non-spatial and GWR models, with marginal improvement with the 
spatial model.  For example AIC values range from 2024 to 9899 between analysis blocks for 
the non-spatial model; the comparable range for the GWR model was 2024 to 9897.  Thus 
while non-stationarity was not significant, nevertheless the AIC values confirmed that it was 
statistically valid to use spatial regression as a basis for exploratory mapping.   




















  Classical Regression 
East Midlands 794350.19 13.00 31.49 7941.58 0.13 794350.20 13.00 0.12 
East of England 233667.98 13.00 27.41 3081.05 0.22 233668.00 13.00 0.19 
Greater 
Manchester 600900.79 13.00 41.98 3666.51 0.17 600900.80 13.00 0.14 
Home Counties 1084418.71 13.00 33.06 9899.22 0.14 1084418.70 13.00 0.13 
Merseyside 414106.86 14.00 39.16 2906.66 0.24 414106.90 14.00 0.20 
North East 
England 573430.79 13.00 39.69 3861.37 0.13 573430.80 13.00 0.10 
North East London 831133.98 14.00 48.18 3955.77 0.10 831134.00 14.00 0.06 
North West 
England 597069.82 13.00 33.31 5442.87 0.11 597069.80 13.00 0.09 
North West 
London 852586.67 13.00 38.08 6096.00 0.14 852586.70 13.00 0.12 
South Coast 396893.62 13.00 27.55 5091.42 0.19 396893.60 13.00 0.17 
South East London 332856.05 14.00 35.44 2800.10 0.15 332856.10 14.00 0.11 
South West 
England 491973.60 13.00 28.83 5799.70 0.13 491973.60 13.00 0.11 
South West 
London 239149.68 13.00 35.67 2024.06 0.04 239149.70 13.00 -0.03 
West Midlands 1459898.48 14.00 39.75 9586.87 0.12 1459898.50 14.00 0.10 
Yorks& 
Humberside 1051371.77 13.00 38.37 7381.87 0.22 1051371.80 13.00 0.20 
 
GWR Estimation 
East Midlands 698472.52 45.81 30.15 7907.82 0.24 95877.70 32.81 0.19 
East of England 208918.95 28.72 26.60 3081.08 0.30 24749.00 15.72 0.24 
Greater 
Manchester 478405.44 42.50 39.19 3656.06 0.34 122495.30 29.50 0.25 
Home Counties 1065104.83 20.76 32.90 9897.26 0.15 19313.90 7.76 0.14 
Estimating disease prevalence in small populations 
 





















Merseyside 374593.21 25.90 38.10 2906.06 0.31 39513.70 11.90 0.24 
North East 
England 219164.36 119.79 29.19 3826.46 0.67 354266.40 106.79 0.51 
North East London 782636.84 23.74 47.41 3955.21 0.15 48497.10 9.74 0.09 
North West 
England 509909.11 47.84 31.83 5434.53 0.24 87160.70 34.84 0.17 
North West 
London 832693.22 22.26 37.93 6101.56 0.16 19893.40 9.26 0.13 
South Coast 348797.59 32.25 26.31 5064.41 0.29 48096.00 19.25 0.24 
South East London 310591.12 24.12 34.91 2804.39 0.21 22264.90 10.12 0.13 
South West 
England 426437.00 47.38 27.65 5789.87 0.25 65536.60 34.38 0.18 
South West 
London 210289.72 23.59 34.42 2024.31 0.16 28860.00 10.59 0.04 
West Midlands 1186389.38 75.62 37.09 9528.81 0.28 273509.10 61.62 0.22 
Yorks & 
Humberside 974670.19 23.58 37.22 7349.17 0.27 76701.60 10.58 0.25 
 
Table 85 summarises AIC scores for remaining stroke admission analyses.  Looking down the 
columns, the results of the spatial non-stationarity test revealed little difference between 
the maximum and minimum AIC values (highlighted in yellow) for the non-spatial and GWR 
models, with marginal improvement with the spatial model. 
Table 85: Stroke admissions: split variable Akaike Information Criterion scores 
Sub regions 
Service Delivery 
Variables ( PCT 
Scores not included) 
Service Delivery 




  Classical regression 
East Midlands 8007.91 7657.21 7958.83 
East of England 3120.28 3120.59 3072.83 
Greater Manchester 3697.11 3695.51 3667.71 
Home Counties 10016.27 10018.30 9897.83 
Merseyside 2964.94 2953.66 2889.12 
North East England 3887.69 3416.61 3870.43 
North East London 3963.55 3963.55 3953.08 
North West England 5484.68 5486.48 5443.39 
North West London 6173.01 6172.90 6100.53 
South Coast 5168.44 5167.20 5092.57 
South East London 2798.94 2798.94 2816.06 
South West England 5844.26 5646.88 5814.22 
South West London 2018.14 2020.14 2010.45 
West Midlands 9645.68 9345.65 9607.95 
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Variables ( PCT 
Scores not included) 
Service Delivery 




Yorks & Humberside 7447.38 7449.41 9620.35 
  GWR Estimation 
East Midlands 7950.02 7618.49 7876.03 
East of England 3107.67 3099.55 3068.79 
Greater Manchester 3655.69 3654.28 3619.75 
Home Counties 9985.54 9990.27 9888.13 
Merseyside 2954.32 2952.80 2882.15 
North East England 3822.19 3374.74 3798.02 
North East London 3955.60 3955.60 3944.95 
North West England 5462.33 5454.94 5408.82 
North West London 6177.15 6177.83 6099.34 
South Coast 5150.98 5091.03 5055.81 
South East London 2799.94 2799.94 2819.65 
South West England 5828.68 5626.68 5758.97 
South West London 2015.22 2017.51 2006.66 
West Midlands 9609.42 9291.41 9467.91 
Yorks & Humberside 7404.12 7401.65 9479.87 
 
The following figures show a small sample of the the GWR analysis carried out for CQC, 
which covered all the English sub-regions we defined pragmatically for mapping purposes- 
specifically, local R-squared results- to demonstrate practice-level mapping and the utility of 
GWR regression diagnostics. We realised that there was little point in having a London inset 
when there was no London data, and that the inset could instead be used to show a higher 
detail map of practices.  We have therefore shown three sub-regions- Greater Manchester, 
Home Counties and Merseyside- with an inset for the sub-region itself. 
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Figure 36 and Figure 37 show local R-squared for stroke admission rates for Greater 
Manchester, considering demographic and service delivery variables separately.  There is 
broad agreement in local R-squared values between the population and service delivery 
maps, though not with the consistency observed for some other metropolitan contexts such 
as South West London. 
Figure 36: local R-squared for stroke admission rates, Greater Manchester, population 
factors only 
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Figure 37: local R-squared for stroke admission rates, Greater Manchester, service delivery 
variables only 
F 
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 Figure 38 and Figure 39 show local R-squared for stroke admission rates for Merseyside, 
using demographic and service delivery variables.  Demographic factors associated more 
strongly with admissions than did care-related factors suggesting that practices in this region 
are managing populations better than might be expected considering population context. 
Figure 38: local R-squared for stroke admission rates, Merseyside, population factors only 
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Figure 39: local R-squared for stroke admission rates, Merseyside, service delivery 
variables only 
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Figure 40 and Figure 41 show local R-squared for stroke admission rates for North West 
England, using demographic and service delivery variables.  There is a clear reversal in the 
directionality of the geographic trend in local R-squared values between the split-variable 
models across the region, with the socio-demographic model showing a general south to 
north statistical incline and the institutional model the reverse.  There was wider spatial 
variability in the predictive power of the service delivery model than for the demographic 
model.   
Figure 40: local R-squared for stroke admission rates, NW England, population factors only 
 
 
Within the more northerly, more rural PCTs there are associations of practices for whom 
service delivery factors predict admissions more strongly than population factors: these 
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associations do not appear to cross boundaries into the more urban PCTs in the centre of the 
region.  In the southernmost, more affluent PCTs of the study area the local R-squared 
values are similar for both models. 
Figure 41: local R-squared for stroke admission rates, NW England, service delivery 
variables only 
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Figure 42 and Figure 43 show R-squared for stroke admission rates for North East England, 
using demographic and service delivery variables.  The highest correlations between 
admissions and population factors are observed in parts of the Tyne and Wear locality of this 
area (up to 0.68 for one association of practices) and much stronger than institutional 
factors, indicating deep underlying socio-demographic problems and little local population 
diversity.   
Figure 42: local R-squared for stroke admission rates, NE England, population factors only 
 
This corresponds to known health promotion problems in the area relating to lifestyles.218  
However, by contrast the South of Tyne and Wear PCTs (e.g. Sunderland) indicate admission 
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correlations with primary care factors over and above that predicted by socio-demographic 
factors, whereas the values are low for Newcastle. 
Figure 43: local R-squared for stroke admission rates, NE England, service delivery 
variables only 
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In the West Midlands (Figure 44 and Figure 45), as with Greater Manchester, general 
consistency was observed in the geographic patterning of local R-squared values between 
the two models.  Socio-demographic factors were stronger predictors of admissions than 
institutional variables. 
Figure 44: local R-squared for stroke admission rates, West Midlands, population factors 
only 
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Figure 45: local R-squared for stroke admission rates, West Midlands, service delivery 
variables only 
 
We explored these relationships further using scatterplots of R squared values for practices 
in two sub-regions.  The first chart (Figure 46) shows a scatterplot of R squared demographic 
vs primary healthcare variables for Tyne & Wear practices.  There is a fairly strong 
correlation between these in this area. 
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The second chart (Figure 47) shows a scatterplot of demographic vs primary healthcare 
variables for Greater Manchester practices.  There is no correlation whatsoever, so 
apparently different relationships hold for these variables between the two areas. 
Figure 47: scatterplot of demographic vs primary healthcare R squareds for Greater 
Manchester practices 
 
In North West London (Figure 48 and Figure 49) whilst population factors are stronger 




















































Primary Care variables 
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anisotropy (directionality in a pattern) across the area without the suggestion of spatial 
anomalies.  The decline in R squared declines from the West, whereas primary care factors 
do not correlate at all, with very low R squareds. 
  Figure 48: local R-squared for stroke admission rates, NW London, population factors only 
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Figure 49: local R-squared for stroke admission rates, NW London, service delivery 
variables only 
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In North East London (Figure 50 and Figure 51) the same scenario is evident for Hackney and 
Tower Hamlets. 
  Figure 50: local R-squared for stroke admission rates, NE London, population factors only 
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Figure 51: local R-squared for stroke admission rates, NE London, service delivery variables 
only 
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Some significant associations were observed in South Coast (Figure 52 and Figure 53).  The 
maps show remarkably strong agreement between the institutional and population models 
in terms of directionality, though greater variability in R-squared values can be seen in the 
healthcare-related model map.  There is no suggestion of performance anomalies in this 
analysis block. 
Figure 52: local R-squared for stroke admission rates, South Coast, population factors only 
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Figure 53: local R-squared for stroke admission rates, South Coast, service delivery 
variables only 
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There is little evidence that urbanity/rurality consistently correlates with the relationship 
between primary care variables and admissions, though there is evidence that more affluent 
with the exception of the Home Counties and locality-specific contexts appear to be 
relevant.  Deprivation has an inconsistent relationship with the effectiveness of care delivery 
regarding admissions with suggested variation in primary care achievement between 
Greater Manchester, Merseyside and central Tyne and Wear on the one hand, and inner 
east London and south Tyne and Wear on the other. 
10.7.5 Discussion & Conclusions 
Scenario 1/ disease detection: outcome=registered and undiagnosed prevalence 
An obvious initial question is: why was there such a discrepancy between expected and 
practice-registered disease prevalence, when the model-based CHD and stroke prevalence 
estimates were based on patient reports of doctor-diagnosed disease?  Reasons are likely to 
include inadequate searching of practice records (which are now mainly electronic) for 
previous diagnoses or CVD-related prescriptions, lack of linkage of practice and hospital 
records (practices still generally enter codes for hospital admissions manually), and high 
population mobility in urban areas with concomitant changes (or delays) in registration with 
general practices.  In the case of modelled hypertension (not included in this report), for 
which the modelled estimates used a combination of doctor-diagnosed disease and blood 
pressure measurements, the gap is greatest in younger and middle age groups, when males 
in particular are less likely to be seen by their practices.   In contrast, diagnosis appears to be 
more complete in the north of England. 
 
For the Scenario 1 stroke and CHD OLS analysis, neither the registered nor the unregistered 
prevalence were standardised by age/sex.  For registered prevalence, we applied a Poisson 
regression where we included registered count of cases as the dependent variable and the 
practice population as the offset.  For unregistered prevalence, we applied a Poisson 
regression where we used unregistered (estimated-registered) count of cases as the 
dependent variable and the practice population as the offset.  This fails to take into account 
the age and sex structure of the practice population.  There are two possible solutions: 
1. for registered prevalence, an OLS regression introducing age/sex standardized 
prevalence (observed count as the dependent variable and the expected count the 
offset) could be run.  For unregistered prevalence, the problem is less of an issue since 
the estimated prevalence from the APHO prevalence models includes age, sex and a 
number of other variables for estimation.  The subtraction "estimated-registered" and 
the ratio "registered/estimated" are therefore comparable between practices 
2. if we wish to see the “otherwise adjusted” effects of age and sex distribution of practices 
on the outcome variable, we would need to include the latter among the independent 
variables of the OLS regressions.  We intend to follow up both these options in 
developing papers for publication. 
 
The multivariate analysis with unregistered CHD count as the outcome variable, using the 
practice population as the offset variable in the Poisson regression, gave an IRR less than 1, 
which is unexpected.  One reason would be the presence of multicollinearity, but only IMD 
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score and estimated smoking prevalence (which uses IMD score as an input) showed 
evidence of multicollinearity (Table 6).  We cannot explain this anomaly. 
 
From a spatial analytic perspective, there are significant geographic discrepancies between 
QOF prevalence and modelled prevalence for all three conditions in much of London and its 
hinterland.  The inclusion of a measure of GP supply in the GWR analyses suggests that, 
despite needs-based healthcare resource allocation in the UK, persistent differences in 
availability of primary care services is an important limiting factor in diagnosis.231  An analysis 
of Gini coefficients to measure geographical equity in GPs per 100.000 population in England 
and Scotland showed that equity in England rose between 1974 and 1994, but then 
decreased, and in 2006 it was below the 1974 level. 
 
Finally, the Scenario 1 analyses presented here should be used to guide practical case-finding 
initiatives in practices.  If they are, the results should be audited and the prevalence models 
validated.  Birmingham University has recently received a Programme Grant from the 
National Institute for Health Research for COPD which has as one of its objectives COPD 
case-finding in practices and through that, validation of the COPD prevalence model and of 
practice smoking status data.  Similar audits are needed for CHD and stroke.  The NHS Health 
Checks programme provides an opportunity to do this, but only if practices ask patients 
about previous diagnoses of and admissions for CHD/stroke.  This is not part of the current 
Health Checks protocol. 
 
Scenario 2/disease management: outcome=admission rates 
For the OLS analysis with MI+angina admission rate as the outcome variable, observed 
prevalence, IMD score, smoking prevalence and Asian population are as expected all risk 
factors for hospital admission- the IRR for the latter is very high.  The IRR for unregistered 
prevalence is less than unity, which (as for Scenario 1) is unexpected, as patients with 
undiagnosed disease might be expected to be more likely to be admitted.  The findings for 
stroke were broadly similar. 
 
In comparison with a similar analysis on COPD admissions we have carried out recently, IRRs 
were generally smaller for CHD and stroke, and the results for COPD were more consistent 
with our prior hypotheses.250  Further analyses could be undertaken with the current 
aggregate HES data, but the questions about the impact of unregistered CHD may not be 
answered until analyses of linked person-specific data are examined to determine how many 
patients who are admitted with second MIs or angina have not been on practice registers.  
We also have some concerns about the provenance of the CQC HES data, as we have been 
unable to ascertain how it was grouped into spells.  There does not appear to be a consistent 
relationship between the spells or admissions in the CQC data and episode-based data from 
HESOnline (the HES team have also been unsure how the data was grouped).  The CQC could 
also consider using a scatterplot of R squareds, with primary healthcare/population axes, 
and cropping as an alternative to remapping. 
 
We are aware that York University and Professor Peter Smith in ICL Business School have 
recently undertaken an analysis for DH and the Health Foundation using person-specific 
data, which could be used to examine these additional questions.  We also had some 
remaining questions about the processing of the HES data within CQC, as we have not been 
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able to determine how it was spell grouped, i.e. how FCEs were linked into spells.  We would 
be able to provide the expertise to advise and audit this process. 
 
Conclusions 
Surveillance for care regulation, both for health and social well-being, can be aided by the 
routine use of mapping and spatial statistics, as this report demonstrates.  Although the 
analysis did not demonstrate that GWR is definitely superior to OLS analysis in this situation, 
it is at least as useful, and in addition provides the opportunity to visualise and investigate 
relationships more easily.  Performance-related practice associations identified by the use of 
GWR provides a basis for further investigation of potential ‘overachievers’ and 
‘underachievers’.  Mapping of results enables visualisation readily interpretable by CQC 
statisticians, and with adaptation cartographic output can be understood by lay members of 
the public, a facet important in a Freedom of Information age.   
 
The key questions for discussion are (a) how the CQC can implement GIS and spatial analysis, 
and (b) incorporate the relevant methods and technologies as routine parts of Information 
Policy and Research. 
 
Perhaps a starting point should be GIS experiences in the NHS.  Research carried out 
covering the period 1991-2001 indicates that whilst the use of GIS for mapping had become 
well-established during this period as a result of the general mainstreaming of spatial 
technologies throughout the economy, the take-up of GIS for analytic purposes remained 
very much a minority activity.  In 1991 71.9% of Health Authorities used such systems and by 
2001 the percentage had grown to 85.7%, accompanying a shift from cartographic software 
usage to fully-functional GIS packages.  Nevertheless the figure for those organisations 
actually using such packages for statistical analysis amounted to only 33.5% even by 2001. 
 
Even with the use of GIS now being pervasive across the NHS, its primary application 
remains one of core mapping as evidenced by the NHS SHAPE facility 
(http://shape.dh.gov.uk/public/mapping.asp), Public Health Observatory interactive 
mapping websites (e.g. http://www.nwpho.org.uk/healthgis/) and the custom package iQ 
HealthMaps (http://www.iq-medical.co.uk/products-healthmaps.php), alongside more 
traditional GIS proprietary software such as MapInfo and ESRI ArcGIS.  This can be largely put 
down to a lack of spatial analysis knowledge within healthcare organisations.  This is not an 
obstacle for the CQC, which could also encourage and disseminate spatial statistical 
understanding.  The use of core mapping with a software package such as InstantAtlas or 
GapMinder is a good starting point, and will generally raise awareness amongst healthcare 
providers and the public.  At the same time the CQC should be developing its spatial analytic 
capacity, and should be expecting NHS organisations to be doing the same. 
 
Whilst the CQC does not have widespread GIS and spatial statistics knowledge, the 
organisation does have broad statistical expertise which can be used as a foundation for 
developing a geographical analysis capability.  A lack of GIS knowledge in the organisation is 
not a fundamental issue as spatial statistical analysis can be performed in specialist 
statistical packages with GIS simply used for map production, and a MapInfo licence is 
already held by the organisation.  The CQC uses R and SAS which could be used for spatial 
statistics; currently CQC uses general linear modelling, and it can then add spatial factors.  
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CQC should also consider GIS software- GeoDA have just brought out an R version which is a 
stepping stone to more specialised software.  The main alternative is Luc Anselin’s analysis 
blocks these may be suitable for some models. 
 
Costs, frequently an inhibiting factor in implementing new information technology in 
organisations including GIS, is also not an obstacle, as the last five or so years have seen a 
boom in reliable freeware mapping packages with basic mapping functionality aimed at 
users who primarily need a basic mapping tool with the ability to convert commercial file 
formats from one to the other.  Packages such as GeoVista 
(http://www.geovistastudio.psu.edu/jsp/index.jsp) and QGIS (http://www.qgis.org/) offer 
cost-free alternatives with user support groups.  Spatial statistics packages, as they are 
typically outside mainstream needs, are often free and developed by academics with 
research and development grants from academic funding councils.277;278 
 
More significant issues will be data sharing with other organisations and arranging spatial 
statistics training for staff.  Data sharing within the NHS has previously been identified as a 
problem for implementing spatial information systems and a core obstacle for routine 
analytic work.  The importance of data provider service level agreements/requirements 
cannot be stressed enough for any attempt by the CQC to make geographical analyses an 
integrated part of its regulatory work.  Staff training in spatial statistics, the relevant 
software and the basics of GIS, whilst inevitably at some initial cost from an external source, 
is realistic for the CQC considering the statistical expertise in the organisation.  However, a 
‘champion’ from within the Commission will be necessary.  With the likely eventual 
mainstreaming of spatial analysis in health services, development of a strategic plan by the 
CQC will be important  to maximise the potential of spatial analytics for health/social care 
regulation.  With this aim in focus we recommend that the model suggested by the Higgs et 
al  study already referred to in this report be followed due to the overlap between GIS and 
spatial analysis.  The suggested stages in a systematic plan for capacity building in GIS are: 
(1) training and guidance, (2) assessment of scope and remit of methods and technologies 
and (3) development of data exchange agreements. 
 
In the context of CQC, training and guidance in the use of relevant methods and 
technologies from an external body will be necessary; a two-day course should cover the 
requisite material.  Core topics covered must include an introduction to GIS, effective map 
communication, spatial cluster/outlier analysis, spatial regression and software 
implementation.  Whilst there are many other aspects to spatial analysis, such as 
geostatistics which is frequently used in environmental health, we do not envisage these 
other methods as being essential to mapping and spatial statistics for health/social care 
regulation.  A possible exception to this could be spatio-temporal analysis for examining past 
geographic changes in quality of care delivery over time and predicting future change.  
Internal assessment of the scope and remit of mapping and spatial statistics within the 
Commission may be preferable using domain knowledge and an internal ‘champion’ rather 
than being tendered out to an external body.  Development of data exchange agreements 
between the CQC and other institutions such as the Ordnance Survey can be developed if 
necessary. 
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The Discussion focuses on the extent to which the research I have undertaken can answer 
the research questions originally posed in late 2007 (or the modified questions). 
11.1.1 How should the prevalence of chronic diseases be estimated?  How do different 
chronic disease prevalence estimation methods compare in terms of their validity? 
These questions are obviously closely related.  The answer depends on the criteria which 
should be used to compare prevalence modelling methodologies, their “fitness for purpose” 
in providing reasonably robust local, small population/area estimates which can be used by 
PCTs, practices and in future GP commissioning groups and LA public health departments.  It 
is important to distinguish between decision-analysis “cost-effectiveness” models and 
population-based “surveillance” models.279 A surveillance or prevalence model differs from 
decision-analysis models in that “rather than representing a hypothetical cohort, it models 
the population, that is, a collection of birth cohorts, over a specified period of time” 
 
We can start by stating that, currently, the use of a highly complex agent-based, discrete 
event simulation models to provide local estimates as well would be a major undertaking.  
Developers of such models have until now focused on model construction- the iterative 
process of scope selection, hypothesis generation, causal diagramming, quantification, and 
reliability testing in large populations, rather than combining simulation models with small 
area covariates.  However it is feasible to do this and it will certainly be done in the future. 
 
It is likely, but by no means certain, that more sophisticated methods of model development 
provide better predictions, but a notable feature of the literature is that very little 
comparative validation has been carried out, and most have compared similar methods.280  
Only one paper which I could find has done this for different types of model- it compared 
Markov and discrete event simulation (DES) models i.e. agent-based models.41 The DES 
model predicted the course of a disease naturally, with few restrictions. This may give these 
models superior face validity with decision makers.  Furthermore, this model automatically 
provided a probabilistic sensitivity analysis, which is cumbersome to perform with a Markov 
model. DES models also allow inclusion of more variables without aggregation, which may 
improve model precision.  However the differences were not great in terms of the actual 
predictions.  Moreover these comparisons are only one aspect of model validation. 
 
I could find no other published comparisons of, for example, models produced by MLM, 
multilevel, Markov, Bayesian or simulation methods using criteria which might be important 
to non-expert model users.  On our part, we were unable to demonstrate, in our practice-
level CHD and stroke modelling, the superiority of GWR compared to MLM methods, using 
the AIC as a criterion. Given the breadth and complexity of modelling methodology, few 
academics have in-depth knowledge of two let alone all of these methods.  Geographers 
understandably favour spatial methodologies (GWR or Bayesian), and classically-trained 
statisticians non spatial methods such as MLM with clustering options.  It appears to me that 
there is a need for methods to compare the fit of various types of models (such as AIC), and 
some comparisons of their application across several diseases.   
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For example, two or more modelling methodologies could be compared to a validation gold 
standard of local prevalence.  This data is difficult to obtain; one option would be using data 
from populations in which extensive case-finding has apparently detected nearly all cases of 
disease.  NHS Health Checks data might serve this purpose, once a large enough proportion 
of the population has been screened.  Unfortunately, although the present national policy 
excludes cases currently on QOF registers, it does not specify that questions about patient-
reported doctor-diagnosed disease be asked to ensure that cases not on practice registers 
are found. 
 
In an important paper just published by the Institute for Health Metrics and Evaluation 
(IHME), Srebotnjak et al propose a validation framework to cope with the problem of 
validating estimates in data-sparse domains.289 The framework combines the three 
conventional approaches to small area measurement, all of which we have used: 
 pooling data across time by combining multiple survey years  
 exploiting spatial correlation by including a spatial component; and 
 utilizing structured relationships between the outcome variable and domain-specific 
covariates to define four increasingly complex model types - coined the Naïve i.e. 
age/race(ethnicity) for each sex, Geospatial, Covariate, and Full models. 
Their Covariate and Full model types draw leverage from the relationships between outcome 
variable and additional domain-level covariates, as in the disease prevalence models.  Spatial 
relationships are accomplished through an additional covariate in the Geospatial and Full 
models.  Thus, their basic model is a generalized linear mixed-effects MLM with binomial 
outcome and logit link function. The combinations of the four model families and four model 
specifications generate a total of 16 models for each sex (for the English disease prevalence 
models the equivalent number is 25, because we used more covariates). 
 
The gold standard serves as a benchmark judged to be the best available direct estimate for 
the small area domain.  The IHME used Behavioural Risk Factor Surveillance Survey data 
(BRFSS, a US equivalent of the HSfE). Their gold standard is counties with sufficiently large 
sample sizes, which can be obtained by choosing small domains with large sample sizes in a 
single survey year, pooling multiple survey years, or increasing domain size. IHME pooled the 
2000-2008 BRFSS and calculated the direct age-standardized, sex-specific BRFSS estimates 
for self-reported Type 2 diabetes prevalence, taking post-stratification weights into account, 
and weighting each survey year equally.  They used as their gold standard the direct, age-
standardized, sex-specific estimates for counties that had more than 900 observations (by 
sex) in both periods 1996-2004 and 2000-2008 (the validation sets). 
 
The second step of the validation framework involves determining the minimum sample size 
needed to achieve sufficient correspondence with the gold standard.  Such a validation 
environment allows the selection of a modelling strategy that optimally mixes the three 
approaches of pooling data across time, harnessing spatial patterns in the distribution of the 
outcome of interest, and adjusting for estimates for local area characteristics.  This approach 
is analogous to that used in the development of risk predictions models, where derivation 
and validation cohorts are often initially derived from the same population: for example, in 
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the case of QRISK2 derivation, random sampling was used to assign practices to the 
derivation or validation cohort, and then their population data was used.111  However, 
validation should still be carried out in other populations if possible.188;281 
 
 The IHME validation framework compares model estimates against these using all available 
observations for the large domains, and systematically reduced sample sizes obtained 
through random sampling with replacement.  At each sampling level, the model is rerun, and 
the validity of the model estimates from the four model types is then determined by 
calculating the (average) concordance correlation coefficient (CCC) and (average) root mean 
squared error (RMSE) against the gold standard.  The CCC is closely related to the intra-class 
correlation coefficient and can be used when the units are organized in groups, and when it 
is of interest to measure the agreement between units in the same group. The RMSE is often 
used to measure the differences between values predicted by a model or an estimator and 
the actually observed values- it is a useful measure to capture the precision of the model or 
estimator. 
 
All the IHME model types had substantially higher CCC and lower RMSE than the direct, 
single-year estimates from the BRFSS. In addition, the inclusion of relevant domain-specific 
covariates generally improved predictive validity, especially at small sample sizes, and their 
leverage can be equivalent to a five- to tenfold increase in sample size in the Naïve and 
Geospatial models. 
 
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has 
published principles of good practice for decision analytic modelling in health-care 
evaluation.282  A Canadian group has also just published developed a comprehensive 
framework for validating population-based chronic disease simulation models, and used it in 
a review of published model validation guidelines.283 Based on the review, they formulated a 
set of recommendations for gathering evidence of model credibility.   Evidence of model 
credibility derives from examining: 
 Evidence from examining model development process 
o Conceptual model: “determining that the theories and assumptions underlying 
the conceptual model are correct and the model representation of the problem 
entity and the model’s structure, logic, and mathematical and causal relationships 
are reasonable for the intended purpose of the model”. 
o Parameters/ definition of variables: the conceptual and operational definitions of 
the variables in the model should be justified.  Evidence that the model is 
sufficiently complete and that the relationships between the variables are 
specified correctly should come from both theory and empirical data evidence 
generally comes from examining the process used to derive a value for the 
parameter (primary source, method of derivation), and comparisons with data 
from other sources. 
o Computer implementation: “Published validation guidelines do not specify how 
the appropriateness of model type should be determined”.  This harks back to the 
methodological discussion above. 
 Evidence from examining model performance 
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o Plausibility (face validity): assessment of output plausibility (face validity), 
involving comparisons of model output with expectations 
o Internal consistency: assessed by considering functional and logical relationships 
between different output variables 
o Parameter sensitivity: “a technique that measures the effect on model output of 
alternative choices about model structure”.  In the context of the disease 
prevalence models, the best approach would be to produce credible intervals for 
the estimates using MLWin 
o Between-model comparisons: “modellers should cooperate in comparing results 
and articulating the reasons for discrepancies”.  This could be done by comparing 
the APHO prevalence models with, for example, Congdon’s prevalence models,46 
or the South London Stroke Register126 
o Comparisons with external data: “all available data should be used in model 
development and data should not be withheld for the purpose of external 
validation”.  If, however, one of the objectives of the model(s) is to encourage 
case-finding in practices, this suggests that QOF register data should not be used 
for model development 
 Evidence from examining the consequences of model-based decisions 
o The impact of models on the quality of decisions could be evaluated directly in a 
variety of ways, including subjective and objective measures. 
 
The YHEC evaluation is useful in meeting the decision-making criterion, by providing 
feedback from model users.  The additional criteria they suggest include: 
 flexibility: including enabling users to input their own local covariate data if it is more 
accurate than that already in the models 
 transparency: ensuring that the models are parsimonious, and provision of good 
methodological detail and clarity of assumptions within accompanying documents is 
important.  Provision of credible intervals for estimates, possibly using Monte Carlo 
methods and MLWin software 
 accessibility: the models should be easy to locate, both within appropriate websites 
and through internet search engines. A single interface, with avoidance of competing 
models which produce different results 
 version control and updates: user registration and email notifications of any problems 
with the models or upcoming work  
 format: useful easily downloadable formats.  Any such estimates should be provided for 
both resident i.e. LSOA and GP-registered i.e. practice populations.  The additional effort 
involved in applying modelled disease odds to resident-based population data is minimal.  
The data could and should be used in both formats. 
 training and support: an obvious criterion.  
In summary, although there are gaps in establishing model credibility e.g. credible interval 
estimates, the majority of the above criteria have been satisfied. 
 
Estimating disease prevalence in small populations 
 
M Soljak PhD Thesis 
227 
 
11.1.2 What is the best available methodology given the requirements for prevalence 
models? 
The IHME and Canadian frameworks described above appears to provide very useful 
technical criteria for assessing internal validity of prevalence models, and could be applied in 
the UK using HSfE data.  They could also be used to compare not only geospatial, covariate, 
and full models but also other modelling methodologies described in the Introduction.  Until 
this is done, hopefully with some agreement between those involved in developing UK 
models, it is not possible to identify the best methodology. 
11.1.3 How valid are the chronic disease model prevalence estimates? 
As discussed in 11.1.2, the internal validity of the prevalence models described here remains 
to be evaluated using the IHME framework or similar.  The external validations described 
provide some assurances, the most obvious being the correlations with QOF-registered 
prevalence described in the analyses in Section 9.  For example, for COPD, it seems that the 
model provides very conservative prevalence estimates which rarely (in only 3.5 per cent of 
practices) exceed QOF-registered prevalence.  In the COPD admission rate analysis, 
undiagnosed COPD prevalence remains a risk factor for higher admission rates after 
adjustment for other population covariates.  This is not the case for the equivalent CHD and 
stroke analyses, but the provenance of the HES data is uncertain. 
 
Moreover, the unregistered/undiagnosed prevalence of COPD and hypertension is greater 
than that for CHD and stroke.  This is plausible, on the basis that the onset of COPD is 
insidious, whereas that for CHD and stroke is often marked by a sentinel event resulting in 
hospital admission and definitive diagnosis (see Table 86).  The COPD prevalence model is 
based on objective spirometry and not patient reports.   
Table 86: Comparison of registered and unregistered prevalence for COPD, CHD and stroke 
  Mean (SD) Min - Max Median 
COPD 
Observed prevalence (%) 1.56 0.82 0.00-7.47 1.45 
Unregistered prevalence (%) 1.50 0.89 000-5.30 1.46 
CHD 
Observed prevalence (%) 3.50 1.19 0.00 - 9.81 3.47 
Unregistered prevalence (%) 0.95 0.87 0.00 - 5.78 0.87 
Stroke 
Observed prevalence (%) 1.61 0.67 0.00 - 18.55 1.61 
Unregistered prevalence (%) 0.42 0.44 0.00 - 3.83 0.31 
 
Finally, there are three other sources of data for external validation: 
 comparisons with disease-specific population-based surveys using objective criteria e.g. 
ECG evidence for CHD prevalence 
 validity of patient-reported doctor-diagnosed disease as a diagnostic criterion 
 studies of individual practices like the limited validation provided by the Westminster 
COPD case-finding pilot, which can be extended when a major cluster RCT of COPD 
screening led by Birmingham University is completed.284  A good validation data source 
would be a number of practices where extensive interrogation and updating of practice 
registers had been carried out, using searches for prescription items and test results for 
specific diagnoses. 
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11.1.4 How useful are chronic disease prevalence estimates for case-finding at GP practice 
(and LSOA) level?  Can chronic disease prevalence estimates be used with practice 
disease register prevalence to estimate the prevalence of undiagnosed disease? 
As an example of how local estimates can be generated and used, a local Canadian public 
health agency (population 250,000) recently published a “textbook” for local disease 
incidence modelling.273  Age standardized incidence ratios for cancer and the prevalence of 
Census covariates were calculated for each of 331 dissemination areas.  The standardized 
incidence ratios for cancer varied dramatically across these areas. However, application of 
the LMI statistic as used by ourselves suggested significant spatial patterns for only two 
cancers, lung and prostate, both in males. Employing Bayesian hierarchical models, areas in 
the urban core were found to have significantly higher SIRs for male lung cancer than the 
remainder; and, neighbourhoods in some urban and surrounding rural areas exhibited 
significantly higher SIRs for prostate cancer. After adjustment for age and spatial 
dependence, average household income attenuated much of the spatial pattern of lung 
cancer, but not of prostate cancer. 
 
This paper demonstrates the feasibility and utility of a systematic approach to identifying 
neighbourhoods, within the area served by a public health unit, that have significantly higher 
risks of cancer. It suggests several hypotheses for these spatial patterns that warrant further 
investigations.  However few public health teams have the skills and knowledge to carry out 
this complex analysis.  It makes much more sense to provide them with local estimates and 
the training to use them properly. 
 
This is what the Informing Healthier Choices project aimed to do with the APHO/ICL 
prevalence models.3  The best way to answer these questions is to assess the impact of the 
models at local level.  An early assessment has been provided in 10.1 Evaluation of the 
uptake of the models by York University Health Economics Consortium and 10.3 Case-finding 
pilots and case studies. 
11.2 The future 
11.2.1 linkages with risk factor prevalence data from GP systems 
I have already illustrated how the current models can be linked, both with each other (10.4 
Modelling risk factor scenarios and impact on disease prevalence) and with other modelled 
data such as smoking prevalence (8.1 Chronic Obstructive Pulmonary Disease Model).  As 
noted above, local estimates of prevalence or population means (for continuous variables) of 
disease risk factors and lifestyle behaviours e.g. current smoking, obesity, blood pressure 
and physical activity, are of great interest to policy-makers, and increasingly to local 
organisations for planning and performance monitoring purposes e.g. in Local Area 
Agreements.  They are also of interest to researchers examining the relationships between 
health determinants, such as income and education, and health outcomes such as disease 
prevalence, SRHS and death, because risk factor prevalence and means provide a linkage 
between determinants and outcomes, and may be used to predict the latter.243  Risk factor 
estimates may be obtained and used for geographically-based populations such as Regions, 
Counties, LAs, and Wards or SOAs, or populations enrolled for healthcare e.g. PCTs, or GP 
commissioning groups. 
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Until now, risk factor prevalence estimates have come mainly from the HSfE, from local 
surveys either run independently from the HSfE, or from synthetic estimates.  The traditional 
("direct") approach to estimation used for the HSfE uses classical design-based survey 
sampling. However, sample sizes are typically small within small areas, so the direct 
estimators have large sampling errors (and hence large confidence intervals), even when 
pooling years of survey data (which prevents trend estimates). When there are no sample 
observations in the small areas of interest, direct estimators cannot even be calculated. 
 
Even major boosts result in a wide margin of error at the PCO or LA level, of the order of five 
per cent for risk factors like smoking and obesity.  In 2004, DH costed a national boost to 
provide this margin at PCO level at £14m, and so did not proceed with it.  The new ONS 
Integrated Household Survey will provide a much bigger sample size, and will provide more 
reliable local estimates of smoking prevalence, but not for other risk factors. 
 
Potential use of primary care data for risk factor prevalence/mean estimation 
The quality and quantity of population-based data collected by primary healthcare teams 
has improved dramatically in recent years, as a result of overall quality improvement, 
specific data quality initiatives, and the impact of pay for performance through the 
QOF.220;221;285  The data is also becoming more accessible through national GP databases, 
local IT projects and, eventually, aggregation through the Secondary Uses Service via GPES, 
which could cover over 50% of English practices.4  This would allow near to real-time 
monitoring of risk factor prevalence data. 
 
There is a large volume of risk factor and lifestyle data in GP systems.  For example, our 
analysis of the 2005-6 IMS national GP database (about 1m active patients) shows that 
overall about 30% of patients have their smoking status recorded in the last 12 months, and 
17% their BMI recorded in that period.  There is therefore the potential to use this data, 
either alone or in combination with other data, to improve local prevalence estimation.  It is 
also easier to measure risk factor prevalence through population-based programmes such as 
NHS Health Checks than it is to ensure QOF registers reflect actual disease prevalence.  
However, there are a number of methodological problems to resolve. For example, the data 
is non-random- sicker and older people and females are more likely to be sampled.  Figure 
54 below shows the percentage of patients with a valid smoking status recorded in the last 
12 months in the IMS database.  The result is that this data source appears to underestimate 
smoking prevalence in younger age groups. 
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Figure 54: Percent of patients with smoking status recorded in last 12 months 
 
Source: IMS GP database, Information Centre for Health & Social Care 
 
Figure 55 compares smoking prevalence by age and sex between the QRESEARCH database 
and the HSfE.  The proportions of males recorded as smokers in QRESEARCH (2004/5) were 
higher in each age band than the proportions reported in the HSfE (2004) data, but for 
females the proportions are very similar in the two sets of data.   Insofar as disease 
developing in middle and old age is likely to produce sampling bias, differences might be 
expected in this age group.  In addition, data has been captured over longer periods than is 
the case in surveys.  In conclusion, once local risk factor prevalence data becomes available it 
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Figure 55: proportion of smokers by age and sex, comparison of HSfE and QRESEARCH data 
 
11.2.2 A simulation model of the UK population? 
A major disadvantage of the current prevalence models is their static, cross-sectional 
structure.  In the US, the Centers for Disease Control are already well advanced in the 
development of dynamic models.54  In San Francisco, Archimedes is continuing to expand 
both in its scope and functionality.57  The UK should be developing equally dynamic 
epidemiologic models.  This requires at the very least a  multidisciplinary team with ongoing 
support, not a lone researcher and a single injection of funding. 
 
In the UK, in addition to the prevalence models described here, there is already a great deal 
of academic expertise in mathematical modelling, particularly for CVD. Examples include the 
Foresight Obesity Report, for which quantitative modelling included cross-sectional 
regression and longitudinal simulation analyses, and the IMPACT CHD model developed by 
Liverpool University.286 A systematic review of policy models covering CHD found 75 articles 
describing 42 models: 12 were micro-simulation, 8 spreadsheet or cell-based, and 8 life table 
analyses, while 14 used other methods.58 This review includes the CHD model developed for 
DH, which has never been used, and the PREVENT cell-based model.287 Healthcare provider 
capacity models have also been developed.288 
 
 Yet there is currently no synergy in UK modelling research or development because of the 
lack of coordination, and no single organisation has the resources to produce a large scale 
model.  A recent survey of academic epidemiologic modellers proposed that the 
development of this discipline is likely to require a framework providing recommendations 
and guidance at various steps of the studies, from design to report.  A possible way forward 
would be the development of a consensus statement about methods and steps similar to 






















































































































NOTE: QRESEARCH denominator is registered patients aged 16+ having smoking status recorded in the past 5 years
NOTE: QRESEARCH data from 491 practices
NOTE: HSE denominator is patients aged 16+
Copyright QRESEARCH 2007 version 14
Comparison of Health Survey for England with QRESEARCH
Proportion of smokers, by age and sex
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13  Technical Appendix 
This appendix provides some further explanation of the less well-known analytic techniques 
used, particularly those related to spatial statistics. 
 
Concordance correlation coefficient 
The concordance correlation coefficient (CCC) measures agreement between two variables 
and correspondence within groups, i.e., how strongly do units within the same area 
resemble each other.  The CCC is closely related to the intra-class correlation coefficient and 
can be used when the units are organized in groups and when it is of interest to measure the 
agreement between units in the same group e.g. practices. 
 
Root Mean Squared Error 
Root Mean Squared Error (RMSE) is a measure for the average squared difference between 
model estimates and the gold standard.  The RMSE is often used to measure the differences 
between values predicted by a model or an estimator and the actually observed values. It is 
a useful measure to capture the precision of the model or estimator. 
 
In the validation framework proposed by Srebotnjak et al,289 the best-performing models are 
those with the highest CCC and lowest RMSE. 
 
The techniques used in quantitative geography and spatial statistics include cluster/outlier 
detection, smoothing, interpolation, GIS, spatial databases, mapping, querying, analysis and 
modelling software.  Some GIS software examples include relatively simple tools for 
mapping and visualisation such as InstantAtlas, GapMinder, ArcGIS, GRASS, and MapInfo. 
 
Ordinary least squares or OLS regression is the classical or ‘global’ method of regression 
modelling.  There are limitations to using OLS models, including omission of spatial 
adjacency and spatial non-stationarity.  Geographically weighted regression (GWR) is a ‘local’ 
method which: 
 accounts for edge effects, spatial influence, and non-random spatial variability in 
strength and outcome 
 allows disaggregation  local estimates of R2, error terms, etc. 
 groups together of proximate, similar outcomes 
 uses customised rather than predefined units (horses for courses) 
 
Spatial statistics software examples include GeoDa, GWR (used for this thesis),  R extensions, 
and S-PLUS extensions.  Stata can also be used for mapping purposes.  Some of the most 
important techniques are outline below. 
 
Local Moran’s I (LMI) analysis 
This is a useful and intuitive cluster/outlier detection technique, which is one of many similar 
techniques; but LMI is more related to mainstream statistical concepts.  How it works: 
 it examines each data point in relation to whole dataset 
 but gives more weighting to nearer data points 
 there is a threshold distance e.g. 2km, 5km 
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 the null hypothesis that there is no spatial autocorrelation 
 scores between +1 and -1 are generated 
 the significance test is a Z scores i.e. >1.96 standard deviations from the mean 
 “Kriging” 





Spatial regression diagnostics: we compared OLS and GWR using Monte Carlo simulations to 
model outcomes for different bandwidths: a ‘microscope’ technique.  We used the Akaike 
Information Criterion (AIC), ANOVA, R2 increases, standardised residuals, and  Cook’s D. 
 
Analysis of variance (ANOVA): the null hypothesis is that there is random variation in OLS 
(global) regression results leading to chance spatial patterns.   
 degrees of freedom 
 F test (Gauss-Jordan method) 
 standardised residuals 
 correlation coefficient 
 
Akaike Information Criterion (AIC):  
 instead of a confidence interval approach, the AIC is a trade-off between R2 and degrees 
of freedom 
 lower AIC  model describes data better 
 different bandwidths will yield different results; an optimal bandwidth is determined 
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Source: Nakaya et al, Statistics in Medicine 2005;24:2695-2717 
 
Source: Fotheringham et al, Geographically Weighted Regression 2002:44 
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14 Pragmatic methods for estimating prevalence in small 
populations 
An excellent guide to prevalence model development can be found in APHO Technical 
Briefing no 8: Prevalence Modelling, which is drawn upon here.290 
 
Prevalence modelling is a technique used to estimate the number of people with a particular 
condition or risk factor in a population when direct evidence is not available. Direct evidence 
may be lacking because surveys or data collection have not been undertaken, are technically 
impractical, or are unreliable. Methods for generating synthetic or modelled estimates range 
in complexity from simple to highly sophisticated. Crude estimates of the number of cases 
can be generated by applying known prevalence rates to a different population, for example 
applying national rates measured in a large survey to a local population; or applying local 
rates for a recent year to a projected future population. Very simple models typically apply 
age/sex specific rates to local population data.  However, many factors in addition to age 
and gender influence prevalence, for example, deprivation smoking and ethnicity can 
influence the prevalence of a behaviour, risk factor or disease, and more complex 
epidemiological modelling techniques are required in order to take such factors into 
account. 
 
Many methods exist for creating synthetic estimates of prevalence, and in many cases 
methodologies are combined and adapted to make best use of the information and data 
available. There is often a balance to be struck between increasing the complexity of the 
model by incorporating more contributory factors and the availability of good quality data at 
local level to populate the model. These input requirements of a model are often restricted 
by what information is available. Complex models can also suffer from difficulty of 
interpretation, which negates the benefit of increased accuracy. All models are based on 
assumptions. Good models clearly state the assumptions that have been made and good 
interpretation of modelled estimates takes into account the limitations of the assumptions. 
The two simplest methods are: 
14.1 Prevalence estimates from studies applied to local populations  
Although this can be a quick and simple method, its usefulness depends on the size of the 
studies and hence the precision of the prevalence estimates, and whether or not they 
include prevalence estimates for population subgroups. Incorporating different prevalence 
rates for subgroups by deprivation, gender and/or age is usually useful and technically 
straightforward. However, increasing the specificity of the model by using prevalence 
estimates in many subgroups (for example gender, age, ethnicity, smoking status and 
employment status) can limit the range of local levels to which it can be applied, because 
there is seldom sufficient alignment between data routinely available at local level and all 
the variables used in the source study.  
 
14.2 Regression models using large surveys  
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Multiple variables from large surveys can be used to model the risk factors for a behaviour 
or disease, using techniques such as multinomial logistic regression. However, it is important 
to limit the factors considered to those for which data are available in the population of 
interest. For example, cholesterol level or family history of disease may be important risk 
factors which were recorded in the source survey, but such information is not usually 
available at population level and therefore these are not appropriate variables to be 
included in a disease prevalence model.  
 
National surveys are usually limited to people living in private households and omit 
populations such as the homeless, those living in institutional care, ‘special populations’ 
(armed forces and prisoners) and people particularly likely to decline to participate. For 
some disease areas, notably some types of mental illness, these omitted populations can be 
particularly important. Despite this limitation, national surveys are often the best source of 
prevalence information available, but where possible should be used in conjunction with 
other evidence about the likely extent to which they miss cases. Models can then be 
adjusted to take account of the resultant under-estimation of prevalence. Although 
regression models most commonly use survey data, other data sources, for example 
information recorded in general practices, can also be used to create this type of prevalence 
model.  
14.3 Validation, confidence intervals and robustness  
The accuracy of model outputs depends on the predictive power of the model and on the 
accuracy of the input data. Models should be subjected to validation checks to ascertain 
their robustness and general applicability. Estimates of the accuracy of prevalence estimates 
based on simple models can be generated by combining the uncertainty in prevalence rates 
from the source study or trial with the stochastic variation expected given the size of the 
local population. This approach results in a range estimate for the prevalence, rather than 
confidence intervals. The range estimates are calculated using the same methods as those 
used to derive the control limits for funnel plots.  However, if there is uncertainty around 
both the population data and the input data, the calculation of confidence intervals can be 
complex. Bootstrapping methods i.e. repeated sampling such as MCMC are commonly used 
in such situations.   Four ways of validating models are described here (14.4-14.7).  
 
14.4 Sensitivity testing  
Sensitivity testing can be useful in assessing how the uncertainty in input data affects 
prevalence estimates. For some models, very small variations in the input data will have a 
large effect on the results. Other models may be relatively insensitive to variability in input 
data. For example, different sources of practice level smoking prevalence data were input 
into the APHO chronic obstructive pulmonary disease (COPD) models. Estimated COPD 
prevalence in general practices ranges from 1% to 7%. In 92% of cases, changing the source 
of smoking prevalence data made an absolute difference of less than 0.3% in the COPD 
prevalence estimate.  Estimates were strongly correlated with each other (r 2 > 0.95). One-
way sensitivity analysis such as this evaluates the impact of a change in one variable on the 
model results. Multi-way sensitivity analysis is more powerful and can be used to assess the 
impact of changing two or more variables simultaneously.  
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14.5 Internal validation  
One method of assessing the performance of a model is to use it to predict the response for 
each subject in the source data (e.g. a large survey). These predictions are called fitted 
values. The differences between the fitted and the observed values are called residuals. 
Residual analysis can be used to check the adequacy of any assumptions used when creating 
the model. It can also be used to identify whether any additional factors should be included.  
 
To check the accuracy of the model, the predicted ‘classification’ of each individual (i.e. 
whether or not they have the disease or behaviour that is being modelled) can be compared 
with their actual classification. This will result in a ‘misclassification’ (also known as a 
‘contingency’ or ‘confusion’) table  
14.6 Receiver-Operating Characteristic (ROC) Analysis  
ROC analysis is a useful way of assessing the accuracy of a model by understanding the 
trade-off between the sensitivity (in this sense referring to the true positive rate; Table 2) 
and the specificity (the true negative rate).12 The method was developed to assess the 
accuracy of distinguishing signal from noise in radar systems and has since been applied in 
many other settings, including clinical diagnostic testing and the evaluation of regression 
models that classify cases into two categories, for example diseased and non-diseased. 
Sensitivity is plotted against 1-specificity (specificity subtracted from one) over a range of 
values and the area under the curve (AUC or AUROC) is used as a summary of the predictive 
or diagnostic accuracy. A ‘perfect’ model that accurately predicts every case has AUROC = 1. 
Typically, models have a convex ROC curve and an AUROC between 0.5 (equivalent to 
random chance) and 1. A model with AUROC < 0.5 is less accurate than random chance.  
 
14.7 External validation  
Modelled estimates can be compared with observed prevalence where such measures exist. 
For example, modelled estimates for small areas can be aggregated to regional or national 
level and compared with survey measures of prevalence. In some models, local values are 
adjusted so that regional or national aggregates are consistent with observed prevalence.  
14.8 Strengths and limitations of prevalence models 
Understanding the strengths and limitations of any model is crucial if the results are to be 
appropriately used. However, this understanding is often hampered by the limited amount 
of information published about the methodology, development and testing of models. The 
following checklist of ten areas that should be reported and discussed in a modelling paper.   
1. Aims of the project  
2. Structure and methods of the model  
3. Data quality (data availability, how up to date,  comprehensive, any gaps in certain 
population groups or interventions, reasons for selecting or excluding specific data 
sources)  
4. Methodological limitations  
5. The assumptions used to address these deficiencies Sensitivity analyses (one-way or 
preferably multi-way)  
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6. Whether the validity of the model was checked (with real observational data or with 
other models)  
7. Replication of the model in different populations  
8. Model results and comparisons with other studies  
9. Social and economic policy implications of model outcomes 
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